var title_f38_14_39136="Atlanto axial dislocation";
var content_f38_14_39136=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F71575&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F71575&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atlanto-axial dislocation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 441px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_14_39136=[""].join("\n");
var outline_f38_14_39136=null;
var title_f38_14_39137="FAST pleural examination probe position";
var content_f38_14_39137=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F55388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F55388&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    FAST: Pleural examination probe position",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photograph shows proper probe positioning to look for signs of a pneumothorax.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Manoj Pariyadath, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_14_39137=[""].join("\n");
var outline_f38_14_39137=null;
var title_f38_14_39138="Patient information: Rheumatoid arthritis and pregnancy (The Basics)";
var content_f38_14_39138=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?37/19/38194\">",
"         Patient information: Deciding to breastfeed (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?37/1/37907\">",
"         Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?16/31/16883\">",
"         Patient information: Rheumatoid arthritis (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?11/52/12098\">",
"         Patient information: Rheumatoid arthritis and pregnancy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?20/61/21463\">",
"         Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?23/44/24264\">",
"         Patient information: Rheumatoid arthritis treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Rheumatoid arthritis and pregnancy (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/rheumatoid-arthritis-and-pregnancy-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1569228\">",
"      <span class=\"h1\">",
"       Can women with rheumatoid arthritis have normal pregnancies?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. It is possible for women with rheumatoid arthritis (often called &ldquo;RA&rdquo;) to have healthy pregnancies. But you will need to work closely with your doctors. They will make sure that you are doing the right things to control your symptoms and protect your baby.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1569235\">",
"      <span class=\"h1\">",
"       What should I do before trying to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It is very important to talk to your doctor",
"      <strong>",
"       before",
"      </strong>",
"      you start trying to get pregnant. You will need to see an obstetrician (a doctor who takes care of pregnant women), your rheumatologist (the doctor who handles your RA), and your primary care doctor. They can make sure that any medicines you take are safe to use during pregnancy. They might also do some tests to make sure your body is ready for a pregnancy.",
"     </p>",
"     <p>",
"      Some RA medicines can cause serious problems for a baby. You will need to stop taking these before getting pregnant:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?41/59/42934?source=see_link\">",
"         Methotrexate",
"        </a>",
"        (brand names: Rheumatrex&reg;, Trexall&trade;) &mdash; If you take this medicine, you should stop it at least",
"        <strong>",
"         1 month (3 months is even better)",
"        </strong>",
"        before trying to get pregnant. This medicine is very dangerous for a baby.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?23/42/24229?source=see_link\">",
"         Leflunomide",
"        </a>",
"        (brand name: Arava&reg;) &mdash; If you take this medicine, you should stop it at least",
"        <strong>",
"         2 years",
"        </strong>",
"        before trying to get pregnant. Or your doctor can give you another medicine to make the leflunomide leave your body faster. Then he or she can do a test to be sure it is out of your body before you try to get pregnant.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you do get pregnant while taking",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?41/59/42934?source=see_link\">",
"       methotrexate",
"      </a>",
"      or",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?23/42/24229?source=see_link\">",
"       leflunomide",
"      </a>",
"      , tell your doctors right away. Your doctors will help you decide whether to stop (or switch) any other medicines you are taking. Plus, they might suggest added treatment.",
"     </p>",
"     <p>",
"      There are also steps that",
"      <strong>",
"       all",
"      </strong>",
"      women should take before trying to get pregnant. (See",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/1/37907?source=see_link\">",
"       \"Patient information: How to plan and prepare for a healthy pregnancy (The Basics)\"",
"      </a>",
"      .)",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1569242\">",
"      <span class=\"h1\">",
"       How will my rheumatoid arthritis affect my pregnancy and my baby?",
"      </span>",
"      &nbsp;&mdash;&nbsp;RA does not usually cause problems with pregnancy or the baby&rsquo;s health. But some medicines used to treat RA can be unsafe for a baby.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1569249\">",
"      <span class=\"h1\">",
"       How will my medicines affect my pregnancy or my baby?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some RA medicines can hurt an unborn baby. You should not use these during pregnancy.",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?41/59/42934?source=see_link\">",
"         Methotrexate",
"        </a>",
"        can cause miscarriage (when the pregnancy ends before 20 weeks). It can also cause the baby to not develop correctly.",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?23/42/24229?source=see_link\">",
"         Leflunomide",
"        </a>",
"        can cause the baby to not develop correctly.",
"       </li>",
"       <li>",
"        High doses of steroids in early pregnancy can increase the risk of a birth defect called &ldquo;cleft palate.&rdquo; (In babies with cleft palate, the roof of the baby&rsquo;s mouth does not form properly.) High doses of steroids later in pregnancy can cause other problems, such as the mother&rsquo;s water breaking too early.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      It is important to talk to your doctors about",
"      <strong>",
"       all",
"      </strong>",
"      medicines you take and follow their directions carefully. Do not start taking any new medicines, supplements, or herbal drugs without talking to your doctors first.",
"     </p>",
"     <p>",
"      Some RA medicines can be taken during pregnancy, but only at certain times or in certain amounts:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        NSAIDs &mdash; These include medicines such as",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sample brand names: Advil&reg;, Motrin&reg;),",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?43/35/44597?source=see_link\">",
"         naproxen",
"        </a>",
"        (brand name: Aleve&reg;), and",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/12/6342?source=see_link\">",
"         aspirin",
"        </a>",
"        . They can safely be used at some times in pregnancy, but not at other times.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Steroids &mdash; These medicines, such as",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?27/36/28230?source=see_link\">",
"         prednisone",
"        </a>",
"        , are fairly safe in low doses during pregnancy. They are often used in pregnant women with RA to help keep the disease under control. (These steroids are not the same steroids that athletes take to build muscle.)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      There are other safe medicines available, too. Your doctors can help you decide how best to treat your RA symptoms without hurting your baby.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1569256\">",
"      <span class=\"h1\">",
"       Will pregnancy affect my rheumatoid arthritis symptoms?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It might.",
"      <strong>",
"      </strong>",
"      Many women with RA notice that their symptoms get better during pregnancy. But some women&rsquo;s symptoms stay the same or get worse.",
"     </p>",
"     <p>",
"      Some normal pregnancy symptoms are similar to RA symptoms, including:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Feeling tired",
"       </li>",
"       <li>",
"        Swelling of the hands, feet, or ankles",
"       </li>",
"       <li>",
"        Joint pain",
"       </li>",
"       <li>",
"        Trouble breathing",
"       </li>",
"       <li>",
"        Numbness or pain in the hands",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Even if your RA symptoms get better during pregnancy, they often get worse again after the baby is born. Your doctor will decide when to start up your regular RA medicines again.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1569263\">",
"      <span class=\"h1\">",
"       Will I be able to breastfeed?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Women with RA can safely breastfeed. But they have to avoid certain medicines while they do. Some RA medicines can get into breast milk and be harmful to a baby.",
"     </p>",
"     <p>",
"      If you want to breastfeed, talk to your doctors. They can tell you which medicines you can take and which ones to avoid. Most of the medicines that are unsafe during pregnancy are also unsafe while breastfeeding. Some women need to stop breastfeeding if they need these medicines to control their RA.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1569360\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/31/16883?source=see_link\">",
"       Patient information: Rheumatoid arthritis (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/1/37907?source=see_link\">",
"       Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/19/38194?source=see_link\">",
"       Patient information: Deciding to breastfeed (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/52/12098?source=see_link\">",
"       Patient information: Rheumatoid arthritis and pregnancy (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/44/24264?source=see_link\">",
"       Patient information: Rheumatoid arthritis treatment (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/61/21463?source=see_link\">",
"       Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?38/14/39138?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16275 Version 4.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-6167F63EEA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_14_39138=[""].join("\n");
var outline_f38_14_39138=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1569228\">",
"      Can women with rheumatoid arthritis have normal pregnancies?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1569235\">",
"      What should I do before trying to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1569242\">",
"      How will my rheumatoid arthritis affect my pregnancy and my baby?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1569249\">",
"      How will my medicines affect my pregnancy or my baby?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1569256\">",
"      Will pregnancy affect my rheumatoid arthritis symptoms?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1569263\">",
"      Will I be able to breastfeed?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1569360\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/19/38194?source=related_link\">",
"      Patient information: Deciding to breastfeed (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/1/37907?source=related_link\">",
"      Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/31/16883?source=related_link\">",
"      Patient information: Rheumatoid arthritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/52/12098?source=related_link\">",
"      Patient information: Rheumatoid arthritis and pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/61/21463?source=related_link\">",
"      Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/44/24264?source=related_link\">",
"      Patient information: Rheumatoid arthritis treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_14_39139="ILS gross pathology";
var content_f38_14_39139=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gross pathology of an intralobar pulmonary sequestration (ILS)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 263px; height: 388px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A large distended systemic artery is present at one border (red arrow). A dilated, mucus filled bronchus (blue arrow) is evident adjacent to the artery. The lung parenchyma has a microcystic appearance, distinguishing it from the adjacent normal parenchyma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Claire Langston, MD and Christopher Oermann, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_14_39139=[""].join("\n");
var outline_f38_14_39139=null;
var title_f38_14_39140="Magnesium citrate: Drug information";
var content_f38_14_39140=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Magnesium citrate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/57/15252?source=see_link\">",
"    see \"Magnesium citrate: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34403?source=see_link\">",
"    see \"Magnesium citrate: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3884001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Citroma&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F190827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Citro-Mag&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F190839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Laxative, Saline;",
"     </li>",
"     <li>",
"      Magnesium Salt",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F190828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Laxative:",
"     </b>",
"     Oral: Solution: 195-300 mL given once or in divided doses",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F190835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34403?source=see_link\">",
"      see \"Magnesium citrate: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Laxative:",
"     </b>",
"     Oral: Solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 2-6 years: 60-90 mL given once or in divided doses (maximum: 90 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 6-12 years: 90-210 mL given once or in divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;12 years and Adolescents: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F190829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F190830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; however, magnesium is renally excreted. Use caution; accumulation of magnesium in renal impairment may lead to magnesium toxicity.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F190812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: 290 mg/5 mL (296 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Citroma&reg;: 290 mg/5 mL (340 mL) [contains benzoic acid, magnesium 48 mg/5 mL, sodium 0.5 mg/5 mL; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Citroma&reg;: 290 mg/5 mL (296 mL) [contains magnesium 48 mg/5 mL, potassium 13 mg/5 mL; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Citroma&reg;: 290 mg/5 mL (296 mL) [contains magnesium 48 mg/5 mL, potassium 13 mg/5 mL; lemon flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Citroma&reg;: 290 mg/5 mL (296 mL) [contains magnesium 48 mg/5 mL, sodium 7.5 mg/5 mL; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Citroma&reg;: 290 mg/5 mL (296 mL) [contains magnesium 48 mg/5 mL, sodium 7.5 mg/5 mL; lemon flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: Elemental magnesium 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F190799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F190816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     To increase palatability, chill the solution prior to administration. Administer each dose with 8 oz of water.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F190815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relieves occasional constipation",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F15125989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Evacuation of bowel prior to certain surgical and diagnostic procedures or overdose situations",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F190837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined: Gastrointestinal: Abdominal pain, diarrhea, gas formation, nausea, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F190819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Low sodium diet",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F190803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Constipation (self-medication, OTC use): Appropriate use: For occasional use only; serious side effects may occur with prolonged use. For use only under the supervision of a physician in patients with kidney dysfunction, sodium- or magnesium-restricted diets, abdominal pain/nausea/vomiting, or with a sudden change in bowel habits which has persisted for &gt;2 weeks. If rectal bleeding develops or a bowel movement does not occur after use, discontinue use and consult a healthcare provider.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuromuscular disease: Use with extreme caution in patients with myasthenia gravis or other neuromuscular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; accumulation of magnesium may lead to magnesium intoxication.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6221401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfacalcidol: May increase the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aluminum Hydroxide: Citric Acid Derivatives may increase the absorption of Aluminum Hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Magnesium Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral magnesium salts within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcitriol: May increase the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: May enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: Laxatives may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. More specifically, concomitant use of calcium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis.  Management: Avoid concomitant use of calcium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives or sorbitol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Magnesium Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Magnesium Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., magnesium-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Magnesium Salts may decrease the serum concentration of Mycophenolate.  Management: Separate doses of mycophenolate and oral magnesium salts. Monitor for reduced effects of mycophenolate if taken concomitant with oral magnesium salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Magnesium Salts may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Magnesium Salts may decrease the serum concentration of Phosphate Supplements.  Management: Administer oral phosphate supplements at least 1 hour before, or 2 hours after, oral magnesium salt administration.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Magnesium Salts may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Polystyrene Sulfonate: Laxatives may enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. More specifically, concomitant use of sodium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis.  Management: Avoid concomitant use of sodium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives or sorbitol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Magnesium Salts may decrease the absorption of Tetracycline Derivatives. Only applicable to oral preparations of each agent.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Magnesium Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14207678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Magnesium crosses the placenta; serum concentrations in the fetus are similar to those in the mother (Osada, 2002; Idama, 1998). The American Gastroenterological Association considers the use of magnesium citrate as a laxative to be low risk in pregnancy, but long term use should be avoided (not the preferred treatment of chronic constipation) (Mahadevan, 2006).",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14207679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Magnesium is found in breast milk; concentrations remain constant during the first year of lactation and are not influenced by dietary intake under normal conditions (IOM, 1997).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9732700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain potassium and/or sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Citrate of Magnesia Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.745 g/30 mL (300 mL): $1.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Citroma Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.745 g/30 mL (296 mL): $1.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Magnesium Citrate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $7.52",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F190813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum magnesium: 1.5-2.5 mg/dL; slightly different ranges are reported by different laboratories",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F190822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Argocytromag (PL);",
"     </li>",
"     <li>",
"      Citramag (GB);",
"     </li>",
"     <li>",
"      Magnesol (PL);",
"     </li>",
"     <li>",
"      Usanimals (MX)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F190802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Promotes bowel evacuation by causing osmotic retention of fluid which distends the colon with increased peristaltic activity",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F190818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of laxative effect: Oral solution: 0.5-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (IOM, 1997)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chernow B, Smith J, Rainey TG, et al, &ldquo;Hypomagnesemia: Implications for the Critical Care Specialist,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1982, 10(3):193-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/14/39140/abstract-text/7037303/pubmed\" id=\"7037303\" target=\"_blank\">",
"        7037303",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gams JG, &ldquo;Clinical Significance of Magnesium: A Review,&rdquo;",
"      <i>",
"       Drug Intell Clin Pharm",
"      </i>",
"      , 1987, 21(3):240-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/14/39140/abstract-text/3552543/pubmed\" id=\"3552543\" target=\"_blank\">",
"        3552543",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Idama TO and Lindow SW, \"Magnesium Sulphate: A Review of Clinical Pharmacology Applied to Obstetrics,\"",
"      <i>",
"       Br J Obstet Gynaecol",
"      </i>",
"      , 1998, 105(3):260-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/14/39140/abstract-text/9532984/pubmed\" id=\"9532984\" target=\"_blank\">",
"        9532984",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Institute of Medicine (IOM),",
"      <i>",
"       Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride",
"      </i>",
"      , Washington, DC: The National Academies Press, 1997.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mahadevan U and Kane S, \"American Gastroenterological Association Institute Medical Position Statement on the Use of Gastrointestinal Medications in Pregnancy,\"",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2006, 131(1):278-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/14/39140/abstract-text/16831610/pubmed\" id=\"16831610\" target=\"_blank\">",
"        16831610",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Osada H, Watanabe Y, Nishimura Y, et al, \"Profile of Trace Element Concentrations in the Feto-Placental Unit in Relation to Fetal Growth,\"",
"      <i>",
"       Acta Obstet Gynecol Scand",
"      </i>",
"      , 2002, 81(10):931-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/14/39140/abstract-text/12366483/pubmed\" id=\"12366483\" target=\"_blank\">",
"        12366483",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vuignier BI, Oderda GM, Gorman RL, et al, &ldquo;Effects of Magnesium Citrate and Clidinium Bromide on the Excretion of Activated Charcoal in Normal Subjects,&rdquo;",
"      <i>",
"       DICP",
"      </i>",
"      , 1989, 23(1):26-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/14/39140/abstract-text/2718479/pubmed\" id=\"2718479\" target=\"_blank\">",
"        2718479",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9580 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-F7325097AE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_14_39140=[""].join("\n");
var outline_f38_14_39140=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3884001\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190827\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190839\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190828\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190835\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190829\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190830\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190812\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190799\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190816\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190815\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15125989\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190837\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190819\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190803\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299631\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6221401\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14207678\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14207679\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9732700\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323350\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190813\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190822\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190802\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190818\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9580\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9580|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/57/15252?source=related_link\">",
"      Magnesium citrate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/38/34403?source=related_link\">",
"      Magnesium citrate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_14_39141="Gadobutrol: Drug information";
var content_f38_14_39141=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Gadobutrol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?30/57/31635?source=see_link\">",
"    see \"Gadobutrol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F13478027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F12765549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Gadavist&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5174308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Gadovist&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F5174312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Diagnostic Agent;",
"     </li>",
"     <li>",
"      Gadolinium-Containing Contrast Agent;",
"     </li>",
"     <li>",
"      Radiological/Contrast Media (Nonionic, High Osmolality);",
"     </li>",
"     <li>",
"      Radiological/Contrast Media, Paramagnetic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F5175443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Diagnostic imaging:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     MRI: 0.1 mmol/kg (0.1 mL/kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     General CNS imaging: 0.1 mmol/kg (0.1 mL/kg); if needed, a second dose of 0.1-0.2 mmol/kg (0.1-0.2 mL/kg) may be repeated once within 30 minutes of the first dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Exclusion of metastatic or recurrent tumors: 0. 3 mmol/kg (0.3 mL/kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Perfusion studies: 0. 3 mmol/kg (0.3 mL/kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     CE-MRA:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Imaging of a single field of view (FOV):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Patient weight &lt;75 kg: 7.5 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Patient weight &ge;75 kg: 10 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Imaging &gt;1 FOV:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Patient weight &lt;75 kg: 15 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Patient weight &ge;75 kg: 20 mL",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F13362717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Diagnostic imaging:",
"     </b>",
"     I.V.: Children 2-17 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     MRI: 0.1 mmol/kg (0.1 mL/kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     MRI/CE-MRA: 0.1 mmol/kg (0.1 mL/kg)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F5175444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F5175445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose adjustment is not recommended; however, use with caution. Risk for NSF development increases as renal function decreases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Hemodialysis: If administered to patients already receiving hemodialysis, consider prompt hemodialysis following exposure. Data has shown hemodialysis enhances gadolinium elimination with average gadolinium excretory rates of 78%, 96%, and 99% in the first, second, and third hemodialysis sessions, respectively (Okada, 2001).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Peritoneal dialysis: Likely to be less efficient at clearing gadolinium (Joffe, 1998; Kuo, 2007).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F5175446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; however, based on exclusive renal excretion of gadobutrol, dose adjustment in hepatic impairment is likely unnecessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F12765550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gadavist&trade;: 1 mmol/mL (7.5 mL, 10 mL, 15 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F5174310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5175447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer as intravenous bolus injection only (rate of ~2 mL/second). Extravascular administration may result in tissue damage and pain. Flush line with NS to ensure complete injection of medium.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F5174314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     U.S. labeling: Contrast medium for magnetic resonance imaging (MRI) for the enhancement and detection of disruptions in the blood brain barrier and/or CNS vasculature",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Canadian labeling: Contrast medium for magnetic resonance imaging (MRI) of CNS lesions (brain, spine, and associated tissues); perfusion studies to diagnose stroke, or to detect focal cerebral ischemia or tumor perfusion; contrast-enhanced magnetic resonance angiography (CE-MRA)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5174304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Gadavist&trade; may be confused with Magnevist&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Gadovist [Canada and multiple international markets] may be confused with Vasovist brand name for gadofosveset [Hungary, Turkey]",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F5174710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Allergic reaction, anaphylactoid reaction, cardiac arrest, dysgeusia, dyspnea, erythema, hot flashes, injection site pain, injection site reaction, loss of consciousness, nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy (NSF/NFD), orthostatic hypotension, palpitation, paresthesia, parosmia, pruritus, rash, seizure, tachycardia, urticaria, vertigo, vision abnormal, vomiting, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F5174319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the manufacturer&rsquo;s U.S. product labeling.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Previous life-threatening hypersensitivity reaction to gadobutrol",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5174320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Hypersensitivity, including anaphylactic reactions (rare), may occur; appropriate equipment (eg, ventilator) and emergency medications (eg, epinephrine) should be available during use. Reactions typically occur within 30 minutes of administration; however, delayed reactions may also occur (hours to days following administration of contrast media). Patients with a history of allergic reactions and/or bronchial asthma may be at an increased risk for developing hypersensitivity reactions; use caution in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nephrogenic systemic fibrosis (NSF):",
"     <b>",
"      [U.S. Boxed Warning]: Gadolinium-based contrast agent (GBCA) exposure may increase the risk for NSF in patients with renal impairment; avoid use unless GBCA-enhanced imaging is essential for diagnostic purposes. The risk is highest in patients with acute kidney injury or chronic, severe renal disease (GFR &lt;30 mL/minute/1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      ).",
"     </b>",
"     The risk appears lower in patients with moderate, chronic renal disease (GFR 30-59 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ), and little, if any, in patients with mild, chronic renal disease (GFR 60-89 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ). An association between NSF and liver transplant patients has been described in combination with advanced renal impairment  (Baron, 2003; Maloo, 2006; Perez-Rodriguez, 2009).  A subsequent study (Chow, 2011), however, refutes this association. NSF, a potentially fatal disease, affects the skin, muscle, and internal organs and can occur days to months after exposure. All patients should be screened for renal dysfunction prior to administration; estimate GFR in patients at risk for chronic renal disease (diabetes, hypertension, age &gt;60 years). In patients at risk of NSF, do not exceed the recommended dosage and allow sufficient time (ie, several half-lives) for elimination prior to readministration (avoidance of readministration preferred). In patients receiving hemodialysis, consider prompt initiation of hemodialysis following administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients with a history of seizure disorder; may lower seizure threshold. Injectable anticonvulsant agents should be readily available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sickle cell anemia: In",
"     <i>",
"      in vitro",
"     </i>",
"     studies, deoxygenated sickle erythrocytes align perpendicular to a magnetic field; the enhancement of magnetic moment by contrast agents may potentiate this alignment possibly resulting in vaso-occlusive complications",
"     <i>",
"      in vivo",
"     </i>",
"     . Sickling, possibly leading to vaso-occlusion, has been reported (rare, case reports) with use of hyperosmolar contrast solutions; believed to result from red blood cell dehydration. Use in patients with sickle cell anemia or other hemoglobinopathies has not been studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extravasation: Avoid extravasation; local tissue damage/reactions may occur. Ensure catheter patency prior to administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Scan interpretation: Use caution when interpreting a contrast-enhanced scan in the absence of a companion unenhanced noncontrast MRI.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F5174716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Contrast Media (Non-ionic) may enhance the potential for allergic or hypersensitivity reactions to Aldesleukin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F13362671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5174315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal reproduction studies. Gadolinium-based contrast agents cross the placenta in humans. Use of gadolinium-based agents should not routinely be administered to pregnant women (Expert Panel on MR Safety, 2013; Wang, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F5174317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5174318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Gadolinium-based contrast agents are excreted in breast milk in small amounts and oral absorption is poor; information specific to gadobutrol is not available. Although some sources state breast-feeding may be continued, some manufacturers recommend discontinuing breast-feeding for 24 hours following administration and discarding milk for that period. Contrast media may temporarily alter the taste of breast milk (Tremblay, 2012; Webb, 2005)",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16324143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Gadavist Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mmol/mL (10 mL): $106.80",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5175450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Renal function; signs of hypersensitivity (during and for several hours after procedure); short- and long-term monitoring of signs and symptoms of NSF/NFD (eg, burning, itching, swelling, hardening and/or tightening of skin, joint stiffness, deep hip or rib bone pain, muscle weakness, limited range of motion, and/or yellowed/raised spots on whites of eye)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5175456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Gadovist (AT, AU, BE, BG, CH, CL, CZ, DE, DK, EE, FI, FR, GR, HN, IE, IT, KP, MY, NL, NO, NZ, PT, RU, SE, SG, TR, ZA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F5175439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Gadobutrol is a gadolinium-containing, nonionic paramagnetic agent. Exposure to an external magnetic field induces a large local magnetic field in exposed tissues. This local magnetism disrupts water protons in the vicinity, resulting in a change in proton density and spin characteristics, which can be detected by the imaging device.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F5174740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Rapid into extracellular space",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Normal renal function: ~1.5-2 hours; severe renal dysfunction (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: ~18-20 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (&gt;90% as unchanged drug); feces (negligible)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Balzer J, Loewe C, Davis K, et al, &ldquo;Safety of Contrast-Enhanced MR Angiography Employing Gadobutrol 1.0 M as Contrast Material,&rdquo;",
"      <i>",
"       Eur Radiol",
"      </i>",
"      , 2003, 13(9):2067-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/14/39141/abstract-text/12928957/pubmed\" id=\"12928957\" target=\"_blank\">",
"        12928957",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baron PW, Cantos K, Hillebrand DJ, et al, &ldquo;Nephrogenic Fibrosing Dermopathy After Liver Transplantation Successfully Treated With Plasmapheresis,&rdquo;",
"      <i>",
"       Am J Dermatopathol",
"      </i>",
"      , 2003, 25(3):204-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/14/39141/abstract-text/12775982/pubmed\" id=\"12775982\" target=\"_blank\">",
"        12775982",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chow DS, Bahrami S, Raman SS, et al, &ldquo;Risk of Nephrogenic  Systemic Fibrosis in Liver Transplantation Patients,&rdquo;",
"      <i>",
"       AJR Am J Roentgenol",
"      </i>",
"      , 2011, 197(3):658-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/14/39141/abstract-text/21862808/pubmed\" id=\"21862808\" target=\"_blank\">",
"        21862808",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Expert Panel on MR Safety, \"ACR Guidance Document on MR Safe Practices: 2013,\"",
"      <i>",
"       J Magn Reson Imaging",
"      </i>",
"      , 2013,  37(3):501-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/14/39141/abstract-text/23345200/pubmed\" id=\"23345200\" target=\"_blank\">",
"        23345200",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goyen M, Lauenstein TC, Herborn CU, et al, &ldquo;0.5 M Gd Chelate (Magnevist&reg;) Versus 1.0 M Gd Chelate (Gadovist&trade;): Dose-Independent Effect on Image Quality of Pelvic Three-Dimensional MR-Angiography,&rdquo;",
"      <i>",
"       J  Magn Res Imag",
"      </i>",
"      , 2001, 14(5):602-07.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/14/39141/abstract-text/11747013/pubmed\" id=\"11747013\" target=\"_blank\">",
"        11747013",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grobner T, &ldquo;Gadolinium - A Specific Trigger for the Development of Nephrogenic Fibrosing Dermopathy and Nephrogenic Systemic Fibrosis,&rdquo;",
"      <i>",
"       Nephrol Dial Transplant",
"      </i>",
"      , 2006, 21(4):1104-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/14/39141/abstract-text/16431890/pubmed\" id=\"16431890\" target=\"_blank\">",
"        16431890",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Joffe P, Thomsen HS, and Meusel M, \"Pharmacokinetics of Gadodiamide Injection in Patients With Severe Renal Insufficiency and Patients Undergoing Hemodialysis or Continuous Ambulatory Peritoneal Dialysis,\"",
"      <i>",
"       Acad Radiol",
"      </i>",
"      , 1998, 5(7):491-502.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/14/39141/abstract-text/9653466/pubmed\" id=\"9653466\" target=\"_blank\">",
"        9653466",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kuo PH, Kanal E, Abu-Alfa AK, et al, \"Gadolinium-Based MR Contrast Agents and Nephrogenic Systemic Fibrosis,\"",
"      <i>",
"       Radiology",
"      </i>",
"      , 2007, 242(3):647-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/14/39141/abstract-text/17213364/pubmed\" id=\"17213364\" target=\"_blank\">",
"        17213364",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maloo M, Abt P, Kashyap R, et al, &ldquo;Nephrogenic Systemic Fibrosis Among Liver Transplant Recipients: A Single Institution Experience and Topic Update,&rdquo;",
"      <i>",
"       Am J Transplant",
"      </i>",
"      , 2006, 6(9):2212-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/14/39141/abstract-text/16780542/pubmed\" id=\"16780542\" target=\"_blank\">",
"        16780542",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Okada S, Katagiri K, Kumazaki T, et al, &ldquo;Safety of Gadolinium Contrast Agent in Hemodialysis Patients,&rdquo;",
"      <i>",
"       Acta Radiol",
"      </i>",
"      , 2001, 42(3):339-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/14/39141/abstract-text/11350296/pubmed\" id=\"11350296\" target=\"_blank\">",
"        11350296",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perez-Rodriguez J, Lai S, Ehst BD, et al, &ldquo;Nephrogenic Systemic Fibrosis: Incidence, Associations, and Effect of Risk Factor Assessment -- Report of 33 Cases,&rdquo;",
"      <i>",
"       Radiology",
"      </i>",
"      , 2009, 250(2):371-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/14/39141/abstract-text/19188312/pubmed\" id=\"19188312\" target=\"_blank\">",
"        19188312",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tomach B, Bremer C, Reimer P, et al, &ldquo;Pharmacokinetics of 1M Gadobutrol in Patients With Chronic Renal Failure,&rdquo;",
"      <i>",
"       Invest Radiol",
"      </i>",
"      , 2000, 35(1):35-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/14/39141/abstract-text/10639034/pubmed\" id=\"10639034\" target=\"_blank\">",
"        10639034",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tremblay E, Th&eacute;rasse E, Thomassin-Naggara I, et al, \"Quality Initiatives: Guidelines for Use of Medical Imaging During Pregnancy and Lactation,\"",
"      <i>",
"       Radiographics",
"      </i>",
"      ,  2012, 32(3):897-911.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/14/39141/abstract-text/22403117/pubmed\" id=\"22403117\" target=\"_blank\">",
"        22403117",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wang PI, Chong ST, Kielar AZ, et al, \"Imaging of Pregnant and Lactating Patients: Part 1, Evidence-Based Review and Recommendations,\"",
"      <i>",
"       AJR Am J Roentgenol",
"      </i>",
"      ,  2012, 198(4):778-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/14/39141/abstract-text/22451541/pubmed\" id=\"22451541\" target=\"_blank\">",
"        22451541",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Webb JA, Thomsen HS, and Morcos SK,  \"The Use of Iodinated and Gadolinium Contrast Media During Pregnancy and Lactation,\"",
"      <i>",
"       Eur Radiol",
"      </i>",
"      , 2005 15(6):1234-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/14/39141/abstract-text/15609057/pubmed\" id=\"15609057\" target=\"_blank\">",
"        15609057",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8632 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-E8883B2495-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_14_39141=[""].join("\n");
var outline_f38_14_39141=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13478027\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12765549\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5174308\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5174312\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5175443\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13362717\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5175444\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5175445\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5175446\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12765550\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5174310\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5175447\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5174314\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5174304\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5174710\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5174319\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5174320\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299376\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5174716\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13362671\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5174315\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5174317\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5174318\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16324143\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5175450\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5175456\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5175439\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5174740\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8632\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8632|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?30/57/31635?source=related_link\">",
"      Gadobutrol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_14_39142="Osteitis pubis";
var content_f38_14_39142=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Osteitis pubis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/14/39142/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/14/39142/contributors\">",
"     Justin A Classie, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/14/39142/contributors\">",
"     Thomas M Best, MD, PhD, FACSM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/14/39142/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/14/39142/contributors\">",
"     Robert H Fletcher, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/14/39142/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/14/39142/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/14/39142/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H13498082\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteitis pubis is defined as an idiopathic, inflammatory disease of the pubic symphysis and surrounding structures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39142/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Osteitis pubis most commonly occurs among athletes but can also occur among non-athletes as a result of any pelvic stress (eg, trauma, pelvic surgery, pregnancy).",
"   </p>",
"   <p>",
"    This topic will discuss the epidemiology, diagnosis, and management of osteitis pubis. Other sports-related injuries and pelvic osteomyelitis are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/57/20373?source=see_link\">",
"     \"Sports-related groin pain or 'sports hernia'\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/37/31321?source=see_link\">",
"     \"Classification, clinical features and diagnosis of inguinal and femoral hernias in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/20/23876?source=see_link\">",
"     \"Pelvic osteomyelitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13498314\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteitis pubis is an inflammatory process involving the pubic symphysis and its surrounding attachments, including cartilage, ligaments, muscles, and the pubic rami (",
"    <a class=\"graphic graphic_figure graphicRef57811 \" href=\"mobipreview.htm?5/56/6026\">",
"     figure 1",
"    </a>",
"    ). The pubic symphysis is mainly composed of fibrocartilage and is a nonsynovial, nonvascular joint. The pubic symphysis is reliant on four ligaments to maintain its supportive integrity. Most of the strength and support arise from the superior and inferior ligaments, whereas the anterior and posterior ligaments are of less supportive importance. The pelvic floor musculature, composed of the levator ani and coccygeus, insert posteriorly at the pubic symphysis. The pectineus, rectus abdominis, and oblique externus muscles, as well as the inguinal ligament, insert near the superior portion of the pubic symphysis. The pubic rami give rise to several muscle origins: adductor magnus, adductor longus, adductor brevis, and gracilis. These muscles make up the adductors of the hip [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39142/abstract/3\">",
"     3",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13498321\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of osteitis pubis among the general population of athletes ranges from 0.5 to 6.2 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39142/abstract/1,4,5\">",
"     1,4,5",
"    </a>",
"    ]. Although many different sports may be associated with osteitis pubis, sports with a higher risk include soccer, football, ice hockey, and rugby [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39142/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many factors are known to play a role in developing osteitis pubis. Repetitive movements within the pelvis, such as those associated with athletic activity, predispose to osteitis pubis. The following conditions are also associated with osteitis pubis: rheumatologic diseases (eg, osteoarthritis, reactive arthritis, spondyloarthropathies), pregnancy, pelvic trauma, and pelvic surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39142/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13498328\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the etiology of osteitis pubis is unknown, repetitive trauma alone or in conjunction with opposing shearing forces across the pubic symphysis is likely the main contributing factor in many athletes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39142/abstract/9-13\">",
"     9-13",
"    </a>",
"    ]. This may be due to different types of movements, including rapid",
"    <span class=\"nowrap\">",
"     acceleration/deceleration,",
"    </span>",
"    kicking, and changes in direction. Overuse of the adductor muscles and imbalances between abdominal wall and hip adductor strength may be other contributing factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39142/abstract/10\">",
"     10",
"    </a>",
"    ]. The underlying cause of osteitis pubis may be a combination of contributing factors, including microtrauma",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    microstrains at the origins of the adductor muscles, avascular necrosis of the pubic symphysis, osteochondritis dissecans at the symphysis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fatigue fracture (fracture resulting from excessive activity rather than a specific injury).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H795410979\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of a patient with osteitis pubis can vary but generally includes the gradual onset of pelvic pain in the absence of systemic symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39142/abstract/1,14\">",
"     1,14",
"    </a>",
"    ]. Pain may be localized to the lower abdomen, hip, thigh, testicle, or perineum. The pain may be exacerbated by playing a particular sport or by a certain position or activity (eg, moving from sitting to standing). The pain can be midline, unilateral, or bilateral. The pain may have an acute onset, particularly after an injury. However, it is often more insidious in nature. Pain may be accompanied by a limp and a wide-based gait (similar to other causes of pelvic or hip pain). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/36/22088?source=see_link&amp;anchor=H20#H20\">",
"     \"Evaluation of the adult with hip pain\", section on 'Gait'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H964209206\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other causes of groin pain that can present similarly to osteitis pubis include osteomyelitis, musculotendinous strain, hernia, stress fracture, intra-articular hip disease, genitourinary disease, and referred low back pain. Osteomyelitis of the pubic symphysis is one of the diseases most commonly confused with osteitis pubis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39142/abstract/2,15\">",
"     2,15",
"    </a>",
"    ]. However, there are some characteristics that differentiate the two entities. As the etiology of osteomyelitis is infectious, osteomyelitis is typically sudden in onset, more likely to be accompanied by fever, and may lead to more severe, escalating pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39142/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/20/23876?source=see_link&amp;anchor=H539708295#H539708295\">",
"     \"Pelvic osteomyelitis\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/57/20373?source=see_link\">",
"     \"Sports-related groin pain or 'sports hernia'\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/36/22088?source=see_link\">",
"     \"Evaluation of the adult with hip pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/37/31321?source=see_link\">",
"     \"Classification, clinical features and diagnosis of inguinal and femoral hernias in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1226587490\">",
"    <span class=\"h2\">",
"     Long-term sequelae",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few long-term sequelae associated with osteitis pubis. Sustained injury to the pubic symphysis and adductor muscles (specifically at the muscle-tendon junction) is a known complication which can lead to chronic pain and disability. Most cases of osteitis pubis resolve with rest. Osteitis pubis does not lead to significant bone deformity, unlike osteomyelitis that can result in severe bone erosion and necrosis, along with surrounding soft tissue destruction. Thus, it is important to consider osteomyelitis in the differential diagnosis along with osteitis pubis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13498335\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of osteitis pubis is often determined by history and physical examination alone. Gradual onset of pelvic pain, along with pubic symphysis tenderness or resisted adductor testing, is characteristic of osteitis pubis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39142/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Conversely, osteomyelitis is sudden in onset and usually associated with fever [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39142/abstract/6\">",
"     6",
"    </a>",
"    ]. If infection is suspected, a complete blood count (CBC) with differential, erythrocyte sedimentation rate (ESR), urinalysis, and blood cultures should be performed. Other laboratory testing, diagnostic imaging, and joint aspiration are adjunctive tests.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H795412105\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gradual onset of pain with history of overuse, new training method, or new activity is indicative of osteitis pubis. In addition to lower abdominal pain, the patient may also complain of radiation of pain into the groin, medial thigh, or abdomen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39142/abstract/16\">",
"     16",
"    </a>",
"    ]. It is crucial to ask the patient about sports and exercise activities, as well as when the pain is most prominent. Specific athletic activities that commonly aggravate this condition include sprinting, kicking, twisting, and cutting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H795411145\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Characteristic physical examination findings include tenderness to palpation of the pubic symphysis and pain with resisted strength testing of the adductor and lower abdominal muscle groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39142/abstract/5\">",
"     5",
"    </a>",
"    ]. To assess the adductor and lower abdominal muscles, the patient should be placed supine on the examining table with hips and knees flexed 90 degrees (",
"    <a class=\"graphic graphic_picture graphicRef75016 \" href=\"mobipreview.htm?35/60/36802\">",
"     picture 1",
"    </a>",
"    ). The athlete then performs an isometric adductor muscle contraction against the examiner&rsquo;s fist. A painful isometric muscle contraction is considered a positive test.",
"   </p>",
"   <p>",
"    Thorough abdominal, genitourinary, and musculoskeletal examination is important in assessing for other causes of pain. These causes include but are not limited to hernias, gastrointestinal disease (eg, diverticulitis), and genitourinary tract disease (eg, prostatitis, cystitis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H795411110\">",
"    <span class=\"h2\">",
"     Diagnostic imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging studies in the diagnostic workup of osteitis pubis may include plain radiographs, MRI, ultrasound, bone scan,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CT scan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39142/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Plain radiographs are often obtained when the etiology of pain is unclear or if symptoms persist despite treatment. If plain radiograph is performed, an antero-posterior pelvic film should be obtained. Abnormal findings on plain radiograph in patients with osteitis pubis are often not present until the patient has experienced several weeks to months of symptoms. These findings may include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39142/abstract/17\">",
"     17",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68903 \" href=\"mobipreview.htm?1/5/1106\">",
"     image 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Widening of the pubic symphysis",
"     </li>",
"     <li>",
"      Bone resorption or remodelling at the pubic symphysis",
"     </li>",
"     <li>",
"      Osteopenia (generalized loss of bone density) at the pubic rami (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef77597 \" href=\"mobipreview.htm?29/48/30464\">",
"       image 2",
"      </a>",
"      ) &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Negative radiographs do not rule out a diagnosis of osteitis pubis.",
"   </p>",
"   <p>",
"    If pelvic instability is suspected (eg, difficulty walking, waddling gait, pain with one legged stance, clicking sensation of pelvic joints), flamingo views should be obtained which can reveal vertical instability (&gt;2 mm of vertical displacement). Flamingo views are anterior stress views of the pubic symphysis where the patient performs a single leg stance, one side at a time (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55643 \" href=\"mobipreview.htm?6/1/6162\">",
"     image 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    If the diagnosis is still in question after history, physical examination, and plain radiograph, further imaging may be required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39142/abstract/1,18\">",
"     1,18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MRI in acute cases may demonstrate fluid in the pubic symphysis joint, subchondral bone marrow edema, or periarticular edema of the symphysis, along with possible visualization of small tears of the adductor muscles. Subchondral sclerosis may be seen with chronic osteitis pubis (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef80072 \" href=\"mobipreview.htm?12/3/12339\">",
"       image 4",
"      </a>",
"      ). MRI is used with increasing frequency due to its high sensitivity and availability. MRI also helps to distinguish between osteitis pubis and pelvic osteomyelitis, in which cortical destruction, marrow abnormalities, and soft tissue inflammation are present. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/20/23876?source=see_link&amp;anchor=H539708311#H539708311\">",
"       \"Pelvic osteomyelitis\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ultrasound may be used to help rule out hernia as well as visualize widening at the pubic symphysis joint. This modality is limited by technician expertise. However, ultrasound does have some role for diagnosis due to its lost cost and wide availability.",
"     </li>",
"     <li>",
"      Bone scan should be reserved for patients in whom MRI",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ultrasound are equivocal. Bone scan should not be a first-line imaging technique, since it requires injection of radioactive tracer. Bone scan allows for greater bony detail in difficult cases and may pick up subtle stress reactions compared with other imaging studies. In patients with osteitis pubis, a large area of bone uptake may be evident near the pubic symphysis.",
"     </li>",
"     <li>",
"      CT scan can evaluate the integrity of the pubic symphysis and associated skeletal structures, but is rarely helpful in making a definitive diagnosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H795411163\">",
"    <span class=\"h2\">",
"     Other studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood testing for inflammatory markers (ESR and CBC with differential), urinalysis, and blood cultures can be obtained to assess for an infectious process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39142/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Blood testing should be performed for patients presenting with fever and at high risk for infection (eg, diabetes, other immunocompromised state, recent surgical intervention). Given its invasive nature, joint aspiration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bone biopsy should only be performed if the suspicion for osteomyelitis of the pubic symphysis if high. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/34/4649?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of osteomyelitis in adults\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13497522\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with most sports-related injuries, active management of osteitis pubis is a vital step towards full recovery and return to activities of daily life, including sports. There have been several studies that have examined different treatment options for athletes with groin pain, including osteitis pubis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39142/abstract/7,13,18,21\">",
"     7,13,18,21",
"    </a>",
"    ]. However, there are no randomized trials, and most studies are comprised of case reports and case series, usually in male athletes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39142/abstract/21\">",
"     21",
"    </a>",
"    ]. The approach to management of osteitis pubis should be stepwise, going from least invasive to most invasive if previous therapy fails. In the absence of clinical trial data and large cohort studies assessing treatment options, we suggest initial management with conservative measures (rest, ice, pain medication, physical rehabilitation), followed by injection therapy, and surgery as a last resort.",
"   </p>",
"   <p>",
"    In patients who present with osteitis pubis due to surgery or trauma and in those with severe symptoms, it may be appropriate to start with more invasive therapy, including injections and surgical treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H795411270\">",
"    <span class=\"h2\">",
"     Medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical management of osteitis pubis includes rest, ice, nonsteroidal anti-inflammatory drugs (NSAIDs), physical therapy, glucocorticoid injections directly into the pubic symphysis, and oral glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39142/abstract/1,22-24\">",
"     1,22-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After the diagnosis of osteitis pubis is established, relative rest is essential. Relative rest refers to refraining from activities that induce any type of discomfort. This usually includes avoiding the sport that immediately preceded pain symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    offending activities that exacerbate the condition. Given low cost, wide availability, and ease of administration, we suggest the use of relative rest, application of ice, NSAIDs, and physical rehabilitation as first-line treatment for both acute and chronic cases of osteitis pubis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39142/abstract/5,21,25\">",
"     5,21,25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/36/5703?source=see_link\">",
"     \"NSAIDs: Therapeutic use and variability of response in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Physical rehabilitation includes assessment of any motor strength",
"    <span class=\"nowrap\">",
"     deficits/mechanical",
"    </span>",
"    disturbances (eg, problems with flexibility and gait), exercise therapy, and the use of local modalities (eg, massage therapy, ultrasound). The main goal of physical rehabilitation is to strengthen and stabilize the pelvis and pubic symphysis. Core strengthening, adductor stretching, and balance control are key components of the rehabilitation program (eg, abdominal exercises with use of the exercise ball, bridging exercises, and side to side lunges for adductor stretch). Physical rehabilitation, usually for six to eight weeks, has been found in multiple observational studies to be effective in reducing pain among patients with osteitis pubis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39142/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the patient remains symptomatic after relative rest, ice, NSAIDs, and physical rehabilitation, a local glucocorticoid injection or an oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    taper is usually the next course of action. Glucocorticoid injection at the point of maximal tenderness is a technique that is often effective without significant adverse effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39142/abstract/7,16,22\">",
"     7,16,22",
"    </a>",
"    ]. Injections may involve different glucocorticoid preparations (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    ) and different adjunctive agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    ) in varying concentrations. We use 1 mL of dexamethasone",
"    <span class=\"nowrap\">",
"     (4mg/mL)",
"    </span>",
"    mixed with 1 mL of marcaine 0.5% and 1 mL of lidocaine 1%. We give up to three injections as needed at two to three week intervals (this is rarely needed). Local glucocorticoid injection is sometimes used at an initial visit in severe, painful cases. Oral prednisone can also be given in severe or refractory cases (prednisone 60 mg for 5 days or a prednisone taper of 60mg x 4 days, then 40 mg x 4 days, then 20 mg x 4 days OR 60mg x 1d, then 50mg x 1d, then 40mg x 1d, then 30mg x 1d, then 20mg x 1d, then 10mg x 2d) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39142/abstract/26\">",
"     26",
"    </a>",
"    ]. There is no evidence to support one glucocorticoid regimen over another. In our practice, we administer glucocorticoid injections rather than oral glucocorticoids, if conservative measures fail. Oral glucocorticoids can be used if patients prefer not to have injection therapy.",
"   </p>",
"   <p>",
"    Complete resolution of osteitis pubis using conservative measures can take as long as two to three months. This long time course for improvement should be discussed with patients. Continued relative rest from offending activities should be employed if the patient remains symptomatic despite initial treatment.",
"   </p>",
"   <p>",
"    Other less commonly used medical therapies include cryotherapy, laser, ultrasound, and electrical stimulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39142/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H795411285\">",
"    <span class=\"h2\">",
"     Surgical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical management is reserved for osteitis pubis refractory to medical treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39142/abstract/23,27,28\">",
"     23,27,28",
"    </a>",
"    ]. Small case series have found that surgical treatment can be effective in most patients who fail medical therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39142/abstract/29\">",
"     29",
"    </a>",
"    ]. There are several surgical procedures used for osteitis pubis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39142/abstract/9,23,27,28,30\">",
"     9,23,27,28,30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Curettage &ndash; debridement of degenerative areas in and around pubic symphysis, involving limited surgical exposure",
"     </li>",
"     <li>",
"      Wedge resection &ndash; trapezoidal portion of the symphysis is resected",
"     </li>",
"     <li>",
"      Wide resection &ndash; similar to a wedge resection but with larger margins involved",
"     </li>",
"     <li>",
"      Arthrodesis &ndash; fusion of the pubic symphysis (with or without bone grafting)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Operative treatment is not always curative, as some patients may suffer recalcitrant pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39142/abstract/31\">",
"     31",
"    </a>",
"    ]. Subsequent pelvic instability may also occur, particularly after wedge or wide resection.",
"   </p>",
"   <p>",
"    One systematic review found that most athletes respond well to curettage alone without resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39142/abstract/27\">",
"     27",
"    </a>",
"    ]. As with medical treatment, full recovery from surgery can be quite lengthy. Whereas recovery from curettage can take three to six months, recovery from resection and arthrodesis at the pubic symphysis may take up to one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39142/abstract/27,29\">",
"     27,29",
"    </a>",
"    ]. The long recovery process is one reason resection and arthrodesis should be reserved for patients who fail curettage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39142/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13498342\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Osteitis pubis is defined as an idiopathic, inflammatory disease involving the pubic symphysis and surrounding structures. (See",
"      <a class=\"local\" href=\"#H13498314\">",
"       'Anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Osteitis pubis is common among athletes but can occur in non-athletes, particularly in those with a history of rheumatologic conditions (eg, reactive arthritis, spondyloarthropathies), pregnancy, pelvic trauma, or pelvic surgery. (See",
"      <a class=\"local\" href=\"#H13498321\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical presentation of a patient with osteitis pubis can vary but generally involves the insidious onset of pelvic pain in the absence of systemic symptoms. Osteitis pubis can be confused with osteomyelitis of the pubic symphysis. Osteomyelitis is more likely to present with acute onset of severe pain and fever. (See",
"      <a class=\"local\" href=\"#H795410979\">",
"       'Clinical presentation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/20/23876?source=see_link\">",
"       \"Pelvic osteomyelitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The diagnosis of osteitis pubis is often determined by history and physical examination alone. The gradual onset of pelvic discomfort, in combination with tenderness over the pubic symphysis or pain with resisted adductor testing (",
"      <a class=\"graphic graphic_picture graphicRef75016 \" href=\"mobipreview.htm?35/60/36802\">",
"       picture 1",
"      </a>",
"      ), is sufficient for the diagnosis of osteitis pubis. Blood testing, diagnostic imaging, and biopsy are adjunctive tests that are performed when the diagnosis is uncertain after history and physical examination. (See",
"      <a class=\"local\" href=\"#H13498335\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The approach to management of osteitis pubis should be stepwise, going from least invasive to most invasive. In patients with osteitis pubis, we suggest initial treatment with conservative measures, including relative rest (refraining from activities that induce pelvic pain), ice, NSAIDs, and physical rehabilitation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If these conservative measures fail, we suggest administration of glucocorticoid injections of the pubic symphysis rather than an oral glucocorticoid taper (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H795411270\">",
"       'Medical therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical management is reserved for patients with osteitis pubis refractory to medical treatment. Curettage of the symphysis is considered to be the most effective and well-tolerated surgical treatment option. (See",
"      <a class=\"local\" href=\"#H795411285\">",
"       'Surgical therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39142/abstract/1\">",
"      Johnson R. Osteitis pubis. Curr Sports Med Rep 2003; 2:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39142/abstract/2\">",
"      Pauli S, Willemsen P, Declerck K, et al. Osteomyelitis pubis versus osteitis pubis: a case presentation and review of the literature. Br J Sports Med 2002; 36:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39142/abstract/3\">",
"      H&ouml;lmich P. Adductor-related groin pain in athletes. Sports Med Arthrosc Rev 1997; 5:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39142/abstract/4\">",
"      Batt ME, McShane JM, Dillingham MF. Osteitis pubis in collegiate football players. Med Sci Sports Exerc 1995; 27:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39142/abstract/5\">",
"      Rodriguez C, Miguel A, Lima H, Heinrichs K. Osteitis Pubis Syndrome in the Professional Soccer Athlete: A Case Report. J Athl Train 2001; 36:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39142/abstract/6\">",
"      Pham DV, Scott KG. Presentation of osteitis and osteomyelitis pubis as acute abdominal pain. Perm J 2007; 11:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39142/abstract/7\">",
"      Holt MA, Keene JS, Graf BK, Helwig DC. Treatment of osteitis pubis in athletes. Results of corticosteroid injections. Am J Sports Med 1995; 23:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39142/abstract/8\">",
"      Mandelbaum B, Mora S. Osteitis Pubis. Operative Techniques in Sports Medicine 2005; 13:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39142/abstract/9\">",
"      Radic R, Annear P. Use of pubic symphysis curettage for treatment-resistant osteitis pubis in athletes. Am J Sports Med 2008; 36:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39142/abstract/10\">",
"      Wiley JJ. Traumatic osteitis pubis: the gracilis syndrome. Am J Sports Med 1983; 11:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39142/abstract/11\">",
"      Williams JG. Limitation of hip joint movement as a factor in traumatic osteitis pubis. Br J Sports Med 1978; 12:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39142/abstract/12\">",
"      Major NM, Helms CA. Pelvic stress injuries: the relationship between osteitis pubis (symphysis pubis stress injury) and sacroiliac abnormalities in athletes. Skeletal Radiol 1997; 26:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39142/abstract/13\">",
"      Meyers WC, Foley DP, Garrett WE, et al. Management of severe lower abdominal or inguinal pain in high-performance athletes. PAIN (Performing Athletes with Abdominal or Inguinal Neuromuscular Pain Study Group). Am J Sports Med 2000; 28:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39142/abstract/14\">",
"      COVENTRY MB, MITCHELL WC. Osteitis pubis: observations based on a study of 45 patients. JAMA 1961; 178:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39142/abstract/15\">",
"      Sexton DJ, Heskestad L, Lambeth WR, et al. Postoperative pubic osteomyelitis misdiagnosed as osteitis pubis: report of four cases and review. Clin Infect Dis 1993; 17:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39142/abstract/16\">",
"      Koch RA, Jackson DW. Pubic symphysitis in runners. A report of two cases. Am J Sports Med 1981; 9:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39142/abstract/17\">",
"      Ahumada LA, Ashruf S, Espinosa-de-los-Monteros A, et al. Athletic pubalgia: definition and surgical treatment. Ann Plast Surg 2005; 55:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39142/abstract/18\">",
"      Knoeller SM, Uhl M, Herget GW. Osteitis or osteomyelitis of the pubis? A diagnostic and therapeutic challenge: report of 9 cases and review of the literature. Acta Orthop Belg 2006; 72:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39142/abstract/19\">",
"      Combs JA. Bacterial osteitis pubis in a weight lifter without invasive trauma. Med Sci Sports Exerc 1998; 30:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39142/abstract/20\">",
"      Karpos PA, Spindler KP, Pierce MA, Shull HJ Jr. Osteomyelitis of the pubic symphysis in athletes: a case report and literature review. Med Sci Sports Exerc 1995; 27:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39142/abstract/21\">",
"      Choi H, McCartney M, Best TM. Treatment of osteitis pubis and osteomyelitis of the pubic symphysis in athletes: a systematic review. Br J Sports Med 2011; 45:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39142/abstract/22\">",
"      O'Connell MJ, Powell T, McCaffrey NM, et al. Symphyseal cleft injection in the diagnosis and treatment of osteitis pubis in athletes. AJR Am J Roentgenol 2002; 179:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39142/abstract/23\">",
"      Williams PR, Thomas DP, Downes EM. Osteitis pubis and instability of the pubic symphysis. When nonoperative measures fail. Am J Sports Med 2000; 28:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39142/abstract/24\">",
"      King JB. \"Treatment of osteitis pubis in athletes: results of corticosteroid injections\". Am J Sports Med 1996; 24:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39142/abstract/25\">",
"      McMurtry CT, Avioli LV. Osteitis pubis in an athlete. Calcif Tissue Int 1986; 38:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39142/abstract/26\">",
"      Vincent C. Osteitis pubis. J Am Board Fam Pract 1993; 6:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39142/abstract/27\">",
"      Mehin R, Meek R, O'Brien P, Blachut P. Surgery for osteitis pubis. Can J Surg 2006; 49:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39142/abstract/28\">",
"      Mulhall KJ, McKenna J, Walsh A, McCormack D. Osteitis pubis in professional soccer players: a report of outcome with symphyseal curettage in cases refractory to conservative management. Clin J Sport Med 2002; 12:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39142/abstract/29\">",
"      Olerud S, Grevsten S. Chronic pubic symphysiolysis. A case report. J Bone Joint Surg Am 1974; 56:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39142/abstract/30\">",
"      Ekstrand J, Ringborg S. Surgery versus conservative treatment in soccer players with chronic groin pain: A prospective randomised study in soccer players. Eur J Sports Traumatol 2001; 23:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39142/abstract/31\">",
"      Moore RS Jr, Stover MD, Matta JM. Late posterior instability of the pelvis after resection of the symphysis pubis for the treatment of osteitis pubis. A report of two cases. J Bone Joint Surg Am 1998; 80:1043.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14593 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-562547D45F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_14_39142=[""].join("\n");
var outline_f38_14_39142=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13498342\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13498082\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13498314\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13498321\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13498328\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H795410979\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H964209206\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1226587490\">",
"      Long-term sequelae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13498335\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H795412105\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H795411145\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H795411110\">",
"      Diagnostic imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H795411163\">",
"      Other studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13497522\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H795411270\">",
"      Medical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H795411285\">",
"      Surgical therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13498342\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/14593\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/14593|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?1/5/1106\" title=\"diagnostic image 1\">",
"      Radiographic features of pelvic instability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?29/48/30464\" title=\"diagnostic image 2\">",
"      Radiograph osteitis pubis A-P view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?6/1/6162\" title=\"diagnostic image 3\">",
"      Radiograph osteitis pubis flamingo views",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?12/3/12339\" title=\"diagnostic image 4\">",
"      MRI osteitis pubis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/14593|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/56/6026\" title=\"figure 1\">",
"      Bones and ligaments of the pelvis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/14593|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/60/36802\" title=\"picture 1\">",
"      Physical examination maneuver for osteitis pubis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/37/31321?source=related_link\">",
"      Classification, clinical features and diagnosis of inguinal and femoral hernias in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/36/22088?source=related_link\">",
"      Evaluation of the adult with hip pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/36/5703?source=related_link\">",
"      NSAIDs: Therapeutic use and variability of response in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/34/4649?source=related_link\">",
"      Overview of osteomyelitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/20/23876?source=related_link\">",
"      Pelvic osteomyelitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/57/20373?source=related_link\">",
"      Sports-related groin pain or 'sports hernia'",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_14_39143="Blastocystis species";
var content_f38_14_39143=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Blastocystis species",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/14/39143/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/14/39143/contributors\">",
"     Karin Leder, MBBS, FRACP, PhD, MPH, DTMH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/14/39143/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/14/39143/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/14/39143/contributors\">",
"     Edward T Ryan, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/14/39143/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/14/39143/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/14/39143/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blastocystis species (spp; previously referred to as Blastocystis hominis) are anaerobic protozoan parasites found in the human gastrointestinal tract [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/1\">",
"     1",
"    </a>",
"    ]. The organism was initially discovered in 1911 and for many years was considered to be a harmless yeast. Studies in the 1970s demonstrated that Blastocystis spp are protozoans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Blastocystic spp are among the most common organisms to be detected in stool specimens, but there has been considerable controversy regarding whether they represent a commensal organism or a true pathogen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/0/10243?source=see_link\">",
"     \"Nonpathogenic enteric protozoa\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blastocystis spp have been observed worldwide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/4\">",
"     4",
"    </a>",
"    ]. The organism resides in the colon and cecum of children and adults. The mode of transmission is not fully understood; fecal-oral transmission has been postulated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/5\">",
"     5",
"    </a>",
"    ]. Some authors have suggested that contaminated water may also be a source of infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. Blastocystis spp have also been found in animals including pigs, monkeys, rodents, and poultry. There seems to be poor host specificity; transmission occurs from human to human and between humans and animals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/10\">",
"     10",
"    </a>",
"    ]. Blastocystis infections are more common among individuals with occupational exposure to animals, supporting the potential for zoonotic transmission.",
"   </p>",
"   <p>",
"    In some epidemiological surveys Blastocystis spp are the most frequently isolated parasite; the prevalence varies between countries and between communities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/1\">",
"     1",
"    </a>",
"    ]. In general, the estimated prevalence of Blastocystis spp is higher in developing than developed countries (30 to 50 percent and 5 to 10 percent, respectively). This may be related to poor hygiene, animal exposure, and consumption of contaminated food or water [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/1\">",
"     1",
"    </a>",
"    ]. Blastocystis spp are found in approximately 15 percent of stool specimens submitted for routine examination in the United States. In one study, 8 percent of stool samples submitted to a Canadian reference laboratory were positive for Blastocystis spp; when Blastocystis was the sole organism identified, 76 percent of subjects continued to harbor the parasite two months after initial detection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Blastocystis spp are also commonly found in the stool of returned travelers from developing countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/6,12-14\">",
"     6,12-14",
"    </a>",
"    ]. In one study of nearly 2000 stool specimens from travelers and expatriates in Nepal, the prevalence of Blastocystis spp was 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/29/29145?source=see_link\">",
"     \"Travelers' diarrhea\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39304?source=see_link\">",
"     \"Evaluation of fever in the returning traveler\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Epidemics attributed to Blastocystis spp were reported in the early 1900s, but outbreaks of infection appear to be uncommon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/5,12,16,17\">",
"     5,12,16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blastocystis spp demonstrate marked morphologic variability and measure between 5 to 40 &micro;m (",
"    <a class=\"graphic graphic_picture graphicRef73525 \" href=\"mobipreview.htm?17/34/17958\">",
"     picture 1",
"    </a>",
"    ). The organism lacks a cell wall but contains mitochondria, Golgi apparatus, and smooth and rough endoplasmic reticula typical of protozoa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/18\">",
"     18",
"    </a>",
"    ]. It reproduces asexually, usually by binary fission. It grows only under anaerobic conditions in culture, and it is highly susceptible to changes in temperature and in environmental tonicity.",
"   </p>",
"   <p>",
"    Four different forms have been described: vacuolar, granular, ameboid, and cystic (",
"    <a class=\"graphic graphic_figure graphicRef74028 \" href=\"mobipreview.htm?43/37/44631\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/4,19,20\">",
"     4,19,20",
"    </a>",
"    ]. It is unknown whether transmission occurs more frequently during a particular stage or stages. The vacuolar form has a characteristic large central vacuole-like body that compresses the cytoplasm and nuclei to the periphery of the cell [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/2\">",
"     2",
"    </a>",
"    ]. The vacuolar and cystic forms have been observed most frequently in stool samples. The ameboid stage is most frequently observed in old cultures or after antibiotic administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/2\">",
"     2",
"    </a>",
"    ]. Some have suggested that the ameboid form of the organism is more likely to be associated with clinical disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/21\">",
"     21",
"    </a>",
"    ]. The granular form is rarely seen in fresh stool.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Genetic variability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extensive genetic diversity has been described among Blastocystis isolates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/1\">",
"     1",
"    </a>",
"    ]. Nine different sub-types have been identified in humans. As a result, Blastocystis in humans is now referred to as Blastocystis spp rather than Blastocystis hominis (the previously used term for Blastocystis in humans). This genetic and species diversity may account for the disparities of previous data in assessing the morphology, life cycle, and pathogenic role of Blastocystis spp.",
"   </p>",
"   <p>",
"    Subtype 3 is the most frequently isolated genotype in epidemiological surveys and is probably the only species of human origin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/22\">",
"     22",
"    </a>",
"    ]. Subtypes 1, 2 and 4 are the next most commonly isolated subtypes in humans; subtypes ST5 to ST9 are found only rarely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/23\">",
"     23",
"    </a>",
"    ]. Subtype 1 probably originates from mammals, subtype 2 is mainly from primates and pigs, subtype 4 is from rodents, subtype 5 seems to originate from cattle and pigs, and subtypes 6 and 7 are from birds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/1\">",
"     1",
"    </a>",
"    ]. Some subtypes have a particular distribution, such as avian subtypes ST6 and ST7, which are more frequently found in Asia and the Middle East [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOGENICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been significant debate regarding whether Blastocystis spp are intestinal commensals or true pathogens. Several experimental studies including work in animal models and cell cultures have been interpreted as supporting a pathogenic role [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/17,24\">",
"     17,24",
"    </a>",
"    ]. Although some prospective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/12,13\">",
"     12,13",
"    </a>",
"    ] and retrospective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/6,25,26\">",
"     6,25,26",
"    </a>",
"    ] studies have suggested a pathogenic role for Blastocystis spp, other studies have shown no correlation between Blastocystis spp and symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/11,18,27-29\">",
"     11,18,27-29",
"    </a>",
"    ]. A number of issues contribute to the controversy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many of the reports that have suggested a pathogenic role for Blastocystis spp have been case reports and uncontrolled or retrospective series. There are no properly controlled prospective studies about pathogenicity or the effect of specific therapy.",
"     </li>",
"     <li>",
"      Criteria are lacking for labeling a specimen as \"positive\" for Blastocystis spp; diagnostic methods differ.",
"     </li>",
"     <li>",
"      The heterogeneity of Blastocystis spp strains, accompanied by variable virulence, might account for differences in pathogenicity. However, evidence remains inconclusive; most studies show no definite correlation between subtype or genotypes and pathogenicity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/30-35\">",
"       30-35",
"      </a>",
"      ]. Emerging evidence suggests that subtype 1 and perhaps subtype 3 are most likely to be associated with symptoms, although subtype 3 isolates are not always associated with symptomatic infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/1,36\">",
"       1,36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Prolonged, irregular shedding of the organism can occur. One study showed that the shedding from day to day varied between 0 to 17 parasites per 40x microscopic field [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/37\">",
"       37",
"      </a>",
"      ]. Once Canadian study described Blastocystis spp two months after first observation in 75 percent of individuals in which it was the sole organism [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/11\">",
"       11",
"      </a>",
"      ]. Many reports of high prevalence of Blastocystis spp among controls could reflect prior infection that has entered a convalescent or asymptomatic chronic carriage stage [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/11,13,38\">",
"       11,13,38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Quantitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The number of organisms may not necessarily correlate with symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/39\">",
"     39",
"    </a>",
"    ]. Some authors have suggested that Blastocystis spp are more likely to be pathogenic if &gt;5 organisms per oil immersion field are detected and that, in lower quantities, the organisms should be disregarded as a potential cause of symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/7,12\">",
"     7,12",
"    </a>",
"    ]. However, others have found no association between parasite concentrations and symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/6,11,13,15,27,40\">",
"     6,11,13,15,27,40",
"    </a>",
"    ]. In one study high numbers of organisms in the stool, although not correlated with symptoms, were correlated with increased likelihood of an acute presentation and with decreased likelihood of clearing Blastocystis spp on follow-up examinations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Copathogenicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blastocystis spp are often found in association with other potential pathogens; reports have suggested that the majority of patients with Blastocystis spp in their stools have an alternative etiology identified on further examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is sometimes inferred that identification of Blastocystis spp in a stool specimen suggests another unidentified pathogen. As an example, one study examined up to 6 samples from 32 patients with stool specimens positive for Blastocystis spp; another pathogen was identified in 84 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/27\">",
"     27",
"    </a>",
"    ]. Initiation of treatment for the other pathogen, led to resolution of symptoms despite the persistence of Blastocystis spp in follow up stool specimens. However, another study of patients with diarrhea in Nepal showed that Blastocystis spp did not serve this marker function for other enteric pathogens, which were detected in 68 and 71 percent of patients with and without Blastocystis spp, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An alternative explanation that has been suggested for the association between Blastocystis spp and other pathogens is that the parasite may be easier to identify in non-formed, watery stools [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/15,18,41\">",
"     15,18,41",
"    </a>",
"    ]. It is also possible that an increase in symbiotic bacterial flora during diarrhea might enhance the growth of Blastocystis spp [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Carrier state",
"    </span>",
"    &nbsp;&mdash;&nbsp;The large number of asymptomatic individuals with stools positive for Blastocystis spp suggests the existence of a carrier state. Other protozoa, such as Giardia, are often found in asymptomatic patients but are pathogens when associated with appropriate clinical symptoms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/28/33224?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of giardiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is possible that individuals with immunity due to prior exposure may be more likely to have an asymptomatic infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/5,42\">",
"     5,42",
"    </a>",
"    ]. Alternatively, pathologic effects might depend upon host factors such as lowered immunity or on disturbances of gastrointestinal function from other causes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/5\">",
"     5",
"    </a>",
"    ]. Symptoms have been described in both immunocompromised and immunocompetent hosts, including patients with HIV and transplant recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/25,43,44\">",
"     25,43,44",
"    </a>",
"    ]. Although there are case reports of greater prevalence and pathogenicity in immunosuppressed patients, such as those with HIV and transplant recipients, more severe symptoms in immunosuppressed individuals have not been consistently seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/44-47\">",
"     44-47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17218354\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms that have been associated with Blastocystis spp infection include diarrhea, nausea, anorexia, abdominal cramps, bloating, flatulence, urticaria, and fatigue. Watery diarrhea is usually described. Both acute diarrhea and chronic diarrhea have been reported. Fever is usually absent.",
"   </p>",
"   <p>",
"    Some studies have suggested a possible link between Blastocystis spp and irritable bowel syndrome (IBS), although a causal relationship has not been proven [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/48-53\">",
"     48-53",
"    </a>",
"    ]. An association between Blastocystis spp and urticaria (acute and chronic) has also been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Disseminated infection is rare; two case reports have described identification of the organism in synovial fluid and peritoneal fluid, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blastocystis spp are identified by examination of stool specimen(s) by light microscopy of stained smears or wet mounts. Microscopic identification can be complicated by the variety of forms of the organism that appear in stool specimens, difficulties in finding it in wet mounts, and disruption of the organism with stool concentration techniques (",
"    <a class=\"graphic graphic_picture graphicRef73525 \" href=\"mobipreview.htm?17/34/17958\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef74028 \" href=\"mobipreview.htm?43/37/44631\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/24\">",
"     24",
"    </a>",
"    ]. Commonly used microscopic methods include a formol ethyl acetate concentration technique (FECT) or permanent stained smears (usually trichrome-stained). Fecal leukocytes are generally absent.",
"   </p>",
"   <p>",
"    Endoscopy usually shows a macroscopically normal-appearing mucosa, and histopathology generally does not demonstrate intestinal inflammation or mucosal invasion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/45,57,58\">",
"     45,57,58",
"    </a>",
"    ]. Not all studies exclude patients who have other pathogens found, so results can be difficult to interpret.",
"   </p>",
"   <p>",
"    A stool culture method is available, but is not performed routinely even though it may be more sensitive than microscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. An enzyme-linked immunosorbent assay (ELISA) assay for detecting serum antibodies to Blastocystis spp has been developed but is also not routinely used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/61\">",
"     61",
"    </a>",
"    ]. Polymerase chain reaction (PCR) techniques with excellent sensitivity have also been developed, but availability is limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. Molecular tests to differentiate between strains are limited to research settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic patients with Blastocystis spp on stool examination do NOT require therapy. Symptomatic patients should have a concentrated stool specimen examined to look for another potential pathogen and should have noninfectious causes of symptoms excluded. If no other pathogen or etiology is identified, it is reasonable to administer therapy for Blastocystis spp with observation for a clinical response, which may be due to eradication of Blastocystis spp or elimination of some other undetected pathogen. However, the following caveats apply:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blastocystis spp is often a self-limiting infection, making therapeutic efficacy difficult to determine.",
"     </li>",
"     <li>",
"      Many mild cases resolve within approximately three days without any specific therapy.",
"     </li>",
"     <li>",
"      The response to specific treatment is erratic.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9022147\">",
"    <span class=\"h2\">",
"     Clinical approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     Metronidazole",
"    </a>",
"    (750 mg three times daily for 5 to 10 days) is generally favored as the agent of choice. Other agents used clinically include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/14/5349?source=see_link\">",
"     tinidazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/38/21091?source=see_link\">",
"     iodoquinol",
"    </a>",
"    and TMP-SMX. In vitro studies have shown good sensitivity of the organism to metronidazole,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX), furazolidone, quinacrine,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    , and emetine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/64\">",
"     64",
"    </a>",
"    ]. Iodoquinol is moderately inhibitory in vitro; diloxanide furoate and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16099?source=see_link\">",
"     paromomycin",
"    </a>",
"    are inactive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Metronidazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    was evaluated in a controlled trial of 76 patients with diarrhea in whom Blastocystis spp was the only stool pathogen identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/60\">",
"     60",
"    </a>",
"    ]. The patients were randomly assigned to metronidazole (1.5",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    or placebo for ten days; those who received metronidazole were more likely to have cessation of symptoms at one month (88 versus 14 percent) and six months (75 versus 33 percent). Other studies have reported no effect following metronidazole therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/46\">",
"     46",
"    </a>",
"    ], and resistance to metronidazole has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/65,66\">",
"     65,66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/14/5349?source=see_link\">",
"     tinidazole",
"    </a>",
"    is better tolerated than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    and may be an acceptable alternative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Trimethoprim-sulfamethoxazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of TMP-SMX (6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    TMP [maximum 320 mg] and 30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    SMX [maximum 1600 mg] per day for seven days) on symptoms was evaluated in a case series of 53 symptomatic patients with two consecutive stool specimens positive for Blastocystis spp and negative for other pathogens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/21\">",
"     21",
"    </a>",
"    ]. Clinical symptoms disappeared in 74 percent of patients treated, and improvement was observed in another 19 percent; Blastocystis was eradicated in 94 percent of patients. The authors concluded that TMP-SMX may affect Blastocystis spp directly or may destroy other bacterial flora necessary for its growth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Nitazoxanide",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a randomized study, 84 individuals with diarrhea and Blastocystis spp in stool were randomized to receive placebo or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/24/5508?source=see_link\">",
"     nitazoxanide",
"    </a>",
"    (patients 12 years or older: 500 mg tablet twice daily for three days; patients 4 to 11 years: 200 mg in 10 mL suspension twice daily; patients one to three years: 100 mg in 5 mL suspension twice daily) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39143/abstract/67\">",
"     67",
"    </a>",
"    ]. Resolution of symptoms was observed more frequently among those who received nitazoxanide than those who received placebo (86 versus 38 percent). It is uncertain whether clinical responses were due to the effect on Blastocystis spp or on other unidentified pathogens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blastocystis spp (previously referred to as Blastocystis hominis) are anaerobic protozoan parasites occasionally found in the human gastrointestinal tract. There has been considerable controversy regarding whether Blastocystis spp represent a commensal organism or a true pathogen. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Copathogenicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Blastocystis spp have been observed worldwide; in general, the estimated prevalence of Blastocystis spp is higher in developing than developed countries. The mode of transmission is not fully understood; fecal-oral transmission has been postulated. Blastocystis spp have also been found in animals, and Blastocystis spp are more commonly observed in the stool of individuals with occupational exposure to animals. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Blastocystis spp demonstrate marked morphologic variability. They measure between 5 to 40 &micro;m (",
"      <a class=\"graphic graphic_picture graphicRef73525 \" href=\"mobipreview.htm?17/34/17958\">",
"       picture 1",
"      </a>",
"      ) and four different forms have been described: vacuolar, granular, ameboid, and cystic (",
"      <a class=\"graphic graphic_figure graphicRef74028 \" href=\"mobipreview.htm?43/37/44631\">",
"       figure 1",
"      </a>",
"      ). Extensive genetic diversity has been described among Blastocystis isolates; nine different sub-types have been identified in humans. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Blastocystis spp are often found in association with other potential pathogens; reports have suggested that the majority of patients with Blastocystis spp in their stools have an alternative etiology identified on further examination. The number of organisms may not necessarily correlate with symptoms. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Copathogenicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptoms that have been associated with Blastocystis spp infection include diarrhea, nausea, anorexia, abdominal cramps, bloating, flatulence, urticaria, and fatigue. Watery diarrhea is usually described. Both acute diarrhea and chronic diarrhea have been reported. Fever is usually absent. (See",
"      <a class=\"local\" href=\"#H17218354\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis is made by examination of stool specimen(s) by light microscopy of stained smears or wet mounts. Endoscopy usually shows a macroscopically normal-appearing mucosa, and histopathology generally does not demonstrate intestinal inflammation or mucosal invasion. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Asymptomatic patients found to have Blastocystis spp on stool examination do not require treatment. Symptomatic patients should have a concentrated stool specimen examined to look for another potential pathogen and should have noninfectious causes excluded. If no other pathogen or etiology is identified, we suggest administering antimicrobial therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ); clinical response may be due to eradication of Blastocystis spp or elimination of some other undetected pathogen. We suggest treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      (750 mg three times daily for 5 to 10 days) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ); alternative agents are discussed above. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/1\">",
"      Tan KS. New insights on classification, identification, and clinical relevance of Blastocystis spp. Clin Microbiol Rev 2008; 21:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/2\">",
"      Zierdt CH, Rude WS, Bull BS. Protozoan characteristics of Blastocystis hominis. Am J Clin Pathol 1967; 48:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/3\">",
"      Zierdt CH. Studies of Blastocystis hominis. J Protozool 1973; 20:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/4\">",
"      Stenzel DJ, Boreham PF. Blastocystis hominis revisited. Clin Microbiol Rev 1996; 9:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/5\">",
"      Blastocystis hominis: commensal or pathogen? Lancet 1991; 337:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/6\">",
"      Kain KC, Noble MA, Freeman HJ, Barteluk RL. Epidemiology and clinical features associated with Blastocystis hominis infection. Diagn Microbiol Infect Dis 1987; 8:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/7\">",
"      Nimri LF. Evidence of an epidemic of Blastocystis hominis infections in preschool children in northern Jordan. J Clin Microbiol 1993; 31:2706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/8\">",
"      Nimri L, Batchoun R. Intestinal colonization of symptomatic and asymptomatic schoolchildren with Blastocystis hominis. J Clin Microbiol 1994; 32:2865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/9\">",
"      Leelayoova S, Rangsin R, Taamasri P, et al. Evidence of waterborne transmission of Blastocystis hominis. Am J Trop Med Hyg 2004; 70:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/10\">",
"      Parkar U, Traub RJ, Kumar S, et al. Direct characterization of Blastocystis from faeces by PCR and evidence of zoonotic potential. Parasitology 2007; 134:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/11\">",
"      Senay H, MacPherson D. Blastocystis hominis: epidemiology and natural history. J Infect Dis 1990; 162:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/12\">",
"      Sheehan DJ, Raucher BG, McKitrick JC. Association of Blastocystis hominis with signs and symptoms of human disease. J Clin Microbiol 1986; 24:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/13\">",
"      Doyle PW, Helgason MM, Mathias RG, Proctor EM. Epidemiology and pathogenicity of Blastocystis hominis. J Clin Microbiol 1990; 28:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/14\">",
"      Jelinek T, Peyerl G, L&ouml;scher T, et al. The role of Blastocystis hominis as a possible intestinal pathogen in travellers. J Infect 1997; 35:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/15\">",
"      Shlim DR, Hoge CW, Rajah R, et al. Is Blastocystis hominis a cause of diarrhea in travelers? A prospective controlled study in Nepal. Clin Infect Dis 1995; 21:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/16\">",
"      Guglielmetti P, Cellesi C, Figura N, Rossolini A. Family outbreak of Blastocystis hominis associated gastroenteritis. Lancet 1989; 2:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/17\">",
"      Zierdt CH. Pathogenicity of Blastocystis hominis. J Clin Microbiol 1991; 29:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/18\">",
"      Miller RA, Minshew BH. Blastocystis hominis: an organism in search of a disease. Rev Infect Dis 1988; 10:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/19\">",
"      Zaman V, Howe J, Ng M. Variation in the cyst morphology of Blastocystis hominis. Parasitol Res 1997; 83:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/20\">",
"      Moe KT, Singh M, Howe J, et al. Observations on the ultrastructure and viability of the cystic stage of Blastocystis hominis from human feces. Parasitol Res 1996; 82:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/21\">",
"      Ok UZ, Girginkardeler N, Balciolu C, et al. Effect of trimethoprim-sulfamethaxazole in Blastocystis hominis infection. Am J Gastroenterol 1999; 94:3245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/22\">",
"      Wong KH, Ng GC, Lin RT, et al. Predominance of subtype 3 among Blastocystis isolates from a major hospital in Singapore. Parasitol Res 2008; 102:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/23\">",
"      Stensvold CR, Alfellani MA, N&oslash;rskov-Lauritsen S, et al. Subtype distribution of Blastocystis isolates from synanthropic and zoo animals and identification of a new subtype. Int J Parasitol 2009; 39:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/24\">",
"      Zierdt CH. Blastocystis hominis--past and future. Clin Microbiol Rev 1991; 4:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/25\">",
"      Blastocystis hominis as a human pathogen. Rev Infect Dis 1989; 11:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/26\">",
"      Qadri SM, al-Okaili GA, al-Dayel F. Clinical significance of Blastocystis hominis. J Clin Microbiol 1989; 27:2407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/27\">",
"      Markell EK, Udkow MP. Blastocystis hominis: pathogen or fellow traveler? Am J Trop Med Hyg 1986; 35:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/28\">",
"      Sun T, Katz S, Tanenbaum B, Schenone C. Questionable clinical significance of Blastocystis hominis infection. Am J Gastroenterol 1989; 84:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/29\">",
"      Chen TL, Chan CC, Chen HP, et al. Clinical characteristics and endoscopic findings associated with Blastocystis hominis in healthy adults. Am J Trop Med Hyg 2003; 69:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/30\">",
"      Clark CG. Extensive genetic diversity in Blastocystis hominis. Mol Biochem Parasitol 1997; 87:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/31\">",
"      Yoshikawa H, Nagano I, Wu Z, et al. Genomic polymorphism among Blastocystis hominis strains and development of subtype-specific diagnostic primers. Mol Cell Probes 1998; 12:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/32\">",
"      Kukoschke KG, M&uuml;ller HE. SDS-PAGE and immunological analysis of different axenic Blastocystis hominis strains. J Med Microbiol 1991; 35:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/33\">",
"      Boreham PF, Upcroft JA, Dunn LA. Protein and DNA evidence for two demes of Blastocystis hominis from humans. Int J Parasitol 1992; 22:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/34\">",
"      Elwakil HS, Talaat RM. Genetic analysis of Blastocystis hominis isolated from symptomatic and asymptomatic human hosts in Egypt. J Egypt Soc Parasitol 2009; 39:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/35\">",
"      Souppart L, Sanciu G, Cian A, et al. Molecular epidemiology of human Blastocystis isolates in France. Parasitol Res 2009; 105:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/36\">",
"      Tan TC, Suresh KG, Smith HV. Phenotypic and genotypic characterisation of Blastocystis hominis isolates implicates subtype 3 as a subtype with pathogenic potential. Parasitol Res 2008; 104:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/37\">",
"      Vennila GD, Suresh Kumar G, Khairul Anuar A, et al. Irregular shedding of Blastocystis hominis. Parasitol Res 1999; 85:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/38\">",
"      Keystone JS. Blastocystis hominis and traveler's diarrhea. Clin Infect Dis 1995; 21:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/39\">",
"      Kain K, Noble M. Blastocystis hominis infection in humans. Rev Infect Dis 1989; 11:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/40\">",
"      Grossman I, Weiss LM, Simon D, et al. Blastocystis hominis in hospital employees. Am J Gastroenterol 1992; 87:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/41\">",
"      Markell EK. Is there any reason to continue treating Blastocystis infections? Clin Infect Dis 1995; 21:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/42\">",
"      Cirioni O, Giacometti A, Drenaggi D, et al. Prevalence and clinical relevance of Blastocystis hominis in diverse patient cohorts. Eur J Epidemiol 1999; 15:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/43\">",
"      Albrecht H, Stellbrink HJ, Koperski K, Greten H. Blastocystis hominis in human immunodeficiency virus-related diarrhea. Scand J Gastroenterol 1995; 30:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/44\">",
"      Ok UZ, Cirit M, Uner A, et al. Cryptosporidiosis and blastocystosis in renal transplant recipients. Nephron 1997; 75:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/45\">",
"      Zuckerman MJ, Watts MT, Ho H, Meriano FV. Blastocystis hominis infection and intestinal injury. Am J Med Sci 1994; 308:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/46\">",
"      Llibre JM, Tor J, Manterola JM, et al. Blastocystis hominis chronic diarrhoea in AIDS patients. Lancet 1989; 1:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/47\">",
"      Garavelli PL, Orsi P, Scaglione L. Blastocystis hominis infection during AIDS. Lancet 1988; 2:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/48\">",
"      Hussain R, Jaferi W, Zuberi S, et al. Significantly increased IgG2 subclass antibody levels to Blastocystis hominis in patients with irritable bowel syndrome. Am J Trop Med Hyg 1997; 56:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/49\">",
"      Giacometti A, Cirioni O, Fiorentini A, et al. Irritable bowel syndrome in patients with Blastocystis hominis infection. Eur J Clin Microbiol Infect Dis 1999; 18:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/50\">",
"      Yakoob J, Jafri W, Jafri N, et al. Irritable bowel syndrome: in search of an etiology: role of Blastocystis hominis. Am J Trop Med Hyg 2004; 70:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/51\">",
"      Tungtrongchitr A, Manatsathit S, Kositchaiwat C, et al. Blastocystis hominis infection in irritable bowel syndrome patients. Southeast Asian J Trop Med Public Health 2004; 35:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/52\">",
"      Stensvold CR, Lewis HC, Hammerum AM, et al. Blastocystis: unravelling potential risk factors and clinical significance of a common but neglected parasite. Epidemiol Infect 2009; 137:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/53\">",
"      Yakoob J, Jafri W, Beg MA, et al. Blastocystis hominis and Dientamoeba fragilis in patients fulfilling irritable bowel syndrome criteria. Parasitol Res 2010; 107:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/54\">",
"      Hameed DM, Hassanin OM, Zuel-Fakkar NM. Association of Blastocystis hominis genetic subtypes with urticaria. Parasitol Res 2011; 108:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/55\">",
"      Lee MG, Rawlins SC, Didier M, DeCeulaer K. Infective arthritis due to Blastocystis hominis. Ann Rheum Dis 1990; 49:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/56\">",
"      Patino WD, Cavuoti D, Banerjee SK, et al. Cytologic diagnosis of blastocystis hominis in peritoneal fluid: a case report. Acta Cytol 2008; 52:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/57\">",
"      Horiki N, Maruyama M, Fujita Y, et al. Epidemiologic survey of Blastocystis hominis infection in Japan. Am J Trop Med Hyg 1997; 56:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/58\">",
"      Zuckerman MJ, Ho H, Hooper L, et al. Frequency of recovery of Blastocystis hominis in clinical practice. J Clin Gastroenterol 1990; 12:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/59\">",
"      Suresh K, Smith H. Comparison of methods for detecting Blastocystis hominis. Eur J Clin Microbiol Infect Dis 2004; 23:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/60\">",
"      Nigro L, Larocca L, Massarelli L, et al. A placebo-controlled treatment trial of Blastocystis hominis infection with metronidazole. J Travel Med 2003; 10:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/61\">",
"      Zierdt CH, Zierdt WS, Nagy B. Enzyme-linked immunosorbent assay for detection of serum antibody to Blastocystis hominis in symptomatic infections. J Parasitol 1995; 81:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/62\">",
"      Jones MS 2nd, Ganac RD, Hiser G, et al. Detection of Blastocystis from stool samples using real-time PCR. Parasitol Res 2008; 103:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/63\">",
"      Roberts T, Barratt J, Harkness J, et al. Comparison of microscopy, culture, and conventional polymerase chain reaction for detection of blastocystis sp. in clinical stool samples. Am J Trop Med Hyg 2011; 84:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/64\">",
"      Wolfe MS. The treatment of intestinal protozoan infections. Med Clin North Am 1982; 66:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/65\">",
"      Zaman V, Zaki M. Resistance of Blastocystis hominis cysts to metronidazole. Trop Med Int Health 1996; 1:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/66\">",
"      Haresh K, Suresh K, Khairul Anus A, Saminathan S. Isolate resistance of Blastocystis hominis to metronidazole. Trop Med Int Health 1999; 4:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39143/abstract/67\">",
"      Rossignol JF, Kabil SM, Said M, et al. Effect of nitazoxanide in persistent diarrhea and enteritis associated with Blastocystis hominis. Clin Gastroenterol Hepatol 2005; 3:987.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5672 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.55.141.10-EC79731216-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_14_39143=[""].join("\n");
var outline_f38_14_39143=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Genetic variability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOGENICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Quantitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Copathogenicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Carrier state",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17218354\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9022147\">",
"      Clinical approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Metronidazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Trimethoprim-sulfamethoxazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Nitazoxanide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5672\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5672|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/37/44631\" title=\"figure 1\">",
"      Blastocystis stages",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5672|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/34/17958\" title=\"picture 1\">",
"      Blastocystis microscopy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/28/33224?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of giardiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39304?source=related_link\">",
"      Evaluation of fever in the returning traveler",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/0/10243?source=related_link\">",
"      Nonpathogenic enteric protozoa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/29/29145?source=related_link\">",
"      Travelers' diarrhea",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_14_39144="Desipramine: Drug information";
var content_f38_14_39144=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Desipramine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?26/24/27013?source=see_link\">",
"    see \"Desipramine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/16/36103?source=see_link\">",
"    see \"Desipramine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F157638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Norpramin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F157639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dom-Desipramine;",
"     </li>",
"     <li>",
"      Novo-Desipramine;",
"     </li>",
"     <li>",
"      Nu-Desipramine;",
"     </li>",
"     <li>",
"      PMS-Desipramine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F157654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidepressant, Tricyclic (Secondary Amine)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F157642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Depression:",
"     </b>",
"     Oral: Initial dose: Start at the lower range and increase based on tolerance and response; usual maintenance dose: 100-200 mg/day, but doses up to 300 mg/day may be necessary in severely depressed patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Neuropathic pain (unlabeled use):",
"     </b>",
"     Oral: Initial: 10-25 mg/day; increase dose every 3 days as necessary until the desired effect is obtained; usual effective dose: 50-150 mg/day (maximum dose: 150 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      MAO inhibitor recommendations:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Switching to or from an MAO inhibitor intended to treat psychiatric disorders:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allow 14 days to elapse between discontinuing an MAO inhibitor intended to treat psychiatric disorders and initiation of desipramine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allow 14 days to elapse between discontinuing desipramine and initiation of an MAO inhibitor intended to treat psychiatric disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Use with other MAO inhibitors (linezolid or I.V. methylene blue):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Do not initiate desipramine in patients receiving linezolid or I.V. methylene blue; consider other interventions for psychiatric condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If urgent treatment with linezolid or I.V. methylene blue is required in a patient already receiving desipramine and potential benefits outweigh potential risks, discontinue desipramine promptly and administer linezolid or I.V. methylene blue. Monitor for serotonin syndrome for 2 weeks or until 24 hours after the last dose of linezolid or I.V. methylene blue, whichever comes first. May resume desipramine 24 hours after the last dose of linezolid or I.V. methylene blue.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F157648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/16/36103?source=see_link\">",
"      see \"Desipramine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Depression:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Not FDA approved for use in pediatric patients; controlled clinical trials have not shown tricyclic antidepressants to be superior to placebo for the treatment of depression in children and adolescents (Dopheide, 2006; Wagner, 2005).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 6-12 years (unlabeled use): 1-3 mg/kg/day in divided doses; monitor carefully with doses &gt;3 mg/kg/day; maximum dose: 5 mg/kg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents: Initial dose: Start at the lower range and increase based on tolerance and response to 100 mg/day in divided or single dose; usual maintenance dose: 25-100 mg/day, but doses up to 150 mg/day may be necessary in severely depressed patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      MAO inhibitor recommendations:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F157643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;\">",
"     <b>",
"      Depression:",
"     </b>",
"     Oral: Initial dose: Start at the lower range and increase based on tolerance and response to 100 mg/day in divided or single dose; usual maintenance dose: 25-100 mg/day, but doses up to 150 mg/day may be necessary in severely depressed patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      MAO inhibitor recommendations:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F157644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hemodialysis/peritoneal dialysis: Supplemental dose is not necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15796019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F157615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Norpramin&reg;: 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg [contains soybean oil]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F157600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088665.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088665.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F157619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of depression",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F157651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Analgesic adjunct in chronic pain; peripheral neuropathies (including diabetic neuropathy); attention-deficit/hyperactivity disorder (ADHD); depression in children &le;12 years of age",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F157663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Desipramine may be confused with clomiPRAMINE, dalfampridine, diphenhydrAMINE, disopyramide, imipramine, nortriptyline",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Norpramin&reg; may be confused with clomiPRAMINE, imipramine, Normodyne&reg;, Norpace&reg;, nortriptyline, Tenormin&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (SIADH: Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Norpramin: Brand name for desipramine [U.S., Canada], but also the brand name for enalapril/hydrochlorothiazide [Portugal]; omeprazole [Spain]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F157652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmias, edema, flushing, heart block, hyper-/hypotension, MI, palpitation, stroke, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, anxiety, ataxia, confusion, delusions, disorientation, dizziness, drowsiness, EEG alterations, exacerbation of psychosis, extrapyramidal symptoms, fatigue, fever, hallucinations, headache, hypomania, incoordination, insomnia, neuroleptic malignant syndrome, nightmares, restlessness, seizure, suicidal thinking and behavior",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, itching, petechiae, photosensitivity, skin rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast enlargement, galactorrhea, gynecomastia, hyper-/hypoglycemia, impotence, libido changes, SIADH",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, anorexia, black tongue, constipation, diarrhea, epigastric distress, nausea, parotid edema, paralytic ileus, stomatitis, sublingual adenitis, unpleasant taste, vomiting, weight gain/loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Micturition delayed, nocturia, painful ejaculation, polyuria, testicular edema, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, eosinophilia, purpura, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, cholestatic jaundice, hepatitis, liver enzymes increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Falling, numbness, paresthesia of extremities, peripheral neuropathy, tingling, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, disturbances of accommodation, intraocular pressure increased, mydriasis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, diaphoresis (excessive), withdrawal symptoms",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F157622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to desipramine, drugs of similar chemical class, or any component of the formulation; use of MAO inhibitors intended to treat psychiatric disorders (concurrently or within 14 days of discontinuing either desipramine or the MAO inhibitor); initiation of desipramine in a patient receiving linezolid or intravenous methylene blue; use in a patient during the acute recovery phase of MI",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F157604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Major psychiatric warnings:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal thinking/behavior:",
"     <b>",
"      [U.S. Boxed Warning]: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (18-24 years of age) with major depressive disorder (MDD) and other psychiatric disorders;",
"     </b>",
"     consider risk prior to prescribing. Short-term studies did not show an increased risk in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years. Closely monitor patients for clinical worsening, suicidality, or unusual changes in behavior, particularly during the initial 1-2 months of therapy or during periods of dosage adjustments (increases or decreases); the patient&rsquo;s family or caregiver should be instructed to closely observe the patient and communicate condition with healthcare provider. A medication guide concerning the use of antidepressants should be dispensed with each prescription.",
"     <b>",
"      Desipramine is FDA approved for the treatment of depression in adolescents.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; The possibility of a suicide attempt is inherent in major depression and may persist until remission occurs. Patients treated with antidepressants should be observed for clinical worsening and suicidality, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. Worsening depression and severe abrupt suicidality that are not part of the presenting symptoms may require discontinuation or modification of drug therapy. Use caution in high-risk patients during initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prescriptions should be written for the smallest quantity consistent with good patient care. The patient's family or caregiver should be alerted to monitor patients for the emergence of suicidality and associated behaviors such as anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, and mania; patients should be instructed to notify their healthcare provider if any of these symptoms or worsening depression or psychosis occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticholinergic effects: May cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention); use with extreme caution in patients with decreased gastrointestinal motility, paralytic ileus, urinary retention, BPH, xerostomia, or visual problems. The degree of anticholinergic blockade produced by this agent is low relative to other antidepressants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic effects: TCAs may rarely cause bone marrow suppression; monitor for any signs of infection and obtain CBC if symptoms (eg, fever, sore throat) evident.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension (risk is moderate relative to other antidepressants); use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedation: May cause sedation, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). The degree of sedation is low-moderate relative to other antidepressants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Serotonin syndrome: Potentially life-threatening serotonin syndrome (SS) has occurred with serotonergic agents (eg, SSRIs, SNRIs), particularly when used in combination with other serotonergic agents (eg, triptans, TCAs, fentanyl, lithium, tramadol, buspirone, St John&rsquo;s wort, tryptophan) or agents that impair metabolism of serotonin (eg, MOA inhibitors intended to treat psychiatric disorders, other MAO inhibitors [ie, linezolid and intravenous methylene blue]). Monitor patients closely for signs of SS such as mental status changes (eg, agitation, hallucinations, delirium, coma); autonomic instability (eg, tachycardia, labile blood pressure, diaphoresis); neuromuscular changes (eg, tremor, rigidity, myoclonus); GI symptoms (eg, nausea, vomiting, diarrhea); and/or seizures. Discontinue treatment (and any concomitant serotonergic agent) immediately if signs/symptoms arise.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Due to risk of conduction abnormalities, use with extreme caution in patients with a history of cardiovascular disease (including previous MI, stroke, tachycardia, or conduction abnormalities) or in patients with a family history of sudden death, dysrhythmias, or conduction abnormalities.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may alter glucose regulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Use with caution in patients with glaucoma; condition may be exacerbated by cholinergic blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Mania/hypomania: May worsen psychosis in some patients or precipitate a shift to mania or hypomania in patients with bipolar disorder. Monotherapy in patients with bipolar disorder should be avoided. Patients presenting with depressive symptoms should be screened for bipolar disorder.",
"     <b>",
"      Desipramine is not FDA approved for the treatment of bipolar depression.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with extreme caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold. In some patients, seizures may precede cardiac dysrhythmias and death.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with extreme caution in patients with hyperthyroidism or those receiving thyroid supplementation due to concerns of pro-arrhythmogenesis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use caution in elderly patients; may cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults. May be inappropriate in older adults depending on comorbidities (eg, dementia, delirium) due to its potent anticholinergic effects (Beers Criteria). May also increase risk of falling or confusional states.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Discontinuation of therapy: Recommended to discontinue prior to elective surgery requiring general anesthesia. Therapy should not be abruptly discontinued.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electroconvulsive therapy: May increase the risks associated with electroconvulsive therapy; consider discontinuing, when possible, prior to ECT treatment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F157649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2D6 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2A6 (moderate), CYP2B6 (moderate), CYP2D6 (moderate), CYP2E1 (weak), CYP3A4 (moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F157609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Tricyclic Antidepressants may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: Tricyclic Antidepressants may enhance the vasopressor effect of Alpha1-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: Tricyclic Antidepressants may diminish the antihypertensive effect of Alpha2-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Altretamine: May enhance the orthostatic hypotensive effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Tricyclic Antidepressants may enhance the stimulatory effect of Amphetamines. Tricyclic Antidepressants may also potentiate the cardiovascular effects of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil adult dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor.  Patients receiving such a combination should also be monitored more closely for evidence of adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Tricyclic Antidepressants may enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Desipramine. Management: Consider lower doses of desipramine in patients treated with boceprevir and monitor for symptoms of desipramine toxicity (including dizziness, hypotension and syncope), due to a possible increase in desipramine concentrations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BuPROPion: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cinacalcet: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Substrates: CYP2B6 Inhibitors (Moderate) may decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Tricyclic Antidepressants may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Dexmethylphenidate may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DULoxetine: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.  Management: When used concomitantly with moderate inhibitors of CYP3A4, eplerenone dosing recommendations may vary depending on international labeling. Consult appropriate labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Tricyclic Antidepressants may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivabradine.  Management: In patients with a resting heart rate over 60 beats per minute receiving a moderate CYP3A4 inhibitor, ivabradine initiation at an adult dose of 2.5 mg twice daily may be considered.  Monitor heart rate closely under these circumstances.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg daily in patients also receiving moderate CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May enhance the neurotoxic effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Tricyclic Antidepressants. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: Tricyclic Antidepressants may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Methylphenidate may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with tricyclic antidepressants for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: May increase the serum concentration of Desipramine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebivolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of CYP2D6 Inhibitors (Moderate).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Tricyclic Antidepressants may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.  Management: Limit the ranolazine adult dose to a maximum of 500 mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, erythromycin, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Tricyclic Antidepressants may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure and/or loss of consciousness may be increased in patients with significant sodium phosphate induced fluid/electrolyte abnormalities.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Tricyclic Antidepressants. The risk of serotonin syndrome may theoretically be increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Cyclic Antidepressants may enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Terbinafine (Systemic): May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: Tricyclic Antidepressants may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Tricyclic Antidepressants may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: Tricyclic Antidepressants may increase the serum concentration of Yohimbine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F157634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Grapefruit juice may inhibit the metabolism of some TCAs and clinical toxicity may result.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, SAMe, kava kava (may increase risk of serotonin syndrome and/or excessive sedation).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10912704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies are inconclusive.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F157646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk (AAP rates &ldquo;of concern&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F157626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Based on information from one mother-infant pair, following maternal use of desipramine 300 mg/day, the estimated exposure to the breast-feeding infant would be 2% of the weight-adjusted maternal dose. Adverse events were not reported. Infants should be monitored for signs of adverse events; routine monitoring of infant serum concentrations is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F157625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Desipramine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $112.37",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $135.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $254.13",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (100): $323.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $425.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (50): $307.93",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Norpramin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $149.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $179.51",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $337.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (100): $430.13",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $565.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (50): $409.49",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F157612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor blood pressure and pulse rate prior to and during initial therapy; evaluate mental status, suicide ideation (especially at the beginning of therapy or when doses are increased or decreased); monitor weight; ECG in older adults and those patients with cardiac disease; signs/symptoms of serotonin syndrome",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     When used for the treatment of ADHD, thoroughly evaluate for cardiovascular risk. Monitor heart rate, blood pressure, and consider obtaining ECG prior to initiation (Vetter, 2008); ensure PR interval &le;200 ms, QRS duration &le;120 ms, and QT",
"     <sub>",
"      c",
"     </sub>",
"     &le;460 ms.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F157627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Deprexan (IL);",
"     </li>",
"     <li>",
"      Norpramin (MX);",
"     </li>",
"     <li>",
"      Nortimil (IT);",
"     </li>",
"     <li>",
"      Pertofran (AT, NL, NZ);",
"     </li>",
"     <li>",
"      Petylyl (CZ, DE, PL, RU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F157603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Traditionally believed to increase the synaptic concentration of norepinephrine (and to a lesser extent, serotonin) in the central nervous system by inhibition of its reuptake by the presynaptic neuronal membrane. However, additional receptor effects have been found including desensitization of adenyl cyclase, down regulation of beta-adrenergic receptors, and down regulation of serotonin receptors.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F157621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Earliest therapeutic effects: 2-5 days; Maximum antidepressant effect: &gt;2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Adults: 15-24 hours (Weiner, 1981)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: ~6 hours (Weiner, 1981)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~70%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/14/39144/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;American Academy of Pediatrics Subcommittee on Attention-Deficit/Hyperactivity Disorder and Committee on Quality Improvement. Clinical Practice Guidelines: Treatment of the School-Aged Child With Attention-Deficit/Hyperactivity Disorder,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(4):1033-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/14/39144/abstract-text/11581465/pubmed\" id=\"11581465\" target=\"_blank\">",
"        11581465",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/14/39144/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Pain Society,",
"      <i>",
"       Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain",
"      </i>",
"      , 6th ed, Glenview, IL: American Pain Society, 2008.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Biederman J, Thisted RA, Greenhill LL, et al, &ldquo;Estimation of the Association Between Desipramine and the Risk for Sudden Death in 5-14 Year-Old Children,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 1995, 56(3):87-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/14/39144/abstract-text/7883735/pubmed\" id=\"7883735\" target=\"_blank\">",
"        7883735",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boakes AJ, Laurence DR, Teoh PC, et al, &ldquo;Interactions Between Sympathomimetic Amines and Antidepressant Agents in Man,&rdquo;",
"      <i>",
"       Br Med J",
"      </i>",
"      , 1973, 1(849):311-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bril V, England J, Franklin GM, et al, \"Evidence-Based Guideline: Treatment of Painful Diabetic Neuropathy: Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 2011, 76(20):1758-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/14/39144/abstract-text/21482920/pubmed\" id=\"21482920\" target=\"_blank\">",
"        21482920",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dopheide JA, \"Recognizing and Treating Depression in Children and Adolescents,\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2006, 63(3):233-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/14/39144/abstract-text/16434782/pubmed\" id=\"16434782\" target=\"_blank\">",
"        16434782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fortinguerra F, Clavenna A, and Bonati M, \"Psychotropic Drug Use During Breastfeeding: A Review of the Evidence,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2009, 124(4):547-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/14/39144/abstract-text/19736267/pubmed\" id=\"19736267\" target=\"_blank\">",
"        19736267",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jastak JT and Yagiela JA, &ldquo;Vasoconstrictors and Local Anesthesia: A Review and Rationale for Use,&rdquo;",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 1983, 107(4):623-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/14/39144/abstract-text/6355236/pubmed\" id=\"6355236\" target=\"_blank\">",
"        6355236",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levy HB, Harper CR, and Weinberg WA, &ldquo;A Practical Approach to Children Failing in School,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1992, 39(4):895-928.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/14/39144/abstract-text/1635811/pubmed\" id=\"1635811\" target=\"_blank\">",
"        1635811",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Merigan KS, and Browning RG, &ldquo;Desipramine and Amantadine Causing False-Positive Urine Test for Amphetamine,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1993, 22(12):1927-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/14/39144/abstract-text/8239121/pubmed\" id=\"8239121\" target=\"_blank\">",
"        8239121",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nelson JC and Devanand DP, \"A Systematic Review and Meta-Analysis of Placebo-Controlled Antidepressant Studies in People With Depression and Dementia,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2011, 59(4):577-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/14/39144/abstract-text/21453380/pubmed\" id=\"21453380\" target=\"_blank\">",
"        21453380",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nelson JC, Jatlow PI, and Mazure C, &ldquo;Desipramine Plasma Levels and Response in Elderly Melancholic Patients,&rdquo;",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 1985, 5(4):217-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/14/39144/abstract-text/4019810/pubmed\" id=\"4019810\" target=\"_blank\">",
"        4019810",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pass SE and Simpson RW, &ldquo;Discontinuation and Reinstitution of Medications During the Perioperative Period,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2004, 61(9):899-912.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/14/39144/abstract-text/15156966/pubmed\" id=\"15156966\" target=\"_blank\">",
"        15156966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Roose SP, Glassman AH, Attia E, et al, &ldquo;Comparative Efficacy of Selective Serotonin Reuptake Inhibitors and Tricyclics in the Treatment of Melancholia,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 1994, 151(12):1735-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/14/39144/abstract-text/7977878/pubmed\" id=\"7977878\" target=\"_blank\">",
"        7977878",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rundegren J, van Dijken J, M&ouml;rnstad H, et al, &ldquo;Oral Conditions in Patients Receiving Long-Term Treatment With Cyclic Antidepressant Drugs,&rdquo;",
"      <i>",
"       Swed Dent J",
"      </i>",
"      , 1985, 9(2):55-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/14/39144/abstract-text/3925584/pubmed\" id=\"3925584\" target=\"_blank\">",
"        3925584",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vetter VL, Elia J, Erickson CH, et al,  &ldquo;Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Stimulant Drugs. A Scientific Statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2008, 117(18):2407-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/14/39144/abstract-text/18427125/pubmed\" id=\"18427125\" target=\"_blank\">",
"        18427125",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wagner KD, \"Pharmacotherapy for Major Depression in Children and Adolescents,\"",
"      <i>",
"       Prog Neuropsychopharmacol Biol Psychiatry",
"      </i>",
"      , 2005, 29(5):819-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/14/39144/abstract-text/15908090/pubmed\" id=\"15908090\" target=\"_blank\">",
"        15908090",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weiner D, Garteiz D, Cawein M, et al, &ldquo; Pharmacokinetic Linearity of Desipramine Hydrochloride,&rdquo;",
"      <i>",
"       J Pharm Sci",
"      </i>",
"      , 1981, 70(9):1079-80.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9329 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-D4C8FA2A70-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_14_39144=[""].join("\n");
var outline_f38_14_39144=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708682\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157638\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157639\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157654\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157642\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157648\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157643\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157644\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15796019\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157615\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157600\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874425\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157619\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157651\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157663\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157652\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157622\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157604\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157649\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157609\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157634\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10912704\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157646\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157626\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157625\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157612\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157627\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157603\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157621\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9329\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9329|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?26/24/27013?source=related_link\">",
"      Desipramine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/16/36103?source=related_link\">",
"      Desipramine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_14_39145="Umbilical cord blood transplantation in adults using myeloablative and nonmyeloablative preparative regimens";
var content_f38_14_39145=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Umbilical cord blood transplantation in adults using myeloablative and nonmyeloablative preparative regimens",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/14/39145/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/14/39145/contributors\">",
"     Nelson J Chao, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/14/39145/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/14/39145/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/14/39145/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/14/39145/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/14/39145/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1254160\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allogeneic hematopoietic cell transplantation (HCT) is an important and potentially curative treatment option for a wide variety of malignant and nonmalignant diseases. The pluripotent hematopoietic stem cells required for this procedure are usually obtained from the bone marrow or peripheral blood of a related or unrelated donor. Umbilical cord blood (UCB), the blood remaining in the umbilical cord and placenta following the birth of an infant, has emerged as an established alternative source of hematopoietic stem cells in allogeneic HCT.",
"   </p>",
"   <p>",
"    Engraftment and survival rates following HCT are optimized when the donor and recipient are genetically compatible. Human leukocyte antigen (HLA)-matched sibling donors are generally the preferred donor source for an allogeneic HCT. Unfortunately, finding an HLA-matched sibling is not always possible. Each full sibling potential donor has only a 25 percent chance of being fully HLA-matched with a sibling requiring a transplant. Therefore, most patients do not have an HLA-identical relative. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/38/26218?source=see_link&amp;anchor=H5#H5\">",
"     \"Donor selection for hematopoietic cell transplantation\", section on 'Matched related donors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When a suitable related donor is not available, a search is conducted to identify a potential unrelated HLA-matched donor. Finding an appropriate donor through a national registry is a lengthy process that is not always successful, especially for individuals who are not of Northern European descent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/38/26218?source=see_link&amp;anchor=H13#H13\">",
"     \"Donor selection for hematopoietic cell transplantation\", section on 'Matched unrelated donors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In comparison, the relative ease of procurement and the lower than anticipated risk of severe acute graft versus host disease has made unrelated UCB transplantation a possible alternative to unrelated donor bone marrow or mobilized peripheral blood progenitor cell transplant. The increased representation of ethnic minorities and the ability to use partially HLA-matched UCB units significantly expands the donor pool. In addition, the use of reduced-intensity or non-myeloablative preparative regimens to allow engraftment of UCB broadens the scope of patients who may benefit from allogeneic HCT, including elderly and medically infirm patients without an HLA-matched sibling donor. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/31/15865?source=see_link&amp;anchor=H61604479#H61604479\">",
"     \"Selection of an umbilical cord blood graft for hematopoietic cell transplantation\", section on 'Advantages and limitations of cord blood'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of UCB transplantation in adults using myeloablative and non-myeloablative preparative regimens will be discussed here. Other issues related to UCB are discussed separately, including the advantages and limitations of using UCB as a graft, the collection, storage, and ethical issues regarding the use of UCB for HCT, and the selection of an UCB graft for a particular recipient. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/47/11002?source=see_link\">",
"     \"Collection and storage of umbilical cord blood for hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61606400\">",
"    <span class=\"h1\">",
"     CORD BLOOD AS A RESOURCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unrelated UCB offers many practical advantages over unrelated donor bone marrow or mobilized peripheral blood progenitor cells as a source of hematopoietic stem cells, including an expanded donor pool, ease of procurement and lack of donor attrition, and decreased graft-versus-host disease. Limitations to UCB included an increased risk of graft failure, delayed immune reconstitution, and unavailability of the donor for additional donations (ie, donor lymphocyte infusions). This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/31/15865?source=see_link&amp;anchor=H61604479#H61604479\">",
"     \"Selection of an umbilical cord blood graft for hematopoietic cell transplantation\", section on 'Advantages and limitations of cord blood'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61606408\">",
"    <span class=\"h1\">",
"     CORD BLOOD UNIT SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main criteria for selecting UCB unit(s) for transplantation are the human leukocyte antigen (HLA) haplotype and the cryopreserved total nucleated cell dose per kilogram recipient body weight. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/31/15865?source=see_link&amp;anchor=H61604486#H61604486\">",
"     \"Selection of an umbilical cord blood graft for hematopoietic cell transplantation\", section on 'Cord blood unit selection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61605612\">",
"    <span class=\"h1\">",
"     PREPARATIVE REGIMEN",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61606814\">",
"    <span class=\"h2\">",
"     Choice of preparative regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;UCB transplantation (UCBT) has been performed in adults using both myeloablative and non-myeloablative preparative regimens. These approaches have not been compared directly in a prospective trial. As such, the ideal preparative regimen prior to UCB infusion is unknown and clinical practice varies by institution. Options include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Myeloablative regimens",
"      </strong>",
"      &mdash; A myeloablative conditioning regimen consists of a single agent or combination of agents expected to destroy the hematopoietic cells in the bone marrow and produce profound pancytopenia within one to three weeks from the time of administration. The resulting pancytopenia is long-lasting, usually irreversible, and in most instances fatal, unless hematopoiesis is restored by infusion of hematopoietic stem cells. An example of a myeloablative regimen commonly used for UCB transplantation is",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      75",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      120",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      and total body irradiation 13.2 Gy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/14/39145/abstract/1\">",
"       1",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/34/25130?source=see_link&amp;anchor=H5#H5\">",
"       \"Preparative regimens for hematopoietic cell transplantation\", section on 'Myeloablative preparative regimens'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Non-myeloablative (reduced intensity) regimens",
"      </strong>",
"      &mdash; A non-myeloablative regimen is one that combines the anti-leukemia effect of more modest doses of chemotherapy with the objective of achieving significant immunosuppression (to allow engraftment), thereby causing less organ and mucosal damage than myeloablative regimens. &ldquo;Non-myeloablative&rdquo; is probably not the most appropriate term, since the doses of alkylating agents typically used will result in long period of severe cytopenias prior to marrow recovery. An example of a non-myeloablative regimen commonly used for UCB transplantation is",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      <span class=\"nowrap\">",
"       40&nbsp;mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      <span class=\"nowrap\">",
"       50&nbsp;mg/kg,",
"      </span>",
"      and total body irradiation 200&nbsp;cGy",
"      <span class=\"nowrap\">",
"       (Flu/Cy/TBI",
"      </span>",
"      200 cGy) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/14/39145/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/34/25130?source=see_link&amp;anchor=H13#H13\">",
"       \"Preparative regimens for hematopoietic cell transplantation\", section on 'Nonmyeloablative and reduced intensity preparative regimens'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For younger patients without comorbidities, we suggest a myeloablative preparative regimen such as those used in the initial studies of UCB transplantation (UCBT). However, many older patients and patients with co-morbidities are not candidates for myeloablative preparative regimens due to high rates of morbidity and mortality with this approach. Because of toxicities from the intensive conditioning regimens to non-marrow organs such as gastrointestinal tract, liver, lung, and heart, UCBT using myeloablative preparative regimen have been restricted to patients younger than 50 to 55 years of age, with none of the series reported thus far including patients older than 60 years of age. &nbsp;",
"   </p>",
"   <p>",
"    Non-myeloablative conditioning regimens are an acceptable alternative for patients who are not candidates for myeloablative regimens. The ability to achieve stable mixed or full donor chimerism using these regimens, with successful eradication of primary disease in the absence of severe therapy-related toxicity in preliminary clinical studies, signifies an advance in the field of transplantation and immunobiology. However, there are several unresolved issues and remaining questions regarding the utility of this novel strategy, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      How does the efficacy of non-myeloablative UCBT differ from that of myeloablative UCBT?",
"     </li>",
"     <li>",
"      Is there a difference in the incidence of graft-versus-host disease (GVHD)?",
"     </li>",
"     <li>",
"      What is the optimal GVHD prophylaxis for patients undergoing non-myeloablative UCBT?",
"     </li>",
"     <li>",
"      How does immune reconstitution differ from that after myeloablative UCBT?",
"     </li>",
"     <li>",
"      Does the incidence of infection differ from that seen in myeloablative UCBT?",
"     </li>",
"     <li>",
"      What is the optimal non-myeloablative preparative regimen?",
"     </li>",
"     <li>",
"      Does non-myeloablative UCBT require a different UCB cell dose?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Future studies should address these questions and carefully define the indications for non-myeloablative versus myeloablative preparative regimens. The benefit of reduced toxicity with non-myeloablative regimens may be offset by the loss of cytoreduction of the tumor cells induced by high dose chemotherapy. The use of non-myeloablative regimens has generally been more successful in patients with indolent lymphoid malignancies or malignancies that are susceptible to graft-versus-leukemia (GVL) effects, such as chronic myeloid leukemia. It is less successful in patients with aggressive malignancies or malignancies that appear relatively insensitive to GVL effect, such as acute lymphoblastic leukemia and high grade lymphoma. The rapid proliferation of these malignancies may outpace the developing immune response. Given the limitation of cell dose of UCB and logistic problem in donor recall, nonmyeloablative UCBT does not afford the same advantage as in non-myeloablative transplant using hematopoietic stem cells from an adult donor, in which the transplant provides a platform for repeated delivery of adoptive cellular immunotherapy with donor lymphocyte infusions or other cellular therapies. In the case of an aggressive malignancy where the delayed graft-versus-malignancy effect cannot be relied upon, it may be more beneficial to use a preparative regimen (&ldquo;reduced toxicity&rdquo; ablative regimen) that provides some disease control and also facilitates engraftment.",
"   </p>",
"   <p>",
"    Another important issue is the potential of non-myeloablative UCBT to minimize the in-patient stay and improve quality of life in the peri-transplant period, while reducing cost. The majority of patients at our institution have non-myeloablative transplantation performed largely in the outpatient setting. The median time for hematopoietic recovery is shorter than conventional UCBT. Longer follow-up with larger number of patients will be needed to determine the incidence of chronic GVHD and the quality of life of such recipients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1254174\">",
"    <span class=\"h2\">",
"     Myeloablative preparative regimens",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61606828\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myeloablative preparative regimens have been used to successfully engraft both related and unrelated UCB in adults and children with hematological malignancies, marrow failure syndromes, and immune deficiencies. The results of several large series have been reported in the peer-reviewed literature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39145/abstract/3-14\">",
"     3-14",
"    </a>",
"    ]. The myeloablative preparative regimens employed in these studies were either total body irradiation (TBI)-based or chemotherapy-based, with inclusion of antithymocyte globulin in some of the patients. The data from these UCB transplantation (UCBT) registries, in which the majority of the recipients were children, point to significant delay in the time of neutrophil recovery, with the median time to absolute neutrophil count",
"    <span class=\"nowrap\">",
"     &gt;500/microL",
"    </span>",
"    ranging between 22 to 30 days. The overall probability of engraftment was between 80 and 90 percent. Despite a higher degree of HLA disparity, grade II to IV graft-versus-host disease (GVHD) in those unrelated UCB recipients is lower than recipients of unrelated bone marrow or peripheral blood grafts from adult donors. &nbsp;(See",
"    <a class=\"local\" href=\"#H426440357\">",
"     'Graft-versus-host disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Much of the initial data on UCBT were recorded in patients with very advanced disease with the expected poor results. Given significant improvements in understanding the biology of cord blood cells, importance of cell dose, use of double UCBT, and better patient selection, the outcomes following UCBT have improved. Analyses of registry data have compared the outcomes of UCB with unrelated bone marrow (BM) or peripheral blood progenitor cells (PBPC):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An analysis of Center for International Blood and Marrow Transplant Research (CIBMTR) database compared outcomes of",
"      <sup>",
"      </sup>",
"      503 children with acute leukemia given an unrelated mismatched",
"      <sup>",
"      </sup>",
"      UCBT with 282 unrelated BM transplant recipients (116 HLA allele",
"      <sup>",
"      </sup>",
"      matched 8 out of 8) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/14/39145/abstract/6\">",
"       6",
"      </a>",
"      ]. HLA allele mismatched BM recipients had",
"      <sup>",
"      </sup>",
"      more acute and chronic GVHD but similar rates of leukemia-free",
"      <sup>",
"      </sup>",
"      survival (LFS). The data demonstrated that even with an allele-matched BM donor, LFS was not statistically different from one",
"      <sup>",
"      </sup>",
"      or two HLA disparate UCBT. HLA-matched UCBT recipients",
"      <sup>",
"      </sup>",
"      had better outcomes compared with HLA allele matched BM recipients.",
"      <sup>",
"      </sup>",
"      In addition, there was higher transplant-related mortality (TRM)",
"      <sup>",
"      </sup>",
"      in children receiving a low UCB cell dose (&lt;3 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        7",
"       </sup>",
"       /kg)",
"       <sup>",
"       </sup>",
"      </span>",
"      and 5 of 6 HLA disparate UCB graft or in children given a 4 of 6 HLA disparate",
"      <sup>",
"      </sup>",
"      UCBT, independently of the cell dose infused. Also of interest was the observation that there was a lower incidence of relapse with the use of two cord blood units. This latter finding has also been observed by the group at the University of Minnesota [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/14/39145/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An analysis of the Eurocord database compared the outcome of 442 children who underwent matched unrelated BM (either T depleted or replete) transplant with 99 children who underwent mismatched UCBT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/14/39145/abstract/15\">",
"       15",
"      </a>",
"      ]. After UCBT, engraftment was delayed and GVHD was reduced",
"      <sup>",
"      </sup>",
"      similarly to T cell depleted BM transplant. The relapse rate and the disease-free survival were equivalent in this analysis.",
"     </li>",
"     <li>",
"      Another Eurocord analysis compared adults with acute leukemia receiving",
"      <sup>",
"      </sup>",
"      either a matched unrelated BM transplant (584 patients) or a mismatched UCBT (98 patients) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/14/39145/abstract/16\">",
"       16",
"      </a>",
"      ]. Despite a delay of engraftment, UCBT gave a similar leukemia",
"      <sup>",
"      </sup>",
"      survival to BM transplantation. Similar data were observed in the CIBMTR and",
"      <sup>",
"      </sup>",
"      New York Cord Blood Bank (NYCBB) where UCBT resulted in similar LFS survival to one antigen mismatched UBMT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/14/39145/abstract/17\">",
"       17",
"      </a>",
"      ].",
"      <sup>",
"      </sup>",
"     </li>",
"     <li>",
"      A meta-analysis included 161",
"      <sup>",
"      </sup>",
"      children and 316 adults undergoing UCBT along with 316 children and 996 adults undergoing unrelated BM transplantation and excluded T cell",
"      <sup>",
"      </sup>",
"      depleted unrelated BM transplant [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/14/39145/abstract/18\">",
"       18",
"      </a>",
"      ]. Pooled comparisons",
"      <sup>",
"      </sup>",
"      in children found that the incidence",
"      <sup>",
"      </sup>",
"      of chronic GVHD was lower with UCBT, but the incidence of grade",
"      <sup>",
"       <span class=\"nowrap\">",
"       </span>",
"      </sup>",
"      III/IV",
"      acute GVHD did not differ. There was no difference",
"      <sup>",
"      </sup>",
"      in two-year overall survival in children. For adults, there was no statistical difference between TRM and LFS.",
"     </li>",
"     <li>",
"      A subsequent retrospective analysis included 1525 adults who underwent UCB (165 patients), mobilized PBPCs (888 patients), or BM (472 patients) transplantation with a myeloablative preparative regimen between 2002 and 2006 for acute leukemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/14/39145/abstract/19\">",
"       19",
"      </a>",
"      ]. UCB units were 6 of 6 HLA-matched (10 patients), 5 of 6 HLA-matched (40 patients), or 4 of 6 HLA-matched (115 patients) based upon testing for HLA-A and HLA-B at antigen level and HLA-DRB1 at allele level. PBPCs and BM grafts from unrelated adult donors were matched for allele-level HLA-A, HLA-B, HLA-C, and HLA-DRB1 (632 and 332 patients, respectively), or mismatched at one locus (256 and 140 patients, respectively). UCBT resulted in the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Similar LFS as that after",
"      <span class=\"nowrap\">",
"       8/8",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       7/8",
"      </span>",
"      allele-matched PBPC or BM transplantation",
"     </li>",
"     <li>",
"      Higher rates of TRM than after",
"      <span class=\"nowrap\">",
"       8/8",
"      </span>",
"      allele-matched PBPC recipients (HR 1.62, 95% CI 1.18&ndash;2.23) or BM transplantation (HR 1.69, 95% CI 1.19-2.39)",
"     </li>",
"     <li>",
"      Lower rates of grade II to IV acute (HR 0.57, 95% 0.42&ndash;0.77) and chronic (HR 0.38, 0.27&ndash;0.53) GVHD than allele-matched PBPC transplantation",
"     </li>",
"     <li>",
"      Lower rates of chronic (HR 0.63, 0.44&ndash;0.90), but not acute, GVHD than after",
"      <span class=\"nowrap\">",
"       8/8",
"      </span>",
"      allele-matched BM transplantation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results support the use of a myeloablative preparative regimen followed by UCBT in adults who do not have an HLA-matched unrelated adult donor available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H426439939\">",
"    <span class=\"h3\">",
"     Toxicity and transplant-related mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data regarding the toxicity and transplant-related mortality (TRM) of myeloablative UCB transplantation (UCBT) are derived from case series and retrospective analyses of highly select, predominantly pediatric, patient populations. These studies have reported TRM between 27 and 39 percent at 100-days post transplant and between 30 and 44 percent at one-year post-transplant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39145/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. A relatively higher incidence of TRM at 100-days post transplant has been observed in adults, ranging between 43 and 56 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39145/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. The high nonrelapse mortality in these series is partially attributable to the high risk nature of the patient population. Infection and acute graft-versus-host disease (GVHD) are the main causes of death within the first 100-days of transplant. Organ toxicity associated",
"    <sup>",
"    </sup>",
"    with the intensive treatment administered to patients before UCBT is another leading cause of nonrelapse mortality in adult UCB recipients.",
"   </p>",
"   <p>",
"    Given the heterogeneity of the",
"    <sup>",
"    </sup>",
"    patient population, conditioning regimen and GVHD prophylaxis regimen employed, as well as the supportive care rendered at the different centers, it is difficult to have a reliable evaluation",
"    <sup>",
"    </sup>",
"    of the possible impact of different pre-transplant variables on TRM. However, among all the different prognostic variables that have been evaluated, increasing cell dose of the UCB graft and improved matching by having more units available could result in better outcomes. Future efforts in lowering TRM should therefore focus not only on improving transplant methodology and supportive care, but also on improving UCB cell dose. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/31/15865?source=see_link&amp;anchor=H61604500#H61604500\">",
"     \"Selection of an umbilical cord blood graft for hematopoietic cell transplantation\", section on 'Cell dose'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61606857\">",
"    <span class=\"h4\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;When compared with recipients of bone marrow or peripheral blood progenitor cells, adults receiving UCB have a higher risk of opportunistic infections for up to two to three years after transplantation. Infection may account for half of all treatment-related-death after UCB transplantation following an ablative regimen. Apart from the prolonged neutropenia associated with myeloablative UCBT, the risk of infection may be an intrinsic property of UCB, because UCB have been shown to be phenotypically na&iuml;ve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39145/abstract/22\">",
"     22",
"    </a>",
"    ] and to expand slowly in response to antigen stimulation, demonstrated a higher threshold for cytokine stimulation, and possess a lower effective cytotoxicity relative to adult donor T cell controls. Moreover, thymic production of new T cells is substantially delayed and remains limited in adult recipients of UCB following an ablative preparative regimen.",
"   </p>",
"   <p>",
"    The increased risk of infection within the first 100 days of UCBT may be related to delayed engraftment, GVHD, and impaired immune recovery. Immune dysfunction is at least partially related to the UCB cell dose. Retrospective studies have noted an association between increasing CD34 cell dose and improved engraftment, fewer infections, lower TRM, and higher survival rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39145/abstract/23\">",
"     23",
"    </a>",
"    ]. While some propose that prolonged neutropenia is the main contributory cause of the increased risk of infection, a high incidence of infection after myeloid recovery suggests the influence of impaired immune recovery and GVHD in causing infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39145/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/31/15865?source=see_link&amp;anchor=H61604500#H61604500\">",
"     \"Selection of an umbilical cord blood graft for hematopoietic cell transplantation\", section on 'Cell dose'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The increased risk of infection in adults after UCBT was shown in a study of 27 adult recipients of unrelated UCB that demonstrated a 100 percent incidence of infectious episode, 55 percent incidence of bacteremia, 58 percent incidence of cytomegalovirus antigenemia, and 11 percent incidence of fungal infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39145/abstract/21\">",
"     21",
"    </a>",
"    ]. In this study, the reported TRM at day 100 was 37 percent, with 80 percent of deaths related to infections. Importantly, more than half of the infections occurred after myeloid recovery.",
"   </p>",
"   <p>",
"    The high rate of infection after myeloid recovery has sparked interest in the recovery of lymphocyte populations after UCBT and their impact on infection. A study of lymphocyte subset reconstitution in children after UCBT demonstrated that, when compared with bone marrow transplant, the median time to reach CD8+ T cell recovery was delayed (7.7 versus 2.8 months), while the median time to reach CD19+ B cell recovery was shorter (3.2 months versus 6.4 months), and the median time to CD4+ T cell reconstitution was similar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39145/abstract/24\">",
"     24",
"    </a>",
"    ]. Another study of immune reconstitution after double UCBT in the setting of high-risk hematologic disease demonstrated decreased T cell and B cell counts with expansion of natural killer cells until nine months post-transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39145/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H426440357\">",
"    <span class=\"h4\">",
"     Graft-versus-host disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients undergoing allogeneic hematopoietic cell transplantation, the incidence and severity of acute and chronic graft-versus-host disease (GVHD) increases with increasing HLA-mismatch. While the incidence of GVHD does appear to increase with increasing HLA-disparity among recipients of UCB, published data from most of the UCB registries have shown that, despite the infusion of an HLA class I and II disparate graft, the incidence and severity of acute and chronic GVHD has been lower than previously reported in recipients of matched unrelated donor marrow or partially-matched family member marrow allograft. In these series of UCBT recipients, the majority of whom are children, the overall incidence of grade II-IV acute GVHD and grade III-IV acute GVHD were between 30 and 50 percent and 10 and 20 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39145/abstract/3-14\">",
"     3-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following studies investigated the relationship between GVHD and HLA-disparity among UCBT recipients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A matched-pair analysis demonstrated a similar rate of acute and chronic GVHD between pediatric recipients of zero to 3 HLA-antigen mismatched",
"      <sup>",
"      </sup>",
"      unrelated donor UCB grafts as compared with those receiving HLA-matched unrelated donor marrow graft [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/14/39145/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A multivariate analysis of data from one of the largest series revealed a significant association between the acute GVHD and HLA disparity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/14/39145/abstract/27\">",
"       27",
"      </a>",
"      ]. The incidence of grade III to IV acute GVHD in patients with no mismatch, one antigen HLA mismatch, and two or more antigen mismatch were 8 percent, 19 percent and 28 percent, respectively.",
"     </li>",
"     <li>",
"      Another study analyzed the relative risk of acute GVHD in 265",
"      <sup>",
"      </sup>",
"      consecutive patients receiving transplants with UCB graft composed",
"      <sup>",
"      </sup>",
"      of one unit (80 patients) or two units (185 patients) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/14/39145/abstract/28\">",
"       28",
"      </a>",
"      ]. There were similar rates of grade",
"      <span class=\"nowrap\">",
"       III/IV",
"       <sup>",
"       </sup>",
"      </span>",
"      acute GVHD among those receiving one or two units. However, the incidence",
"      <sup>",
"      </sup>",
"      of grade II to IV acute GVHD was significantly higher among double UCBT recipients",
"      <sup>",
"      </sup>",
"      (58 versus 39 percent). Three risk factors for grade II to IV",
"      <sup>",
"      </sup>",
"      acute GVHD were identified in multiple regression analysis:",
"      <sup>",
"      </sup>",
"      use of two UCB units, use of nonmyeloablative conditioning, and",
"      <sup>",
"      </sup>",
"      absence of antithymocyte globulin in the conditioning regimen.",
"      <sup>",
"      </sup>",
"      Despite the increased GVHD, transplantation-related mortality (TRM) at one year was significantly lower after double UCBT (24 versus 39 percent)",
"      <sup>",
"      </sup>",
"      even if recipients had grade II to IV acute GVHD (20 versus 39 percent). These data suggest that, despite a higher incidence",
"      <sup>",
"      </sup>",
"      of grade II acute GVHD in recipients of two partially HLA-matched",
"      <sup>",
"      </sup>",
"      UCB units, there is no adverse effect on TRM.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Together, these studies suggest that, while the incidence of GVHD increases with increasing HLA-disparity among patients undergoing UCBT, the incidence is lower than that of patients undergoing a matched unrelated donor marrow transplant with similar HLA-disparity. In addition, although the rate of GVHD is higher among recipients of double UCBT, there does not appear to be an adverse effect on TRM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61606886\">",
"    <span class=\"h4\">",
"     Organ toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of myeloablative preparative regimens is complicated by toxicity to non-marrow organs such as gastrointestinal tract, liver, lung, and heart. While the specific organ toxicity varies with the preparative regimen used, these toxicities are the major limitation in applying myeloablative preparative regimens to older adults and patients with comorbidities. In one series, 35 percent of deaths after UCBT were related to the preparative regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39145/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/34/25130?source=see_link&amp;anchor=H3#H3\">",
"     \"Preparative regimens for hematopoietic cell transplantation\", section on 'Common toxicities'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1254202\">",
"    <span class=\"h2\">",
"     Non-myeloablative preparative regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to UCBT using a myeloablative conditioning regimen, the published series on non-myeloablative UCBT involves smaller cohorts of patients with either refractory hematological malignancies, or patients who were otherwise poor candidates for a conventional transplant approach. Because most non-myeloablative UCBT are performed in situations where standard transplants would not be considered, no comparative studies between myeloablative and non-myeloablative UCBT are likely to be performed in the near future. In general, we reserve non-myeloablative conditioning regimens for patients who are not candidates for myeloablative regimens due to older age or comorbidities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61606967\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial studies suggest that non-myeloablative preparative regimens followed by UCB transplantation (UCBT) are feasible and result in high levels of engraftment in patients who are not candidates for myeloablative preparative regimens. In addition, there is great interest in applying non-myeloablative UCBT to children since many of them have non-malignant conditions that otherwise would not require intensive cytotoxic therapy to address the underlying disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39145/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/34/25130?source=see_link&amp;anchor=H13#H13\">",
"     \"Preparative regimens for hematopoietic cell transplantation\", section on 'Nonmyeloablative and reduced intensity preparative regimens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The successful engraftment of a single UCB graft following a non-myeloablative conditioning regimen consisting of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    <span class=\"nowrap\">",
"     120&nbsp;mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    <span class=\"nowrap\">",
"     2&nbsp;g/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    and antithymocyte globulin (ATG)",
"    <span class=\"nowrap\">",
"     90&nbsp;mg/kg",
"    </span>",
"    was first demonstrated in two adult patients with non-Hodgkin lymphoma (NHL) and reported in 2001 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39145/abstract/30\">",
"     30",
"    </a>",
"    ]. Since then, the largest published experience comes from the University of Minnesota using a preparative regimen consisting of fludarabine",
"    <span class=\"nowrap\">",
"     40&nbsp;mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    cyclophosphamide",
"    <span class=\"nowrap\">",
"     50&nbsp;mg/kg,",
"    </span>",
"    and total body irradiation (TBI) 200&nbsp;cGy",
"    <span class=\"nowrap\">",
"     (Flu/Cy/TBI",
"    </span>",
"    200 cGy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39145/abstract/26,31,32\">",
"     26,31,32",
"    </a>",
"    ]. This preparative regimen is generally preferred to busulfan-based regimens because retrospective analyses have demonstrated that",
"    <span class=\"nowrap\">",
"     Flu/Cy/TBI",
"    </span>",
"    200 cGy provided more reliable sustained donor engraftment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39145/abstract/33,34\">",
"     33,34",
"    </a>",
"    ], although the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35414?source=see_link\">",
"     thiotepa",
"    </a>",
"    to busulfan-based regimens may overcome the difficulty with engraftment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39145/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Retrospective analyses and one prospective trial have evaluated the use of non-myeloablative UCBT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39145/abstract/2,29,31,36-43\">",
"     2,29,31,36-43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective analysis from the University of Minnesota included 110 patients with a median age of 51 years who were transplanted with a single- (15 percent) or double- (85 percent) UCB graft after",
"      <span class=\"nowrap\">",
"       Flu/Cy/TBI",
"      </span>",
"      200&nbsp;cGy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/14/39145/abstract/31\">",
"       31",
"      </a>",
"      ]. Equine ATG",
"      <span class=\"nowrap\">",
"       45&nbsp;mg/kg",
"      </span>",
"      was given to 35 percent of patients who had received fewer than two cycles of chemotherapy prior to initiation of the transplant conditioning regimen. Graft-versus-host disease (GVHD) prophylaxis was provided with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil. Fifteen patients experienced graft failure. The cumulative incidence of neutrophil and platelet recovery was 92 percent and 65 percent, respectively. Treatment-related mortality (TRM) was 19 percent at 180 days and 26 percent at three years following transplantation. In this group of patients with a highly diverse spectrum of hematologic malignancies, overall and event-free survival rates at three years were 45 percent and 38 percent, respectively. This report firmly established the concept that a highly immunosuppressive non-myeloablative bone marrow conditioning regimen was capable of providing reliable engraftment from a mismatched unrelated UCB graft.",
"      <br/>",
"      <br/>",
"      A subset analysis of the 65 patients with T and B cell lymphoma or Hodgkin lymphoma reported three-year rates of TRM, progression-free survival, and overall survival of 15, 34, and 55 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/14/39145/abstract/39\">",
"       39",
"      </a>",
"      ]. These results are comparable to those achieved using non-myeloablative conditioning followed by matched sibling or matched unrelated donor grafts [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/14/39145/abstract/41-43\">",
"       41-43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The French Society for Blood and Marrow Transplantation and Cellular Therapy (SFGM-TC), in collaboration with Eurocord, reported a multicenter retrospective study of UCBT utilizing a regimen similar to the one used by the Minnesota group (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      <span class=\"nowrap\">",
"       50&nbsp;mg/kg,",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      <span class=\"nowrap\">",
"       200&nbsp;mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      and TBI 2&nbsp;Gy) in 155 patients with acute and chronic leukemias (myeloid and lymphoid), myelodysplastic syndrome, Hodgkin lymphoma, and NHL with a median age of 47 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/14/39145/abstract/36\">",
"       36",
"      </a>",
"      ]. Two UCB units were infused in 59 patients (38 percent). The cumulative incidence of neutrophil engraftment was 80&nbsp;percent. Autologous recovery occurred in 14 percent of patients. Grade",
"      <span class=\"nowrap\">",
"       III/IV",
"      </span>",
"      GVHD and chronic GVHD were observed in 12 percent and 39 percent of patients, respectively. The TRM was 18 percent. These data are comparable to those reported by the Minnesota group and seem to confirm the feasibility of this transplant approach.",
"     </li>",
"     <li>",
"      A registry study from the European Blood and Marrow Transplantation (EBMT) group using data from Eurocord&ndash;Netcord included 104 patients with lymphoid malignancies who underwent UCBT, 64 of whom were transplanted with non-myeloablative conditioning [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/14/39145/abstract/40\">",
"       40",
"      </a>",
"      ]. The cumulative incidence of neutrophil engraftment was 84 percent by day 60. The cumulative incidence of relapse or progression was 31 percent, and the probability of progression-free survival was 40 percent at one year.",
"     </li>",
"     <li>",
"      A registry study from the Center for International Blood and Marrow Transplant Research compared outcomes among 584 patients with acute leukemia who underwent reduced intensity conditioning followed by a 7 or 8 of 8 HLA-matched peripheral blood progenitor cell (PBPC) transplantation or a 4 to 6 of 6 matched double unrelated UCBT (dUCBT) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/14/39145/abstract/32\">",
"       32",
"      </a>",
"      ]. Patients who received",
"      <span class=\"nowrap\">",
"       Flu/Cy/TBI",
"      </span>",
"      200 cGy followed by a dUCBT had similar rates of transplantation-related mortality (TRM) and overall mortality to those who received an 8 of 8 matched PBPC transplant, and lower TRM (but not overall mortality) than those who received a 7 of 8 matched PBPC. The probability of survival at two years after",
"      <span class=\"nowrap\">",
"       Flu/Cy/TBI",
"      </span>",
"      cGy followed by a dUCBT was 38 percent. Survival at two years was lower for patients who underwent dUCBT following another conditioning regimen (eg, alkylating agent,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      , with or without TBI).",
"     </li>",
"     <li>",
"      The Blood and Marrow Transplant Clinical Trials Network performed two parallel multicenter phase 2 trials using non-myeloablative conditioning followed by either double unrelated UCBT (50 patients) or partially HLA-mismatched (haploidentical) related bone marrow (50 patients) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/14/39145/abstract/2\">",
"       2",
"      </a>",
"      ]. Patients who underwent",
"      <span class=\"nowrap\">",
"       Flu/Cy/TBI",
"      </span>",
"      200 cGy followed by UCBT had a median time to recovery of neutrophils",
"      <span class=\"nowrap\">",
"       &gt;500/microL",
"      </span>",
"      of 15 days (94 percent recovered by day +56) and a median time to recovery of platelets",
"      <span class=\"nowrap\">",
"       &ge;20,000/microL",
"      </span>",
"      of 38 days (82 percent recovered by day +100). Primary and secondary graft failure occurred in five patients and one patient, respectively, and two patients had autologous bone marrow reconstitution. Grade",
"      <span class=\"nowrap\">",
"       III/IV",
"      </span>",
"      acute GVHD was seen in 21 percent and chronic GVHD occurred in 25 percent. One-year rates of non-relapse mortality and",
"      <span class=\"nowrap\">",
"       relapse/progression",
"      </span>",
"      were 24 and 31 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These encouraging observations were a result of selective ablation of the lymphoid cells using lymphotoxic agents, large progenitor cell doses and drugs to prevent host-versus-graft as well as GVHD. While the total numbers of mononuclear cells in UCB are limited, the progenitor content and the proliferative potential of cord blood cells are high. Non-myeloablative preparative regimens allow engraftment of the UCB stem cells, establishing full-donor chimerism with a lower risk of transplantation-related morbidity in older patients and in patients who are deemed unfit to undergo transplantation using conventional myeloablative preparative regimens.",
"   </p>",
"   <p>",
"    The nature and extent of prior cytotoxic therapy is recognized as an important factor in the likelihood of donor stem cell engraftment following non-myeloablative bone marrow conditioning. It is assumed that patients carrying the diagnosis of acute leukemia or lymphoma will have had significant cytotoxic chemotherapy exposure prior to transplantation. In contrast, many patients with chronic phase chronic myeloid leukemia or myelodysplastic syndrome, and certainly those patients with non-malignant conditions, will enter UCBT with little or no prior cytotoxic therapy. Prior cytotoxic chemotherapy exposure is not specifically addressed in the published non-myeloablative UCBT studies to date. It should be noted that fewer than 5 percent of the patients in the largest of the prospective studies carried the diagnosis of myelodysplastic syndrome or non-malignant disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39145/abstract/31,37\">",
"     31,37",
"    </a>",
"    ]. Therefore, the likelihood of donor engraftment of the UCB stem cells following non-myeloablative conditioning may be considerably lower in the previously untreated subset of patients compared with what is reported in these studies. (See",
"    <a class=\"local\" href=\"#H61606814\">",
"     'Choice of preparative regimen'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61607183\">",
"    <span class=\"h4\">",
"     Regimen intensity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal intensity of non-myeloablative preparative regimens is uncertain, and several factors must be considered, including the aggressiveness of the underlying disease, the age of the patient and the immunocompetence of the recipients, and the genetic disparity between the donor and recipient. A wide range of non-myeloablative conditioning regimens has been employed. These regimens are designed not to eradicate the underlying malignancy but to provide sufficient immunosuppression to facilitate engraftment. The question posed is how immunosuppressed the patients need to be to overcome the risk of graft rejection. The benefit of reduced toxicity with non-myeloablative regimens may be offset by the loss of cytoreduction induced by high dose chemotherapy.",
"   </p>",
"   <p>",
"    As noted above, the use of non-myeloablative UCBT has generally been less successful in aggressive malignancies that are likely to recur rapidly and outpace immune reconstitution. Given the increasing indication of applying non-myeloablative UCBT in older patients with refractory malignancies, future efforts may focus on the development of a more tolerable regimen that has broad anti-neoplastic and immunosuppressive activity that not only facilitates engraftment, but also provides some disease control. The challenge becomes greater when mismatched UCBT is used, where HLA disparity and lower cell dose is associated with higher risk of graft rejection. Further studies are necessary to define the best regimen that reduces the risk of rejection without increasing the risk of relapse and regimen-related toxicity. (See",
"    <a class=\"local\" href=\"#H61606814\">",
"     'Choice of preparative regimen'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H426440669\">",
"    <span class=\"h3\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-myeloablative preparative regimens are considered to have a better toxicity profile than myeloablative preparative regimens with less non-hematopoietic organ toxicity, improved immune reconstitution, and possibly less graft-versus-host disease. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61607001\">",
"    <span class=\"h4\">",
"     Immune reconstitution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients undergoing bone marrow or mobilized peripheral blood progenitor cell transplantation, non-myeloablative preparative regimens have been associated with a more rapid reconstitution of T cell repertoire complexity than that seen following myeloablative preparative regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39145/abstract/44\">",
"     44",
"    </a>",
"    ]. There is a paucity of data regarding the immune reconstitution of UCB recipients following non-myeloablative preparative regimens. One study compared immune recovery in five recipients of UCBT following a non-myeloablative preparative regimen with recovery in adult recipients of UCB following a myeloablative regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39145/abstract/45\">",
"     45",
"    </a>",
"    ]. When compared with those receiving a myeloablative preparative regimen, patients receiving a non-myeloablative preparative regimen demonstrated the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A shorter time to the recovery of normal absolute lymphocyte count (6 to 12 versus 24 months)",
"     </li>",
"     <li>",
"      Higher numbers of phenotypically na&iuml;ve (CD45RA+) T cells at 12 months after transplantation with this rapidly expanding na&iuml;ve population outnumbering the memory cells",
"     </li>",
"     <li>",
"      A markedly more diverse and robust T cell repertoire at similar time points",
"     </li>",
"     <li>",
"      Shorter time to detection of T cell receptor excision circle (TREC), which are generated within the thymus and identify new thymic emigrants and those that have not divided (12 months versus 18 to 24 months after transplantation)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The above study demonstrated that adults receiving a non-myeloablative preparatory regimen followed by UCBT have a rapid quantitative and qualitative recovery of peripheral T cells with a complex diversity. The ability of patients receiving non-myeloablative transplantation to recover within a few months suggests that the peripheral &ldquo;niches&rdquo; in which T cells can proliferate are preserved in these patients compared with those receiving myeloablative regimens. Moreover, the presence of TREC-positive cells within one year suggests that thymic recovery is likewise accelerated in recipients of non-myeloablative regimens compared with recipients of myeloablative regimens. These favorable results of T cell recovery suggest that it may be possible to have an excellent outcome with an unrelated mismatched UCBT in adult patients who are unable to undergo myeloablative conditioning. The primary difference between the recipients of myeloablative and nonmyeloablative regimens is the extent of physiologic damage caused by the preparatory regimen. When the damage is relatively mild, as in non-myeloablative regimen, the donor T cells are able to expand effectively in the periphery and the development of new T cells through the thymus is also accelerated compared with the rate of development in those receiving ablative regimens. Alternatively, the lower incidence of graft-versus-host disease (GVHD) in non-myeloablative UCBT may also play an important role in the preservation of the peripheral and central niches for T cell development.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61607107\">",
"    <span class=\"h4\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients receiving UCBT following a non-myeloablative preparative regimen have a shorter period of neutropenia and more rapid immune reconstitution with more diverse T cell repertoire [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39145/abstract/45\">",
"     45",
"    </a>",
"    ]. Whether the more favorable immune recovery can be translated into faster development of effective immune responses against opportunistic infections, and therefore improved transplantation outcome, remains to be determined in clinical trials.",
"   </p>",
"   <p>",
"    Our clinical observations suggest that recipients of nonmyeloablative HSCT may have different, but not necessarily decreased, risks for invasive bacterial, viral, and fungal infections.",
"    <sup>",
"    </sup>",
"    One of the main reasons is due to the employment of differing non-myeloablative or reduced-intensity regimens, and each of these regimens varies in its hematological and non-hematological toxicities. The risk of infection in both myeloablative and non-myeloablative allogeneic hematopoietic cell transplant recipients are dependent on the degree of",
"    <span class=\"nowrap\">",
"     immuno/myeloablation,",
"    </span>",
"    severity of GVHD and its immunosuppressive therapies, as well as the rate of immune reconstitution. Preliminary results suggest that non-myeloablative conditioning regimens may decrease risks of bacterial infections associated with mucosal damage and persistent neutropenia; however, risks for late viral and fungal infections persist during severe GVHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39145/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1254244\">",
"    <span class=\"h4\">",
"     Graft-versus-host disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;UCBT has been associated with a reduced risk of developing severe GVHD in children and adults, even when cells from partially HLA-mismatched donors are used. Non-myeloablative preparative regimens were introduced with the hope that patients would experience less GVHD following reduced intensity conditioning regimens. This was based on the hypothesis that less tissue injury would occur due to lower dose of cytotoxic agents and the induction of mixed chimerism could reduce the incidence of GVHD. However, GVHD remains the significant cause of morbidity and mortality following non-myeloablative conditioning. Previously published reports on non-myeloablative have shown a 38 to 60 percent incidence of grade II to IV of acute GVHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/14/39145/abstract/31\">",
"     31",
"    </a>",
"    ].",
"    <sup>",
"    </sup>",
"    The early data suggest that the incidence of acute GVHD is somewhat lower compared with myeloablative regimens.",
"   </p>",
"   <p>",
"    In addition, studies on immune recovery have shed some light of hope that patients undergoing non-myeloablative UCBT may experience less GVHD. These studies on immune reconstitution among patients receiving following UCBT and bone marrow transplantation have demonstrated the potential benefit of minimizing thymic damage through non-myeloablative conditioning. The early restoration of thymic function could allow early dominance of thymus-dependent phase and thus preventing the exclusive expansion of peripheral T cell clones. In addition, the increased level of T cell repertoire complexity observed in patients receiving non-myeloablative regimens may lead to increased numbers of alloreactive immunoregulatory cells such as those marked by CD4",
"    <sup>",
"     +",
"    </sup>",
"    CD25",
"    <sup>",
"     +",
"    </sup>",
"    expression and thereby suppressing GVHD. Nevertheless, determining whether the incidence and severity of GVHD following non-myeloablative conditioning and UCBT is lower than myeloablative UCBT will require clinical trials in comparable groups of patients.",
"   </p>",
"   <p>",
"    GVHD remains the leading cause of death among patients receiving non-myeloablative conditioning. Thus, optimizing the GVHD prophylaxis regimen is of paramount importance in improving the transplantation outcome. Although acute GVHD tends to be less severe after a non-myeloablative preparative regimen, it frequently occurs after the early termination of immunosuppressive therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1254265\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Umbilical cord blood (UCB), the blood remaining in the umbilical cord and placenta following the birth of an infant, has emerged as an established alternative source of hematopoietic stem cells in allogeneic hematopoietic cell transplantation.",
"     </li>",
"     <li>",
"      UCB transplantation (UCBT) has been performed in adults using both myeloablative and non-myeloablative preparative regimens. These approaches have not been compared directly in a prospective trial. As such, the ideal preparative regimen prior to UCB infusion is unknown and clinical practice varies by institution. For younger patients without comorbidities, we suggest a myeloablative preparative regimen such as those used in the initial studies of UCBT (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, many older patients and patients with co-morbidities are not candidates for myeloablative preparative regimens due to high rates of morbidity and mortality with this approach. Non-myeloablative conditioning regimens are an acceptable alternative for such patients. (See",
"      <a class=\"local\" href=\"#H61606814\">",
"       'Choice of preparative regimen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Myeloablative UCBT is associated with an overall probability of engraftment between 80 and 90 percent. There is a significant delay in the time of neutrophil recovery, with the median time to absolute neutrophil count",
"      <span class=\"nowrap\">",
"       &gt;500/microL",
"      </span>",
"      ranging between 22 to 30 days. (See",
"      <a class=\"local\" href=\"#H61606828\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Myeloablative UCBT can be associated with a transplant-related mortality as high as 50 percent in adults, although studies using modern regimens suggest that transplant-related mortality is decreasing. When compared with recipients of bone marrow or peripheral blood progenitor cells, adults receiving UCB have a higher risk of opportunistic infections for at least two years after transplantation, accounting for up to half of all treatment-related-deaths. Despite a higher degree of HLA disparity, grade II to IV graft-versus-host disease (GVHD), especially chronic GVHD, is lower than in recipients of unrelated bone marrow or peripheral blood grafts from adult donors. (See",
"      <a class=\"local\" href=\"#H426439939\">",
"       'Toxicity and transplant-related mortality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Non-myeloablative UCBT is associated with an overall probability of engraftment between 80 and 90 percent. When compared with myeloablative regimens, there is a faster time to neutrophil recovery, with a median time to recovery of neutrophils",
"      <span class=\"nowrap\">",
"       &gt;500/microL",
"      </span>",
"      of approximately 15 days. (See",
"      <a class=\"local\" href=\"#H61606967\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Non-myeloablative UCBT is associated with a non-relapse mortality rate of approximately 25 percent. Non-myeloablative preparative regimens are considered to have a better toxicity profile than myeloablative preparative regimens with less non-hematopoietic organ toxicity and improved immune reconstitution. Initial studies also suggest that patients undergoing non-myeloablative UCBT experience less GVHD. (See",
"      <a class=\"local\" href=\"#H426440669\">",
"       'Toxicity'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39145/abstract/1\">",
"      Barker JN, Weisdorf DJ, DeFor TE, et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005; 105:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39145/abstract/2\">",
"      Brunstein CG, Fuchs EJ, Carter SL, et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 2011; 118:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39145/abstract/3\">",
"      Rocha V, Wagner JE Jr, Sobocinski KA, et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N Engl J Med 2000; 342:1846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39145/abstract/4\">",
"      Gluckman E, Rocha V, Boyer-Chammard A, et al. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med 1997; 337:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39145/abstract/5\">",
"      Rubinstein P, Carrier C, Scaradavou A, et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 1998; 339:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39145/abstract/6\">",
"      Eapen M, Rubinstein P, Zhang MJ, et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet 2007; 369:1947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39145/abstract/7\">",
"      Wagner JE, Barker JN, DeFor TE, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002; 100:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39145/abstract/8\">",
"      Wagner JE, Kernan NA, Steinbuch M, et al. Allogeneic sibling umbilical-cord-blood transplantation in children with malignant and non-malignant disease. Lancet 1995; 346:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39145/abstract/9\">",
"      Locatelli F, Rocha V, Chastang C, et al. Factors associated with outcome after cord blood transplantation in children with acute leukemia. Eurocord-Cord Blood Transplant Group. Blood 1999; 93:3662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39145/abstract/10\">",
"      Kurtzberg J, Laughlin M, Graham ML, et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 1996; 335:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39145/abstract/11\">",
"      Wagner JE, Rosenthal J, Sweetman R, et al. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease. Blood 1996; 88:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39145/abstract/12\">",
"      Cairo MS, Wagner JE. Placental and/or umbilical cord blood: an alternative source of hematopoietic stem cells for transplantation. Blood 1997; 90:4665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39145/abstract/13\">",
"      Verneris MR, Brunstein CG, Barker J, et al. Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood 2009; 114:4293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39145/abstract/14\">",
"      Gluckman E. Current status of umbilical cord blood hematopoietic stem cell transplantation. Exp Hematol 2000; 28:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39145/abstract/15\">",
"      Rocha V, Cornish J, Sievers EL, et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 2001; 97:2962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39145/abstract/16\">",
"      Rocha V, Labopin M, Sanz G, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004; 351:2276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39145/abstract/17\">",
"      Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004; 351:2265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39145/abstract/18\">",
"      Hwang WY, Samuel M, Tan D, et al. A meta-analysis of unrelated donor umbilical cord blood transplantation versus unrelated donor bone marrow transplantation in adult and pediatric patients. Biol Blood Marrow Transplant 2007; 13:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39145/abstract/19\">",
"      Eapen M, Rocha V, Sanz G, et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol 2010; 11:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39145/abstract/20\">",
"      Gluckman E. Hematopoietic stem-cell transplants using umbilical-cord blood. N Engl J Med 2001; 344:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39145/abstract/21\">",
"      Saavedra S, Sanz GF, Jarque I, et al. Early infections in adult patients undergoing unrelated donor cord blood transplantation. Bone Marrow Transplant 2002; 30:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39145/abstract/22\">",
"      Risdon G, Gaddy J, Broxmeyer HE. Allogeneic responses of human umbilical cord blood. Blood Cells 1994; 20:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39145/abstract/23\">",
"      Barker JN, Scaradavou A, Stevens CE. Combined effect of total nucleated cell dose and HLA match on transplantation outcome in 1061 cord blood recipients with hematologic malignancies. Blood 2010; 115:1843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39145/abstract/24\">",
"      R&eacute;nard C, Barlogis V, Mialou V, et al. Lymphocyte subset reconstitution after unrelated cord blood or bone marrow transplantation in children. Br J Haematol 2011; 152:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39145/abstract/25\">",
"      Ruggeri A, Peffault de Latour R, Carmagnat M, et al. Outcomes, infections, and immune reconstitution after double cord blood transplantation in patients with high-risk hematological diseases. Transpl Infect Dis 2011; 13:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39145/abstract/26\">",
"      Barker JN, Davies SM, DeFor T, et al. Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: results of a matched-pair analysis. Blood 2001; 97:2957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39145/abstract/27\">",
"      Rubinstein P, Stevens CE. Placental blood for bone marrow replacement: the New York Blood Center's program and clinical results. Baillieres Best Pract Res Clin Haematol 2000; 13:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39145/abstract/28\">",
"      MacMillan ML, Weisdorf DJ, Brunstein CG, et al. Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors. Blood 2009; 113:2410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39145/abstract/29\">",
"      Pulsipher MA, Boucher KM, Wall D, et al. Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313. Blood 2009; 114:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39145/abstract/30\">",
"      Rizzieri DA, Long GD, Vredenburgh JJ, et al. Successful allogeneic engraftment of mismatched unrelated cord blood following a nonmyeloablative preparative regimen. Blood 2001; 98:3486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39145/abstract/31\">",
"      Brunstein CG, Barker JN, Weisdorf DJ, et al. Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood 2007; 110:3064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39145/abstract/32\">",
"      Brunstein CG, Eapen M, Ahn KW, et al. Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes. Blood 2012; 119:5591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39145/abstract/33\">",
"      Komatsu T, Narimatsu H, Yoshimi A, et al. Successful engraftment of mismatched unrelated cord blood transplantation following reduced intensity preparative regimen using fludarabine and busulfan. Ann Hematol 2007; 86:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39145/abstract/34\">",
"      Horwitz ME, Morris A, Gasparetto C, et al. Myeloablative intravenous busulfan/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients. Biol Blood Marrow Transplant 2008; 14:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39145/abstract/35\">",
"      Sanz J, Sanz MA, Saavedra S, et al. Cord blood transplantation from unrelated donors in adults with high-risk acute myeloid leukemia. Biol Blood Marrow Transplant 2010; 16:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39145/abstract/36\">",
"      Rocha V, Mohty M, Gluckman E, et al. Reduced-intensity conditioning regimens before unrelated cord blood transplantation in adults with acute leukaemia and other haematological malignancies. Curr Opin Oncol 2009; 21 Suppl 1:S31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39145/abstract/37\">",
"      Uchida N, Wake A, Takagi S, et al. Umbilical cord blood transplantation after reduced-intensity conditioning for elderly patients with hematologic diseases. Biol Blood Marrow Transplant 2008; 14:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39145/abstract/38\">",
"      Yuji K, Miyakoshi S, Kato D, et al. Reduced-intensity unrelated cord blood transplantation for patients with advanced malignant lymphoma. Biol Blood Marrow Transplant 2005; 11:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39145/abstract/39\">",
"      Brunstein CG, Cantero S, Cao Q, et al. Promising progression-free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation. Biol Blood Marrow Transplant 2009; 15:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39145/abstract/40\">",
"      Rodrigues CA, Sanz G, Brunstein CG, et al. Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 2009; 27:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39145/abstract/41\">",
"      Dean RM, Fowler DH, Wilson WH, et al. Efficacy of reduced-intensity allogeneic stem cell transplantation in chemotherapy-refractory non-hodgkin lymphoma. Biol Blood Marrow Transplant 2005; 11:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39145/abstract/42\">",
"      Faulkner RD, Craddock C, Byrne JL, et al. BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood 2004; 103:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39145/abstract/43\">",
"      Vigouroux S, Michallet M, Porcher R, et al. Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Haematologica 2007; 92:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39145/abstract/44\">",
"      Morecki S, Gelfand Y, Nagler A, et al. Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen. Bone Marrow Transplant 2001; 28:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39145/abstract/45\">",
"      Chao NJ, Liu CX, Rooney B, et al. Nonmyeloablative regimen preserves \"niches\" allowing for peripheral expansion of donor T-cells. Biol Blood Marrow Transplant 2002; 8:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/14/39145/abstract/46\">",
"      Bhushan V, Collins RH Jr. Chronic graft-vs-host disease. JAMA 2003; 290:2599.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15767 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-1A4E1675F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_14_39145=[""].join("\n");
var outline_f38_14_39145=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1254265\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1254160\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H61606400\">",
"      CORD BLOOD AS A RESOURCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H61606408\">",
"      CORD BLOOD UNIT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H61605612\">",
"      PREPARATIVE REGIMEN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H61606814\">",
"      Choice of preparative regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1254174\">",
"      Myeloablative preparative regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H61606828\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H426439939\">",
"      - Toxicity and transplant-related mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H61606857\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H426440357\">",
"      Graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H61606886\">",
"      Organ toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1254202\">",
"      Non-myeloablative preparative regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H61606967\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H61607183\">",
"      Regimen intensity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H426440669\">",
"      - Toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H61607001\">",
"      Immune reconstitution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H61607107\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1254244\">",
"      Graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1254265\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/47/11002?source=related_link\">",
"      Collection and storage of umbilical cord blood for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/38/26218?source=related_link\">",
"      Donor selection for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/34/25130?source=related_link\">",
"      Preparative regimens for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/31/15865?source=related_link\">",
"      Selection of an umbilical cord blood graft for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_14_39146="Child asthma action plan PI";
var content_f38_14_39146=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F78132&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F78132&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 628px\">",
"   <div class=\"ttl\">",
"    Child asthma action plan",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 608px; height: 789px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAMVAmADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3lvEHiO81zW7PQ9D0ie20y6S0aa81WSB5HaCKYkItvIAAJgPvdj0qb7d44/6F7w3/AOD6f/5Do8G/8jH47/7DUf8A6brOuqoA5X7d44/6F7w3/wCD6f8A+Q6Pt3jj/oXvDf8A4Pp//kOuqqG9uobKznurqQRW8EbSySN0VVGST9AKAOb+3eOP+he8N/8Ag+n/APkOj7d44/6F7w3/AOD6f/5Drz3TPiB8RfGtjda74B8PaHH4cidxbnV5JftF+EOCY1QgKSQR83Ge5wad4o+LuraZ4T8F6g2jJompazqa2V5a6zFIn2aMEiRxkoccqwY8YPI9AD0D7d44/wChe8N/+D6f/wCQ6Pt3jj/oXvDf/g+n/wDkOofDnxJ8J+J7TVp/D+tQXi6YhkuvkkTy1AJ3YZQWXg8qCK8yu/i/4jg8HeD762fw3qWpeIdZNjFJaW90tv5IbYdqylJN4c4yePY9aAPU/t3jj/oXvDf/AIPp/wD5Do+3eOP+he8N/wDg+n/+Q6oa78WPBGheIJND1PxBbQ6qg+aEq5CnGdrOBsU+xIPI9ai+B/i/VfHXw/ttf1y3s7ee5mlWNLVWVNiMVB+ZmOchu9AGp9u8cf8AQveG/wDwfT//ACHR9u8cf9C94b/8H0//AMh1wnx8+Ld/4Dls9N8LWdrqGtPE95dJcIzpb2yjG5grKQSehzj5T6ivQT4w0my8EWPibW763sdOntYbgyuSF/eKGAA6knPAGTQBD9u8cf8AQveG/wDwfT//ACHR9u8cf9C94b/8H0//AMh1n6J8WvA+t6TqmpaZr8M1ppkRnuyYZUeOP+9sZQzDt8oPPHWvPr39oG3vfh54v8QeHoLf7VpN3Db2lvdRyESxyOqrI5G0ZYCUhA2Rs560Aeo/bvHH/QveG/8AwfT/APyHR9u8cf8AQveG/wDwfT//ACHVHwV8TfDPibUItFtNas7jxAkCyXFvArhN4UFwjEbWAJPRmxVOb41fDyEoJvE1tGzXLWgDQygiRSAcjbwuT984XrzwcAG19u8cf9C94b/8H0//AMh0fbvHH/QveG//AAfT/wDyHUehfEjwhr3iafw/o+u213q0IYtDGGwdv3tr42tj/ZJ71RuPi94DtvEv9gTeJLVdUE3kFNkhRZM42mTbsBzxy3WgDS+3eOP+he8N/wDg+n/+Q6Pt3jj/AKF7w3/4Pp//AJDrqq8J8TfG29s/i/Y+HNHsrSfw6moQaXf38iOzLcyE5RGDBRtxg5B5VvagD0z7d44/6F7w3/4Pp/8A5Do+3eOP+he8N/8Ag+n/APkOrXjLxn4e8F2Ed54n1SHT4JW2x7wzPIR12ooLNjjOBxkVzmufGHwdpngU+KoNUS+095DbwLAjb5ZwpYRbSMoSB1YADIz1GQDZ+3eOP+he8N/+D6f/AOQ6Pt3jj/oXvDf/AIPp/wD5DrhbX4sza3pvgKbRL3Q7W78Q3Bjnt723u3OFZRIkJRAC67sbnIQkcHGcdRrfxf8AAWia82jan4ktIdQRtjoEkdY29GdVKKR3BIx3xQBpfbvHH/QveG//AAfT/wDyHR9u8cf9C94b/wDB9P8A/IdSeJPHfhnw1c6bBrmr29m2opJJas4YpIqKGZt4BVRgjkkZ7Zp3grxx4c8b21zP4W1SO/jtnEc21HRkJ6ZVwDg4ODjBwfSgCH7d44/6F7w3/wCD6f8A+Q6Pt3jj/oXvDf8A4Pp//kOub+MHjbX/AA5rfhLQ/CMOky6rr1xJCp1JZDGioF5OxgRy3Xnp0rL0jx5400X4m6R4U8f2nhx01a2lngudGaYCHy1Zj5glOcYTsB16nnAB3H27xx/0L3hv/wAH0/8A8h0fbvHH/QveG/8AwfT/APyHXE/DP4vx6p8O7/xd46n07SNPXUJLW1MSON8YVSPlyxZ8luFH8PSux0L4leEde8O6nrmk61FcaZpiNJeSCORWhUAnJjKh+inHHODjNAEv27xx/wBC94b/APB9P/8AIdH27xx/0L3hv/wfT/8AyHWdpvxd8CanrGnaVY+IraW/1BUa2i8uQbtwyqklcKx4+ViDyOOa7ugDlft3jj/oXvDf/g+n/wDkOj7d44/6F7w3/wCD6f8A+Q66qigDlft3jj/oXvDf/g+n/wDkOj7d44/6F7w3/wCD6f8A+Q66qigDlft3jj/oXvDf/g+n/wDkOj7d44/6F7w3/wCD6f8A+Q66qigDlft3jj/oXvDf/g+n/wDkOj7d44/6F7w3/wCD6f8A+Q66qigDlft3jj/oXvDf/g+n/wDkOj7d44/6F7w3/wCD6f8A+Q66qigDlft3jj/oXvDf/g+n/wDkOj7d44/6F7w3/wCD6f8A+Q66qigDlft3jj/oXvDf/g+n/wDkOj7d44/6F7w3/wCD6f8A+Q66qigDlft3jj/oXvDf/g+n/wDkOj7d44/6F7w3/wCD6f8A+Q66qigDlft3jj/oXvDf/g+n/wDkOj7d44/6F7w3/wCD6f8A+Q66qigDlft3jj/oXvDf/g+n/wDkOj7d44/6F7w3/wCD6f8A+Q66qigDlft3jj/oXvDf/g+n/wDkOj7d44/6F7w3/wCD6f8A+Q66qigDlft3jj/oXvDf/g+n/wDkOj7d44/6F7w3/wCD6f8A+Q66qigDlft3jj/oXvDf/g+n/wDkOj7d44/6F7w3/wCD6f8A+Q66qigDlft3jj/oXvDf/g+n/wDkOj7d44/6F7w3/wCD6f8A+Q66qigDlft3jj/oXvDf/g+n/wDkOj7d44/6F7w3/wCD6f8A+Q66qigDlft3jj/oXvDf/g+n/wDkOj7d44/6F7w3/wCD6f8A+Q66qigDlft3jj/oXvDf/g+n/wDkOj7d44/6F7w3/wCD6f8A+Q66qigDlft3jj/oXvDf/g+n/wDkOj7d44/6F7w3/wCD6f8A+Q66qigDlft3jj/oXvDf/g+n/wDkOj7d44/6F7w3/wCD6f8A+Q66qigDlft3jj/oXvDf/g+n/wDkOj7d44/6F7w3/wCD6f8A+Q66qigDlft3jj/oXvDf/g+n/wDkOj7d44/6F7w3/wCD6f8A+Q66qigDlft3jj/oXvDf/g+n/wDkOjS9e1z/AISq10bXtI020+1WVxeRTWWpPc/6l4UZWVoI8Z88EEE/dPFdVXK6l/yVPw9/2BdT/wDR9hQAeDf+Rj8d/wDYaj/9N1nXVVyvg3/kY/Hf/Yaj/wDTdZ11VABXN/EnSrrXPh94j0vTuby70+eGFc43OyEBc+/T8a6SigD5z+HXxh0Xwr8NNK8OLpeq3PjLT4vsv9gpaSLNJLk87tpABznu3P3TV3x6s3jH4yfCjSdf0yK2aO2n1S8095BOsTbchGOAGw0QHTB5r3+igD5U8Q6iItV+P/iFdsaR28GjJsHVnAgP45UfnUXh7TDJ43+BPhsqNthpbazIuOEaXdNz77ox+Jr6wooA+MdK8U6ToPwc8f8Ah7XrC6l8c3l1O1/FLauxyxULMzkYVVJyMkHccgfNmvoX4d3Fl4C+A2iXuqsIbWx0pLuf13OPMKj1Ys+AO5Nek0UAfKOkeFPiR4n0HxV4xFv4Z2eLbGQMuovcG6gtMHYkWwbR8oUjOc4Un0qca5oGs/s5+CbLxY2uWVmH2LrFhbiaKwmt3ZE87B3YKkYAU57YI4+p6KAPmv4a+JdcuvD/AMRtak8rxDDYaa8em+JF0v7LcX22Nj5Z+UMyqQuc5II5JyK5GSfTdV/Z/wDhr4W0mUzHUNfitLwbGT5yzNIuWAzgzJ8wyOK+wqKAPANce1tv2kYHs7eGC08LeFZbjZGoUIPnGOOgAkXj615gdLS3/Zc0SJIkGpeK9eRZJCo3viSQKT3IHljH+8fWvs6igD561KFbH9oVI9A09Hj8JeEZHtrSNcbnwwVBgdSJVGPrXk8uvXHjGz8JaGL3S4LPU9dhW+0nTNC+xwW0jOB885HzSYyMLnjOSa+3aKAOB+NfjV/BPgqaewUy65fuLLTYVGWed+Acd9vX3OB3r538c+BvHvgb4RRNqqeF307TdTi1eae3kuHvnuWfYGkZgEb74U47Adep+xqKAPnTx5r2maF8d9D8X+MlnXwx/Ym7S7j7O0qLcklsAKDh8E/mp46jG+J0tovwDvtTs/DFz4WTxRrUTX0cjPKwTeXE7KR8gJQfKAByMZyM/Tt7d21haS3V9cQ21rCpeSaZwiIo7ljwB9ah0jVtO1qyF5o9/aahaElRPazLKhI6jcpIyKAPn7Vbq38W/tD+DY/Dr77DTPDzXtozoyjLxv5TYYZA+aE8iuF8O67p2lfBbXfAMuj30/xE1K6kgnsGtHaWR2cbZWfGMKvTnORnoc19kUUAfNuleHBN8avh14Z1pI7xvDXhhJ50cB0E/Kd+oU7CD7Cum/Z/UX/jn4q66gHlXOtfZI2HQiEvz+IdTXtlFAHgHxR0f/hNP2ivDGgDUdS05LDSJb1rrTZ/JniZmZflfBxnaueOhrV8ReANF+HfhDxd4rW91fWNf/sueGPUNYuvtEybk2qqnAGMkds4yM4OK9qooA+QtP1eXwh8PvhdplxDpNjY3iTai2s6jpLX5gmaRmRYkUEh9pXkc/d5ABzRsNQuD8HvjB4j1G7kutS1PUIdNaaW3W3kk2soJaJeEJWQ5HqPxr7LooA+cfF+gWmm658DPCNjbxx+Rci9mCIAxaJY2Zmx3YhyT7V9HUUUAFFFFABRRRQB5B4k0nxJ4g8a+J7fQ7uWA24tUgum127tls2aMEstrGpim9cOQD0PFc/43+KWszzeJ9K0a7soo4bW+8u4jgKzWjW5GQ2J9+5lDkFo4wOGBcAivf6KAPBtV+KWuaTqMttYR6TcRvPKyXc86JBeMPLwkTT3aCPIbPyGTAZcIeSbXi/xz4sGieIGt5tNtYXGrWlr5NtJ9oga2hdw5k83aWIQjhRgkNk42n2+igDzLxVd63c3HgaXw/qsc929vNdkQOUtdR2xI20jc3yOC20kttLA5OOeFvfjBfaJ4cmvbOVJZpLvUbtbXUoyZnhS6ZREpeaPYVXIIUSMoH3MDn6HooA8Z1P4geLoV1K4tjoAtoxrMtur2kzMEsJtgDETAEuO4A29cHO0SaV8T9Y1HxpPpkkOlafZL5gIupYVlgjEHmLcEG5WR0zyVEKjac7+DXsVFAEVq/m2sMnmxzbkDeZEMI+R1Xk8HtyfrUtZGueH7PW3ha8m1OMxAhfsWp3NoDn+8IZF3dO+cVmv4F0ljk3fiPoBx4i1AdBjtPQB1NFcr/wgekf8/niT/wAKPUf/AI/R/wAIHpH/AD+eJP8Awo9R/wDj9AHVUVyv/CB6R/z+eJP/AAo9R/8Aj9H/AAgekf8AP54k/wDCj1H/AOP0AdVRXLP4F0l3Zjd+I8scnHiLUAPyE/FB8C6SUC/a/EeASf8AkYtQzzjv5/tQB1NFcr/wgekf8/niT/wo9R/+P0f8IHpH/P54k/8ACj1H/wCP0AdVRXK/8IHpH/P54k/8KPUf/j9H/CB6R/z+eJP/AAo9R/8Aj9AHVUVyzeBdJYKDd+I/lGBjxFqA755/f89aT/hA9I/5/PEn/hR6j/8AH6AOqorlf+ED0j/n88Sf+FHqP/x+j/hA9I/5/PEn/hR6j/8AH6AOqorlf+ED0j/n88Sf+FHqP/x+lfwLpLHJu/EfQDjxFqA6DHaegDqaK5YeBdJCFftfiPBIP/IxahnjPfz/AHpP+ED0j/n88Sf+FHqP/wAfoA6qiuV/4QPSP+fzxJ/4Ueo//H6P+ED0j/n88Sf+FHqP/wAfoA6qiuV/4QPSP+fzxJ/4Ueo//H6U+BdJKBftfiPAJP8AyMWoZ5x38/2oA6miuV/4QPSP+fzxJ/4Ueo//AB+j/hA9I/5/PEn/AIUeo/8Ax+gDqqK5X/hA9I/5/PEn/hR6j/8AH6P+ED0j/n88Sf8AhR6j/wDH6AOqorlm8C6SwUG78R/KMDHiLUB3zz+/560L4F0lQwF34j+YYOfEWoHvnj9/x0oA6muV1L/kqfh7/sC6n/6PsKs2vhDTbVGWO51xgxyfN1y9kPbu0px0/n6mq2pf8lT8Pf8AYF1P/wBH2FAB4N/5GPx3/wBhqP8A9N1nXVVyvg3/AJGPx3/2Go//AE3WddVQAUUUUAFFFFABRRRQAV4t8T7mXxH8bfBnga6dv7Ca2k1S/t8kLdbfMCI4H3l3R8qeDnkHivaa57xN4M0LxLeWl5q1m7XtoGWC6t7iW2mRWBDKJImVtpBPGcc0AeS/AqbVorv4hnwpZWVxocevvDp1rcXbW1tGoLmQxFI5MDmLChQMHt0PafEbwjqfxG8IQ6Bqeoafod2bhLq4gt2a+SWJCdq5PktgttJOOq4967jQtH07QNLg03RrOGysYBiOGFdqr3P1JPJPU1U1vwxpms3cd1eJdx3aR+Us9pez2smzOSu+J1O3ODjOOB6CgDzf4GXtjdeIvF+nN4W8N6Xq+g3IspNQ0WyW3juUZn4A5ZceWMgseSPSo/ip8SLz4f8AxQ0k6jekeF7jSLiVrTy0/eXMe4rh9u4FvkUDOMkcV6h4a8OaR4Y077DoNjFZ2xcyOEyWkc9WdjlmY4HLEmuJ8a/Dy68ZfE7w7q2tGwPhrQ43lhtwWaee4YqfnBXaEG1Tjcc7enPABwJ8a/Ee2n8KeHrt55vEWv8AmandC2t7ZZbG0BO2CES7Yy4VSSZCSDxz33rfxb4q0HSL2w8dXeoWF9qGpCDQJYrW1uNQuos5KmOItCHAwNxGBu6dK9Q8ReFNG8RXFncapau13ZljbXVvPJbzw7hhgssbK4BHUA4NZV18NPCl3a2kM+nTM1rdNew3AvrgXCzsAGk88P5hY7V5LH7o9BQB5Xo3xK8S2UnxRGo3N7LZ+HbFJLU6nBbLcw3LodqObf8AdsC4Pr2z3FaFndfFiD4V2/ia21iLXtXvbCGSHTV0yKMw+YyuZSQQZHVDtCgKOeQSOe/T4WeDU0XWNITRtun6vMtxfRLdTDznVtwJbfkAHnAIHtW7qvhnStUsrO0uoJVis8fZzb3MsDw4AA2vGysOBjg9KAOO+EPioeJbnVYxreuXNxYBI7rTtc06G1urWRs4J8pVXBCtgYJHc9Kpan4q1jX/AItat4Q0rVToOnaJp63d5exwxyTSyOqsoHmqyKgDgk4ycEZHUd/4c8M6T4bS6Gj2nlPdSebcTSSvNNO/955HJdj9SazfEHw/8M+INVfUtT05mvZYPs00sFzNbmeLIPlyiN1Ei8DhsjtQB85654m174m/Dr4b6ZrN3JFea9rL21wkMSIl1BE65mIKnlSRwPlJByp4x9La9qtn4O8G3F/rOqMltYwAPe3ESsxbhVJSNVBJYgbVAz04pjeCfDp1fRNTXS4o7vRImh08xsyJboy7SAikKeD3BrQ8SaFpvibRLrSNctEvNOuVCywsSA2CCOQQQQQCCCDxQB4rpXjnxNF8UfCGlrqGuXGkapaz3N0NasrOHdEiFhNEIAJEHynCyYPTrnjntZ+JvjHUfhhfeOdN1yTTnvNVXTtI0qC1gdNu7GZGkjZncgN0IAK9OcD23Tfh14d0XVn1rRdP2a6tobSK7u7qe4wmMKG3ucgYAz12jAIFefWHwamu9X0NtQsdJ0XSNNvP7SmstN1C6u0urn1VJVVYEyOQoORxngUAV7vxj4517xr4g8O+HP7R8jw9axQTXWnxWRmnvHQlXkFywUR7lb5UGfl6jIr1n4fS+IZ/BumSeNLeK28QFGF3HEysoYMQDlSVyVCk4OMk1Dq3gTw/quq3OpXFrcw31zGIriayvp7RrhQMASeS678Dgbs8cVv6dZW2m2FtY2MKQWltGsMMSDCoijCqPYACgCxRRRQAUUUUAFFFFABRRRQAUUUUAFFcFf8AxHt9O8Za/od9YvFHpenHUI7rzci52qpeMLt4Yb0xyc7ulP8ADXxL0jVNK0ifURJp99fxRyPbLHJOlsZHKIJJlTYm5gQN5XPagDuqK8+/4WjpNz4gtdO03E1vMsZF5Os0MbF7hIQI8xHzAS5w6nYSMFgMkadr8RvDN3byzWl3dzqnlkLFp1y7yq5YI8SCPdKh2N86Bl460AddRXKaT40tNYTWZ9NRZ7OxtYrqKcOR56ujNjBXK4245yfYYrlvCnxetdWa0k1BdDhtJ7F7+V9P1j7a9kqqrFbhPKTyz82Op+YYxQB6pRXJy/EPw3FZ/aJLq7X960JgOnXIuAyp5hzB5fmABMNuK4xzmopfiX4SiMxbVSYYopJWuFtpmhYJF5zqsoTY7iMFtiktgdKAOxorhbr4m6J9q06105bu6ubu8t7UrJZ3EAiErYBZnjADbfmCEgsuCOCDSeJviNa6J4ri0FdN1G6uWa3V3jtJyi+dKFGGWIqwCCV8g8mMr1ztAO7oqGzuUu7dZolmVGJAEsTxNwSOVYAjp6cjkcGpqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArldS/wCSp+Hv+wLqf/o+wrqq5XUv+Sp+Hv8AsC6n/wCj7CgA8G/8jH47/wCw1H/6brOuqrlfBv8AyMfjv/sNR/8Apus6j13xguieMYNLvLe7ks5bBrkNZ6fcXcocSBcEQq2Fwe4696AOuoryjw98Z9Hnj8P2mslY9V1CC1aYxPFHHFJP9xRG8nmsORkqrhQRuI5qzf8AxYtJNSbTNItJG1KK9tYnimeF/MhkuFhYqElJRvm4Emw8g4xmgD06ivJPCXxYu75kl1vQ7mGzkgsnaW2RCLZrieWIGQmUkqSseNgYjJJA7dZrWq69deK5tD8NyaZavaWMd7PPqEEkwk8x5EREVHTH+qYs+TjIGDQB19FcFefEvTtKv9J03WISt9fRx5e1uIZIRKy52oC6yOMjG5UK8jJFZl18a/DtjDp0uqWl/p4vrZL6NbuS1jYWznCTbTNlg3PyoGcbTlRxkA9Qorz3x54s1bSPFVlpWmSxQxS2Ml0z/wBiXWqOWV1ULst3UqPm+8eO3eo7H4lyJDb22q+GtXGsbbWGeG2EOwXU0YkEK75VOcFiSwAUKct0yAejUVwll8TtIupBCbLU4b0yxQLayxIJGke4eBkGHIzG6MX5wFwwJBFYcfxYE+laLcWdlcTRzS2Ed/qElssVvD9oRJCuzzmdX8tw3G9RkAsTQB6vRXmWk/Gbw/q9uzaXaX95cGSCOK1t5LaSSXzmKoflmKpyORIUZcjIFalx48XRde03QvEdsseqaizywtFLDFDHCZisSs0sql5Qu3csYc5yQMEZAO5ooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOP1n4faPq/iCPWLuS8+1JdxXZVHUIxjTaI2G3JQ4UkZ5KjnGQciH4P+G4L/AE27QyvNZRxxZuLa1uPNCMWXJlhYqfmIzGU7dwDXo9FAHntr8KdIgnsmfU9XuLexWKK0tppIjHBFHMkyRDEYJXKAfMS23jPTCT/CuxuNKt9Nn17X5rG18tba3mkgliiiRXUReW0RSRdshGZFdvlX5uBXodFAHJeFfAWl+GdKu9P0+a8a3ubZLVvNdSVRFZRtwo5w59egqG6+HGh3OlW2nyG6EEWljSJSrqDcwKoCeb8uGZSNykAYJPYkHs6KAPP7D4WaXptpAmlaje6deQSO6X1jbWVtLh02MpWO3EbAgDkoWBAIIxTL34T6Re2tzZ3Gq64+nTCZvsjXKOqTSwNC829kMjOVdz8zMu5icZr0OigDj73wDY3WvLqY1LVIFN1b30tnE8fkzTwKqo7ZQtnaiggMAdo4yM0mpfDjwzqfiweI9Q023udS82OYtLBE4YpE0a5yuSAGB6/eRD/CK7GigDJvxrFlpsa6RHb6teCQ7zqN19lGw5Od0ULAkfKANg45JyOcv7d44/6F7w3/AOD6f/5DrqqKAOV+3eOP+he8N/8Ag+n/APkOlN9422Ajw/4c3ZOR/bs+McY5+x/WupooA5ZL7xsT8/h/w4Bg9NdnPOOP+XP1pPt3jj/oXvDf/g+n/wDkOuqooA5X7d44/wChe8N/+D6f/wCQ6Pt3jj/oXvDf/g+n/wDkOuqooA5X7d44/wChe8N/+D6f/wCQ6Vb7xtht3h/w4DjjGuznJz3/AND44zXU0UAcr9u8cf8AQveG/wDwfT//ACHR9u8cf9C94b/8H0//AMh11VFAHK/bvHH/AEL3hv8A8H0//wAh0fbvHH/QveG//B9P/wDIddVRQBywvvG2wk+H/Dm7IwP7dnxjnPP2P6UJfeNi6h/D/hwLnkjXZyQPp9jrqaKAOV+3eOP+he8N/wDg+n/+Q6Pt3jj/AKF7w3/4Pp//AJDrqqKAOV+3eOP+he8N/wDg+n/+Q6Pt3jj/AKF7w3/4Pp//AJDrqqKAOWS+8bE/P4f8OAYPTXZzzjj/AJc/Wk+3eOP+he8N/wDg+n/+Q66qigDlft3jj/oXvDf/AIPp/wD5Do+3eOP+he8N/wDg+n/+Q66qigDlft3jj/oXvDf/AIPp/wD5DpVvvG2G3eH/AA4DjjGuznJz3/0PjjNdTRQByv27xx/0L3hv/wAH0/8A8h0r33jYOwTw/wCHCueCddnBI+n2OupooA5q3vPGDbvtGheH09NmtTPn65tBUF/uPxQ8ObwA39i6lkA5APn2HeusrldS/wCSp+Hv+wLqf/o+woAPBv8AyMfjv/sNR/8Apus612j0oeJklMsA1s2hVY/O/eG33gk7M/d3Y+bHXjNZHg3/AJGPx3/2Go//AE3WdZPi3wvqWo+Nk1zTFWK7sNOX7FcM4CtOJWLQuOux0O0nGBkEcqKANXRPCPhpF06/0LzkgihiSB7HUp1hmjT7m8JJtlABwC4bjjpUWnfDXwrp08Etrp0we3KGEPezyLEElWVVRWchVDorBQAOvGCc+baR4f8AiBYv4Nt4NPvrSHTl05Lkx6iphMQcfaUZBOqEhSesUm4DhlOBV2Dwd4zh0yKYX2vvqS2UMpR9adlN4LjLAgybSvlcFfuEdQW5oA9GsvAnhyysprS309lgl8jerXMrZ8mVpohksSArsSAOMcdABVnxD4T0fxBcRXGpQT/aI42hE1tdzWzmNuqM0TKWQ/3Tke1efeDdD8ZWmtajL4nk1m7t2Dh47e42R3DGdWR4nN6TGFXPyrFECuQQxwD6FrPi7w1od4LTWvEOj6ddFQ/k3d7FC+09DtZgccHn2oAzX+G/hVrxLldMaJkMLLFDdTRwgwqFjbylcJlVUKDtzjjpVx/BeiH+zjFDd2zafbpaQNaX9xbt5KfcjcxuDIo9Hz1Pqar/APCx/A//AEOXhv8A8GkH/wAVR/wsfwP/ANDl4b/8GkH/AMVQBvHTLQ6wmqGL/T0ga2WXceIywYrjOOqg5xnis7U/CWi6mb1ru0cyXk0VxLJHPJG4ljUKjoysCjAADKkVS/4WP4H/AOhy8N/+DSD/AOKpR8RPBJQuPGHhzaCAT/acGAT0H3vY/lQBLZeCPDllcaPPb6Ygn0lpms5Wkd3Rpc+YzMSS7NkklsnJz1qnD8NvCkMtk8WmOq2YgEUQu5/LJhULEzx79rsqgLuYE44JxU6fETwS7qieMPDjMxwANTgJJ9PvUn/Cx/A//Q5eG/8AwaQf/FUAT6f4L0SwihhgivGggmjnhim1C4mSFo/ubFdyEA/uqAParOueGdM125gm1RbuYQlSIRezpAxVtyl4VcRvhgD8ynoPSs//AIWP4H/6HLw3/wCDSD/4qj/hY/gf/ocvDf8A4NIP/iqAOqorlf8AhY/gf/ocvDf/AINIP/iqVfiJ4Jc4Txh4cY4JwNTgPAGSfvelAHU0Vyv/AAsfwP8A9Dl4b/8ABpB/8VR/wsfwP/0OXhv/AMGkH/xVAHVUVyv/AAsfwP8A9Dl4b/8ABpB/8VR/wsfwP/0OXhv/AMGkH/xVAHVUVyy/ETwSwYr4w8OEKMsRqcHAzjJ+b1IpP+Fj+B/+hy8N/wDg0g/+KoA6qiuWf4ieCUdkfxh4cVlOCDqcAIPp96k/4WP4H/6HLw3/AODSD/4qgDqqK5X/AIWP4H/6HLw3/wCDSD/4qj/hY/gf/ocvDf8A4NIP/iqAOqorlk+Ingl3VE8YeHGZjgAanAST6fepP+Fj+B/+hy8N/wDg0g/+KoA6qiuV/wCFj+B/+hy8N/8Ag0g/+Ko/4WP4H/6HLw3/AODSD/4qgDqqK5X/AIWP4H/6HLw3/wCDSD/4qj/hY/gf/ocvDf8A4NIP/iqAOqorlf8AhY/gf/ocvDf/AINIP/iq6HTb+z1SyivdMu7e8s5RmOe3kWSNxnGQwJB5BFAFmiiigDGvvFXh7T9VTTL/AF7SbXUnKhbSa8jSZi33cITnntxzUl74j0Sw1SDTb7WdNttRnx5VrNdIksmem1CcnPsK4XxTputS3vjWxtvDM2p2+uwRQ29w09utsh8nYTKGk8wBTz8qMeOKoX3hjW7TQfFHh4eH11mXW/uas08KxjMSoGnDt5gMZXK7FfouCDkgA9Fi8U+H5dabSItd0p9WVihslvIzOGHJHl53ZHpitmvFbLwp4pi8R28Tx6xJaQa+NQ8yd7E2LxdGk4JufMILYB4DEV6Y2taR4d0S0l1y9j0WBz5aDV79N+7k7TI0jBjgE/ePFAG9RXK/8LH8D/8AQ5eG/wDwaQf/ABVH/Cx/A/8A0OXhv/waQf8AxVAHVUVyv/Cx/A//AEOXhv8A8GkH/wAVSr8RPBLnCeMPDjHBOBqcB4AyT970oA6miuV/4WP4H/6HLw3/AODSD/4qlf4ieCUOH8YeHFOAcHU4BwRkH73pQB1NFcr/AMLH8D/9Dl4b/wDBpB/8VR/wsfwP/wBDl4b/APBpB/8AFUAdVRXK/wDCx/A//Q5eG/8AwaQf/FUf8LH8D/8AQ5eG/wDwaQf/ABVAHVUVyz/ETwSjsj+MPDispwQdTgBB9PvUn/Cx/A//AEOXhv8A8GkH/wAVQB1VFcr/AMLH8D/9Dl4b/wDBpB/8VR/wsfwP/wBDl4b/APBpB/8AFUAdVRXLJ8RPBLuqJ4w8OMzHAA1OAkn0+9Sf8LH8D/8AQ5eG/wDwaQf/ABVAHVUVyzfETwSoUt4w8OAMMqTqcHIzjI+b1BpP+Fj+B/8AocvDf/g0g/8AiqAOqorlf+Fj+B/+hy8N/wDg0g/+Ko/4WP4H/wChy8N/+DSD/wCKoA6qiuV/4WP4H/6HLw3/AODSD/4qlf4ieCUOH8YeHFOAcHU4BwRkH73pQB1NFcsPiJ4JKFx4w8ObQQCf7TgwCeg+97H8qT/hY/gf/ocvDf8A4NIP/iqAOqorlf8AhY/gf/ocvDf/AINIP/iqP+Fj+B/+hy8N/wDg0g/+KoA6qiuV/wCFj+B/+hy8N/8Ag0g/+KpT8RPBIQOfGHhzaSQD/acGCR1H3vcfnQB1NFcr/wALH8D/APQ5eG//AAaQf/FUf8LH8D/9Dl4b/wDBpB/8VQB1VFcr/wALH8D/APQ5eG//AAaQf/FUf8LH8D/9Dl4b/wDBpB/8VQB1VFcs3xE8EqFLeMPDgDDKk6nByM4yPm9QaF+InglgxXxh4cIUZYjU4OBnGT83qRQB1NcrqX/JU/D3/YF1P/0fYVZtfG/hS7RntPE+hzqpwTFqETAdPRvcfmKral/yVPw9/wBgXU//AEfYUAHg3/kY/Hf/AGGo/wD03Wdb51G1GrDTPN/04wG5Ee0/6sMF3ZxjqcYzmsDwb/yMfjv/ALDUf/pus6j13weut+MYNUvLi7js4rBrYLZ6hcWkpcyBskwsuVwO569qAOi0fU7TWdLtdR02XzrK6jEsMm0ruU9DggEfiKNU1O00uKGS+l8pJp4raM7S2ZJHCIvAPViBnoO9eN6R8I9astY8O3VzeW86afBZxmSK5RJLYw/eWIvayOyN1IEkW7cwOetM0r4U+IxrxvtSfQlhmmt5bqK3Py3BjuklLkCBSSUDjEjSHJxvweAD13Q/Eela7LKmk3YuGiijnbCMoCSFwhyQAcmN+np7iofEHivSNAuIrfUZ5/tMsbSiG2tZrmQRr1dliViqD+8QB715hoPwfubCwUyQaLHqNsunrZTQs37jyLuSWVlPlgoXRx0HJLAnHJ7zW9K1618Vza54aj0u6e7sY7KeDUJ5IRGY3keORGRHz/rXDJgZwvIoA6ixu7e/soLyymSe1njWWKWM5V0YZBB7gg1PXjWufDjxVqnijTdSmu9DdrQ22buNBDKyqm2WPb5LMqklyAsqrg4ZSfmqje/Bm8WHw5Hpz2UMdnp0NtcpbyxwFLpSDJdRO9rMTI3GWHlsdi5bsAD1XXvFmlaHfw2N8b97uaJp1is9PuLtvLBALERI2Bkgc461q6Zf2uqadbX+nzpcWdzGssMqdHUjINcx4g8GrrvjK11O9nuY7GHT5LUraX9xaSl2kRhkxMuVwp4J64471yus/CiF7y+udO03RJUFxZG1tbrcEktYYlRreRtjFVJUNwGBKruBoA9arNn1uxt7Gxu7mSWCG9kihhEsEiOXkICKyFQyEk9GAx3xXmei/C7U7O70cyXNhDpxmMuqWEBcx7Irh7i1hhJA3LGz7TuC5UAAYAAyNP8AhFrlsmjRyNokk9p/Z5/tPzZPtNotvCkbwwjy+ULKZBll5Y5XoQAe60V4f4a+D19aWUdpq/2C4gN1aSXMRnR4btIWYszxpaxZds872kLA4ZjjJ6j4eeB7/wAL+L9ZvVh0620i8WQrFG6Tzu5k3KTJ9njcKBuGxnl6jBAHIB6RRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXK6l/wAlT8Pf9gXU/wD0fYV1VcrqX/JU/D3/AGBdT/8AR9hQAeDf+Rj8d/8AYaj/APTdZ1z/AI91LxH/AMJmmmaBLrvlDTPtPlaSthnzDIVBkN2Pu8AYXmug8G/8jH47/wCw1H/6brOul+zQfazdeRF9qKeV52wb9mc7d3XGecUAeS2Hj7xJoN3qi+KrG3vLW0uba1nmtpgrwzNp0U8ixxhPnXzN5yXBG8AAgcXU+J2qNcWlj/wjtidUvTZvbRpq26ExXKylWeQQ5Vh5JyoVhgggtXoz6Xp7yySvYWjSSTLcO5hUlpVUIHJxywUBQeuAB0qpp3hjQdMXbpuiaXZr5wuMW9pHGPNAID8AfNgkZ68mgDz+x+LlxfalZ2lr4YvZ2xH9t+ziecwlpniOwxwMjKpjZiZGiyOgJyBU+K/xA8Q6F4ug0jQbQMnkRlmENxIzPLMiqcJayD5VSbgE5yeCyhG9Jm8K+Hpri1nm0HSZJ7Qk28jWcZaElixKHGVyxJ47kmr8mnWUt2LuWztnul2YmaJS427tvzYzx5kmPTe3qaAH2bXLwZvYoYZtzDbFKZF27jtO4qvJXBIxwSRk4yZ6y7vR1Olmy0i6l0RTIZBJp8UIYFmLN8skbp8zEknbkkk5zWT/AMIvq/8A0PfiT/vxp3/yLQB1VFcr/wAIvq//AEPfiT/vxp3/AMi0f8Ivq/8A0PfiT/vxp3/yLQB1VFcs/hjVmOR458RrwBgQaf6df+PWgeGNW2Ff+E58R5JB3eRp+R7f8ev+cUAdTRXK/wDCL6v/AND34k/78ad/8i0f8Ivq/wD0PfiT/vxp3/yLQB1VFcr/AMIvq/8A0PfiT/vxp3/yLR/wi+r/APQ9+JP+/Gnf/ItAHVUVyx8MatsC/wDCc+I8gk7vI0/J9v8Aj1/zmk/4RfV/+h78Sf8AfjTv/kWgDqqK5X/hF9X/AOh78Sf9+NO/+RaP+EX1f/oe/En/AH407/5FoA6qiuV/4RfV/wDoe/En/fjTv/kWlbwxqxCgeOfEYwMEiDT+eep/0X/OKAOporll8MasAwPjnxGcjAJg0/jnqP8ARf8AOaT/AIRfV/8Aoe/En/fjTv8A5FoA6qiuV/4RfV/+h78Sf9+NO/8AkWj/AIRfV/8Aoe/En/fjTv8A5FoA6qiuV/4RfV/+h78Sf9+NO/8AkWlHhjVthX/hOfEeSQd3kafke3/Hr/nFAHU0Vyv/AAi+r/8AQ9+JP+/Gnf8AyLR/wi+r/wDQ9+JP+/Gnf/ItAHVUVyv/AAi+r/8AQ9+JP+/Gnf8AyLR/wi+r/wDQ9+JP+/Gnf/ItAHVUVyx8MatsC/8ACc+I8gk7vI0/J9v+PX/Oa6Kyhkt7SGGa5mu5I1CtPMEDyH+8wRVXJ9gB7UAeX6P4nvo9DsPFmseKgIbiSfzdFFtCUG1ZD5EW1RL5q7Bks7DhuAMYmj+JuqNcWlj/AMI9ZHVL37G9tGmq74TFcrKVZ5BDlWHknKhWGCCC1d5D4b0ODWJdWg0bTI9VmBEl4lrGJnB4O5wNxz7mm6d4Y0HTF26boml2a+cLjFvaRxjzQCA/AHzYJGevJoA88i+LGpOtijeGraO51FYDZxtqmFbzJmhPmN5XyYcAjAbIPY/LVKT4tX1vq9yX0x5iyW9lFp8ReZEu/tN9HK4kiieR0ItRgiM9B8oJNeia34K0DWba1t7vTLQQW7owjS3j2uisW8pgVIMZJJK96tyeFvD8libKTQtKezaJIDA1nGYzGhLIm3GNqlmIHQFiR1oA8xm+Kut2urSy3Xh6WO1lsrMW9jKJ1nW4luLiMl0FuZNhELEYQnCoQuZCEk8SfE/Wn8OXh0zRW0vUYLAXly19I0L24ad4UMUcsIMuTGW+YJ8rLxk7a9Gfwh4bkgEL+HtHaEW/2QRmyiKiHfv8rG37m4BtvTPPWkl8HeGZoLSCXw7ozwWYZbaNrGIrACckINuFz3xQBzHjzxjqvhjxJK9rbW15pdro8uo3UE10tuwVJBlkOxi744Ckqp7sDjNjQ/Hl1reuz6LY6NGup2Yla9Se7KJbqJFWE5EZJMkbGQDAxtwfWup1Xw/o2r3NvcatpGnX1xbkNDLc2yStEQcgqWBI554qlp/hPTba91u7uQ2oz6vOk9ybxI3GIwBFGqhQNqY+XIJzySTzQB0FFYes6Lf6heCa08T6xpce0L5FpFaMmf72ZYHbJ+uOOlUf+EX1f/oe/En/AH407/5FoA6qiuV/4RfV/wDoe/En/fjTv/kWj/hF9X/6HvxJ/wB+NO/+RaAOqorlh4Y1bYV/4TnxHkkHd5Gn5Ht/x6/5xQnhjVldWPjnxGwByVMGn4Ptxa0AdTRXK/8ACL6v/wBD34k/78ad/wDItH/CL6v/AND34k/78ad/8i0AdVRXK/8ACL6v/wBD34k/78ad/wDItH/CL6v/AND34k/78ad/8i0AdVRXLJ4Y1ZTk+OfEbcEYMGn+nX/j1pP+EX1f/oe/En/fjTv/AJFoA6qiuV/4RfV/+h78Sf8AfjTv/kWj/hF9X/6HvxJ/3407/wCRaAOqorlf+EX1f/oe/En/AH407/5FpV8MasAwPjnxGcjAJg0/jnqP9F/zmgDqaK5X/hF9X/6HvxJ/3407/wCRaV/DGrM7MPHPiNQTkKINPwPbm1oA6mvIdK8Razpul+F9c1LxJPfR6rcyQ3Gn3UNsiLGFlYvEyRoy7BGCSzMMZzjqPSdC0u703z/tmu6lq/mbdv22O3XysZzt8mKPrkZ3Z6DGOcw6d4S8N6bdTXOneH9ItLmZWSWWCyjjeRW+8GIXJB7560AecJ8U9X1SVbfT9Jtba4gv7BZy1xMVkt7jzCNhe3UknyzyFK4IKsa3/AHxB1DxkBJb+HJrS3kjiuYZ7g3CRtCz4YF3t1UyhSGCoXVum8DmultvBvhi0t3t7Xw5o0MDsjNHHYxKpKMWQkBcZUsxHoSSOtSWvhPw5aTyzWmgaRBNLKs8jxWUas8itvVyQvLBvmB6g89aANqisHVtC1G+vnntfFWtabEwAFvaxWbRrgdQZIHbnryx/Cqf/CL6v/0PfiT/AL8ad/8AItAHVUVyv/CL6v8A9D34k/78ad/8i0f8Ivq//Q9+JP8Avxp3/wAi0AdVRXK/8Ivq/wD0PfiT/vxp3/yLSv4Y1ZjkeOfEa8AYEGn+nX/j1oA6miuWHhjVthX/AITnxHkkHd5Gn5Ht/wAev+cUn/CL6v8A9D34k/78ad/8i0AdVRXK/wDCL6v/AND34k/78ad/8i0f8Ivq/wD0PfiT/vxp3/yLQB1VcrqX/JU/D3/YF1P/ANH2FOi8M6skgZvG/iKQD+FoNPwfytQajvwV+KHhwFixGi6kCxxk/v7DnigB3g3/AJGPx3/2Go//AE3WddVXK+Df+Rj8d/8AYaj/APTdZ11VABXmPhfx1dWvwx13xN4gaS/fT769jCxoiMyRzska8AAYGAWPbk5rsNe8XaHoNy1vqt95EyxxzMoid9qSSiFCdqnGZGCj8T0BIz9K0TwRL4l1VNO0LRV1uyIF5ImnIkimdCeX2DduVjnBPUg0Ac1P8UNUi8QweHR4ctJNee6+zMiaoTbKDbGdWEvk5PyqQRsBHBGcisyb43M+hjVLDw8ssMWmW2pXST6gImTz5TGqR/u234KnJO3jHBJxXqGn+GdB02O2TTtE0y0S2kaWBYLSOMROy7WZQB8pK8EjqOK8z+IPhbwFP4m0+x1EarBc29imzTdI0p7iMWwlJGBHBIYQWBBMZQkcHIxQBrfFHxBfL4SvNU8NatrOk3OnXUFs6vpoiSbzbiOMn/SYDvADNhozjJ5zxWbJ8UrrSLnW7H+xNX1i10RbqObVJUZS8sEJm/emO3WFFb7gIYt0JTByfVLm2s9WsBFe2sdzay7JPJuYcg4IZSUYcEEA8jII9RVK58M6DdahPf3OiaXNfTxNBLcyWkbSSRsu0ozEZKleCDxjigDzjV/izq+koj3XhW0YDTbbVZhHqpJSKefyVVcwgM44JGQvX5uBncs/iM02j6y1xo91HrGnT3dp9ntIZ7yB5YVDD9+sQVQ2V+/s7/WuwuNA0e5BFxpOnygwpbnzLZGzEjbkTkfdVuQOgPIrB0zxh4Th1i502wc21zLqD200g06aGCW86MhmMYjaQ4x94k4HWgDl7DxZc6D4StvFOt+K01hbnSPt50lYbdGZjs+aArtYRqW2tv34yCSMcyz/ABQ1SLxDB4dHhy0k157r7MyJqhNsoNsZ1YS+Tk/KpBGwEcEZyK7yw8M6Dp815LYaJpdrLeArcvBaRo04PUOQPmByeuapXOm+GfC2mRXMWhWtta2UjSxLp+lmVoXcbWdI4ULAlTgsB068UAeX2Xxk1i5XVNai0W2l0eLStOuoLM3eyXzbmcxHLeWQec+nCKcZY7eqj+JV3FrZsr/RIIoIdUt9FuZYb8yOl1MgZdkZiUvENy5clT1IUgE1q+FrfwR4r0yC+0XQrGayjhSGCWbRmt1MQYSKsfmRrlAwDDblQRnrVrxXd+EvDeoWmu69aWceqSt9nt7pLAz3TYUkqnlo0hAUMTjgDrQB59qXi/xVN8BdG1nTNR2+Jb+8htlufIjO4vcmPGwrt6YHSub8P/G/V59b1LVrmGS60KezthpunpEFPntLHC7FkRpMeZ5owAx44UnFe1aNdeE9UtNN07SV0ue1aBNTs7aKFdixhwUlVcYUh+QeDuB7g1d/4RXw8LZ7YaDpP2d4jA0X2OPY0ZcuUIxjaXJbHTJJ60AeaeI/irq3/CNXq2GgT6ZrCaRe6hIdQdrf7OsJ2LJEssQMuWIYKypkdcE4pmh/FLUTJJYJYtqWqySuE+2XsVtAFis4Z5CHWH5c+ZwrbucksqjjvNV0jwZDLoWg6loujkTtLHpto+no8akIXkCDaVT5QSemfejStP8ABvinSJ2stI0m+077U6SpJYKEM8X7skq6jLLt2hsdAMHFAHFQfFK+l8VPpml6V/aEt7dRQ2yXGoxJDEGsFuSVeKJsrgnJ3SZPKnGFpdK+NDatdaPHpvhbUrpbq1trq68hZZXt1mZlG3ZEysF2kku0fA4yQRXf6zbeGvD9rdeIdSsNPtkslNzLeC0DSR7Y/L3ZVS2dny8c7eOnFYrz/D6PU9Jt/sWjG9tbpNOsNlgrG2mMfnLGhCfu/lO7qAM+tADvAnji68Rave6bqujnRL6GMzJaTvMZ2j3lN5DQpGRnHMbyDnGa7isvR/DuiaLPcTaNo+m6fNcczSWtqkTSc5+YqBnknrU2jatZa1ZG70ycTQCWSEnaVKvG5R1IIBBDKRyKAM/WNSubbxV4esYXAt7z7R5ylQd2yMFee3Nb1cr4i/5Hvwj/ANvn/ooVzHjfSvEF18TFutC8uCIeG7mCS4uLCS5iYmaM+UNsiYkOMjk8A/KeoAPUaK+fPCl3470Xwv4f062tNWtJbbT7BLGxXTd8N05bFwt3IyEwbR0+aPjn5ulW7zXPisniiTTLeC7ew+1/2Ut+bBMfPO0gvPuY2pbgIf4d555oA94orwr46ad4lj8c6Z4j8Kabe3l7pWmv5RgidgzySeUUyByQsu/HXCE9Bmub8JxeNvh34ZvdJ02y1g2kcGsR2vkaW05e8WUC2kPyMQrLkgn5G96APpmivD9U1PxtfvqtlfprY822aKKxg0dZLWeBrIkyPPhSkvm5G0MTkKBGc5Gz8GIvEljFFoXiBb+fSYtB0+SA3tmsQhlZGWW3BVF3bQFBDZYdzzQB6vRXhMHhq48Mar4y1Dwz4bj09/7ZtYobyz0pGmgsWhiE72qbDvwd3yqGGc/KSMV6F4OguvEnhK6tvGdiNQtXu5UgGqWSo91bK+YpJoCoCvxnGxegOAaAO0or5us4/Efgr4T+HoPCHh/V9P8AEU9lJPctaaYhEsqN8qXA+zyOXIJ258vPI39K09NvPHmkXPi19J0e+RLu61G8sl+yEie58uIp5gdcqm0MUIIDOCp7AgHv1YXgfU7jWPC9lfXpU3Eu/cVGBw7AcfQCsT4TXviS+0W7l8UymVvPxbNLbywzhNoyJA9vAD82cFYwMcZJGTe+F3/IiaZ/21/9GvQB1VFFFABRRRQAUV8+eIvD3ima38SfZrdjp0vjOC6Fp/ZsrXEqBrfMySB8eWNpz+7P3W+b02o9V+It5Lew20mowakYL9p4ptNRbWzdGza/Z5THibfgAjfJwxPykAUAe00V4/8ADbXviFrXjBE8R2N1p2iOs+pL51oIyInIjgtCSo+dMNIejcjPHBw/E2h3Ms/i2OfQNTufG1zqXmaHqyWkkiwxHb5JS5AKQqmG3KWXPPBzQB75RXznp/hjxFpXxAXW0bXGkl8S3olcWKbZkFsRA0hWHd5TMzR7idiKzFShy1aPh/Wvijf2FmL6a7t5LjULKG5xprefaq5cT432qR+UBtwQZdpHLsDQB73RXK/DO61u78Kq3iYXB1KO6uYS9xAIXkjSZ1jcqAo5QKcgAHqK6qgAooooAK57Rb65uPF3iS0mlLW9r9m8lMD5N0ZLfma6GuV8O/8AI9+Lv+3P/wBFGgDqqKo/2rZf23/ZAmzqIt/tZhCk4i3bQxOMDLZAGcnBx0NXqACiquq39tpWmXmo38nlWdpC9xNJtLbERSzHABJwAeAM0+wu4NQsLa8s5PMtriNZonwRuRgCDg88gjrQBPXJfFLXb3w74QmvdOaOGd7i3tvtMi7ktVllWNpmB4IUMTzxnGeK62o7mCG6t5YLmKOaCVSkkcihldSMEEHgg0AeLeNPF/ijwjc65pmnaomuNbw6fOl3epFHJbNPc+S0beVGFJYYZcqCASfmwA0elfFnWNHuNa/4SiwjvLJNV1aC2mtpx5ka2kbS+V5YiUFdqEBy24nqO9er2/hTw7baVcaXbaDpMOmXBzNaR2cawyHOfmQDB6DqKlh8N6HD5Yh0bTI/LkkmTZaoNryLtdhxwWUkE9SODQB55Z/FXVby30tIvCMsV9qN+llALuae2t3V4GlEiySW4ZgNhVgI8A8gsCMv+IPj7U/CPjd0WH7bp8ehpdGwDrHvne+hgDeYVJGBIeOh9B1He6f4W8P6bHDHp2haVaJDN9oiWC0jjEcu0rvUAcNtJGRzg4qxf6JpWozmbUNMsbqYxiIyT26OxQOHC5I6B1VsdMgHqKAPO7z4o6rbWV1KfCu+Sx1G4sL+WK5mmt7YRRpJ5haK3eQhg4x+6AGDkjjOdD8T9eHiXUreDTNM1Kzn1Wy03Tgl80SqJ7UziRm8kkqRyTjIzgA4y3fa7o3hGa9srHWtG0i4uNRuZJYI57BJfMmEe53OVIDbEGWOM4Az0FaTeHNDbUVv20bTTfqUZbk2qeYCgKoQ2M/KCQPQHigDz66+L6WKym/0UoYb7VLOVYbrzGxZQNKXUFBndtxg4xkEk1DqXxD8QyXXhy2tNN0m1uLvV7a2uETU1uA0Etu0y8iPchIU53IPujaWDbl9EXwvoC6tJqi6HpQ1OQkvdi0j85iVKnL43HKkjr0JFZlhpng2W8vfDdlo+kB9PeG+nslsFWON33eXLjbtLfI3IyRjtQBwOkfGKVfDovH0ua7hsbKO+1Ga5vESYRyTvEoiVIVWVhsOeEHQZJNatj8VNQutRNunhcyRyyalBaCC+DzTy2ZwVKGNQofsdxIORjoT3Z8LeHy9ix0LSt1jk2h+xx5t8nJ8vj5OeeMc1KfD2ilQp0fTiAZSB9lTgy/609P4/wCL+93zQBkfD3xY/iqwunu7NNP1C1kVLiy3TeZAWQOocSwxMCQeykHqCa6usPyfD/gjw/fXVvZWWj6Tao11cC0tRGigDLNsjXk4HYE1swTJcQRzRNujkUOpxjIIyKAH0VkX3iPTLLVm0yaWdtQWBLowQWsszeU0nlhsIp43dfQZJwATWvQAUUVRv9WstPvdPtLycRT6hK0NsCpxI4QuVzjAO1WIyRnBxQBerldS/wCSp+Hv+wLqf/o+wrqq5XUv+Sp+Hv8AsC6n/wCj7CgA8G/8jH47/wCw1H/6brOuqridGtJb+7+JNnbXT2c9xqQijuI87oWbTLMBxgg5BOeo6da82/4Ub44/6LR4k/75n/8AkmgDo/GXg3U9d8XeLLeBQg1PT9NuLK8lRjCklrcM5hdgONxKnjnBJAODUPiD4bax4iTXL7VrfTDqGo39rdR2cOoHyIlgi8sbnktXWUnJO1ocdOcjNYX/AAo3xx/0WjxJ/wB8z/8AyTR/wo3xx/0WjxJ/3zP/APJNAGnJ8KvEF14j0DUdT1K1lFna2kTmydLQ2skTlmMANvJhWyAVRoc4IPBAHReNfBusan4/i17T4oLi1GmCxMX9u3elyBxKz7t1ujFlwQME9a4r/hRvjj/otHiT/vmf/wCSaP8AhRvjj/otHiT/AL5n/wDkmgDpNV+GGp6j4pvLyPUobHSLm2e7W2jkeR4NVa3Nv54JA3BUO7ccMWGcDrWL4f8AgxewRaPDrA0+4tbfUoru8tJJ1mt5kS3kjLJEttEodmdSwbduCglietX/AIUb44/6LR4k/wC+Z/8A5Jo/4Ub44/6LR4k/75n/APkmgDovhh4WuLfx9r17JFdR6BpUs1vocVxbPBs+0MJbgojgHaGARWAwRnHFTR+BPEMtxe6fc/2THo1x4l/t43UdzI9xsWVZViERiCqSUUFt5wM8GuX/AOFG+OP+i0eJP++Z/wD5Jo/4Ub44/wCi0eJP++Z//kmgCtrHw58QaTF4h1+8i05b2S1WS0i0C0d2e+iuPOgk8qOFSN3Kszs5GSSxBwvrfgDw9caL4Egsbwg6rdJJdXzk53XMxLyEnnOGYjPoBXlv/CjfHH/RaPEn/fM//wAk0f8ACjfHH/RaPEn/AHzP/wDJNAGpc/CrWm8K+HdOk/sbUpLDRn0xoLyWQQ207YxdwkRkmRcYGQhx0YV1HxD8E33iLwxommoLLU57BlMk97cTWk7MIyvmxzxBij55IKMDnHHBrg/+FG+OP+i0eJP++Z//AJJo/wCFG+OP+i0eJP8Avmf/AOSaANSf4YeJEe1vWk8Pa1rH9gjS7i71dC5aUSFt5BjbzAUJj3Ng8AkNytc5qnw41/RtH0nSbH5dU1DVLy2Z9PheSG3026VfODyLFHHHsIBUbVBI+VeSBf8A+FG+OP8AotHiT/vmf/5Jo/4Ub44/6LR4k/75n/8AkmgD0fxV4GTWNU8HC1c2ukaI8wkjt7ua2lEZgMaLG8ZDDB25+YcZ69D5tL8EtbaCxgfUIZbaCa7Plpe7Hh82581Jkllt5j5oXgkBWyPv4Jy7/hRvjj/otHiT/vmf/wCSaP8AhRvjj/otHiT/AL5n/wDkmgCbxN8JfE+s63r16k+gQfbrO9sg8I8lp1l2mJ5gkIJcbRuLO47qF5Btz/B24uPFDz3FnoE+kTa7Dq1wJAS80a2zRtE8fl7WxIzOMtg72JAOc53/AAo3xx/0WjxJ/wB8z/8AyTR/wo3xx/0WjxJ/3zP/APJNAEOjfDjVrDxD4U8PztLLYi3V9eeGGX7K6W07S2iiVlVXY7whUchU9MV6j8LrC6tLHxBc3dvNbDUNbvLyGKZCjCMvtUlTyN2wv/wKvNP+FG+OP+i0eJP++Z//AJJo/wCFG+OP+i0eJP8Avmf/AOSaAPVfEX/I9+Ef+3z/ANFCuqr5l1X4N+MbfxLoVpJ8W/EE0115/lXDCbdBtQE7f9Iz8w4OCPxrb/4Ub44/6LR4k/75n/8AkmgD3+ivAP8AhRvjj/otHiT/AL5n/wDkmj/hRvjj/otHiT/vmf8A+SaAPf6K8A/4Ub44/wCi0eJP++Z//kmj/hRvjj/otHiT/vmf/wCSaAPf6K8A/wCFG+OP+i0eJP8Avmf/AOSaP+FG+OP+i0eJP++Z/wD5JoA9/orwD/hRvjj/AKLR4k/75n/+SaP+FG+OP+i0eJP++Z//AJJoA9/orwD/AIUb44/6LR4k/wC+Z/8A5Jo/4Ub44/6LR4k/75n/APkmgD3+uV+F3/IiaZ/21/8ARr15V/wo3xx/0WjxJ/3zP/8AJNYngz4N+MdS8NWd3afFvxBYwyb9tvEJtqYdgcYuAOSM9O9AH01RXgH/AAo3xx/0WjxJ/wB8z/8AyTR/wo3xx/0WjxJ/3zP/APJNAHv9FeAf8KN8cf8ARaPEn/fM/wD8k0f8KN8cf9Fo8Sf98z//ACTQB7/RXgH/AAo3xx/0WjxJ/wB8z/8AyTR/wo3xx/0WjxJ/3zP/APJNAHv9FeAf8KN8cf8ARaPEn/fM/wD8k0f8KN8cf9Fo8Sf98z//ACTQB7/RXgH/AAo3xx/0WjxJ/wB8z/8AyTR/wo3xx/0WjxJ/3zP/APJNAHv9FeAf8KN8cf8ARaPEn/fM/wD8k0f8KN8cf9Fo8Sf98z//ACTQB7/RXgH/AAo3xx/0WjxJ/wB8z/8AyTR/wo3xx/0WjxJ/3zP/APJNAHv9cr4d/wCR78Xf9uf/AKKNeVf8KN8cf9Fo8Sf98z//ACTWJpXwb8Y3HiXXbSP4t+IIZrXyPNuFE26fchI3f6Rn5RwMk/hQB3njPwZea94w8V2r2T3Ftq2m2L28xnaCJWglk3xNJ5Uq/wAatsZGDc8cHGXqPwu8VS6LbRW8vh83Z0XUNFljBNtDDHcOGjZPKhCsVAw2EjBJzgdKpf8ACjfHH/RaPEn/AHzP/wDJNH/CjfHH/RaPEn/fM/8A8k0AaFz8J9bk/tZMaFPcXdrcRR6pPNOLlFksxALfaoA8pWGQWLDHIj3c11fww8B3HgvUdUaIafBYXVjYRJBaAgfaIY3WaRl2gfMSpznLY5xXCf8ACjfHH/RaPEn/AHzP/wDJNH/CjfHH/RaPEn/fM/8A8k0ALD8H/EEx1mTU4tCb+0IoA1rp9wLSBpopWbzCotGUghvuyJISeCxGMdtd+B9Rv/hFB4Y1RbG4v0C5S0lFlB8sm5V+WBkIAwCDDtYj7ozxxH/CjfHH/RaPEn/fM/8A8k0f8KN8cf8ARaPEn/fM/wD8k0AVtU+HHiG71bRtJu9J0S9aLQr6ATNCYbO0Z7hfLKtFCFMyq24Yjj3EMQF61raj8KvFV74lW+Op6TA0drcWQ1K3Hl3U6SWZhV5cRbmdZMNzKRjoFIGaX/CjfHH/AEWjxJ/3zP8A/JNH/CjfHH/RaPEn/fM//wAk0AW9S+Emt3mgwWkEGgadFHeRzy6bZzObe5CwGJncywyRhy2GwID05LNhxaPwcMljr8eoRwajPdWVla2UtxfH7RF5SYkDTmAjB+Uf6shwuGXHFZX/AAo3xx/0WjxJ/wB8z/8AyTR/wo3xx/0WjxJ/3zP/APJNAGjqHwr8R6l4Rm0q7uNEjePTbu0so4FEUcUk8yMC3lwopxHGBuWNclm+UdS9fhFf6drs2paAuiWki6pJc2+Q+1LZrMxeSyhehlO5kBwRyTnisv8A4Ub44/6LR4k/75n/APkmj/hRvjj/AKLR4k/75n/+SaAH2fwd1kaNq1tf2+isbq9tb6G0s7pYLaKSONkfKfY2iZTwQrRN15JK7m1NL+GPiO38S2OsX17o9wYI9PSWzjQwwSmFJkdgqp8jJ5oaMrgblOQvBGR/wo3xx/0WjxJ/3zP/APJNH/CjfHH/AEWjxJ/3zP8A/JNAHSeBPCut/Dya7a206xnsLy4t4EtoJRNcDfMQ80k62sbMFVs4k3H5T+8GQKl+J/wzu/F+t6rqNv8A2d5sujRWNi9yzbre5S4eTzRhTt+VsBh83UcA88t/wo3xx/0WjxJ/3zP/APJNH/CjfHH/AEWjxJ/3zP8A/JNAFzW/hDrl/rPi27Gowu2qR3q20zXQj4nj2pDMgti7Rp2/fEDaCEHIqWz+Fmv2flXlnHoVrNb6pYahDpdvcSJasbeKSORy/lZWSXzMnCH7gyWPNZ3/AAo3xx/0WjxJ/wB8z/8AyTR/wo3xx/0WjxJ/3zP/APJNAE0Xwg8Rf2VFBNd6T54to4n2yybdw1U3hx8mceWcf73HTmoF+D2vTwa7LNZ+G7DUNRvIrhm0+4KwSQxyAi1MTWpRVI+ZnYSbmA3KR0X/AIUb44/6LR4k/wC+Z/8A5Jo/4Ub44/6LR4k/75n/APkmgDb0z4Qsj239qx299bW+iT2EUU94XkgneYuDHKsCBFVWKqyoCoOAuKq6V4E1vRLTw1o721p5MfiGC+j+wxowtYIYWLtNNHBCrMxG0EoCd+CW5NZ3/CjfHH/RaPEn/fM//wAk0f8ACjfHH/RaPEn/AHzP/wDJNAHv9crqX/JU/D3/AGBdT/8AR9hXn3hf4P8Ai/R/Eem6jffFjX9TtbWdJZbKYTbJ1ByUbM5GD05B+leg6l/yVPw9/wBgXU//AEfYUAHg3/kY/Hf/AGGo/wD03WddVXK+Df8AkY/Hf/Yaj/8ATdZ11VABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQByviL/ke/CP/AG+f+ihXVVyviL/ke/CP/b5/6KFdVQAUUUUAFFFFABRRRQAUUUUAFFFFABXK/C7/AJETTP8Atr/6Neuqrlfhd/yImmf9tf8A0a9AHVUVm65otrrUMUd5LqEaxtuBs7+e0JPuYXUkexyKx/8AhA9I/wCfzxJ/4Ueo/wDx+gDqqK5ZfA2kqHAu/EeGGDnxFqB754/f8dO1c54t03Q/Dk+k25i8aajd6pcNbW0Fn4jvAxYIznJkukUDap70AemVh+Op7608Fa9c6RKItQhsZpYH8vzMOqEjC5GTxx79j0rgXPhu0vprPWovGukXMWmS6syXfiS7I8mNyrgNHduCwwGwD0Yc5yBb8E+J7P7bdWvh7w54yvH8u1luWvtSScW4lj8xBi4uyVO1vmCDtg5wKAOQ8PfEHXALeKyvdMv7q5OiWf22Tz5oibhJg7eX55UMpQA7Su4g7u21D8YfFNtoz3l1Y6TcySafPdRi3hdBEYb5LV3fdLhkwzSYyu0LgtjLDv7T4oWV09uyaDri2t1ezadbXLC3KT3EfmAxqomLjJiYAsoHTJA5q/4T+IekeK9QtrPRYryaR7T7XcMUULZfMU8qb5srLuVhtAP3SemCQDzu6+Lev2en6Pe366DDZ3Ekqu9vNb3c90qyBUaGBLwdQcEI8zBhjB79d8VfG194V1fQbOzvdF063v4Lyaa71WJ3SMwrGyKNsiY3FyvJ6kYyeDe0/wCJNheal9nfStWtrM6nJo6ahMsPkNdI7JswshkAZlIBKAHI6ZrF1P4heFpvFupSvpGsXeq+FYLlkmhjBEibo0ufKHmAPsO3duGRg49wDm7D4weJ7vXIrV9DsbP/AESG4ktLqWOKYh7bzWlTfOrsqvxsWJshWyykYrrofGPiC3+CqeL7yHT7rVJ7OG9jhtreRIYUkCcuC7MwQMzMQRwMYGMnQg+J2iXd7FFp8F/e2k2oQaZHfwIht3mljMmAxYEhVA3HHBYDnnHc0AfPFv8AE3UNKi8WXSeIdO1G5k1UQ2EggaWzmC2iOUhDXCLGGIyB5jZJO0MTXT+G/iXr+s+I/D+jfYLBZtWgtdVWURyGNLB7ctNzu5kWUeWD0+ZSR1r2Csq38PaZb+I7rXkgdtVuYVt3nkmkfbEDkIisxVFyMkKBk8nJ5oA1a5Xw7/yPfi7/ALc//RRrqq5Xw7/yPfi7/tz/APRRoA6qiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5XUv+Sp+Hv+wLqf8A6PsK6quV1L/kqfh7/sC6n/6PsKADwb/yMfjv/sNR/wDpus66quN8OxrNqnxEikGUfVVVhnGQdNswawf+ER0T/ny/8iv/APFUAeoUV5f/AMIjon/Pl/5Ff/4qj/hEdE/58v8AyK//AMVQB6hRXl//AAiOif8APl/5Ff8A+Ko/4RHRP+fL/wAiv/8AFUAeoUV5f/wiOif8+X/kV/8A4qj/AIRHRP8Any/8iv8A/FUAeoUV5f8A8Ijon/Pl/wCRX/8AiqP+ER0T/ny/8iv/APFUAeoUV5f/AMIjon/Pl/5Ff/4qj/hEdE/58v8AyK//AMVQB6hRXl//AAiOif8APl/5Ff8A+Ko/4RHRP+fL/wAiv/8AFUAeoUV5f/wiOif8+X/kV/8A4qj/AIRHRP8Any/8iv8A/FUAeoUV5f8A8Ijon/Pl/wCRX/8AiqP+ER0T/ny/8iv/APFUAeoUV5f/AMIjon/Pl/5Ff/4qj/hEdE/58v8AyK//AMVQB6hRXl//AAiOif8APl/5Ff8A+Ko/4RHRP+fL/wAiv/8AFUAdN4i/5Hvwj/2+f+ihXVV4zqXh3Sodf0e2jtdsNx53mr5jndtQEc5yOfStb/hEdE/58v8AyK//AMVQB6hRXl//AAiOif8APl/5Ff8A+Ko/4RHRP+fL/wAiv/8AFUAeoUV5f/wiOif8+X/kV/8A4qj/AIRHRP8Any/8iv8A/FUAeoUV5f8A8Ijon/Pl/wCRX/8AiqP+ER0T/ny/8iv/APFUAeoUV5f/AMIjon/Pl/5Ff/4qj/hEdE/58v8AyK//AMVQB6hRXl//AAiOif8APl/5Ff8A+Ko/4RHRP+fL/wAiv/8AFUAeoVyvwu/5ETTP+2v/AKNeuZ/4RHRP+fL/AMiv/wDFVk+FPDulX+gWtzd2vmTPu3N5jjOHIHAOOgoA9mory/8A4RHRP+fL/wAiv/8AFUf8Ijon/Pl/5Ff/AOKoA9QrjPiR4J/4TL+xT5+nr/Zt01z5OoWH22CfMbJtePemcbs9eoFYX/CI6J/z5f8AkV//AIqj/hEdE/58v/Ir/wDxVAD/ABN8KYPEeh+HtPvLuysf7LuHLrpOn/ZoJraQ/vYBEZG2B8Lk7jyM454l1L4am48c6j4jifw3O121uyx6nof2uS2MSBR5UnnJtzjP3eDj0qv/AMIjon/Pl/5Ff/4qkbwnoSqWazAAGSTM/H/j1AC6B8I7PQta0vWtOvYYtZtb66nuLoWY/wBLgndmaFxuzlQwCyZJG3pg4rrPCHhWLw3f+JLqOZJW1nUm1BtsIQx5RF2E5O7lWbPH3jx3PFWugeGLuaSK1S3mljVJHSO6ZiquCUJAbgMAcHvirP8AwiOif8+X/kV//iqAJbP4b6hDcPFPr1tJpI1uXXo7dNPZZRO0jSIrSecQyK5BwEUnb1FReGvhHbeHr3w3qFlq90+p6a8zXk0zSSR3omDeaBE0hSHcxDZUHlRnPWj/AIRHRP8Any/8iv8A/FUf8Ijon/Pl/wCRX/8AiqANrwz4Dj0DwroOiwT2ky6ZfNeeY9qy7svI3yqsg2sPMxuJYcH5Tnjtq8v/AOER0T/ny/8AIr//ABVH/CI6J/z5f+RX/wDiqAPUKK8ot/Dvhu5muIreKGWW3YJMiXLM0bEAgMA3BwQcHsan/wCER0T/AJ8v/Ir/APxVAHqFcr4d/wCR78Xf9uf/AKKNcz/wiOif8+X/AJFf/wCKrJ03w7pU2v6xbSWu6G38nyl8xxt3ISec5PPrQB7NRXl//CI6J/z5f+RX/wDiqP8AhEdE/wCfL/yK/wD8VQB6hRXl/wDwiOif8+X/AJFf/wCKo/4RHRP+fL/yK/8A8VQB6hRXl/8AwiOif8+X/kV//iqP+ER0T/ny/wDIr/8AxVAHqFFeX/8ACI6J/wA+X/kV/wD4qj/hEdE/58v/ACK//wAVQB6hRXl//CI6J/z5f+RX/wDiqP8AhEdE/wCfL/yK/wD8VQB6hRXl/wDwiOif8+X/AJFf/wCKo/4RHRP+fL/yK/8A8VQB6hRXl/8AwiOif8+X/kV//iqP+ER0T/ny/wDIr/8AxVAHqFFeX/8ACI6J/wA+X/kV/wD4qj/hEdE/58v/ACK//wAVQB6hRXl//CI6J/z5f+RX/wDiqP8AhEdE/wCfL/yK/wD8VQB6hRXl/wDwiOif8+X/AJFf/wCKo/4RHRP+fL/yK/8A8VQB6hRXl/8AwiOif8+X/kV//iqP+ER0T/ny/wDIr/8AxVAHqFcrqX/JU/D3/YF1P/0fYVjaN4Y0i11a0ngtNsscqsrea5wQfc1s6l/yVPw9/wBgXU//AEfYUAReF/8AkM/ED/sLp/6brOmU/wAL/wDIZ+IH/YXT/wBN1nTKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDB1j/kafD/AP28f+gCt6sHWP8AkafD/wD28f8AoAreoAKKKKACiiigAooooAKKKKACiiigArB8Df8AIrWX/A//AENq3qwfA3/IrWX/AAP/ANDagC9rGtaVosUcms6nZafHIdqNdTpEGPoCxGTWX/wnnhD/AKGvQP8AwYw//FV0lFAHOL468JMGK+KdBIUZYjUIeBnGT83qRSf8J54Q/wChr0D/AMGMP/xVdJXGfEXxLf8Ah+bQYdNMKHULtoJJHsZrxkURs+ViiZWY5UDjtz2oAv8A/CeeEP8Aoa9A/wDBjD/8VUWr3umeMvCevaf4e1Wx1GaS0kh/0O8VtjujBAzI3ygkd+uD71zer+Pr7w35EuteRPZ3Wm3E9tKthNZySXUTf6oxSOWUMpXGeSQT0PDNP8XeJJvEtzpGoS2VtNaJaCUW+hXd4GeWJWcGSOTbGASQC3bnsaAMzTPDfi4Q2lqF1ez09X0uNojqnzpHGsousMspIByh4OSNuOmBW/4Rv4hQaSyWl3qZupbKZJfP1HzTvW8QxhcyDaxtww3Arkn5mB5F/QPiFrur65bafC+mtdXN5dQC1Om3EflQxNIvn+e0myUAqm5FAPzEZGK6LwJ4o13xHqtzb3un29jDpam11ElSTJeA8rCd2BHt2tk5PzqPegDlrjQvG8NjpUlvNrV9cxPIwtZ5xBCimQFVldL0yNgZwS03y8Fc9dr4pPqEnijwxY2P9rSpcW9+0lrpt+bR5WVYthLb0Hysc8kcZ69Cmn+M9dNwLy8GmPpbeIJNE+zxW8iTKPNaNJPMMhVuQCRsHGcEVkad8T9W1vxNq2laGdDldkuDpKMzGSR4HAZZgH+Xeu4qcLwM80AR2WgfEUaxG+oaneNstYgJbdw0TMLfbJGwM6AEyZO8RMc4IYDIrp4tD8Q23wlWwtLm+PieS1iad575pJfOwnmqsrMQpIDAEHaCc+pqno/jfXNZg03VbTT7a20fUNUhsYY7iNjP5W1/OkJDYHzrtXj+Ek5yMel0AeJHw54rgtdeXTdH1WD+0tQ82GSTV/8ASIEFuqK7slwpf5xggyNgDOHqz4ZbxFP480zQrzVLp0t7O11XVVW8LvBcLD5bW7lSQFd9sm0HBGTjBr2SigArB0f/AJGnxB/27/8AoBrerB0f/kafEH/bv/6AaAN6iiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAsaf/x/Qf74o1L/AJKn4e/7Aup/+j7CjT/+P6D/AHxRqX/JU/D3/YF1P/0fYUAQeGvM/tb4heTH5kv9rJsTONx/s2zwM9qzceJ/+hZ/8n4q2fBv/Ix+O/8AsNR/+m6zrqqAPPMeJ/8AoWf/ACfiox4n/wChZ/8AJ+KvQ6KAPPMeJ/8AoWf/ACfiox4n/wChZ/8AJ+KvQ6KAPPMeJ/8AoWf/ACfiox4n/wChZ/8AJ+KvQ6KAPPMeJ/8AoWf/ACfiox4n/wChZ/8AJ+KvQ6KAPPMeJ/8AoWf/ACfiox4n/wChZ/8AJ+KvQ6KAPPMeJ/8AoWf/ACfiox4n/wChZ/8AJ+KvQ6KAPPMeJ/8AoWf/ACfiox4n/wChZ/8AJ+KvQ6KAPPMeJ/8AoWf/ACfiox4n/wChZ/8AJ+KvQ6KAPPMeJ/8AoWf/ACfiox4n/wChZ/8AJ+KvQ6KAPPMeJ/8AoWf/ACfiox4n/wChZ/8AJ+KvQ6KAPItU/t3/AISPQ/O0Py7n9/5MP2uM+b8g3fN0XA5561tY8T/9Cz/5PxVs+Iv+R78I/wDb5/6KFdVQB55jxP8A9Cz/AOT8VGPE/wD0LP8A5PxV6HRQB55jxP8A9Cz/AOT8VGPE/wD0LP8A5PxV6HRQB55jxP8A9Cz/AOT8VGPE/wD0LP8A5PxV6HRQB55jxP8A9Cz/AOT8VGPE/wD0LP8A5PxV6HRQB55jxP8A9Cz/AOT8VGPE/wD0LP8A5PxV6HRQB55jxP8A9Cz/AOT8VYvg7+3f+Ecs/sGhfarb59k32uOPd87Z+U8jnI/CvXa5X4Xf8iJpn/bX/wBGvQBjY8T/APQs/wDk/FRjxP8A9Cz/AOT8Veh0UAeeY8T/APQs/wDk/FWTr/h7Vte+yHUvCs5e0kMsEkGs/Z3jcqVJDRsp6Ejr3r1migDx678I3t7Zafa6h4PlvYrC5F3bm71jz3SUEkEu7FmHPQkj24FNuvCOo3GsXGqHwxqEN7clDM9t4hkgWTYNq7ljkCnAGOlex1leLNVfQvDGratFatdvY2slwIFYKX2KTjJOAOP/ANfSgDzKPwhdxJYrH4LC/Ybt763Yaou6OZyxdg27OCWOVPynOMYrR03Sda0yW+ksfCflPfXBurg/2kjb5CqqW5Jxwq8DA4pNL+KoKKdT02+a6lTTUSytreIOJrtJCv7wzlWUlOM7doIznJ2uX41+HV0+W8vLHVrKFbZrmM3CQr5wWdbd1UiQgFZXCksVXqQSATQBj2/ge5t797uPwfcea1xJd7G1xmiWaTO6RYy5RW+ZvmABGeMVZt/Cd7b22jW8HgwRxaO2+xC6ooMJ2lTznLZDHO7Oc81owfGnw1cf2aLeO6c3sskO5prWOOJ0cKymV5hG55BAjZyQcjNdN4v8ZQeGtR0ywOl6nqV5qEdxLDFYrESFhCs5JkdAOHGOecEdcAgHH2Ggavp+nWdjY+FZre0tJTNFHFrG35iWY7iGyyksTtbI9uBWrjxP/wBCz/5PxVSh+OHg+bU7ezhmuH8+ON0kHlD5pIfNRPLLiTJXA3BNoYgFga37bx/YSfD8+MLnT9Ts9MaNJYYpkjM06ybRGVVHYfMXAAJBz1wMGgDNx4n/AOhZ/wDJ+KjHif8A6Fn/AMn4qoW3xTltYvFd5rujz29rpF8lssAkt4p0UwLITIZJxGxyTjYxyMYB61rab8UdE1K9sbO1ttRa7vZ7aKCHyk3PHPB56z43cRhA249QVIxQBBjxP/0LP/k/FWLpf9u/8JHrnk6H5lz+486H7XGPK+Q7fm6Nkc8dK9drlfDv/I9+Lv8Atz/9FGgDGx4n/wChZ/8AJ+KjHif/AKFn/wAn4q9DooA88x4n/wChZ/8AJ+KjHif/AKFn/wAn4q9DooA88x4n/wChZ/8AJ+KjHif/AKFn/wAn4q9DooA88x4n/wChZ/8AJ+KjHif/AKFn/wAn4q9DooA88x4n/wChZ/8AJ+KjHif/AKFn/wAn4q9DooA88x4n/wChZ/8AJ+KjHif/AKFn/wAn4q9DooA88x4n/wChZ/8AJ+KjHif/AKFn/wAn4q9DooA88x4n/wChZ/8AJ+KjHif/AKFn/wAn4q9DooA88x4n/wChZ/8AJ+KjHif/AKFn/wAn4q9DooA88x4n/wChZ/8AJ+KjHif/AKFn/wAn4q9DooA88x4n/wChZ/8AJ+KjHif/AKFn/wAn4q9DooA4bSv+Eh/tK2+1eH/Ig8wb5ftsbbB3OByav6l/yVPw9/2BdT/9H2FdVXK6l/yVPw9/2BdT/wDR9hQAeDf+Rj8d/wDYaj/9N1nXVVyvg3/kY/Hf/Yaj/wDTdZ11VABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQByviL/ke/CP8A2+f+ihXVVyviL/ke/CP/AG+f+ihXVUAFFFFABRRRQAUUUUAFFFFABRRRQAVyvwu/5ETTP+2v/o166quV+F3/ACImmf8AbX/0a9AGxrkOsTQxjQr7T7OUNmRryye5DD0AWWPB98n6Vj/YfHH/AEMPhv8A8EM//wAmV1VFAHLrZeNQH3eIPDhJHykaFOMHI6/6Zzxn0rL1u/8AEGgwRza7428F6bDI2xJLzSZIVZsZwC16MnHau8rzv4taNrOpX3hO80KDUJW06/eed9Pe2E8aGB0BQXJ8s8sBzngmgCTTNW1vVQTpfjvwRegRGcm30t5P3e4rv+W9Py7lYZ6ZUjtS2finRZoLnTfFnjbwbqCX8SxxwWrLal45FIIIa4kLhgwxjH45GOX8d+EvFWu2Wh3uhJfw6rPDPouqSanJarcCymbJlbyD5R2FcgJz83TOasWvh3XfD/xB1qfSbLxFFoc4sY7YaU+mmJ0hhVCsguD5gAxj5McZ9qANTTbH4Xw3/wBms9V0mW+tHhmMba0ZpYzaBzGWDSlsRhnyDxjrwBi7H4Q8AXSWNjEllKbqyl+yRpqDl5beSZbh3jw+SPMCuHXlTjBArjPDfgTxRp+oeHptSSW90mHW727m0ppLdRaGSSUw3SOuGcbXJaMsT83A4wOr+Ffgc+F9Y8TXVxbSRo941vpfmTCQRWHEixxgE7F815flODwOOBQBNLp/gPxBOnhuTXRqVxbl4300+Ip5pH2tl1mj84mTBHIcNjGOnFQ+ONO8KeIvEtjcav4ksbdNAhuIry0S/wDIkQXAjVd8iSK0Q+UDB+9vx9eb0/wz4j3rp0nh+5gEHiyfXV1Bri3MbQec8gVAJC+91IXBVQAxyRWb4a+GniSHW9P1bxFa2N8muC8g8QWSIqvFFcHzBvk80rJsZUUbFGATjPWgD0NdB8DabrLW0Nxa2F88cNk9jDqjwLIDGUiRoFkCsxRSFJUkheOnHQP4Z0eTwqnhuSyV9ES3S0W2Z2IEagBRuzuyMDDZzkZzmvO/BfgC503wn4cTV7O8l1uPWl1C9lMkU0hKeZHG0jlwCixeWPl3EdlPOPXaAOKPwu8JHcW0+6aVp2uXmbUbkyvI0flsWkMm5gyDaQTgjqDUWi/Duy0vxzb+II5IfIsNLj0nTbRIWDW8S93lZ2MjdVBwMKccnmu6ooAK5Xw7/wAj34u/7c//AEUa6quV8O/8j34u/wC3P/0UaAOqooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuV1L/AJKn4e/7Aup/+j7CuqrldS/5Kn4e/wCwLqf/AKPsKAIPDal9V+IaB3jLaqo3ocMv/Ets+QexrG/se4/6GDX/APwNP+Fbfhf/AJDPxA/7C6f+m6zplAGP/Y9x/wBDBr//AIGn/Cj+x7j/AKGDX/8AwNP+FbFFAGP/AGPcf9DBr/8A4Gn/AAo/se4/6GDX/wDwNP8AhWxRQBj/ANj3H/Qwa/8A+Bp/wo/se4/6GDX/APwNP+FbFFAGP/Y9x/0MGv8A/gaf8KP7HuP+hg1//wADT/hWxRQBj/2Pcf8AQwa//wCBp/wo/se4/wChg1//AMDT/hWxRQBj/wBj3H/Qwa//AOBp/wAKP7HuP+hg1/8A8DT/AIVsUUAY/wDY9x/0MGv/APgaf8KP7HuP+hg1/wD8DT/hWxRQBj/2Pcf9DBr/AP4Gn/Cj+x7j/oYNf/8AA0/4VsUUAY/9j3H/AEMGv/8Agaf8KP7HuP8AoYNf/wDA0/4VsUUAY/8AY9x/0MGv/wDgaf8ACj+x7j/oYNf/APA0/wCFbFFAHH6npsyeIdFiOsavI0nn4le6JePCD7hxxnofWtj+x7j/AKGDX/8AwNP+FQ6x/wAjT4f/AO3j/wBAFb1AGP8A2Pcf9DBr/wD4Gn/Cj+x7j/oYNf8A/A0/4VsUUAY/9j3H/Qwa/wD+Bp/wo/se4/6GDX//AANP+FbFFAGP/Y9x/wBDBr//AIGn/Cj+x7j/AKGDX/8AwNP+FbFFAGP/AGPcf9DBr/8A4Gn/AAo/se4/6GDX/wDwNP8AhWxRQBj/ANj3H/Qwa/8A+Bp/wo/se4/6GDX/APwNP+FbFFAGP/Y9x/0MGv8A/gaf8Kx/COmzXHh60lTWNXtlbfiK3uiiL87DgY49frXYVg+Bv+RWsv8Agf8A6G1AE39j3H/Qwa//AOBp/wAKP7HuP+hg1/8A8DT/AIVY1jVrbSYo5LqO9kV22gWtlNckfURIxA9zWX/wmel/8+uv/wDghvv/AIzQBc/se4/6GDX/APwNP+FH9j3H/Qwa/wD+Bp/wqovjHTGDEWuvYUZOdCvh3xx+5560n/CZ6X/z66//AOCG+/8AjNAFz+x7j/oYNf8A/A0/4VHdac9rbS3Fz4k12KCJDJI73xAVQMkk46AVX/4TPS/+fXX/APwQ33/xmm6hLaeMvDWtaZbQ3cfn2zwZv9Ont1DOrBSBKi7sHnjOOPagB2nwDUBm08Q+JHTy45lkM8io6uMqVYqA3HUAkjjOMirn9j3H/Qwa/wD+Bp/wrzez+GGoHyEu4dGjtRLpbS2sTs8bJbCUSjBjAO/zAcEc5bPqaf8AwqPVotJe2sbrT7WWSxmt5jE7ATH7Yk0StmM5QRKY+QducBSM5APVP7HuP+hg1/8A8DT/AIUf2Pcf9DBr/wD4Gn/CvM7n4X6otjpf2EWX261eR1a8uo7iC23yBsRwmzCEcEjaIiM4Bx02vil4fu9e8UeGEt9JtNThjt79ZFvQ4tlZkiCl2VW2nIJXI5K8YPIAOy/se4/6GDX/APwNP+FH9j3H/Qwa/wD+Bp/wrzGy+FWswaxFcXWrC88u1iiS688RyqyW/lFCDA7NGxySBKoO7JBIyenj8CyW3wlXwtYGzs9Qa0iSeWIERzTKE3liAGIfaVJxnaenagDZsEjv7y/tbTxNr8k9hKIblftTjY5UOBkrg/KwPGetXv7HuP8AoYNf/wDA0/4V5jcfDTW5dO1a0hsvDNta6jffaPsq/vFtk8gRr5TPAQGDDPCDI6Fad4Z8IajD480yyu1lfTNPs7W9vn8qQQy6jFD5KmORgPMypVyR0KDPPFAHpn9j3H/Qwa//AOBp/wAKx9M02Z/EOtRDWNXjaPyMypdEPJlD9845x0HpXYVg6P8A8jT4g/7d/wD0A0ATf2Pcf9DBr/8A4Gn/AAo/se4/6GDX/wDwNP8AhWxRQBj/ANj3H/Qwa/8A+Bp/wo/se4/6GDX/APwNP+FbFFAGP/Y9x/0MGv8A/gaf8KP7HuP+hg1//wADT/hWxRQBj/2Pcf8AQwa//wCBp/wo/se4/wChg1//AMDT/hWxRQBj/wBj3H/Qwa//AOBp/wAKP7HuP+hg1/8A8DT/AIVsUUAY/wDY9x/0MGv/APgaf8KP7HuP+hg1/wD8DT/hWxRQBj/2Pcf9DBr/AP4Gn/Cj+x7j/oYNf/8AA0/4VsUUAY/9j3H/AEMGv/8Agaf8KP7HuP8AoYNf/wDA0/4VsUUAY/8AY9x/0MGv/wDgaf8ACj+x7j/oYNf/APA0/wCFbFFAGP8A2Pcf9DBr/wD4Gn/Cj+x7j/oYNf8A/A0/4VsUUAY/9j3H/Qwa/wD+Bp/wo/se4/6GDX//AANP+FbFFAFPR9Kni1S1kbW9amCyKTHLdlkbnoRjkVqal/yVPw9/2BdT/wDR9hRp/wDx/Qf74o1L/kqfh7/sC6n/AOj7CgCLwv8A8hn4gf8AYXT/ANN1nTKZoTzx33xHezt/tN0upgxQbwnmv/ZtntXceBk4GT0zXDf238T/APolf/lxWv8AhQB3lFcH/bfxP/6JX/5cVr/hR/bfxP8A+iV/+XFa/wCFAHeUVwf9t/E//olf/lxWv+FH9t/E/wD6JX/5cVr/AIUAd5RXB/238T/+iV/+XFa/4Uf238T/APolf/lxWv8AhQB3lFcH/bfxP/6JX/5cVr/hR/bfxP8A+iV/+XFa/wCFAHeUVwf9t/E//olf/lxWv+FH9t/E/wD6JX/5cVr/AIUAd5RXB/238T/+iV/+XFa/4Uf238T/APolf/lxWv8AhQB3lFcH/bfxP/6JX/5cVr/hR/bfxP8A+iV/+XFa/wCFAHeUVwf9t/E//olf/lxWv+FH9t/E/wD6JX/5cVr/AIUAd5RXB/238T/+iV/+XFa/4Uf238T/APolf/lxWv8AhQB3lFcH/bfxP/6JX/5cVr/hR/bfxP8A+iV/+XFa/wCFAG9rH/I0+H/+3j/0AVvV5Vqmt/EX/hI9D874aeXc/v8AyYf7etj5vyDd82MLgc89a2f7b+J//RK//Litf8KAO8org/7b+J//AESv/wAuK1/wo/tv4n/9Er/8uK1/woA7yiuD/tv4n/8ARK//AC4rX/Cj+2/if/0Sv/y4rX/CgDvKK4P+2/if/wBEr/8ALitf8KP7b+J//RK//Litf8KAO8org/7b+J//AESv/wAuK1/wo/tv4n/9Er/8uK1/woA7yiuD/tv4n/8ARK//AC4rX/Cj+2/if/0Sv/y4rX/CgDvKwfA3/IrWX/A//Q2rB/tv4n/9Er/8uK1/wrG8Ha38Rf8AhHLP7B8NPtVt8+yb+3rZN3ztn5SMjnI/CgD1WiuD/tv4n/8ARK//AC4rX/Cj+2/if/0Sv/y4rX/CgDvK4X4m6rq1heeGrXRpr6M3968My2K25mdRC74UzjYOVB5xwDTf7b+J/wD0Sv8A8uK1/wAKoau3jvWoUh1j4M2WoRRtvRLrW7OVVbpkBlODQBR8U+LNb8G/YZ76XUbiDULCeC3gvo7bz0v1bMQYwDYQ6tgAEj5R3zl2k33iqXxdqGlXeoa9eLp62SSSafFp6R73hVpGk81Q2C2T8nQfhVmBPG9vZ21pB8FrCK1tZRPBCms2SpFICSHRQuFbJPI55NQX9j4u1G/N9qHwO0q6vTgm4n1axeQ44HzFc8YFAGP4d8V+I9R17TbObVdSha+1C9gElxBaC0aGJpF2wlU8zzlwhAfg4JIIrq/h3qfibWNX1CPW7qJbfRGbTZhCiYvrkYYzn5coNjJ8oxyx9MVWDeOxFDEPgzZCOGf7TEn9t2eI5sk+Yo28Nkk7hzkmrFtf/EW1edrb4RwwtPIZZjHr1opkcgDc2BycADJ9BQBk6b4i11Jk1GbWJriKTxPNo/8AZ8kMIj8jzmQFSqB9yqN2Sx4U5FY+keNfEmv+Irq3s9UnsrPWFuU0WSXTtsUMkLAx/vGTbIJEVyQC2O2Dit6Gz8YQahLfwfBDS476UuZLhNXshI+/O7LBcnOTn1zzVpZPHqxWUS/BuzEVkQ1qg1uzxbkDAMY2/LwSOMUAV/DeteLfEGnaVrolNta3uqxRNYQxJIsNqgdJSz7S2WkXOc8ALjqc+o15qr+PEt7aBfg1ZrBay+fBGNbs9sUnJ3oNuFb5m5HPJ9avf238T/8Aolf/AJcVr/hQB3lFcH/bfxP/AOiV/wDlxWv+FH9t/E//AKJX/wCXFa/4UAd5WDo//I0+IP8At3/9ANYP9t/E/wD6JX/5cVr/AIVjaXrfxF/4SPXPJ+GnmXP7jzof7eth5XyHb82MNkc8dKAPVaK4P+2/if8A9Er/APLitf8ACj+2/if/ANEr/wDLitf8KAO8org/7b+J/wD0Sv8A8uK1/wAKP7b+J/8A0Sv/AMuK1/woA7yiuD/tv4n/APRK/wDy4rX/AAo/tv4n/wDRK/8Ay4rX/CgDvKK4P+2/if8A9Er/APLitf8ACj+2/if/ANEr/wDLitf8KAO8org/7b+J/wD0Sv8A8uK1/wAKP7b+J/8A0Sv/AMuK1/woA7yiuD/tv4n/APRK/wDy4rX/AAo/tv4n/wDRK/8Ay4rX/CgDvKK4P+2/if8A9Er/APLitf8ACj+2/if/ANEr/wDLitf8KAO8org/7b+J/wD0Sv8A8uK1/wAKP7b+J/8A0Sv/AMuK1/woA7yiuD/tv4n/APRK/wDy4rX/AAo/tv4n/wDRK/8Ay4rX/CgDvKK4P+2/if8A9Er/APLitf8ACj+2/if/ANEr/wDLitf8KAO8org/7b+J/wD0Sv8A8uK1/wAKP7b+J/8A0Sv/AMuK1/woA9E0/wD4/oP98Ual/wAlT8Pf9gXU/wD0fYVxnhzV/iFNr1hHqnw4+wWLTKJrr+3LeXyUzy2xRlsegrs9S/5Kn4e/7Aup/wDo+woAPBv/ACMfjv8A7DUf/pus66quR8KzxW2t/ECe5lSGCLV0eSSRgqoo06zJJJ4AA71J/wALH8D/APQ5eG//AAaQf/FUAdVRXK/8LH8D/wDQ5eG//BpB/wDFUf8ACx/A/wD0OXhv/wAGkH/xVAHVV5KfiRqSWFt4glk0dNFn1E2i6YUf7cYPtX2bzw+/BIfBKCPGD9/Ndh/wsfwP/wBDl4b/APBpB/8AFVxGrW3we1LVodVbxLoMGowXYvoZYdcQJFPvVmkWIyGLcxUbjsye/PNAGhqvxf0lfDQ1CxhvoXmsrq9haa1SUKsFwIHDIJlySxyAGHHJI6U7xh8UvsHhvxHe6FpV9M2mJcLFfT2++ykmgYLIhKPuGCSAWChsHaTis57P4MP9qD674fZLiKWB4z4hJRY5ZBJIqL52EBcBsKBzn1NS6hH8G9Rnv5b3XPDcpvvN85TroCZlx5jIgl2oz4G5kAJ7mgDq4fiBolzoX9opfWtqtxJNBp5u540F/JGdpMI35cF/lA4J9OQT594M+MN7dww32vS2MthHo7arqSW2l3FpJYjC+WFMsjCdXJZQUAHGc4rs9P8AFHw106LUYrLxT4bii1CV57hBrEZVncAMQDJhc4524ycnqSayZJfg/La2FvJrnhdobGxfTYFOsocWzqFMTfvPnGAMbs4PIweaAKdx8Z7O/NhJoCoIC16t8JlS4eEw2b3CFDFN5b52jID+q5U8i/ZfGfw/PqMGlILm51N4VKqghjEs5gE3lCNpS65HG4gxg/LvzSSXfwomtba3uvFWjXcduJliN14kadkE0RikAZ5i2CjEYzgZyMHmpNM1L4V6Xetdad4p0O2d41jeOLxDthkAjEYLxebsZtqgbipbgc0AZNz8R/FEfwR0/wAXR2OntreoTwJBbPAwi2yyBF4WZievBLL7qOlZ2j/HmCfXtXuL+CBPC8Nnby2UsYxNPM5jRlLu4jCh3ZcnaBsJJGDXXR618LY9A0zRU8S+GxpmmyQy2sP9sx/u2hYNGd3mbjhgDyTnvmse3tPgtbWa2ttrHhiKFYvJTZriqyKJjOCrCXKsJCWDAhh0BwAKALWp/GTTJ/C11feGbO81C/TTru9EYSN0thBlS0xEgDJvwP3bNkZI45qTRvirFKJIJ7G+1LVGlKRWWnWiq5CW0U0hBeYhwPNHPyk5ChSeTHq8/wAJdYtILfU/FGjXKwwSWwkk8SMZXikILxySedvkUkDhyRxUUy/B2WKRP7f8PRl5TKZItf8ALkDGJYjh1lDAGNFUqDggcg0AaD/FO2g8RXOl/wBnarfXElzHb2trb2SQyqWtFuCHMswydpPVU2ngjjcYl+N3hE3Ojw+ZdL/aUMEys/loYRMxVAyFw7HI58tX2jk4HNMsrn4Q2Wqwajaa94Yhu4HWSJk1lAqFYPs4wvmbcCIBcYx36803S7j4S6TNYS6X4m0OyeyhS3i+z+IjGGjQkqsgEwEoBZsb93U0AdJ4E+IGl+NLi9i0yC4ha0JDrcSwCQ/MVyYlkaSPp/y0Va7CvONI134ZaTq0+qWvi7RpNQmj8lp7vxD9pYR7t2xfNlbYuecLgVu/8LH8D/8AQ5eG/wDwaQf/ABVAHVUVyv8AwsfwP/0OXhv/AMGkH/xVH/Cx/A//AEOXhv8A8GkH/wAVQAeIv+R78I/9vn/ooVl+LvHcvh3xqmky20ktk+jTXytb2M91KJkkVVBEQbbHgnJIAzj5h0Odrvj7wdL4z8Lzx+LPD7ww/avMkXUoSqZjAG47sDJ6ZrSufFPw2udYOqT+KfDbX5tHsPN/teIfuHYMyYD45Kg5xnjrQBkeGPi7aXXhnTb7V7K5ab7Ha3OqXNlEotrAznCbg77yD1+QPgcnFTz/ABp8NW989jNb6ml8iOTbmJN/mi5NuIPv48wuCQM4285FU4l+DkK2SRa74bSK0jihSJddAjkSI7oxKvm4m2nkeYGxUkknwek1k6s+teFjqBvk1Pzv7Yjz9oRSqvjzMcAnjpnnGeaAHfEz4mXPgfxtpFpcQWreH5bSS4vZmVvNjI3BCpBxgsFByCfm4rM8BfGZ7zw5cTeL9PaHVra1v76aOwhxGsVq4V1G+TO/np09xWz4n1H4TeKXd9e8QeGLxngFs27WI1zGJFlA+WQfxopz14x0JFZ+owfBrUUlW617w9iV7l5DH4g8ov8AaG3TBiswJViAdp+UY4AoA2r34m20ltqZ0fStVuRaQPuvfswe1hnFv54jk2vvHBXLbdoLAbsmrHw08e/8Jjp8cFzYz6draada30qTInlOJkJWSLbIxKZU8MQ2MZrCnPwdnvWupde8NmRkCMn9uqI2IiMQcxiXYZBGSofG4DvWloeufC7Q7sXWleJvDcE4s4dPDf2zG37iEERphpCOMnnqe5NAFDTfHWuWGr6/H4kuNNu7fTdRh0uC303TXjnvZ5o0dApkuGVOXIw3HGdwrstL12XxPoV3LoDrp2owXD2kseo23nfZpUYb0dI5FDHHQrJjkHJ6Vy93qvwpu11QXHiPw2x1K4ju7lxrSKxmRVVJEYSZjYBFwUK4xmtDQfFvw40GwFnpfivw3FBvaVi2sRSPI7HLO7s5Z2J6liTQBzuj/FO60v4c6b4s8aJbz2+oR+aqaZFHb/Z1BwQRPc7pSeMeWM+3Srml/FuwS58Txayoxo9xdSM1qn+qtIgmx5AzZLOzFRtHUchQM1SvLf4M3mm2Gnz674d+yWVtJZwImv7MQuQWjYrKC6kgHDE8ip2Pwdbzt+t+F3MzTtKX1pG8zzkVJQ2ZOQwReDwCoIwRmgDrvAPjjSfHFld3Gjl1a0lEM0bvFIVYqGGHid0YEH+FjjkHBBFJ8Lv+RE0z/tr/AOjXrP0Txh8PtFsvstl410dod24favEAuWHsGllZgOOmcVlfDjx94OtPBmnQXfizw/BMnmbo5dRhVhmRiMgtnoaAPT6K5X/hY/gf/ocvDf8A4NIP/iqP+Fj+B/8AocvDf/g0g/8AiqAOqorlf+Fj+B/+hy8N/wDg0g/+Ko/4WP4H/wChy8N/+DSD/wCKoA4fWfivfWB1m3SzVr208RxaTC32C4a3NuzQgl5h+7En7xsDcP4fl5537j4s6LBby3Tafq7WPlXM1rcrFGUvVtz++8ob93ygM3zhchSRmq1zqnwpuba8t5vEfhtobvUF1SZf7aQb7lShEmRJx/q04HHHTrUdpefCS0vbi6g8Q+GhJMkyFG1tHijWU5lEcZkKR7/4tgXPegDW8N/FHw/4j8RnRdKF3LeC5ubcnYuzbCFLTZ3cxksFU9SewAzWLrHjzxBBYeKNfs4tKGheHr57SWzljka5uVi2+ayyhwqH5vlUo2cckZp/hm7+Efhi+jvNC17wvaXKWgsFkXWI2Pkhy4U7pDn5jnceTxk8Ckv7r4SX2rS6jc+IvDjTzSpNPGuuqkE8ifdeWESiORhgcspPA9KAMrTPixrknjY6ff6CY9Hk1a509ZQsavDHBAZHZj553MPlYgIuFBA3scDU0z44+GNUiU6dbaldXEk9vBFbw+Q8knnFhG3EpVeVIKuVdcjKjNSSX3wme6S5PiPw4J0v5NTDrriqfPkXY7HEvKsowUPyEcEUyyu/hPZWtraweKdFNraXMV3bQy+IzJHBJHnZ5atMQijP3VwvtwKAO48IeIrXxToceqWMVxBG0ksLQ3CqJI3jdkdW2kjhlPIJFbVcJofi74c6FYtZ6V4r8NwWzSyTlP7Xib55HLucs5PLMT6c8Vo/8LH8D/8AQ5eG/wDwaQf/ABVAHVUVyv8AwsfwP/0OXhv/AMGkH/xVH/Cx/A//AEOXhv8A8GkH/wAVQB1Vcr4d/wCR78Xf9uf/AKKNH/Cx/A//AEOXhv8A8GkH/wAVXNaF4+8HReM/FE8nizw+kM32Xy5G1KEK+IyDtO7BweuKAPT6K5X/AIWP4H/6HLw3/wCDSD/4qj/hY/gf/ocvDf8A4NIP/iqAOqorlf8AhY/gf/ocvDf/AINIP/iqP+Fj+B/+hy8N/wDg0g/+KoA6qua+IXiKbwx4ba9tII57ya4gs7dZSRGJJpFjVnI52gtk45OMcZzUX/Cx/A//AEOXhv8A8GkH/wAVVLWfGfw61rS7jTtV8U+F7qyuF2SxPqkGGHUfx5BBAII5BAIoA5vxZ8RPEPg2XU7DVLKx1e/hhs7m3msImt4yk9x5BDpJK2GDdMP82R90BiDRPjDHHc6xF4q0y5sYbbUdRtre6iRDEyWqGRkbEjN5gRTkhdpPQ1L5vwjbTtQspvEuhTx35iNzLceIfNnk8pg0f75pjINpAIwwx2o8z4PlQr694alAuLm6Il1xX3SXCGOZm3SnduViCDkc8YNAFnTvjNoOqW9udLsNTvrye9SxSztmtpH3vE0qkuJvLwVVv48gghgMGrHjL4inwn4va01C0aXSY9HW/cW8e+581ruK3VRlwpX97kjrxwexr2ep/Cy1j01F8WaNMNNuPtVobnxGbgwybCnBkmY42sRt+7z0zTte1X4Va/fNeav4j8N3Fy1utqX/ALaRP3azJMFwsgH+sjRs9eMdMigB1/8AF/RtPt1e903VLef7fNp0sM720PkyxIrtvleYQgEOuPnJOeBwcV/+FrtB4i1XT7nw/qM0MWo2um2Js2gdp5ZoDMNxMoUAgZBzgDGT1AW9vvhVeQX0MnizSIor65ku7pbbxK0AnkdFRi/lzDIKqo2n5fbk1HHP8IotTiv4fEHhyO4ilgnQJrirGskMZiibyxLsyqHb05HXOBQBqSfFfQYI2kvLfULVI7u+s5TJGh8t7SJpJSdrnIwpC4ySewqvqvxKuoX8PraeGNXibUtUisWW9SNCI3iaUPGwk2OSB2b5cMGwcKc+T/hT0urz6lLr/hyS5meeV1fXg0RaaMxynyjL5YLoSGwvPHcCi3Pwgt4Io4vEWghormK8SY+Id0yyxoUjPmmbfhVJULnaASMYoAn0r4v6U+ixXl1Bf3SRWy3WoXVvaJFFZRPK8aNIhmZhnYxwhc4BJAFXYfizpEl3NE2la3HGhvljnMEbrO9of3yoquXJ7jKgH1yCBkCL4NLFaxLrnhsRW8YhEY10BJIxIZAkq+biVQ5LAPuAJ4q7BqHwot5YJbfxL4eilgkuponj11VZHuTmZgRLkFv/AB3+HFAHV+BPF1j400b+0tMRo4N23a9xbysOAefJkcKefukhh3Aro6898PeJPhr4f+1nTfFugiW7cSXE1xrq3MsrBQo3SSysxwoAAzgDpWx/wsfwP/0OXhv/AMGkH/xVAHVUVyv/AAsfwP8A9Dl4b/8ABpB/8VR/wsfwP/0OXhv/AMGkH/xVAHVUVyv/AAsfwP8A9Dl4b/8ABpB/8VR/wsfwP/0OXhv/AMGkH/xVAHVVyupf8lT8Pf8AYF1P/wBH2FTWPjzwhf3kNpY+KtAubqZgkUMOowu7segVQ2SfYVDqX/JU/D3/AGBdT/8AR9hQBX8PQxXGp/ESGeNJYZNVVHR1DKynTbMEEHqCO1c3/wAIH4Q/6FTQP/BdD/8AE10/hf8A5DPxA/7C6f8Apus6ZQBzf/CB+EP+hU0D/wAF0P8A8TR/wgfhD/oVNA/8F0P/AMTXSUUAc3/wgfhD/oVNA/8ABdD/APE0f8IH4Q/6FTQP/BdD/wDE10lFAHN/8IH4Q/6FTQP/AAXQ/wDxNH/CB+EP+hU0D/wXQ/8AxNdJRQBzf/CB+EP+hU0D/wAF0P8A8TR/wgfhD/oVNA/8F0P/AMTXSUUAc3/wgfhD/oVNA/8ABdD/APE0f8IH4Q/6FTQP/BdD/wDE10lFAHN/8IH4Q/6FTQP/AAXQ/wDxNH/CB+EP+hU0D/wXQ/8AxNdJRQBzf/CB+EP+hU0D/wAF0P8A8TR/wgfhD/oVNA/8F0P/AMTXSUUAc3/wgfhD/oVNA/8ABdD/APE0f8IH4Q/6FTQP/BdD/wDE10lFAHN/8IH4Q/6FTQP/AAXQ/wDxNH/CB+EP+hU0D/wXQ/8AxNdJRQBzf/CB+EP+hU0D/wAF0P8A8TR/wgfhD/oVNA/8F0P/AMTXSUUAcDqvgnwqniTQ4k8M6GsUnn70FhEA2EBGRt5xW1/wgfhD/oVNA/8ABdD/APE1NrH/ACNPh/8A7eP/AEAVvUAc3/wgfhD/AKFTQP8AwXQ//E0f8IH4Q/6FTQP/AAXQ/wDxNdJRQBzf/CB+EP8AoVNA/wDBdD/8TR/wgfhD/oVNA/8ABdD/APE10lFAHN/8IH4Q/wChU0D/AMF0P/xNH/CB+EP+hU0D/wAF0P8A8TXSUUAc3/wgfhD/AKFTQP8AwXQ//E0f8IH4Q/6FTQP/AAXQ/wDxNdJRQBzf/CB+EP8AoVNA/wDBdD/8TR/wgfhD/oVNA/8ABdD/APE10lFAHN/8IH4Q/wChU0D/AMF0P/xNYng3wT4VuPDdnLP4Z0OWRt+XewiYn52HUrXf1g+Bv+RWsv8Agf8A6G1AEP8AwgfhD/oVNA/8F0P/AMTR/wAIH4Q/6FTQP/BdD/8AE10lZFt4m0G6+2fZtb0ub7GhkufLu428hR1Z8H5QMHJOKAKX/CB+EP8AoVNA/wDBdD/8TR/wgfhD/oVNA/8ABdD/APE10MciSxrJE6vG4DKynIIPQg0+gDm/+ED8If8AQqaB/wCC6H/4mj/hA/CH/QqaB/4Lof8A4mr8HiLRLi5ureDWNNluLVWa4iS6RmhC9S4ByoHfNK/iHRkginfV9OWGWFrlJDcoFeIYzIDnlRkZbpzQBn/8IH4Q/wChU0D/AMF0P/xNH/CB+EP+hU0D/wAF0P8A8TWydTsFuRbm9tROYTciMyru8oHBkxnO3P8AF0qSyu7a/tYrqxuIbm2lXdHNC4dHHqCOCKAML/hA/CH/AEKmgf8Aguh/+Jo/4QPwh/0Kmgf+C6H/AOJrpKKAOb/4QPwh/wBCpoH/AILof/iaP+ED8If9CpoH/guh/wDia6SmSSJFG0krqkaAszMcAAdSTQBz3/CB+EP+hU0D/wAF0P8A8TR/wgfhD/oVNA/8F0P/AMTW/a3EN3bRXFrNHPbyoJI5Y2DK6kZBBHBBHcU37XbfbRZ/aIftZj83yN437M43beuM8Z6ZoAwv+ED8If8AQqaB/wCC6H/4msXSvBPhV/EmuRP4Z0Noo/I2IbCIhcoScDbxmu+rB0f/AJGnxB/27/8AoBoA8puNf8DwarrOmv4B0IXlhqMVjGrWsIFwjSrG0iny+Cpdcrz95eeeNRT4WNvFqzfD/wAOr4akvvsC3vkQ+cD5vk+YYfKwE8zjO/djnbXT6l8MdB1FzJcveed/ax1lZVdQySkJuQfL/qz5a5ByeOtW08B6etxGPtuonS47z7emll0Nss27fkfJvxv+bZv257UAcHqJ0nTW8Tfa/hr4P8vQLdbi4MToxkDozIEBth/dwckYzxmtnwvY+DdXs7m6m8L+CZooTEuNFVNSdS5xh1SBSvb143E4AzXV6r4M07Ux4kE812v9vQRwXOxlGxUUqCmVODgnrmrVhol5aW0kLeI9WuM7Ajyx2oaIKckLthAO4cHIPHTB5oA4Hx9/whng+7jim8C6JdI9hc3u6OwiyDFswu0RnglxluigEnipbuHwbYaV4Zub/wACaQs+t3CQLFBpQkEJZS2TmFW6DoVB69gSOu8W+C9O8UXCzahNdxstncWIEDKBsmADHlT8w2jHb1Bq1rPhq21W20iJ7i6gbS7iO5t5YSm7eisgzuUgghiDx9MUAeaaPq/w71Hw5dX0nhLw/ZX9vBPcta3Om4jMcUhQsJRAQ4+6TsViN2McV1Ol6T8PNT1ObT7Lwzo01zAdsxj0UGGNsAlTL5WzdyOM59qJPhXokmmQ2JutS8mK0urJSJE3bLiTzHJ+TqD09uoNakHgbT4vF0PiI3Fw95CrLGvlQIACmzDMkayOMdndhnnHAwAc/qS/C/TdXl0u70DRxexSJC8cehGQCR03om5YipZl6KDk9Bk8UiH4VutkyaNoDJdoskbjRwVVWfy1Mh8vEQLgr8+3kEV0l34K0661qbU5J7sXEt/b6iyq67RJDH5agDbnaR1Gc56EdKxovhP4ejudPn/fSvZoY/8ASIbecSqZWlw3mRNjDOwym0478UAc/q1/8PLbUBbWHhPw9cxrbXs8tzLpoiiQ26gkBvJbzFJ3Asm7G08E8VpSD4ZpL9mbQvDn23yt23+yx5O/yvN8sy+VtDbRnb97HO3tWlL8L9JlDxNqGq/ZPIvLaG2Ekfl26XP+sCfJu75G4tj6cVbi8AWEE9wbbUtWt7W4+aezinVYpZPJ8rzGwu4nbjK52kgEqcUAc9Zy/DCU2UM+heH0u7hLZisejl4kadQYgZDCAA2eC23PcA8VqaPpnw31jUJbLTtA0GW4jVmwdJRFdVbYzRs0YWQBuCVJANWYPhvpENsIFub8p/oByXTP+hgCL+Hvj5vXtirXhTwFo/hjVLm90xBvm37Q9vBujDNuIEqxiUjPZnbjHoKAOaiHw5F9LZXHhvQWvRdTW0cFlo7XMjCIgMzKsGVxkZPK+jGtTxDpHw78PPapqvhzRY5Lrf5KRaMszPsXc2AkbHgc0/WPhlpGq29zBPdXixXF5NeuBHbuweUjdsd4mZMY4KEMPXpXQat4cs9UvtMup5LhZNPSZIgjjBEsfltuyCTx0569c0AcjHF8L5bmygi0Xw+7XiQvE6aQpjxLnygziPahbBwGIJ7Co1Pwra3u5/7H8PiG1TzXY6OoDpv2bo/3f70b8LlNwyQOpq/YfC3QLHUNNvIhJJLYwQQD7RBbzeYIRhCWeIsjYxkxlM4HpTLL4T+HrKxvrS282OO527HSG3SW3KyCRSkqxB2wyqfnZx8ooAwNO1H4bTrqL3/hTR7OO2vJbWMHR/MkkWOON3kaMQ7owvmANuHy45IqzrMnw7stUsdPsfC2g39zPfW9lIY9NQRxeaMg+b5ZQttIOzOSDmtK5+E2i3bma8vL67vGu5bxri5itpizyJGrgo8Jjx+6UjC5BzggcVoP8O9L/tSO6gu7+2t0vIdQ+wwNGtuZ4lCq23ZkZVQCAQOOgoA0P+ED8If9CpoH/guh/wDiaP8AhA/CH/QqaB/4Lof/AImukooAyNE8GeF7LV7O5s/Dei29xFKrxyxWMSOjA8EELkGt/Uv+Sp+Hv+wLqf8A6PsKNP8A+P6D/fFGpf8AJU/D3/YF1P8A9H2FAEXhf/kM/ED/ALC6f+m6zplP8L/8hn4gf9hdP/TdZ0ygAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAwdY/5Gnw//ANvH/oArerB1j/kafD//AG8f+gCt6gAooooAKKKKACiiigAooooAKKKKACsHwN/yK1l/wP8A9Dat6sHwN/yK1l/wP/0NqALniSwm1Tw9qmn205t57u1lgjmH/LNmQqG/AnNeX3ei+MLi2hj07S5tNey0W4s0HmWYUTmHbH9lkT96gLgElmUdOBivYqKAPJ5fDvjk3t3BbaldR2aWcl5bTS3hZjePAIxA3OfLRw8gzlcsvXFbfw+0fxDB4c1O3168vknuV2wpdEO1u3l7WZX+0TMwJ55YYOcAA4rvaKAPHZvCuvX3h3w9o6aH/Z82iWk0Ul2s8JS6Jt3i2RbW3YkZgzF1XHuea5f/AIVj4rs9PFjb2xuLL/hHpoYo2uI91vdzLGZIclsFfMVmBHA3EZ6V9FUUAeW+K9A1DxZomjQnQtT028sriCCWR7mBGktJPkuVBjlbK7ByDgnjAPNdB8QrHVW8PWlh4YsJGw4jzbXbWzWyBCFZQssW4A7Rt3jjscYrsqKAPJdK0rxtDq3hm5u11O5dLe2iv0uLsLbxFRiVwY7gb3PX54pATjkdr/jnQvFN/r2qXejT6kkUdpafYUg1AwxmcTky5TeAf3Z53DB9yBj0uigDxy60H4hvqHiSS21K7hkk+0i0O8NBKjMDEqk3B8t1UYBEKc5yx4NRT+HfGjaVbxXDa3e2rNd7rNbtbaaJnjUQlnN1J5kQYOcNIx+blWAAr2iigDxfwr4Z8d2GpaRFLdXVnaWtlaRoEZZYE2WwSSKRftAH+sydwic9CGA4rU+G/h/xDZeLINQ1601BWTRzaXFzeX63PnXPnKzNGA7FUIGQMKB0wO/qlFABWDo//I0+IP8At3/9ANb1YOj/API0+IP+3f8A9ANAHHXeo+L5vEtxaRtqUQe9nhMSWS/ZorLyj5dwk5Q5m3bflLHkkFMDNcH4X0nxX4W05bjSLfV/t0nh+F44JLFRGs5mPnK22LiRUww3ZdjjO/AFewXXj3QYrq7s47p3vbd5YdjQSojTRoXMQlK7N2BnGScdM1S8LfEzQtb03TpppZLG9u1gzaywy/K0xIQBygDKWUqHHy5HXkUAczFf+O7q101Ptt5ErpqEjzwaeTIQiRmBZPOto8OWLjiNQw6c8jX8S3V/d+FfATaujxS3uo6f/aUbIUw5QvsZe374ICD9K6C38deH7m7t7W0uri5uJ95RLeynl+VZDGXO1DtTepG44U4ODVK/8b+HBBdw69LbGOG7mhMSQy3IAgZSZHXyvlCkqS2CqnGGNAHaUV55q994Lvp9W1DxBoumX4sZvs8l2mmSXzKoiWTMhEJ2gK2cgsuP4s5Ag2/C06omnDRNCa5eSGIbdGBjDzKHiBkEewFgRjJ56dQaAPSqK5v/AIQPwh/0Kmgf+C6H/wCJo/4QPwh/0Kmgf+C6H/4mgDpK4v4vWt/d+BblNKa+Fws9u7LZJvkaMTJvAXaScLk4A5xjkZB0P+ED8If9CpoH/guh/wDia2NL0yw0m0FrpVla2VqCWENtEsaAnqdqgCgDyozeLlvryHS/7QsoJtRvpDcRaXGryotpG0LNmLBLSAruIyeV7ACB9a+IcOlufLv5nePTp5JWsQjwCVJDcJGFhfOxhGMGORl3HIPb2iigDyS21jxtDqfh5r+S5vIZkiW4trCwlhBJlILyPLa4xs2llLQkYOB0q18SNf1+y8VPp2h3moRkaO93BBZWKXJluRLtQPlGKoehOQB6jv6jUH2S2+2i8+zw/axH5Xn7Bv2Zzt3dcZ5x0zQB5V/bHxBbxDqiSxG3iiimMduttI6MBBmNonEBUv5nZpjnkbBwT0jyeJLX4a29+lze3mvpDBezRSW0Ykf7jSwCNUGMjeoH3snrXcUUAeI2et/E99H1aS5tbhLqzt4njH2QAzGeRHOweWSWhj3oQAfm6hjgVJd6z8Rlg01Ynwkiystz9inbc3mLsS4UWe8fKTkiOIHqGHQ+1UUAePaPFq8Gr+KLLWrK6t/Dt9c6lI7rDlJWMacyFlyse0NtYEBmBB7A9l8MtVkvfB2kW928jatDpttLcLIjLkOnyNuIwc7TkjOCDnniuruYIbq3lt7mKOaCVDHJHIoZXUjBUg8EEdqbBa28EkkkEEUbybQ7IgUttGBkjrgcCgDyrTvEHitNDvJtRj8SS3xhi86KHSo4/sk5lKsIXKMZEC4JxHLwMhsnA5HxBbeK/EGhLPq2l6lPqI0jULVyLNwzH7VF5YwEXJKLkYVcgE4HNfRNFAFjT/8Aj+g/3xRqX/JU/D3/AGBdT/8AR9hRp/8Ax/Qf74o1L/kqfh7/ALAup/8Ao+woAr+HZFh1T4iSyHCJqqsxxnAGm2ZNYP8Awl2if8/v/kJ//ia6bwb/AMjH47/7DUf/AKbrOuqoA8v/AOEu0T/n9/8AIT//ABNH/CXaJ/z+/wDkJ/8A4mvUKKAPL/8AhLtE/wCf3/yE/wD8TR/wl2if8/v/AJCf/wCJr1CigDy//hLtE/5/f/IT/wDxNH/CXaJ/z+/+Qn/+Jr1CigDy/wD4S7RP+f3/AMhP/wDE0f8ACXaJ/wA/v/kJ/wD4mvUKKAPL/wDhLtE/5/f/ACE//wATR/wl2if8/v8A5Cf/AOJr1CigDy//AIS7RP8An9/8hP8A/E0f8Jdon/P7/wCQn/8Aia9QooA8v/4S7RP+f3/yE/8A8TR/wl2if8/v/kJ//ia9QooA8v8A+Eu0T/n9/wDIT/8AxNH/AAl2if8AP7/5Cf8A+Jr1CigDy/8A4S7RP+f3/wAhP/8AE0f8Jdon/P7/AOQn/wDia9QooA8v/wCEu0T/AJ/f/IT/APxNH/CXaJ/z+/8AkJ//AImvUKKAPGdS8RaVNr+j3Md1uht/O81vLcbdyADjGTz6Vrf8Jdon/P7/AOQn/wDia9H1G+tdNsZ72/njt7WBS8kshwqivCtc+NmpXN7KuhWcFvp+/EVxOpaRwOpK9AD1qZSUdWYYjFUsOuaq7HXf8Jdon/P7/wCQn/8AiaP+Eu0T/n9/8hP/APE1ylh8SvEt45+zajpDuORFNH5e72Br0bwD49tvFE1zp91bPp2s2oBltJSDvX++h7rmiMlLYmhi6WI/hu5if8Jdon/P7/5Cf/4mj/hLtE/5/f8AyE//AMTXqFFUdJ5f/wAJdon/AD+/+Qn/APiaP+Eu0T/n9/8AIT//ABNeoUUAeX/8Jdon/P7/AOQn/wDiaP8AhLtE/wCf3/yE/wD8TXqFFAHl/wDwl2if8/v/AJCf/wCJo/4S7RP+f3/yE/8A8TXqFFAHl/8Awl2if8/v/kJ//iayfCniLSrDQLW2u7ry5k3bl8tzjLkjkDHQ17NRQB5f/wAJdon/AD+/+Qn/APiaP+Eu0T/n9/8AIT//ABNeoUUAeX/8Jdon/P7/AOQn/wDiaP8AhLtE/wCf3/yE/wD8TXqFFAHl/wDwl2if8/v/AJCf/wCJo/4S7RP+f3/yE/8A8TXqFFAHl/8Awl2if8/v/kJ//iaP+Eu0T/n9/wDIT/8AxNeoUUAeX/8ACXaJ/wA/v/kJ/wD4mj/hLtE/5/f/ACE//wATXqFFAHl//CXaJ/z+/wDkJ/8A4mj/AIS7RP8An9/8hP8A/E16hRQB5f8A8Jdon/P7/wCQn/8AiaP+Eu0T/n9/8hP/APE16hRQB5f/AMJdon/P7/5Cf/4msrTvEOlQa9q91JdgQ3Hk+WfLfnapB4xxzXstFAHzbY6PoU2oapca1rk8kE2qT6hbWkAbylMkexXbMe7eAW43FenBqvr+g+H/APhHpbTQdSZ706ZBpMT3rOixRxOXSXKREmQMc9gcDpX01RQB87X2heDb7TNFsZ9UnWDS4Y4o/LtE3NsIO7zGiaRCSOSjr1qSXSPCf264vbLxBq1hfTzXMklxa/K5WcqXjBMZwuVUgjDAjhq+haKAPnPWPDvgzVTd+freqLHd3D3E0YG9HLRJEQQ8TZwqAhj8wOSGFWrfSvB8JUjV79iLmyu8svV7VFSPpH0IQbvU5xivoKigDyiy8T6Pb26xzavNdOCx82aAhjkkgfIijjOBx0Azk5NT/wDCXaJ/z+/+Qn/+Jr1CigDy/wD4S7RP+f3/AMhP/wDE0f8ACXaJ/wA/v/kJ/wD4mvUKKAPL/wDhLtE/5/f/ACE//wATR/wl2if8/v8A5Cf/AOJr1CigDy//AIS7RP8An9/8hP8A/E0f8Jdon/P7/wCQn/8Aia9QooA8v/4S7RP+f3/yE/8A8TR/wl2if8/v/kJ//ia9QooA8v8A+Eu0T/n9/wDIT/8AxNH/AAl2if8AP7/5Cf8A+Jr1CigDy/8A4S7RP+f3/wAhP/8AE0f8Jdon/P7/AOQn/wDia9QooA8v/wCEu0T/AJ/f/IT/APxNH/CXaJ/z+/8AkJ//AImvUKKAPPNG8T6RdataQQXe6WSVVVfKcZJPuK2dS/5Kn4e/7Aup/wDo+wrqq5XUv+Sp+Hv+wLqf/o+woAPBv/Ix+O/+w1H/AOm6zror26S1jDMMseAo71zvg3/kY/Hf/Yaj/wDTdZ1b1py15t7KoFJuxMnZBJqlyxO1lQegX/Gmf2ld/wDPX/x0f4VUoqbmV2W/7Su/+ev/AI6P8KP7Su/+ev8A46P8K8/+KEsjW2gaeZZIbHUtWhtLx43KExFXbZuHIDMqqcdjjvWB8QPD/hrw5oGttpQj0i8u9Dv4lsbQCOG7CwFizxgYLIOjcH5iCT0oBN9z1/8AtK7/AOev/jo/wo/tK7/56/8Ajo/wr5/8QavrmhaA+m3WprqUF14VmvfLubSApDLGEACrswyYbG193Tr2qzb6rqEHjnVdN025+wzavqtjBJdrGjGFF05JGCBgV3NswMggZPFMevc93/tK7/56/wDjo/wo/tK7/wCev/jo/wAK8v8AhPDc2+s+OYb28N9cJq4VrgoqF8QRYJCgANjAOABkHgdK5iw1bxONJSfT1votJF7qSTy6HYW0k6yrcMI90TLhkwGJKjeT1PNINe57v/aV3/z1/wDHR/hR/aV3/wA9f/HR/hXFpq8t/wDDaXVNJ1FLm5fTXlhvUg8sPKIzh/LbO35hnac46V4gPjR4gZ7C7hYy2U2l/ZIk8hc3WqCOIswO3PDzD5RgfKeKeoLmZ9R/2ld/89f/AB0f4Uf2ld/89f8Ax0f4V806t4z+IIutTtbPVoYW8PrBBdTTRWUcd1cOAW81pZE8tScquxTkD1qv471K6u774iarNGqXsOmWWgRxq2f3k5VpUU5IIBLCjUdn3Pp7+0rv/nr/AOOj/Cj+0rv/AJ6/+Oj/AArF0DTk0jQtO02PGyzto7dcdMIoX+lX6VybvuW/7Su/+ev/AI6P8KP7Su/+ev8A46P8KqUUXC77lv8AtK7/AOev/jo/wo/tK7/56/8Ajo/wqpRRcLvuW/7Su/8Anr/46P8ACj+0rv8A56/+Oj/CqlFFwu+547+0D4iv9QntfDBmEVtJGLt3IA8xgxCgeoHXFeIWOjX9neQub+4khQ7pEyDu56V9ZeMPC2neKdNe11CFDIFIhmx88TEdQfyrw3UtDl1HT9K0mW/s9K1a2unt7lVUtvUdHJ+lRKMpbM83FYWtWm3Gas+jRy0l6Q6sBHBESfnlcc49MV0ngvV75/iB4UaxvmurtJyjFMErAVO8H/ZFeoeM/DFkvhLSrewtLO51K3nhNoCgCzOcKzHHbaWY/QV4dYx+Ifhz48v7qK2iup7bdGzBPkdX+bj0ohSSd0Z4bKlRqKpGW34n2F/aV3/z1/8AHR/hR/aV3/z1/wDHR/hXA/DPx3aeNtJeVVW31GA7bi13ZKejD1Brs6vU9a7Lf9pXf/PX/wAdH+FH9pXf/PX/AMdH+FVKKLhd9y3/AGld/wDPX/x0f4Uf2ld/89f/AB0f4VUoouF33Lf9pXf/AD1/8dH+FH9pXf8Az1/8dH+FVKKLhd9y3/aV3/z1/wDHR/hR/aV3/wA9f/HR/hVSii4Xfco6l470nS737HqfiLSrO7AB8i4uoo356fKSDzTdT8e6PpV0bbU/EmkWdyAGMVxdQxvg9DhiDg15Joeg6h43vfiHcwara2el6tqJ02Um0M0rxW6hMxv5gVc5YZKN3PpXO3B1O10fx9rWlXVrDokt+mh3Ly2jTTx2kKLAZYz5iqcbzwVOeTkYxTK17nv+p+OtK0qWKLVPEWlWUksYljS5uYoy6HOGAYjIODz7Va0zxVbaq0i6Xq1lemJUZxbyxybA4yhO3OAw5HqOleC+Fb+00jxvr4tPF3h3S4tNt7TRrc6uBK8scMQyy4njwCxPr+GKs+PbjVNM+J15pejZOoeLdJt7aO4jUhI5Edlkkxk4CxbmHJxxQGvc9huPiLoNusTXHinRIllUvGXvIVDqGKkjJ5G5WH1BHar9p4rtb24hgs9XsbieaD7TFHFLG7SQ5x5igclM8bhxmvCPDV1YaF498Spp/iXw5oVvpsVto9vFqqiR3SJMsVAmjxlycnnJ9Dmsfx7eanZ+LPEXj/TZDN/YdzFpDiLIRo2gxIepxiSRSBzjjmgNe59AXHxE0K2SFrjxTosSzJ5kRkvIVEi7iuVyeRuVhkdwR2rW0/xANSs47vTr+C7tJc7JoGSRHwcHDDg8gj8K8XvdJNnpfwj8JeXhvtMd5Oh7m3hMjg+29uldR8VvGlz4St7Uae9oLuaOaZY7iLcJRGF+RSZYxuJYcAs2AcI1Ate56T/aV3/z1/8AHR/hR/aV3/z1/wDHR/hXhniX4haxImu2FvcWFtI2lTXNn9kVbiaMrbeaTIyzh4z94AmLbkr8x6FI/GniDRtI1DUlvdN1S0kmvBAxSQ5eKxa4V1bzCPKJjxsHZs76NQ17nun9pXf/AD1/8dH+FH9pXf8Az1/8dH+FeQXXjjxBpF5L/a50mW1trxbSb7Payqzb7M3AZf3jfdwFxgluo29K0/ht41vPFEeti4NjKbIRvDPAFjjkV1Y87ZZQACpGd2fVVIIpai1PTP7Su/8Anr/46P8ACj+0rv8A56/+Oj/CvEdP+KWppo1xqV9FY3kdjMsd6thGrqvmI/lCKWOeVXPmKqnO0gOCVHGb9v4q8YyX8VpMdBhle+Omt/okrbJVshcu/wDrRlchlC8dQc8YL1Hr3PX/AO0rv/nr/wCOj/Cj+0rv/nr/AOOj/CvDNL+Jmt6yVjtpdGiuZ1tkjsRDI9x++s0maYfvBlI3c5GOVGCwOCX+D/iDqksGhWs1/pV5I/2C3MGxzdXiyonmTo3mEYjLMH+U8xPkrwKNQ949w/tK7/56/wDjo/wo/tK7/wCev/jo/wAK8UsPH3ik6ZZX94NEaKSy0/UJI4raVSUuZ/KMYJlOGH3t2CO23vXQ/Drxle+ILrVbXUTYzXVoA4XTtkkQBZgF81ZpAzHaOGWM/wCzS1DU9K/tK7/56/8Ajo/wo/tK7/56/wDjo/wrxDQfihrV3p9xqV/aacLKz8me9SJozNaxF9silEnd9yAhtzpHwjjYCRixb/EPxH/wkOk6feafp9u10ltI0EjxRPIkxJOwyXCtlFIBCxybmVh8uRT1D3j2f+0rv/nr/wCOj/Cj+0rv/nr/AOOj/CvHLTxx4oTRvDl1dwaXPN4jt4vsX2e2kVYJ3aM7ZMyHcojZ3yNv+rI9KyZPiLfrrZvLnU9OiEem3O6xSOQizlN3bxILlTIAWAYncfLwGboDkmoanvP9pXf/AD1/8dH+FH9pXf8Az1/8dH+FeK6b8SdeurSxP2KxeXULiTT7R0jO37Ssyjc4WVxsMTF8K7f6tsMQRXqelXH2mz8z7Xa3n7yRfNthhPldl2/eb5lxtPP3lPA6BaibaNf+0rv/AJ6/+Oj/AAo/tK7/AOev/jo/wqpRRcLvuW/7Su/+ev8A46P8KP7Su/8Anr/46P8ACqlFFwu+5b/tK7/56/8Ajo/wo/tK7/56/wDjo/wqpRRcLvuW/wC0rv8A56/+Oj/Cj+0rv/nr/wCOj/CqlFFwu+5b/tK7/wCev/jo/wAKP7Su/wDnr/46P8KqUUXC77lv+0rv/nr/AOOj/Cj+0rv/AJ6/+Oj/AAqpRRcLvuW/7Su/+ev/AI6P8KfHqlwp+cq49CMfyqjRRcLs6e0uEuYg6cdiPQ1zepf8lT8Pf9gXU/8A0fYVf0JyLh07MufyqhqX/JU/D3/YF1P/ANH2FUjWLug8G/8AIx+O/wDsNR/+m6zqDxJrWlWOqyQ3up2NvMFUmOWdEYDHoTU/g3/kY/Hf/Yaj/wDTdZ14X8abWW9+K1xaWy755xbxRrkDLMigDJ46moqS5Vc58XVdKCaV9T2Kz1fTb1wtnqNncMe0U6uf0NX6+Yz4X1eNZXktxGsUEtySZF5SOTy3IwezcV3fwh8XXs2qLomozPcRSoxgdzlkZRnbn0wD9MVnGpd2aOSli+aSjNWueqavpllrOnTWGqW0d1aSjDxSDIODkH2IOCCOQaxoPA+gRR3qtaT3BvLVrKaS6vJriQwMMNGryOWVTnopFdNRWp2nP6n4P0LVAgvrHzQtk+nj99IuIHxuThh12jnrx1pLvwboN2t4J7Ek3csM8rrNIriSJAkbqwYFGCqBlSD+ZrZv7lbKxuLp45pVhjaQxwRmSRsDOFUcknsBXHT/ABHs7WZ7a90TW7bUBJbxrZvHEZJPPLCNl2yFcZRgckEHqKAVzoPDnhrSvDcd2mj27wi6l8+dnnklaSTABYs7E5IAzzz1qhL4D8OuqbLOeB1aZhJbXk8Eh8198gLo4YqW52k49AKqR+P7KZYIrfStWm1KSaeFtPjjjM8Rhx5hb95swNyYIY53DGScVnt43v1+EFp4tNvA17KkDtCkbFDvmVCAu7OcMcc9aB6nb2Wm2djpcWm2ltHDYxReSkKDCqmMYrn7P4eeFbKLRYrbSI0TRpnnsR5sh8qRyCzElvmOQPvZxgY6Ulv41S4iuUi0HW21G3ultZdPEURlRmjEiszCTywhU/eLgZ464FZ8XxO0ydoIrTS9Yubp0kkltYoYzNAElaJ9yb8uQyNxHvOBnFAampq3gDwtq/iODXtR0a3n1WEqVnYsMlehZQdrEccsD0HpTpvAnhub7R5umhvP1FdVlzNJ89yOjn5un+z932q34n8Rw+HxpyyWd7eTahc/ZbeG1VSzSbGcZ3MoAwh5JwO+BkjDT4j6dPAjWOmaveXIilnubWGKPzbRI5GjcyBnAzvRgApYnacA0BqdxRWPc69Auh2mqafbXmqQ3Yja3SyjDNIHwVPzEKowclmIA7muck+JWnL9niXS9Wk1GWa4gNgqwiZHg2+YOZArH51wEZi2RgGgVju6K8w1j4janZ6xPBBodw1rHe2MCb41EsizqSVCmQEOeMBgAMHditd/iLZ/6LFDo2sz380tzC1nHHD5sT2+0yByZAnRgQQxB+pAIOzO4ori9O+IWn6grG20zWHD2a39qFtwzXcRcJmNVYnhmAO8Lwc/d5rZ8OeIYtcm1G3+xXtheWEqxXFtdhN6lkDqQUZlIII6NQKxt0UU12VFLOQqjqScUAOr5/8AElqk/wAQ9bvbaNUhSQRPE/IkkAG5vbNev674x0HQyV1DUoUl27hEh3OwzjgCvEb27mn1m81lIZUtb65Z/JYfOqnGCfyq4IqKux/ifV/Fd5qtjcafIkMVsmyGOFtoi4xn8qhtr6cauLXU7prm/liDt3VR2z71rVx0yXVz4l1y/wBMw32aGJUz0eRc7l/I1paxdktjU0Yp4P8AiRpGswB1sLxza3Kr0QtwDX0zXzmbcaroiw3OQ00YJI6q3XP4GvWvhNr1zr/g6Ca+Qi6tpHtZH7SFDjcPqMfjUTXUma6nZUUUVmQFFFFABRRRQAUUUUAFZmo6/o+mXkFpqWrafZ3U+DFDcXKRvJk4+VSQTzxxVHwjoV9oZ1X+0NdvNX+13b3EX2gY+zoeka8nge2B6Ad+J8WeHvEMc/i2LSrCW+bW3jmt7lDauibYhH5NwlwDmMMNwCKxwexoGen295bXMlxHbXEM0lu/lzLG4YxvgHawHQ4IOD6irFeQalofxBih1C4025na++2mKCJrwCE28lqkbSKu7C+XKN6rgHhsD5ubujeHvGFn4/V7nVNRk0WB1EUrOJo5oBCF2SBpxhywJLCFmzzvwcACx6Nd6lY2bbbu9toG3pHiWVV+ZzhByerEEAd+1XK8Y8ZeBdX1LxNrslrY3sltqF/ptytwl+FVY4yolwDICrjGQQvA4U9qgu/DnxCMyQQ32qx2MVzdpbvHcieaNDODDI+65j8weXxh2kxyCnOQBZHt1V7a8trp51tbiGZreQxTCNwxjfAO1sdDgg4PqK4H4t2Piu/sba38K29y1wIZG+2W181uY5Rt2gp50YIPzcnfj+73rn7Tw34yg8S6lc6dDeafPd6sbv7XJeo1oYDbhWV4Fc5cuBg7DjHUAcgWPZqK8hstB8bf2ZdtDLqtpdwWcEqpd6kJvtd/G+9ihDsEhcAoUO0HcPlGKrXnh34gtLpEn9p6gjTQme6MEwl+y3TzFyCjXEStGqFUA/eLhTheQaAsevteWyXsdm1xCt3IhkSAuA7ICAWC9SASMn3FWK85+Img+Ir/AMRw3/hsGN49JuLYTiVUIdpYW2KSchmRHAbGAcEkVlW/hzxXearZJLJrll4fOoSyG3k1Ym6hg+zEASSrKWYGbkAOxUHqOwFj0vV9IstXW2XUYmmjt5kuETzGVS6nKllBAYAgHDZGQDjirjzRxyRxvIivISEUsAWIGSAO/AJr501bUvFGmCy0rXNQ1ZfEJtNNW3jh1Hy8MZyswZQw+0MwA5UPgDkr39A8b+GvFF94i0jU7WaO6mtVvI4JLPdai1aSPETyK0xEgDAbto5HG0jigLHolpp9rZ3V9cW8Wya9lWa4bcTvcIsYOCePlRRxjp65q3Xjej+GvGsum6fBqd7rSo2qWz3cf2vyXSBYpBMVlW5kdkZiny5XBGVUdobjwn41YXDpd62HkTVSANZcDduzYgDzOO/THo/HFAW8z2qivPvEWn+MLjTNLJuftNus0D3tlp+bS8eMRkOouPOCk7yD8uzIHX1w5NG8cFrfDap9o8m1Wzl/tRGjs2VyZvtQBQTkrjkI/px94gWPW5HWNGeRlRFBLMxwAB3JpI5EljWSJleNwGVlOQQehBrxfVvBvjC/sL+KSbU5Wvl1eKWKXVCYtj5NoAm/aBn0GQCQ3HFXLDwv4rj0vW5Ld9YtLgRWUWn202qlsRrHGLhVxKyK7EOAzZwSCCOtAWR6Rf2eky6/plzfPH/akSyfYkknI/hw7JHnBIU4LYJAPUA1r15boHh/xEPF+i6hfW92ul2tzetDHe3a3E9rDJDGqK772L5dXIwzYB5Po3VPDXii88X3Fz9p1dNOk1iMbYdUeJBYfZsSYRZBt/egdAHHUY5NAWPRLrSLK61az1K4iaS7swwgYyNtj3DBITO3dgkbsZwSM06/1fTdPdkv9Qs7V1iM7CadUIjBALnJ+6CQM9MkV5Joeg/Eb+09Dk1W/v4lhitg7rIs6oVLeasy/aUDbhty2yU4xgqRzmDwn45JurlbfVV1gaJPaNeyaojebdNcRtuhPmZjQopwPkAxjAPJAt5nut5dW9jay3N7PFb20SlpJZXCIijqSTwBUysGUMpBUjII715FrGjeNpB4iFoNXN9Mt79nuo9WWO3ZGINuscRJKOo43fu8cks+cVLB4f8AGserC8iu9QWVtTuhia/8yBLVrciImLeVwJcHpuH0oCx6zRXidj4b8cjw3Kl9f+IPtfnW7m3ikQl2VWEhEhvg5jYkZAeLkAhAMiuq8SWPi68+H2jQ2KtbawkkLX8FvcsztGAd6LIZUYnO0k+apOCNx7gWPQqK8oPhzxp/xIIF1XUpLe7iSDVpZLgQy2yxy+YrKFkcb2TMTFWYnhietZLeG/iHJaa0suo6oLqZlVfKnCJIPtaNvikNyTGREGG0RRgg4IY8kCx7bVe8vLaxhEt7cQ28RZUDzOEXcxAUZPckgAdya8wgTUT8Wx4d07V7yXRbVIdUuR9uklkgZYzGtu7MS21z5chUnnDHvmmfEHw54l1fxDc+TbX95ZNdWE1mYr5Y7eCOORWmEkTONzkjcDtbjABGMECx61RXhmoxeLtMtvEmsarNd6DZR2X2iATas0sS3Uc4ZVBaZyVkXC4CoDnbsyAT6J8N5NVfQoptaivjd6gG1F5JpVaOHzWJW3QFty7E2jG0D3zkABo6+iiigQUUUUAaGif8fh/3D/SqWpf8lT8Pf9gXU/8A0fYVd0T/AI/D/uH+lUtS/wCSp+Hv+wLqf/o+wqkaw2Dwb/yMfjv/ALDUf/pus68U+K872vxmW4iMQkhltZFMzbUyAhG49h6mva/Bv/Ix+O/+w1H/AOm6zrxP4sRPP8ZRFFDFcPJJaqsUv3JCQgCt7HoayrfCjkx/8NeqN7X7jU7nwnqd5Bp/hr7IltJbvc2d60hRXfeyrzgksc4rgPhP/wAj/pf/AG1/9FPXd+N73SNf03WbWz+zXGoaTCzGLy54Y4lVgrtEPMKZBP8AdGa4T4T/API/6X/21/8ART1lL4kcNX+NDW+35n0VRRRXQeoZviLTpNX0G/06G8mspLmFoluYfvxEjG4cj+Y+orz/AEj4UtY6ymoNqtqG8+1neK2sDEpMDuw5MrMSwfBLFiMemFHp08scEMks8iRxRqXd3OFVRySSegqhp2v6PqaxNpurafeLKzJGbe5STeyjLAYJyQDkjsKATZzA8C3Vrq82raTrEdtqUl1dTB5bPzU8qcR7oyu8EkGJWDZHPUEZFWE8FMPh1aeFn1Eu0Hk5uzD98xzLJnZu4ztx1759q2ZfFPh+G5S3l13SkuHfy0ia7jDM25k2gZyTuVlx6qR1BpH8VeHks2u317SltVlMBmN5GEEgBJTdnG4AE464FA7s5rxJ8PptW1LULyHV1hF5dxXLW8tu7wsEg8rY4WRC4z8w5GCOhrHPwkk/4R5NGOrafLaBpivnaOhaAySF98BV1MTjOARlcAfKO/ax+M9Bl1+z0iDUrWW5u7R7yFo50ZHjUjod3JI3MMA8Ix7VYj8VeHpbKS8j17SXtI3ETzreRlFfGdpbOAeDxQF2R6v4eGoXHh6QXToNIuhcjeu9psQvHgnIwfnznnp05rmLf4d3mnXV5d6PrqW13ei5iuHlsvNUxSzvMoUeYNroZHAYkg55WuvtPEeh3s0UVnrOm3EssRnjSK6R2eMEguADyoIPPTiptJ1nS9Zjkk0fUrK/jibY7Ws6yhG9CVJwfagV2YGt+DFu/B2meH9Mvns7ew8lV81WkWZI12hJQroWB4Jww5APtXOQfCuW30GXS49T0qe2lup7l4bvRUlhBkRR8qBwyMpUlWDDhsEEjNeiatq2m6NbC41fULOwgZtgkupliUn0yxAzQ+rackNxK+oWixW8ayzOZlAiRhkMxzwCOQTRcd2cXbfDqS2u7Jo9ZaS2t3sJWWaAvLI9qu0EybwMMDyNpwe/ar1j4H+y+JP7V/tDd/pN7ceV5GP+PhYlxnd/D5XXHOe2Oeh/t/R/t89l/aun/bbdDLNb/aU8yNAMlmXOQMdzTtK1vStXeZdJ1Sxvmhx5gtrhJSmem7aTjPvQF2cTc/DSSTSNOsoNceB7PR49J8xICPMCyROWYBwdrCPaVB6MfmrX+H3gz/hEX1Z/tdvN/aEqTFILXyEjKrtOBvYnOAckk5ySSTmuwooC7CuA8W+H9Xn1q/1a3ji1FFtlSzs5JWQJIDySOhB56139FCdhHh8r3d54bsV13S7TStQhmdnJgKqy46BhmuUtoPEF1qdoxiik09XbckDrxjp15NfTLojjDqrD3Ga8B8a6np8nxZhuUt4nstP2wME4EjsfmJx1Izj8KuMmUmy1BaXdxfQ2sdrKLicnYrjG7HU/hVrXfCOraJpRngithCSXnZGwYwerH1riTrc3h/xfezWNxJLcWd06wxs2QEYdCD2waXxx4w1bxXbRaddXyWasd7QA7Qxxjn29qq7K1Zf1GdorOOx0yNp9Qul2QRRfMcnjcfQe9e8+D9JGh+GNN04ABoIVD47vjLH8ya+d/hXqtxofj/R4polLXubCRjyCvDKynt0FfUNTNkzCiiioJCiiigAooooAKKKKAMjw/wCJNI8Rfbv7FvUu/sU7W1xtBGyQdRyBn6jIPrVC/wDFkVp4ytNCNq7xyoPNuw3ywyuHMUZGOSwjfvx8v94VuWWn2dh5/wBhtLe28+QzS+TEqeY56u2Byx9TzXOX3gDQr6e8u7mDfqlxcrdLqRRDdQOpUoI5NuVVdigD0znOTkDQnk8c+Hkht5Ptzv8AaIo5oUitpZJHVywQBFUtuJR/lxu+VuODUCePtDZ3YXYkgKxeSIIZpZ5Hfzfl8pY92R5L8DJG1twXHMSfD3SoGupbG5v7O6mv/wC0Y7iJ0LW8mHG2MMpXZ+9l+Ugj943tiG3+G+m2jpPY6jqttfI6yrdpJG0gfMxZ/mQqS/2iXcCCORgDFGg9CxH44tz4b0LV5LO4Karcx26Rwo8uzcxG4lV6cZ5A9Kq6B8SNK1jR9Nu1/wBGublIHlt50mXYJM/cby8S4IYZHy5HJFa0fhK0i8PaZpEN5epFp80c8M+5GlLIxYbiVIOcnPH+NUk+H2lJb6VCLi+26bbQ2kJ3plkiJKlvl5PPOMfhQGhNafEHw3d2bXMF7O0eImRTZTrJKJSRGY0KbpAxVsFAehqXS/HGgard21rp11cXM9wpdVjspzsUSPGS52YjG+Nxl8dKxtf8BOLCwbw9cumo2ENpbQPcShMR25fDBhGwDkSMCSjL/s1W0X4Zx/2fop1++km1Cwne6JhSE5ka5afiZovNAy2DtZA2OgyRQGhpeIvH9pofiN9JmsruRo1tWeVYZCuJpHT5cIdxG0YA5Ykgcq2NE+N9AEFnN9rn8m6OEk+xzbUPmeXiQ7MRHeCuH28gin6n4TtNR8SRazLdXiTRpAphQp5bmGR3QnKlsgyOOCAQemQCMG/+FmjX06STXuolVlacRkwuqubiSfcpaMlDulYZQjK4BzQGhr6b410268O6hrV2txZWNleTWcjTQSBspL5YYLt3HJx0BwSQeVOC08eeHrqV44ru5EiLIzLJYzxkGPG9PmQfOMj5Pvcjjmph4Ss/7Gv9Me6vHtbu+e/OSm6J2mExVSF+7vyecn5iM9MUtX8A6bqaSLJeajAzzXE++CVVYNMAGxlTxxwD75yKA0Ip/iNo0eq6dbK0vk3X2hGaSGWOaOaIwgReQyeYWbz1IGM45wQeNqw8T6TqGrSada3Ej3SNInNvIsbtGcOqSFQjlTwQpJHOehrlYfhHoESjbcXwlSaW5ikQQxmGaQQZkQJGFVgbdCMDGS2QQcDW0LwBpGieI59Zshi4mkklKtbW3ytISWIkEQl5JPBcjnGMYFAaFCf4mafba/cadc2V9HFb3NxbSTrbTOcxRxuWVFjJYHeenQKG6MK37Xxdol3qcVjbXhlmlIVHWCQwsxTzAgl27N+w7tu7OO1VT4LsTrl5qZu74vcmVjDuTy0aWJI3K/Ju5EadSRmqGjfDTQ9H1u31Oz3GaFUAEtvbSEsqBA3mGLzFOFBwrgZzgDJoDQteKfHukaDFqsbSNNqFjbyS+R5cixvIsLTCIzbSiuUXOCc4OcGquq/EXTLbRri+sB9okgind7adZraQmO2ecKA0fRlThjhcHIJOAbWs+BrTVZdWD6nq1taaor/arS2mRIndofJL/dLZ24+XdsJUEqaNc8BaXrM13JdT3qNco8b+W6DAa2e3OMqf4HJ+uO3FGgaEN147hk1SPTNCspNSv2Sf5DvgjMkWNyLKybHwxKkqTtI59K3dF8Q6drc1zHpkk8wt3ZHlNrKkRYEqQsjKFfBBHyk1maT4LtNM1mG/g1DUXjt3ne3s3aPyITM26TaAgbk88scdBgcU/Q/BlhpHia+12GeaS9u0aNwYoIlwzBjnyo0LnIHzOWIGeeTkFoJd+O/D1o90t1eTxG2G5t9nOPMHmCPMXyfvfnZV+TdyR61l638SLLTdSithYX7o0dtK0kttNCVWWcQ/caPcWGc7ep6AdcRQfCzSYbu9uhf38k93BJbSPNFay5jeRZCG3wnzMFAAZNxwSPTFjTvhrpGnmy8i7vwtqUYJmIK5S5+0KSqoAoDEjam1dpwB0INB6F2f4h+GbeKGWa/mVJFdj/oc+Ywj+W5kGzMYV+Dv2470+Tx74eisWvHuboQRvIkv+gXG6HYAXMibN0YAYHcwAwetRTeAtLmXUVae9Av1nWTDpwJZvObb8v8Ae4Gc8evWs7xD8LdH12a9e7vdRVLyWWWaIGF03SLGpKh422keWuGXDDnnHFGgaHQeIvF2heHEZ9av1tUWD7TuMbsDHvRNw2g5+aRBgc/MO1Vrnx54ct55IZNQYtE7JKyW8rpFtbaWdlUqq7sjcSFyCM8Gk8U+B9J8Tw6XFqhuGTTyfLCMo8wEAFXyDkZVWwMcqKy4fhfpEGlxafb3+qxWptfsV0qyxk3sRkeQiUlCclpJOU2n5zzQGhpjx94faZYY7i9lleaSCNYtOuZDI8ZIk2bYzuCkYYjIB6mrY8W6M2oXFklxO9xB5gYJaTMHaMZdEYLiRwM5RSW46Vl6x8PdM1TQoNJnublbSKaebmK3lYtK7O2GkibbgscFNrD1zzTNN+HGj6XrdxqmmyS213L5rK4trZ5IpJFIaRZXiMm7knBcryQQRxQGh2iMHUMM4IyMjB/KnU1AVUAsWIGMnqadQIKKKKACiiigAooooAKKKKANDRP+Pw/7h/pVLUv+Sp+Hv+wLqf8A6PsKu6J/x+H/AHD/AEqlqX/JU/D3/YF1P/0fYVSNYbB4N/5GPx3/ANhqP/03WdeJ/Fq2lvPjJ9mt5fJmmktY0l/uMVUBvwJzXtng3/kY/Hf/AGGo/wD03WdeHfGNpU+LcrW0ywTqbcxyuwURttXDEnoAec1lW+E5Mw/hr1L/AIkj8Tz2+s2d9Lp8dqtrJdPqFlaoP7QEbqCrOuOcnJHUEciuU+E//I/6X/21/wDRT1sjRvFNh4Z1u8tta0640mdWN4IbpZVck844wGPtg1jfCf8A5H/S/wDtr/6KesX8SPOld1YN3+fqfRVFFFdJ65j+MNPGq+F9VsDZi9+0W7x/ZjP5Pm5H3d+DtJ9cfWvKNUttX0DQ77VbxJItQgvbWXRo9R+zG9upgpjeJmg4k3IzKucsBkngV7fUC3du149os8Ruo0WR4Q43qhJAYr1AJBAPsaBp2PIr74e6lDpWt2dtZrdPN4dtrGOYugM1yJZZJepBGWYNk4GT7U3xfpN5pvj6xvY9HF3a3Gt2slrbxvGplEVjMGKhmABXGRuKglRzXs1QWd1b3trHc2U8VxbyDcksTh0YeoI4NFwueNXHgbxDcW99GlgtsNVsdSiEazpssmmuFmSN8NyrBSCUDAFumOa0NU8M6zrvivT9XPh8aZaQTWEclrLNCzOsMju0hCMV2oGCrzuPoOleuUUXC55Jc+CdRfyQNIikRtc1S7mj89Ig8E8M6ISwJI3b0HAJGckcVa8Gx6p4VnubjVNOv006cWVjAt0bSW7EjSFAPMiI3wpvGN/zgE4HWvUap22pWN1MsVre200rIZVSOVWJQNtLAA9A3GfXigLnHfEXRNVvdd0DVdKW+lSxS5ikjsWthMDIEw6i5BjI+Qqehw3HcHnB4B1aIeF7WzhaLTp4Y7bW45blHZIopvPjXcqoG5LxnauAGx05r2CigLniZ8Da9uuLKW31KdYry+vYbgXNnHbsZVl2kfuzOXYSBWVmC/7WABXX+EPDt9pevaLPJZpBbW/h2KwmKMmBOrqdmAecfNyOOTzzXbXF3b20kEdxcRRSTv5cKu4UyPgnaoPU4BOB2BqegLhRRRQIKKKKAOc8ZaxPY2qWGk7ZNbvv3dtH12esjeir1+tcjdeAtO0m40aHTIo5tVkZvMefLK/GXkYeuen1q1bDVD468UGwW0fVCbaKOWbOILUqWyB3JYH8awF8R/8ACQ/ER4Ly1uV0+O4OmR3EasEbcvPzepYY+lUg9DtNL8B+GBaXIFpb3b3Dk3E5O5mfvz2+leKfEnRdM8M+IptK3JLaFI5E3nc6B8/LnrxXqvxI02Pw74AWLQ55NMs7e4VpfJ6sjHByevUiuFs/BmnatZSaBqkLDxBcxfadP1F0ZTNt58tiTySKcSouxi/CfRR4g+INmbR/LsdDxcvvyWkZuABX05Xlfw713wxoWigw6ZJpM0z7bk7C+ZF+U5IycV6XYX9rqEAmsriOeMjOUbP5+lTJ3Ym7ss0UUUhBRRRQAUUUUAFV7+RorG5kjOHSNmU+hANWKrakrPp10qKWYxMAAMknBoA8s8L6Z4w1rwra6xcfGGzsnbT4dRurZtFtWa0jkTcC53AgYzhiBnBqT4czeLJPGMa+I9fudT0i4sJL3T/Nso7J5FEioJHjTkAhiVDE8EEgHGOI08aNKPCVxq/gf4iJPpumw2Wp2tpo37jUjFsKeYS4LKrLnBHzDaDjFeqaJ4mk8X/EZdQi8OeItHtLbSXty2r2P2cO5mRgFOSDwD3qnY1klY39f8TWGhajpVlfeb5uoy+VGUUEJyq7n54Xc8a55+Z1HerU2vaRb24nn1WwjgIkYSPcIFIjO1zknGFJAPoeDXP+JfAlr4j1DUbvUr28Ek1strai3nlgFsBltxCOBIS5DfMMfKoxxk5knw1Ms+oXT6vuup3hnty1qDHbzLKk0rbN3zLJKisVyMevepM9Dqx4n0dlSZNRsmsWt3ufti3cXkhEZVJzuzjLDkDaOhIJANFvHGhr4cvdda6X+y7WZoDPvQrIQQAUIbBBJGDnmufl+Gks073kusxnUHle5LrZYh843EMwPl7/ALgMABUsSdxO4GtaLwdcf8Ihq+kT6lC13qNxLdNcx2myNHdw/Ee8nAI/vZ9880BoaGo+M9Asra9kXVLO6ls4xJNb21xG8qKSBkru4HzDk4qw3irw8umx6i2u6SNPkcxJcm8j8pn/ALofOCfbNcbe/DK4vbd7afWrf7Mj3U1uF08b1kuH3P5jGQ+YoJOFwO2S2Kk1P4d6lqEdy0niJIrq9nklvGt7N4Y5A0UcQCBJg6ELGOrsGLHcCMAAWR2r6/o6Xz2T6tp63kcXnvAblBIseM7yuchcc56YqufFnhwWlvdHX9IFtcOY4ZvtseyRx1VW3YJGRwK49fhjJ/Zr6Y2sQtYOu8509Gn877OISwkZjhCBnaBuwSu/aSDNe/D7Ubua7un1rTlvr6CW1u3TR1EbROsa/IvmZDgR/ednznGMAAAaHa6rrOl6QYBq2pWViZ22RC5nSLzG44XcRk8jp61Tn8XeG4Jp4p/EGjxywMUlR72NTGwbbhgW4O4EYPfisjxb4Ml1m10yLTdRGnXFhE0MV6ElNwilVB2tHLGP4QSGDKSBlapz/DmOW1niOoLvlj1VDIbYE5vX3bj83JQcf7X+z0oDQ6HWfFuiaTFqXnahay3en2sl5NZQzo1x5aIXOI9wPQd8DnrUkvinQoLZJ7vWdOto2k8nM91GmJMA+Wcn7wBHHWuM1D4XzXlhc6e2txrYSNcToBZZmWaa3aAsZN/zIA5O3APQbsCmTfCki0s7az1lo4LM3EcEcizhRBOUZ4mMU8bN86kglsYbBBwDQGh6RHe2sq3BiuYHFsxScrID5TBQxDf3TtYHB7EGsv8A4S7w2LBb7/hIdH+xNJ5QuPtsfll8Z27t2M45xTP7Jv5PDupaQ11b2qNEbaxnt0Zmii8pVBcOTuYPv78jbk5ya4z/AIVdeCO6kGuxf2hPMJhdmG6EkBEXl/umF0HXIxwXK9sYwACVjudJ8R6bqd7c2kM6pdQTyQCKR1DSlApZkGSWUb15qVfEGjNqUunrq2nm/iUvJbC5TzUA6krnIA78VznhXwI3h7xLdazHqslzNebhdiWLmYbU2HO7hlKscgYO88DANZFx8PbvXLnW49Wuo7bTLi+up4Yo7dTMxltzAH80P93a7HaVByBk44oHZHZ/8JZ4c/s3+0P7f0j7B5nlfaftsflb8Z2792M47Zp8niXRFu2tF1awe+CeYLVLlDKw2B+Ezk/KQfoQelcdYfDi9sJob221m1/taJmHnz21xcxujR+WQyTXLnIGMFWUdiCKpeH/AIbXlnd3lnLepHo0N1aywbrdWmuDDZxRK+8P8i7wwKFc/LwQDyBZHd6N4o0fVhYpbX9st7eW0d3HZSTILgRugcExgk9D9Khm8ZeH7fUdSsrzVrK1l07y/tDXFwkaoXBKjJPX6+ormPDHwxXQtVsbkambq3tjFJ5UguFPnJCsW9Qs4iGQv8UbHBIyeK09b8G3l54m/tuw1W3t50linhjnsjMqukckR3YkXIKyHGMEEA5PSgNDpbzWtLstMTUbzUrK309wpW6lnRIm3dMOTg57c1Un8WeHLeQJPr+kROY/NCvexqSm3duwW6bSDn0OaxbjwPnwXp2hQ3cJms5hOl1NDINr5ZiyCGWNkOXOMPwOOah03wA1tJDNeas99cpd2l2808OXkMEXlgElieSScnJHv1oDQ6b/AISPRPPsYf7Y03zr5Q9on2pN1wp6GMZ+YH1Gap6b4x0K90ZdTk1C2srfy1lkW7njjaJWJCl/mwuSDjnmuWtvhlLbQ/ZotZi+xzCAXatYgyP5UrSL5b7/AN394DkN0yMZqra/CT7FpIsbPW5I1W5iv1PlyL/pKK6M+Y5VcKyMo2hhgqCDyRRoGh6NPq+m2+ljUp9Qs49OKhxdPOqxFT0O8nGD9aZDrmkzQefDqljJD5aTeYtwhXY7FUbOfusysAehIIHSsA+DTH4W0rS7O8hgutNulvYpmhkmiModmO5JJWcgl26yZBwQRgViL8NLuJJxBr0SfbVX7dmwyHK3Mlx+6AkHljdK4wd/GOc80BodNpnjnw1qKAw61p6M91LZxpLcxq0kkb7SFG7nOQRjqGU9xSah420XT7S2luruFbi5dEhs1uIWnk3SiLcqhyGAY5JBOAD3GK5+4+Hd49359rrcVo4vLi4W4gt5o7hY5pzMYt6zhGAYsPnRl6fLwcs/4VpPGpittZhW3mkt5bkSWG92MNw0y7G8wbAd205DeoxkigNDutP1jTNRuLm30/UbO6ntm2zxwTq7RH0YA5U8HrV+uB8HeAJfCtw0tnqUc7Rwi2t3uEuZGjhMiuykNcFMkLjKImDzgjKnvqBBRRRQAUUUUAFFFFAGhon/AB+H/cP9Kpal/wAlT8Pf9gXU/wD0fYVd0T/j8P8AuH+lUtS/5Kn4e/7Aup/+j7CqRrDYPBv/ACMfjv8A7DUf/pus68Y+J8C3Xxuht3VGSWe0jKyLuUghBgjIyPbNez+Df+Rj8d/9hqP/ANN1nXjPxMi8/wCOFvCJZIjJcWaeZGcMmdgyp7EVnW2Ry4/4F6o2PGiHVtKuRe6bbxCHT7i5gZPOVIfKmMQVU37ASAW6fgetcB8J/wDkf9L/AO2v/op69D8RaV4jj0PUjqmpa3LZf2dcyyCZxsEizbY1OByCgzivPPhP/wAj/pf/AG1/9FPWMviRwVf40G12Poqiiiug9QwPH0+o23grW5tFD/2jHaSNAY13MG29VHdh1A9cV422q6bYeNZr/wAP+Iby70mI6T9svZL6SYJGZpg4eRiTs5UsCcAsRgYwPoOigadjxfQ9Ql8SeNLOL+19Tk0uXU9UZBb3ssSyoiW5jGUYEoNxIAOOfQnPP2V/qt94Y1O/m1zWVuNP8LRahAY76RR54kuDvYA/PwgBDZBHUHAx9EUUXC54edbkm8QWbX2uX9v4hk8RRQHTY7uRYzZEjZ+5B27GTa2/HJJGe1a/xl16PT70Wi3GpRXn9nSTQCLVGsYt+7CsoQb5pAR9zBGCMjnI79/DWmSazHqc63c91HJ5sazXs0kUb4I3LEzmNTgnBCjGa2qAueNaPrMepa7aHxL4h1SyuZbXTX06C0uHQXYkizIfLQESbnLBmxlAAQV61g+GZL2PTDa+HtSvTPY6TPe/ZxeyOPtMN4GMbKWOCyrsKns545zX0HRRcLng+oa/ql9Bo+s3V9JZ6FrdxeXSi61abTo40VUS3jM0asUyqvJtGAzE5J6HpvEGpalD8C47+61Wdb0pbFr+0MiOUNwg3qWRGJKHuozk8YNepVT1bTbTVrFrPUIvOt2dHKbiuWRw6nIIPDKD+FAXPEtQ1SKPVLOXTtS1HU/D9nq4ktLpZzdyFv7PuDKsUjk78EDAJIDEj2qHw9rd/q2oajDoGo358nR01GFH1l74zTwzIxDN91S4Ox41JXDDIHSvf6qarp9vqunT2V5532eZdriKZ4WI9NyEMPfB5HHSi4XOW+HOsrrNtc6pcXjbtYnkurC0ml+ZLSPbGhWMngHAc4HWTmu0qGztoLK0htbSJIbeFBHHGgwqKBgAD0AqagQU12VEZnYKqjJJOABTq8p/aB8QXNj4es9C0uQpqGtTC3yvVYv4vpn/ABoSuC1OX13x6t18SLk+E7Sa/tpYEtL+4jOAQrE/IfXBxmr/AIt8SancaZosGn+HJ9N0f7fAjzTjDghuMAdvem+FbK38M2sNtp0CZiXgkdX7sfWuW+IHxONvpgsrG5GpXLTq7LjcsTIcj9a05S3Hses/Gq4tm8KR6Xc7z/aNwkREakuIwQzsAPQDH41n2OiaHq0EEPhnxNK91ZTJcW8bTbijKP7p+bGM5rzvQviBrt78RvC2qa+tulrcF7IRxocJvGMk+ucV7nrPgzQtXy1zYRpOc4mh/dyD/gQ5qdtCXocLaeHboeKdf1Sw0yf7PcMsyMJdjeZgB1VTwRnnmuVuvFd14Z1eQ22l3Vvr05BhhK4S6jJwd69AR6ivRX8I+ItFhC+FPEcxjH/LvqQ89AOpweory5bnUJ/iJr194pkt/t9ksVqiwnKJnuM9M046sIq7O3bxJ8QrC1OqXdhpt7bIN8tjbk+cqeor0Lwj4hs/FGg22q6eSIphhkb70bjqp9wa8L8NeJ9RbxxLGXzEjyIUA5ULjr9c12nwLkA1TxtbQnFrFqStGmMBSyknFEo2G1Y9ZoooqCQooooAKo67qUOi6JqGqXSyPb2NvJcyLGAWKopYgAkDOB3Iq9XNfE3/AJJv4r/7BN3/AOiXoAt/2jr3/Qj+IP8AwI0//wCSqdpOsy3mq3mm3ukahpV7aww3DR3bQNujlaRVKmKRx1ifIJB6etei159ff8lT1r/sDad/6PvqbRpKKSNSiiikZhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAaGif8fh/3D/SqWpf8lT8Pf8AYF1P/wBH2FXdE/4/D/uH+lUtS/5Kn4e/7Aup/wDo+wqkaw2Dwb/yMfjv/sNR/wDpus68W+KcUM/xqjhum2W8k1okjbtuFIQE57cd69p8G/8AIx+O/wDsNR/+m6zrw/4wC1PxekGobvsW628/b18vau7H4ZrKt8JyY/8Ahr1R0Pjmygg8O3l1Z2ulm5kjeOYLqW9IYw52tHHuOZGXbk9iOBzXA/Cf/kf9L/7a/wDop67TxPDZQeGtYF5pvh+3snEjWNzZyRvLO5dPJCBfmVQgbdnrntXF/Cf/AJH/AEv/ALa/+inrGXxI4Kn8aHy/M+iqKKK6T1QooooAKKKKACiiigAooooAKKKKACiiigAooooAK+f/AIwtL/wuzwushP2cW5KBugOT0r6Arx/9ofRJ30zS/E+noz3WjzhpFUctEev5f1px3HHc5+6vJLiLXbG2wt7bwZQdyGU4P9K4LwdDpTaGkB8OXF9dom66cTFAzk963tZvp2ls/FvhtRexNF5V1bpyWXr+YpNM8VtqmDYac+n2q/NdXMw2qmOoHqa23NNzlvEd/qc+taJFd/6MsNyjWdnFHtjjAI5Pcnivc4viRqAlJltYGj9BkGvHtONx4z8cNqFvBI9najyrRAPvt/er0L/hEtc/58W/OuapLWyPmc1xdf2yhhr2jvbudOPibNls6cnthzXk3jG9aXxRqmqy2zLp+qxLHP5XJgZfuv712kfg/XXdV+xEZOMk8Cui0z4azO6Nqd2gjzlo4xnI9M1MZST0MMJicydROza81ZHjui6/q813Fb6fBHqN10D2sBD3AA43HoB61778J/C0/hfw2y6kVbVb6U3V2Rzhz/D+A4rp9J0ix0m2SCwtooUQYyqgE/U1frVybPqOZtahRRRSAKKKKACqOuw2NzomoQawY10yW3kS6MknlqIipD5bI2jbnnIxV6ua+Jv/ACTfxX/2Cbv/ANEvQBgf2n4D/wCh8l/8LO5/+SK3PB58NTXd/deHNYXVrl0ijuZTq8moOqKXMalnkcqMtIQOM5Neq159ff8AJU9a/wCwNp3/AKPvqbRpKNluJe6Zd3Fy8sOu6laxtjEMKW5ReO2+Jm9+SetQf2Lf/wDQzav/AN+rT/4xW5RSMzD/ALFv/wDoZtX/AO/Vp/8AGKP7Fv8A/oZtX/79Wn/xityigDD/ALFv/wDoZtX/AO/Vp/8AGKP7Fv8A/oZtX/79Wn/xityigDD/ALFv/wDoZtX/AO/Vp/8AGKP7Fv8A/oZtX/79Wn/xityigDD/ALFv/wDoZtX/AO/Vp/8AGKP7Fv8A/oZtX/79Wn/xityigDD/ALFv/wDoZtX/AO/Vp/8AGKP7Fv8A/oZtX/79Wn/xityigDD/ALFv/wDoZtX/AO/Vp/8AGKP7Fv8A/oZtX/79Wn/xityigDD/ALFv/wDoZtX/AO/Vp/8AGKP7Fv8A/oZtX/79Wn/xityigDD/ALFv/wDoZtX/AO/Vp/8AGKP7Fv8A/oZtX/79Wn/xityigDD/ALFv/wDoZtX/AO/Vp/8AGKP7Fv8A/oZtX/79Wn/xityigDD/ALFv/wDoZtX/AO/Vp/8AGKP7Fv8A/oZtX/79Wn/xityigDD/ALFv/wDoZtX/AO/Vp/8AGKP7Fv8A/oZtX/79Wn/xityigDD/ALFv/wDoZtX/AO/Vp/8AGKP7Fv8A/oZtX/79Wn/xityigDD/ALFv/wDoZtX/AO/Vp/8AGKP7Fv8A/oZtX/79Wn/xityigDD/ALFv/wDoZtX/AO/Vp/8AGKP7Fv8A/oZtX/79Wn/xityigDD/ALFv/wDoZtX/AO/Vp/8AGKP7Fv8A/oZtX/79Wn/xityigDD/ALFv/wDoZtX/AO/Vp/8AGKP7Fv8A/oZtX/79Wn/xityigDD/ALFv/wDoZtX/AO/Vp/8AGK21BCgEkkDqe9LRQBoaJ/x+H/cP9Kpal/yVPw9/2BdT/wDR9hV3RP8Aj8P+4f6VS1L/AJKn4e/7Aup/+j7CqRrDYPBv/Ix+O/8AsNR/+m6zryD4xeFNd1Xx7e3enaXd3Fs8cQWSOMkEhADzXr/g3/kY/Hf/AGGo/wD03WddHL981him1DQmtQVePLJnyP8A8IH4o/6Ad/8A9+jXTfDfwj4g07xpp11e6ReQ28fmbpHjIAzGwH6kV9IUVwKpJO5hHLKcZKSb0Of+zzf88pP++aPs83/PKT/vmn+L/EUXhvTYZzbS3l1dXCWlpaxEBp5nztXJ4AwCST0AJrn9T8Z65oVlqk2v+FxF9l0y41GGaxvGubeQwoWaGSQxIYnPGCVIPOCSMVuq9R9Dr9lE3fs83/PKT/vmj7PN/wA8pP8AvmsKL4oaDc6DdX1tcBLmDTf7TMN3FPAjRADLq/lEugJxvjV/pU8XxC06K+12HVV+yQ6bc2trHJHvne6eeBJVVI1TeW+fAUAk4zx0B7ap2D2Ue5rfZ5v+eUn/AHzR9nm/55Sf981T8CeNLXxjNrv2CBkt9NvBaLI+5WlPlqxJRlVkILFSp5BX8Kqw/EfQ0tBLfXOJWluUWKxguLttkEhR3ZViDKAcZJXaCcBm6k9vU2sHso9zW+zzf88pP++aPs83/PKT/vmtaxv7S/02DULO4jlsp4hPHMp+VkIyGz6Y5rkPD3xX8EeItXs9L0bX4Lm/u1ZoYfKkQsFzkfMoAPyk4OCRyBgikq9R7IfsV3Nn7PN/zyk/75o+zzf88pP++aytK+KXgrVvE58Pad4gtZ9W3FBEqvtdh1CyFdjH2DHNQfDr4naJ4/1fXLTQvNaLTWQCZ0ZfODZ+YAjgZBAycnngU/bVEr2F7KPc3Ps83/PKT/vmj7PN/wA8pP8AvmqSfETwqy6cRqy/8TG+bTbUGGQGS4VtrJjbkYOBk4HI55qrqfxU8F6Zpk+oX2uwxWkN49gX8qRt8yY3qgCkuBkZZQV560e3qdg9lHua/wBnm/55Sf8AfNH2eb/nlJ/3zWDf/EvTWuvBqeH1j1eDxLdPDDNHMYxHHGMySYKkkr0KnB+lX/h341j8YeGLnXXtU0+xjuZ4o3efeskUZx5pJVdoODxzjHWh16iV2g9lHuX/ALPN/wA8pP8Avmj7PN/zyk/75pYfGXhiaxa9h8R6LJZrIIWnW+iMYfBbaW3Y3YBOOuATUl14r8PWul2+pT65paWFySLe4a7jEc5HZGJwx4PANL6xU7B7GPci+zzf88pP++aZNZvNE8ctuzxuNrKyZBHoaqy+PNJi8C6f4smS5j0u9+zlA4QPGJnVFL/NtABcE8nAB61pHxZ4dGjjVjr+kjSi/lC9+2R+SX/u787c+2aft6nYPYx7ni+v/BKeG9kvPBWo3OkPJkvblS0RJ9B2qpp3wN1HUHB8X6zc3UI5+z2yeWhPv617pN4q8PQR2Mk+vaTHHf4Noz3kYFxk4Hlkn5+SOma2qPrVRFez0tc4fw94TsPD1ssOlad5KqNuQpJ/Otj7PN/zyk/75roKKn6zIiOGhBWjoc/9nm/55Sf980fZ5v8AnlJ/3zXQUUfWZlexRz/2eb/nlJ/3zR9nm/55Sf8AfNdBRR9ZmHsUc/8AZ5v+eUn/AHzR9nm/55Sf9810FFH1mYexRz/2eb/nlJ/3zR9nm/55Sf8AfNdBRR9ZmHsUc/8AZ5v+eUn/AHzWb4m0ObXPDeraT+8g+32ktr5vl7tm9Cu7GRnGc4yK7Kij6zMPYo4vf4+/6Cvh7/wRT/8AyXUOl6PrY1/UNX1y6tbu5ubW3tFWzsXtkRInmYEhpZCSTMe46Coh4k8Q+IfEfiDT/CX9lW1tojLbyXOoQyTC5uSu4xqEddiqCoLnccnhTWJ8V/iVrHg2z0y3sdPsbvWRAL7VYwXkitbYFUdlPynl2wpP905FaKvUbtoNwutWdLejxCly62Ok2M1uMbXmvZI3PHOVELAc57n+lQ58V/8AQE0v/wAGUv8A8j1bl8T3T/FKz8M2aWz2X9kvqV1KQS4zIEjCkHHPzE5B/CuDvviR4pk+GC+L9N/sRDPqL2lpaTWcsn2hDc+TGd4mXacBiTg5wMAUlWqPsT7KJ2OfFf8A0BNL/wDBlL/8j0Z8V/8AQE0v/wAGUv8A8j1z/ib4i6v4P1+5sNYOm6pFZaSdRnaztXt3klknWGCFA0sm0lick545A451l8U+ItB8TeH7Dxf/AGO1trSThTYxyRtZyRRmQqxZ2Ei7QRuATBHTFHtqnkHsolrPiv8A6Aml/wDgyl/+R6M+K/8AoCaX/wCDKX/5HrgfCHxp1bxFo1ugsLG31241y1sY4Gjcp9knBdZcb858tJDnOOBxzivWvGfiMeFtHl1ObStQ1C0hVpJzZmHMKAZ3ESSJn/gOT7USrVIuzSD2UTDz4r/6Aml/+DKX/wCR6M+K/wDoCaX/AODKX/5HrWi8Y6YBLDfumn6vFC87aRcXVu14EVS2dkcjAgqMjnp1xToPGvh19Gh1S51nT7K2kWIt9ruo4zE0iB1R8thXKnOM/pS9vU7D9lEx8+K/+gJpf/gyl/8AkejPiv8A6Aml/wDgyl/+R66vU9a0vStPW/1TUrKysWIC3FzOkcZJ6YZiBz2qhqXjDw5pqE3euaZG/wBmN2sZu4w8kIXdvVc5K4GcjiksRN9A9lEw8+K/+gJpf/gyl/8AkejPiv8A6Aml/wDgyl/+R60rDx54cutN/tCXVrCzsWeNI57m8gVXZ4kkAGHODhwNrYPBOCCCdNfEehvq40ldZ006ocEWYuk845UN9zO77pDdOhzR9Yqdg9lE5rPiv/oCaX/4Mpf/AJHoz4r/AOgJpf8A4Mpf/ketj/hM9CTxBf6Ld6hbWeoWhXMdzPHGZQYxIWQFssAp5OOMVsW2pWN1IY7a8tpnEKXBWOVWIifOx8A/dba2D0ODjpR9YmugeyicfnxX/wBATS//AAZS/wDyPRnxX/0BNL/8GUv/AMj1uHxn4XFg98fEmiiySXyGuPt0XlrJjOwtuwGx261JJ4r8Ox3zWUmv6St4qeaYGvIxIE2B923OcbCGz6HPSj6xU7B7KJz+fFf/AEBNL/8ABlL/API9GfFf/QE0v/wZS/8AyPVvSPiP4Y1HSIdVbV7Gy0+ZI3jmvLyCMMXBOwjeSrDawIYDkHGcHG62u6V5DSpqVk6AoMrcJyXUNGM5xlgQV9QRim8RUW6D2UTl8+K/+gJpf/gyl/8AkejPiv8A6Aml/wDgyl/+R63dP8XaDfT2tqmr6amo3ESTLYm9hacBoxIPlVzn5WBypIIOQSMGrGl+I9E1ZLl9L1nTb1LUBp2trpJBEDnltpO0fK3X+6fSl9Yn2D2UTms+K/8AoCaX/wCDKX/5Hoz4r/6Aml/+DKX/AOR609C8e+GdatNNmtda09JNRz9lt5bqNZZcMVwqbsk5BGBWpqniDRtJu7e11TV9Osrm45hhublI3k7fKrEE/hR9YqbWD2UTmM+K/wDoCaX/AODKX/5Hoz4r/wCgJpf/AIMpf/keujsPEWl3dr5/221ixIsTI9zExR3fYikqxGWPAGcknHXip9I1vStZ8/8AsfU7G/8As7bJvstwkvlt6NtJweDwaPrE+weyicrnxX/0BNL/APBlL/8AI9GfFf8A0BNL/wDBlL/8j1tjxr4WJjC+JdEJkl8hMX8XzScfIPm5b5l468j1qd/FPh9L64sn13Slvbb/AF8BvIxJF/vLnI/Gj6xU7B7KJzufFf8A0BNL/wDBlL/8j0Z8V/8AQE0v/wAGUv8A8j1vX3inSrLVodPmuY/MZZmlkEieXb+UiOwlJPyHbIjc9jngYpYfF3hudLN4fEGjyJeyGK1ZL2MidwQCqYb5iCyjAzyw9aPrFTsHsomBnxX/ANATS/8AwZS//I9GfFf/AEBNL/8ABlL/API9dRLr2kQ6uuky6rYJqjJvWza4QTFcE5CZ3YwDzjtWFqnxJ8J2EVq663p94Lm4a1QWl1FKfMEbPtOG4Pyhf950H8QpqvUfQPZRKmfFf/QE0v8A8GUv/wAj0Z8V/wDQE0v/AMGUv/yPWrZeO/C91o0ep/2/pUNoxVHaa8iXypGQv5bndhXCgnbnPyn0q0PF3hs211cjxBo5t7TZ9olF7Hth3fd3ndhc9s9aPb1OweyiYGfFf/QE0v8A8GUv/wAj0Z8V/wDQE0v/AMGUv/yPXaWV1b31pFdWU8VxbTKHjmhcOjqehDDgj3FT1P1mYexRwmfFf/QE0v8A8GUv/wAj1tLbz7RuhcN3ABNdDRR9ZmHsUZujxSJdkvGyjaeSMelUNS/5Kn4e/wCwLqf/AKPsK6SH7/4Vzepf8lT8Pf8AYF1P/wBH2FdlCbnG7Dl5dA8G/wDIx+O/+w1H/wCm6zro5fvmuc8G/wDIx+O/+w1H/wCm6zro5fvmoxfwfMqO42iiivONDkfiLol/qlppF7o0cU2paPqEeoQwSybFnAVkePdztJV2wSOoGeM1g+Lf+Ex8V6LrVha6FJpNhLo95AYLya3ea8uJIWWNEMcjKignJZmGeBgDmvTKKpTsKx4p8QPA+v6pDappunCQR+E7nTCBNGoFw4i2x8sP7p56cdafceDfENt4vufENvppuhaarZ3cVoJ41N1ELBbeQqSwAdGJI3FQdp55Br2iiq9q7WCxwXwv03WLXUfF+oa3pR0s6pqn2q3gaaORvL8mNQWKMwDZU5Geueo5ri4fBerWmnxNP4f1j+0FvNRkiv8ARNWht7qFJbhnRWDsI2jYFW5LEEcr1r2W91OwsN/269tbbZC9w3nSqm2JMbpDk8KMjJ6DI9atIyuiujBlYZBByCKOdrULHGSWvij/AIVJcWt9svvFr6XJE3lMiB7hkIHPyqMEjJ4HBxXnlr8LdUQ/D7TYrKO0sdH0i7N3cK6fLfTwhDwDuYhstkZHHWveKKSqNbBY+ePBngDxhMfBOha3oFho2keFbz7e+oQ3aTNfyKxK7UX5lz33dfbAFd78CtF1/QfD+r23ijSksL2fVJ7syLdJN9p8w5L/AC/dHQcnJxkgV6VRTlVclZhY+XNf+EnjZ9R8R6rptvuu7PWTd+HoftEQCrJcebJLy2FPyoMHB4PHSt7xH8K9b8PzeDrnwtpra2mk6dLZzW8WqPp8gnclmuFlVlOCzHIzkgAe4+hahu7mCzt3uLuaKCBOWklcKq/UngVXt5CseD6d8OvEWkanpU9jotrCNJ8PXskK2l0TE2p3GQY086VnHylcuxx15HAHZ6D4W1TQfgRa+HrTT7K51mLTtrWd0EkiaZzvdWBOxsMzdTtJHXFel0VLqt7jseDaV4N8WXnjT+1Nb02eWCTU9NujJdG0VhHBHdqxMcTFRtMkWAC5wQc8ELp2PhTXNF1661Q+Hv7WtpJtXgjsVnhUolzOkiSjewUKyqVYA7gCODyK9mqne6nYWG/7de2ttshe4bzpVTbEmN0hyeFGRk9BketHtW+gWPNX8IatL8EfDnhyawV9RtjpwubZpEICxTxNKCc7ThVboTntmqes+H/Fll4i1q90PSo2hudZ+1xTxR20txGhso4zJEJnVFJdWViSGx0BB59gRldFdGDKwyCDkEVHLcwRTwwSzxJNNkRRs4DSYGTtHU4HPFCqMLHz9b+AvE9p4TsrddDvP7bW2u7dpYrqymt5Q93LKkdzBKAjRESBt0Y3AkjaMCvoG1Eq20IuTGZwgEhjGF3Y5xntmpqKUpuW4JWCiiq9zeW1rLbx3NxDDJcSeVCsjhTK+C21QepwpOB2BqBliiiq8t3bRXcFrLcQpczhmihZwHkC43FV6nGRnHTIoAsUUVXtbu2uzMLW4hnMMhhl8tw3luMZVsdGGRweeaALFFFFABRRRQAUUUUAee3XgDUY9Q8QHQ/Ekmlafrs63N5HFbZuI5NoVzBMHHllgo5KMQeRis7UPg9Z6tB4nk1jWNQudU1hGhjukmmiS3hCbYY2iWXbMEPzEvncSc4ya9Toq1UkuorHnL/D7U7bUjqGj+IorW9uNKh0u9lmsPN3iMYEsWJF8tuTwd46cHFW774c2cmg+ENEsbprfTPD17BeCN4/Ma58oHCscjBLNuJwee1UPF/izxHp/ie8stI/shbO2fTYcXUEjyM95O8IO5ZFACEK2MEnkZHUcsfiz4iTVbOwks9KEgkkhkeRordL10vJYGEJmuUKELEGwBMcuAQBgtaU3qLQ6/xB8MbbXtS8WXl9qUofWo7RLcxRBWsjb/MpBJIfL4YggenvRqHw/wBR1qW5vvEGvxXWrLp8+n2EsFiYYLPzk2ySiIyMWkI77wMcYFcLN4/1bUfE9i8t/ZEeUFl0u1eaJ7Rm1WyhC3G2T5pAjNjhRhmBUqx3X/8AhZWq3UNhLJPo8s7TLJJY2wuI5tPfZMfJuMPtZhsHDFc4PyEAMHyzDQ3oPhDY2njDwz4gs74Ry6Hpq2CwNb7kndI2jjlbDjlQx474HIrtPEuiTeIPB19o11dxx3F5amCS5jhOwMVwWWMsSBnkKWP1PWvLtT+JvijSLKJb+HR5JporC5N3FD5cNrHcpcNtdZrhFJDQBQxlQHf0yAraFj8S9WbxD4ZtNRXSIbfVIoQ0NpLDdzvI7suQEucrHwrblSYAE5IwaTjN6sNDT134a3useKX1SbxCVtRcPcRWv2d/k3W7QlTiURtgMSG8vf1BYg1nQfBxrLR9PsNO16SKOwlaW3DJOoUyRBJgTDPG5DMN4+fjcwO4Hiz4o8fa7p/xMh8N6fY2H2ZjbBTdSxRyXCyFt7xl50LbMfcRJCSCCVyM4E3xV8UppOoXLaTYxNpc8OmahI0bbIrxpWWRwXlRfKWMI3zOvMq5cAGmvaWVmGh3eteCbi68NaFpGk6qNMj0wBDsjmYSIIym1WEyypjOQRIemDurE0X4VT6Tp0emw65byWLRwifzdNWSVpIoPJVo3ZyI12hcjaTndtZdxqhoXjnxnr92LWyt9BguF0JtSCkfaluJfOmjjCPFOUVG2Ix+ZyORk9Rt+CfHepeJ/CeveJLfTVaxt4z/AGfaqjCeeSOENKrZOP8AWkoMD+E9eKXvxQaFO0+GGoWU63ltr9n/AGjsaEvLphkhMTWtvbsPLMud3+jKwbdgbmBBBrS0X4bQaQkCQX7SLBfWd2jSQAuVt7SO2CFs8k7C27HG4jHevO9K+Jt6ur6xql74j0ySM6Xp3l/ZoHks7eeWSTcjRtOqq4+6ztIg+UZx92tLSviv4lvbLw+n9nad9u18GCyIify47iK6aKfzMSH5REBIAD2YZbiqcagaHbat4FmvvEt3qL6jAdOuby0v5bMWQMzSWyrsVZi+ApK8gr0JGRkk1Phr4Kl03wnrFpq6XFtLqjSQrC0qtLa2aqY4IdyErlY+eCQCx5NZ/wATNf12PxLF/wAI3banc2vh6Jb/AFAWUkapIzMD5UgeRSw8lZW2qGO54zjgZ5/U/EusW1p4m1O11K8u9Ev9WjtreWORibJj5DRlCORFIrlSOgbb/faklJq1wOqg+HOrQ3Nlfpr2l/2nZQi1gf8AsRRCYREY8OglDM+D97eFHQIAWBseHPhjBoVvbwwaiZRBf2l6rvbjeRBapbhCQe+wtnHG4jHc8pour2z3Vk+neIr668Wt4kuLefThqstx/oovpUcPbFysaLbjcGCrjauDzz7Ho9x9r0y3n+2Wl9vXP2i0GIpOeqjc3H/AjUzcl1A4Hwn8MG0S70O4utWivTpYiRVFn5YdY7eWBOsjYO2QEn1U8DPFSx+FF1ZWlpZQeIIvsEb2csyNYEySSW6hBtbzcKpAHG0nP8WOK9WoqfaSHY8u/wCFVrD4buNPXUBcStJbS7hD5TP5NilqE3ZO3dsLbudu4jB6mX4RaJ4isNS1e/8AE9nHaNNZWFlCipEhIgWUEkRySAj94AGJBOPuqMCvTKKHUbVmFjymx+FN3a24tDr9s9lKLZLpf7N/eusErPH5bmQ7DggElW5GQFzUXxJ8M+JNS8WTHQ7GOXT9SgsYbqeTymCeRcPJ1Z1aPAbOVWXd0whG4+t0Ue0d7hY82i+FluL7SpptUmaC1SRbmCOLYLo7pWhYnJ2mMzyEdcnaeMYrQ+HPgL/hDnlaS/F8/wBnjtIpD9p3rEmdqnzZ5F4yfuKgGTgAcV3NFJzk1ZsLHlN/8IlnsNJt49WAFrYtp9wrpcJHcxNJvPywXERBJJzuLA8ccVhxeAPEmp65cadewR6fokD6k9td7InbNxMJFOVk3Sc8kMkeAMZc4avcqKpVZBY8xufhpqd1Lf3c/iSJdTu5riczw6dtRDLDbxABDKTgC3/vZ+bqCMm14L+HEnh7xCNXu9Y+3zeZdylWhk4a4S1U4eSWR8D7McZJOJMZ+Xn0Sil7SVrBY881v4eXer+MU1i410NZx3aXcdi9u5UFYvLKNiUIynk5Me4ZI3Y4rNtvhZfw2UVv/wAJGoigukmgtxbTvbwRiCeF0jSW4dlLLOTw+0FFwnXPqtFHtJbBY8/tvhvDBrmj6gL2Mx6dHZIIPsoAc20N1EDndxn7UG6HHl45zkZZ+FN3b2umx6X4iFpJZ2FtYlhaMBKInlYklJUddxl/gdWBX7xyRXqlFHtJBYwPAvh8+FvC1loxu2vDbb/37KVL7pGfnLMcjdjJJzjNb9FFQ3d3YwooooAfD9/8K5vUv+Sp+Hv+wLqf/o+wrpIfv/hXN6l/yVPw9/2BdT/9H2Fejhf4ZnLcPBv/ACMfjv8A7DUf/pus66OX75rnPBv/ACMfjv8A7DUf/pus66OX75oxfwfMI7jaKKK840CiiigDD8cX66X4O1q+ka+RILSRy1iF89QFPMe4EBh1BIwOtfP0HiW5u7rWLay8TNp2mKLCZDd67c3cMjFpldWvU+aFWwm5kYqpAGQSVH07RVwmorYTR8t6vd2+oaRc315cakkz+FNYt7VrvVXuFumjkx+7cbVnXYWIJXJChjkqGro9U+36X4ksvDtrrmuDT7ltFkkZtQlaUGV50lCuW3IrhFyoIAI+UCvoGir9r5CseBwahfaLd2N2+ta/cQx63q+mvH9redjaww3Doqo5KvIpjBV2BYnAJI4q78HPEjan49mtLS9u5tNk0Zbgpcay+pFpllUFyxG1Hw43IhwMjIU8V7fRUuomth2PCpb26m+Jl3pJ8Q3122oXd1ZhLHU5oZ7FGibHmWbjaI04KzxlSSAcnODUOsa94kFlcXuoanp6Qatp/h64jtLl4BLOhY3bjaQeWZUDei8GvfJo1mhkicuFdSpKOUYAjHDAgg+4Oap6Ho9joWmx2GlQeRbIWbaXZ2ZmJZmZmJZmJJJJJJJp+0XYVjwu5vNU0uOKeDXdZkYatrOlgTX0kgFvFBcNGCCeWVkUiQ5ftuxgVkXd5Fqfgy4Sy1/VtX0/+wbe81aSfUJpPs94J4sBju/dkqZt0YwAEUkd6+lL21hvbOe1uU3wTxtFIuSNysMEZHPQ0WVrDZWcFrbJsggjWKNck7VUYAyeegp+18gseHWmty/21H9k13UJvEf/AAkUdtb6b9ukkjk0veAsnkliroYP3nnkElud2eKz/DcV/d6NoDXHiHxE7al4ev7+5b+1Z8tNC8QiKndlMeYeFxuwN27nP0RRS9r5DsfO+keJb8eJ/Dt5ea/PqFxerpe7ToNQltriIywR7yLVlMVxCSWdnXDLk4YbK1vjlBaR+IdUnubiaKebwfqaW6G6dElddpKhN21yELMVwfuhsZUEe5UUe01TsKx4BrGqDwle3elXOq69Npktnpc43as0RWV2nV91zIcwRMIlztK4OAu3NVvAmoJq3iLwveatqN35dvreo2dq0uqTyKAYo3ii8xiplzuONwJZcDkYr6Ioo9rpsOx4n8VLnUI/Efi24tNX1W0bSdBtLy0jtrySOJZjPNl2jBCvkIAQwII6g4GKXiTWV8OazrmkX2p67Lp0epWvkmTWWtlBe1Z3WW6c7o4yVyFVh82AMDIr3mikqltLBY+ctE8S+IovCNnc22oX9zNrUt14dtvMuJJjbXP2lvs8m5wrZETSkuwViI0z6Dv/AIv3d7oukeGodO1C9hP2iaF5FnYPKFsbgje2ct8yq3PcA9a7u90PT77WLLU7uFpryy3fZy0rlIyQQWEedm7BI3Y3YJGa06bqK97CsfPl1f61o2hONO1jWZ5L3wpbajcSTXUlxJG5mjWWaPcTsYRu5wuB8oOMimeLbu1dYn8E69q2r+Vputm2umuZJ3jl8iAhIZyNzgHkEMxDEjPGB9DUUe162Cx8+614y/tbxMG0/wARXH/CMi20pdSurW8dEgjZ7jzHEin5CWEKO4IIGQSMcYtrqrWp2afrLf8ACLz65qTPfXWtT2CzOI4PJD3aK7ngyFc437QSTwD9OUUKql0Cxxvw4uTdaFpEuqaqt7rklgHbbPKBLDvOyXyXCdRgeYY1J+ldlRRWbd3cYUUUUhhWf4g1WDQtB1LV7tJHtrC2lupViALlY0LEKCQM4BxkitCuV+K3/JLvGH/YGvP/AEQ9OKu0hDv+Ej1n/oRPEf8A3/0//wCSqs6B4ibVdVv9NutH1LSb2zhhuGjvGgbfHK0qqVMUrjrC4IJB6etdRXIWn/JU/EH/AGBdN/8AR99XZWoQhByRKbbNHWvEOi6EYRrer6dpxmyIhd3KQ78f3dxGauwXdtcSyRQXEMssYVnRHDFQwypIHTI5HrXBeKNK1i38R63e2GmXl+mqWUFvHc2ElqJ7UxsxaIrdfJ5b7uSA3U/LnBrnG8O/EOx0yFtPnxfQWtvZrBFcJHagPA0cjpGpVFMT+W4AUZCsF61zKCa3Kue0UV5R4e8P+MLD4ieZe3+pzaNDKwSV5PNilt/KCojhrrhwcEsLfcWBJYgmu0vfHXhKwu5rW+8U6DbXULFJIZtQhR0YdQylsg+xqXHtqFzo6K5YfELwWULDxf4d2ggE/wBpw4BPQfe9j+VJ/wALF8E/9Dh4c/8ABnB/8VS5ZdgudVRXK/8ACxfBP/Q4eHP/AAZwf/FUf8LF8E/9Dh4c/wDBnB/8VRyy7Bc6S7t0u7Wa3lMqxyoUYxStG4BGDtdSGU+hBBHY1V0HR7DQNIttL0i3W2sbZSsUQYtgEknJJJJJJJJJJJrF/wCFi+Cf+hw8Of8Agzg/+KpT8QvBYQMfF/h3aSQD/acOCR1H3vcfnT5ZdgOprJufD+m3PiK01y4geXUrSJord2mcpErfeKx7tgYjgtjcRxnHFZf/AAsXwT/0OHhz/wAGcH/xVH/CxfBP/Q4eHP8AwZwf/FUcsl0A6qiuV/4WL4J/6HDw5/4M4P8A4qj/AIWL4J/6HDw5/wCDOD/4qlyy7Bc6qiuXPxC8FqFLeL/DoDDKk6nByM44+b1BoHxC8FsGK+L/AA6QoyxGpwcDOOfm9SKOWXYLnUUVyv8AwsXwT/0OHhz/AMGcH/xVH/CxfBP/AEOHhz/wZwf/ABVHLLsFzqqK5X/hYvgn/ocPDn/gzg/+Ko/4WL4J/wChw8Of+DOD/wCKo5ZdgudVRXLD4heCyhYeL/Du0EAn+04cAnoPvex/KlT4heC3dUTxf4dZmOABqcJJP/fVHLLsFzqKK5X/AIWL4J/6HDw5/wCDOD/4qj/hYvgn/ocPDn/gzg/+Ko5ZdgudVRXK/wDCxfBP/Q4eHP8AwZwf/FUf8LF8E/8AQ4eHP/BnB/8AFUcsuwXOqorlk+IXgtzhfF/h1jgnA1OE8AZP8VJ/wsXwT/0OHhz/AMGcH/xVHK+wXOqorlf+Fi+Cf+hw8Of+DOD/AOKo/wCFi+Cf+hw8Of8Agzg/+Ko5ZdgudVRXK/8ACxfBP/Q4eHP/AAZwf/FU4fELwWwYr4v8OkKMsRqcHAzjn5vUijll2C51FFcr/wALF8E/9Dh4c/8ABnB/8VTn+IXgtHZH8X+HVZTgg6nCCD/31RyvsFzqKK5X/hYvgn/ocPDn/gzg/wDiq6KwvbXUbOK70+5hurWZd0c0EgdHHqGHBH0oaa3Atw/f/Cub1L/kqfh7/sC6n/6PsK6SH7/4Vzepf8lT8Pf9gXU//R9hXoYX+GRLcPBv/Ix+O/8AsNR/+m6zro5fvmuc8G/8jH47/wCw1H/6brOujl++aMX8HzCO42iiivONDmvGl54otP7J/wCES02yv/MvUS++0y7PKtz9515GSPx/3TUHxPu7qy8IzTWtxc2kXnwLd3VqCZYLYyqJpEwCQQhbkA4GSOldDf6lY6d5H9oXlta/aJVgh8+VY/MkPRFyeWPYDmm6lqdppgtjfS+ULmdLaI7SQ0jnCrwOMnjJwM1Se2gjymfxjp2iTGHwp4mil0ue5SOXVdZuJb+ws38p32JMZAXZtq5BlwpIxycU+3+K159ms0vYLG31O7k0sW1mwcPOlxMEmdAxBIAyVOMDK5z37Sb4h+FodPv76TVV+y2F3LY3DrBIxSaKNpHUALlsIjNkAggHBNdSpWSMEYZGGeR1Bq20t0I8Ih+IXiHxDcaTaWeqaKtzNJZXDC0imBs5JJSr21wPNy5UD5l+QnuF4NaNn488RXmtwWtuNLi1CeSGwkmkjnkgBW71CFpFh80AZ+yqwGd3zYLMAuPSfDXhDRPDUskmj2kkLvGsGZLiWbZEpJWNN7NsQEnCrge1bM1wkU0ETrKWmYqpSJmUEKT8zAYUYHViATgdSBQ5x6ILHjN18VNaigtjLJoVnOI4v3NxDIW1FzdSQSfZ/wB4NoQRhyDvI3DOB8x9trn9Z8H6HrOqx6jqNm8t0ixqdtxKiSCNy6CSNWCyBWJIDg4JroKmTi9kNBRRRUDCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqpq2n2uraXeadqEXnWd5C9vPHuK743UqwyCCMgkZBzVuigDlv8AhB9L/wCf3xL/AOFHqH/x+r+g+GtO0O6urqy+3SXN0kccst5fz3blIy5RQ0zsQAZHOBj7xraoqnOTVmxWQUVl6nrdrps6w3EWou7LvBttPuLhcZI+9GjAHjpnP5iqn/CWad/z763/AOCW8/8AjVKzA36KwP8AhLNO/wCffW//AAS3n/xqj/hLNO/599b/APBLef8AxqjlYG/RWB/wlmnf8++t/wDglvP/AI1R/wAJZp3/AD763/4Jbz/41RysDforA/4SzTv+ffW//BLef/GqP+Es07/n31v/AMEt5/8AGqOVgb9FYH/CWad/z763/wCCW8/+NUf8JZp3/Pvrf/glvP8A41RysDforA/4SzTv+ffW/wDwS3n/AMao/wCEs07/AJ99b/8ABLef/GqOVgb9FYH/AAlmnf8APvrf/glvP/jVH/CWad/z763/AOCW8/8AjVHKwN+isD/hLNO/599b/wDBLef/ABqj/hLNO/599b/8Et5/8ao5WBv0Vgf8JZp3/Pvrf/glvP8A41R/wlmnf8++t/8AglvP/jVHKwN+isD/AISzTv8An31v/wAEt5/8ao/4SzTv+ffW/wDwS3n/AMao5WBv0Vgf8JZp3/Pvrf8A4Jbz/wCNUf8ACWad/wA++t/+CW8/+NUcrA36KwP+Es07/n31v/wS3n/xqj/hLNO/599b/wDBLef/ABqjlYG/RWB/wlmnf8++t/8AglvP/jVH/CWad/z763/4Jbz/AONUcrA36KwP+Es07/n31v8A8Et5/wDGqP8AhLNO/wCffW//AAS3n/xqjlYG/RWB/wAJZp3/AD763/4Jbz/41R/wlmnf8++t/wDglvP/AI1RysDforA/4SzTv+ffW/8AwS3n/wAao/4SzTv+ffW//BLef/GqOVgb9FYH/CWad/z763/4Jbz/AONUf8JZp3/Pvrf/AIJbz/41RysDforA/wCEs07/AJ99b/8ABLef/Gq2bWdLm3jnjEipIoYCSNo2APqrAEH2IBpNNDLMP3/wrm9S/wCSp+Hv+wLqf/o+wrpIfv8A4Vzepf8AJU/D3/YF1P8A9H2Fejhf4ZnLcPBv/Ix+O/8AsNR/+m6zro5fvmuc8G/8jH47/wCw1H/6brOujl++aMX8HzCO42iiivONDF8S+F9G8TfYP7dsI7z7DcLdW+9mGyReh4IyPY5B7im+NdKudZ8NXlpp7wx6gNk9o82dizxuskZbHON6LnHaq3jTxDqGgDSf7M8P3utfbL1Lab7McfZkbrK3B4HvgepFU/itqmo6R4QNxo01xDePe2durW6xNKVkuI42CCUFNxViAW4BIzirSegjhrj4Ran5E0EF/ZtFL4eltHEhYb9TeGSEznCnCFZXz1I4461N4j+E91Ok0GhjTrfTPtcVyum5RIZSLcxuzh4Jk3bsNkxtnrkHmr/gvxjqieIH03Vzfy289+bGM6sbaK7tnS2kmk3rbrsKHYmw8Ehi2SMVJpHxRu9SFhcx6BCumTnT0mn+35kja8cIgVPLw4ViMksvByAelaXqXFoYkXwp1m38QWV/9qivo7eK3EYur2PfEIowphL/AGNneJyDu2tECHbK9zUh+EmrnRry3TTfDWmX90l0Z57G4cRyvLZzwIojFugjRGlXAG44LEkt97otM+Kt5Jp2nahq/h+Gysbu3tb5pY9Q87yLaZzH5jjyl5VihIGRtYnIxit6bxpfN4U8ParZ6LG93rdzHDBaz3ZiVEkDsju/lsR8igkbcjdjnHI5VEGh59428FP4dukl07w/b6lokspK6XDbTSwJJ9mCea6RRuQ+5cqwU5JJZkOGr1f4d2Vxpvw/8M2F9E0N3a6XawTRt1R1iUMD9CDXGj4rTNaPdJocXkWdvFcajvv9rxb7iSDEK+X+9w0THJ2ZGB1OA27+K9zYm7gv/DsttqYuEgtbFzctJKrSFPMbbbEbeAcxed1A60pKclawaHqtFcS3ja5XwbZau+iTW+o3d2ljHY3jPbKJWk2As8kYYIfvBjHkgj5cnFVvCvjy/wDEHiQ6RHo1rC1qkhv5f7QLrEySvHiLEf7zJQHJ2cE5GRg58j3Hc7+ivLPFfxK1Gxg1X+z9KtRDHPd6fbXMl7+8+0wwPKWaHyzhPkbB3EnjIAOaz9K+JWs6VaX154ksI7vTo7owedbzjzYnXT1uSixiNQ65WT5iwOWHy4HD9nKwXPY6K8v074l6tqENgkPhSSK9vr2K1gF1LcW0Dq8E028SS2ysxUQkMFQj5lIY5rc8ReM7jSvEE2n2+mW9xb2cFvcXs81+tuyJNK0a+UrLiQgoSQWTPAGScUuSWwXO0oryCf4pX08eiyPYR6fHfC21GI290t00tm7kMrgoux+nALDrhuDW74E8Wat4h8VXEeoW9tZ2T6PaX9vbQXK3GPNeX5mfYpDFVUFeVGMgnNN05JXYXPQqK8vt/inLCssmv6J/ZKQXEaXMc0swlt4JHeNZ2DwKjL5gRfkd1+Yndxgss/iXrV5LAsHhWBBNLbQAT6mUZZLiHzY9yiE4AGNx6jPAaj2cguep0V5RYfFe8vkSaHw/bi2Q2kVwW1LEiS3EhiVUTyvnUOOTlTjkAn5aqeGfijq7aHa3GraXZz+RHbPqFwt8EcCeVkQxReWA+AASCV9AWNHspBc9ioryW4+K2qQWs15J4ZthaJbS3ob+0zvMEc3kudvk8PkgqucEZyykYPUeFfGNxrHiXUdH1LSjpVxbiSSCOZpvNniSQIZBuhWMryvKSP8AeGcUOnJahc7KiiioGFFFFABRRRQAUUUUAFFFFABRWaNd0g3UFsNVsDcXEskEMX2hN8kkZxIijOSykEMByMc1PFqNjNdm1hvLaS6AYmFZVLgKQG+XOeCyg+hI9aLCLdFFQ3l1b2VrLc3k8VvbRKXkllcIiKOpJPAFAyaiqd/qdhp5QX97a2pcMyieVU3AYyRk9BkZ+oqV7q3juoraSeJbmZWeOJnAd1XG4gdSBuXOOmR60WAnoqG1ure7jZ7WeKdEd4maNwwDoxVlJHcMCCOxBFTUAFFRXM8NrC01zLHDEuMvIwVRk4GSfc0hurcXiWpniF06GVYS43lAQCwXrgFlGfcetAE1FRzzRW8Ly3EiRRKMs7sFUD3JptrdW93Gz2s8U6I7xM0bhgHRirKSO4YEEdiCKAOf8Y6vc6fc6NaWbmJry4k8yQKCRHFDJKQMgjLFFXkcAkjkCuEsvi7cxaZFdXmhhrIo0Mdw1+vmyzrbJN86iJUVTvwWB4IJ24r1HVtJttUNmbkMHtJxcRMuMhtrKRyDwyM6kejHp1rGs38FT6lJodm3h2S/h379PiMBlTKbHzGOR8mFPH3eDxWkXG2qEc3bePdRj8cQaZqdpaxLK0VnLDb3iTx28pNwxk8wIGOViQbGCEZ6DvhXXxfvJ7Cy1aDTI7XSYJFa923ayTSZsXujEkZQZXbt+fcDkEYxk16d/wAIj4bFj9iHh7R/sQAHkfYo/LwGLAbduOGYn6kmnx+FvD8d1b3MehaUtzbxiGGVbOMPFGAQEU4yFwTwOOTRzQ7C1OZ034gzz+DNX12/0G5s3sQCkUnmxR3AZVKlXmijOMthjswMHBYYzz0fxN1fTrjxFHqWl2lw+lyT3V0iX4VYLaNYQVhbygZn3OxwwTsCQSBXpNpomhaLpV3bWmmaZp+mSKz3EUVvHFCwIwxcABSMdc9qwdBtvh1rTRW3h+HwlqDWLfaI4rJbaU27HA8wBM7T8qjcMdB6U0466Ac/qPxXutPlmtbzw7JDqbXotLWzZrkySKfNIlYLbHKEREgxedyQDjk1t+IfHkmk+DLDW/7L8q7uozKdOv2mhmUKjO4CpDIxKhTnKgY5JFbreEPDTRXkTeHtHMd64kukNlFidgchnG35jkk5OeasXnh3Rb2xtbK80fTriztCGt4JbZHjhIGAUUjCkDgYpXh2Hqebj4wzfZDfv4ejGnPvjgk/tAeY8q26TAMpjCqhDgbtxwQflxVrUPFHib/hB/Ft4n2SDV7PUxZwrHOHjt1IhB2uYvmILsQWTqeRxiu+i8O6JFbrbxaPpyQKGCxraoFAZPLbAxjlAFPqvHSltdB0aw0x7C00rTrbT2be1tFbokRIxyVAxn5Rz7D0o5o9EB5snxW1KD7FF/wjFzetKs0i/ZpZbmeSGGbyWcpFbkB2YEhTtTGPmBOKv2vxPuJdW0+3l0SFLTUJglvMt/vcJ9qFvukQR4U7jnaGPpnOcdidB8Nazp9hI2laPf2Kf6TZsbeKWNd/zeZGcEDdnduHXrWPqmg+CIdZvb/Uo9EikmhkhvYZ1gWOfJSZnmUj5mAVWy3QHPoad4PoLU5q3+L8l1f+RaeGry4ij/4+JIDLL5WZJUVspCUCfu9zF3TAJwG21NYfFDUrvyLb/hHbOLU7iGK7hhk1XbEYHgebLSGIYcBCNoUjJzuABNda2i+DDFbXjab4e8qykNpBOYIcQSGUoYlbHyt5jFdowdxI6mr954Y0C9tvs95oel3FviMeVLaRuuIwRGMEY+UEgegJxReHYNTz+9+J1ze2muppliLa60O1l1G7bz0lAijZHiQYUhvPh3HII29ieDXrFcufBWmudZaaW5lbV54pbpmKDMcWNkA2qMRgAjH3iGb5snNdRUSa6DQUUUVIwoqKCeK4VmgljlVXZCUYMAynDA47gggjsRUtABRRRQAUUUUAFFFFAD4fv/hXN6l/yVPw9/2BdT/9H2FdJD9/8K5vUv8Akqfh7/sC6n/6PsK9HC/wzOW4eDf+Rj8d/wDYaj/9N1nXRy/fNc54N/5GPx3/ANhqP/03WddHL980Yv4PmEdxtFFFecaBWb4gn0i00xrjxDLYQ6fFIkjS3zIsSOHBRiX4BDbSD64xzWZ408Haf4v/ALJ/tOa9i/s29S+h+zTeXudOgbg5H0wfQiq3xQ03UNU8KrDo8VzLeRX9lcgWrRLKFiuY5GZPNIj3BVJAbgkDOapJXWoi5Fa+FPF1rJeRQaHrltI6h51SK5RmjztBbkErubHpuPrWhBoWkQQrDBpVhHEpiKolugUGI5jOAP4CAV9COMV5boXhPxVLr0tzcyavaWU91cXZa5vIYZ3l+zwJEbgWjBHXfG2FGRgfMOcHO0zQ/iHa6BcxXa6zd3EzQJNF9r2Nld5eaKT7eWIJ2goGtwRggDlTfKv5hHpHifw94d1HSW0Kea20uKaGKzMdr5MMjW5YhYBlThGKsAFweDgg1vGPTZriKxZbSSeyCXEcBCs8AO5UcL1X7rgH2YDvXiWneAvFN5qulz6/b6o9w8FlHd3aapjYIbucsP8AXFgxieEqy5I+f5gzNu2LXwv4zm1C1tb+61ldKS4jjd01ZlkMCXV+eXWTeSYXtMnO4/Lk5U4biv5gPTJfDGgSz2k8uiaW81mxa2ka0jLQEtuJQ4ypLEnjvzVSPwz4SSa+0+PRNCWW8QTXdstpCGnXccNIuPmG4HBIPOe9eK+I9S13RL6y0jV7/Wv7WMNsunpDqpQjN7KrGRd4NyWiEY4EjLjLbM7j6F4+8Ma1qPiS+1bRjex3EOkxRWb216YA9ws7NtcBhuG09Hyhz3PROLW7A7j+wdH/ALFOj/2Vp/8AZBG37D9mTyMZzjy8bcZ56daba2Oi6GbWO1tdO04uBaW6xxpDuHzOIkAx/tttH+0fWvIb/RPiJe67qUkMWq2Vnc+bG4TVeP8Aj6iZGjP2ghf3Sv8AdjiIyQQ2RU/iHwl4tk10LpUerPLa3sktjqFzq3nWsMP2N44gYnkLmRZWGWKFjkncwOKORfzAerv4d0STU5tRk0fTW1CeMxS3RtUMsiEYKs+MkEcYJ6U+20HSLWCKG20qwhhicSxxx26KqOE8sMABwQnyZ/u8dK8p8KeFvGUt1pkWvXmux6cLwSXURvWhYKtvKMiRbyaR1aUxfLlQMfdAJrc8faV4qu/EskujLqjxG3t1sJbXURb29pMJWMrXERceapQpj5ZOARgE5pOOtrgdfb6B4a0C2e5ttJ0fTLeBzdvLHbRQrGwRlMpIAAIVnG70JHQmpm07Qtdk0/WGs9M1KSJRLZXxijmKA8ho5MHA6HKmuIvvCOrXnwi13S7ptRutd1COYlJtSdyW8xjGqsX2ou3aNoIBHDZyc48+ieN28WXot01q00cxXdoJY9S89mj8orBJH5tzjfkKeY0YMeXbJIOW/UD0q10Dw3pl1ttdJ0e0ubmXz8R20cbyyJzv4GWYZJz1GasaP4e0bRZJpNG0jTtPkm/1rWlskRfkn5ioGeSevrXiz+E/Hc9pYzR2+oQ6nZx3sFrdSak5kXzIY9kkqNdyjlxIoCu38JwvboPCHhnxU2qaSdcutcTTIpp5pYJLxoih2ReWrMt5O8iFlc4ZyBkjABxTcdPiA7HVPAHh680i60y0sLfSrS9kRr1dOt4oTdKpz5ch2HKnvjDehHNb50vTzMZjY2pmMiylzCu4uq7VbOOoHAPUDirtFZ8zGc1ZeCPD1nr0mrxaXZm8wghLW8eLbaCP3Xy5TOSTg81Zj8JeHIrq1uYvD+kJcWrF7eVbKMPCSxYlDtypLEnjuSa3KKOZhYzH0HSJITC+lWDRGJoSht0KmNm3MmMfdLckdCeaTTdA0bSry5u9M0nT7O7uTmea3tkjeU5z8zKAW555rUopXYBRRRQMKKKKACiiigAooooAKKKKAPK/BfgzUtP8ftrGoW1xFCrasVZbw7D5195kWY1fB3RszcjsueVXGCfh9ryanr9xaRatayLFq0ljNFqpRpZ5ZIXt/mEu7adpyrYXKncOQT7lRWntHe4rHlXhLSPG8PxClvNdu706eZZnO0h7eSFl/dR4+1YRlO3lbcElTliDms/x54a8V6tP4lt7e21i5a7WZbaZNWSOyNu1vtWIwMT+8EnOdq88+Zj5T23i3x9pnhfWbHTtQguWku2iRJI3hUBpH2KNryK789ditgcnFcLovxhvbd7m48W6S1nYGLzrd4xDGfmuGhSMs1wy/wAJy7bBkHIUAFrXM/eSESeJPCXix7vU7DTn1K70RmkNutzqPmlg0VseTI5YjzFmwG+7zjAIzf8ACegeIoviDZajrNpqbC3j1BLi9uNRWa3lMk0Zi8iLeTGuxcEBE6DIPWt/wt8R9M8Uaha2mjWN/cGWJppZkaBorYLI0Z3sJSG+ZOPL3gggg4yRfXXNS/4WMNDms7aPS20+S6in8wtLK6PCp46Ko80juSRngdZcpbNAcLdaN43j8Q2V5CNWulTULpjBJe7bUQNfSPGzFLpGyISuFMcqgBV2g5rd8Z6D4gv/ABNe6hpdzqccUFlZCxjt9QaGFpxcymfdGHCt+7KA7wQQcckcLJ8SodL1XXIdfsbmHTrK/ktY9QhjUwgJaLcFX+feXwJOQm3gDINaen+PrK61O10250zVdP1C4nihW3ukj3ASQzSpISjsNpFvKOu4MMEChuW9gPONW8I+MtTsLi3urbXJXCM95v1kGK+lF1G8ZtkEo8oCNZOD5Y5UYJAYdr8QdH8Sape2cehy6jb2LW0UU5t77yXU/bbVnOd4O4QLP8wzxkZO7B1/C3je18S6i9rpum6kI44UmlupViWKPdu2qfn3FjtbopA7kZFcdo3xZvXuZJNY8PXkNhHBJLK0AiZoAt3LBvc+dgqAighQW3BiAVwad5N7bAaWs+GNXu/ht4h0WRdQu5jdytYI+oMZnhEgZF85pMnjI+dvY1zp8G+MLDSryTw7LqVlfXtxqskkU2omRESS4LwYTzNqyFSfnUhtzHcw7dFcfGXwzFqGp2ai6mlsjMuIXgdpmiba6pGJPMBznBdVDAEgnjPV+HPEo1x5449K1G0ltrh7W7S58kG2kCJIA22RgdyyKQU3D1xRecVqg0MLwLpXiO38H6ta6ldXsV/O0v2P7by9tmMBfm+03DMu7LcyEjJGAMVwcXhnxnDo2kWem6JcWbaRpNxH5cz2DpJfGBkSa3kGZkZpDvZ2ZPp1r3mioVRodjxG78G+OrbxFpcNnretNpiW9qWuxdNcFLhWBmaVZLmMFWCgY2SrgnCqck0n8MfE6aPWml1TVUvZyYR5M6rC6vcp+8iY3R8spEGwFhizyDuPJ97op+1YWOA8N2fiPw5oPiuQWt/qt1/aEz6TZ3WoCZnh2IqfvJHO1SwZiC3APA7VyNloHipdES5k0rXF1u81GG41+VLu2guL2Da/7m2dJz5caHYAC6HbnByTXttFJVGFjwW78JfEa40idJL7WFuYdLK2SQ6wUK3El0xAkcSAyNFDsyzZDcjLV0nh/QvGy/E+5v8AV9RvxpEd1O0QRg9tPbFNsUbL9oG1lOGJFvncD85Br1aim6rYWPEPFOj/ABFvfEWsy6TDqVrbSx3kMbR6lhHBjIgeMG42odwXpEhUn7zDJGlq/hvxPa3l3a2n9v6h4fW7ZoYYtZK3LhrWMK3nSShvLWYSEozd8hWHB9doo9o+wWPKNW8PeI4vhV4P03Tk1SPVdOtLaK5trGdUDMkAVkkdbmA7Q3dJOo6MK5vU/Bfi+4HiRYtPvEk1WPzZlGqeZbyu2nxx7AJJSflmVxllHGzkhRt97ooVVoLHmd94V1W6+H2oaQYJI7q48RNegRTqjiA6qJ/MVweD5XzDnI6YzxXM+LtB+IKWU9j4ej1aTyJLp7C5OrFmUeYDEshNwjMNoIBk83HQqOte5UUKo0Fjzrwbp3iWx8faxJfpqM2i3JmkSfULnJjJkUpHFGlzImzBbnyoiABndk1yOsp4o8NR+JdWvbvUobC1f7da3N/fFWuJVnDJarGlzIjJIm9MCOI8oME9Pc6KSqa7BY8YtvCPjGdY7i91LWzcv/ZzuIdVeJF8y4dr5Qm8cLG+1cjgKuzkCsm407xj/bUuixTa8+oQ2Uz2Lpq+Et8303kT3GZP3yiIICDvYjgqTyPfaKftX2Cx4O3hHxfp8WrW2m2mviN7jUHsGt9bEax3ElyXhuJN02Xi8splSGO5ZCYyX3HRvfB/jCaC+mN/rn2ydNYfbFrLogk83NgEUSAIu3JwMDHD8YFez0Ue1YWPMvCuneLLX4gS3WoJqM2mXEZM0l5c/u4W2JhYUS5ZCNwP3oEIyfmPQ+m0UVEpcwBRRRSGFFFFAD4fv/hXN6l/yVPw9/2BdT/9H2FdJD9/8K5vUv8Akqfh7/sC6n/6PsK9HC/wzOW4eDf+Rj8d/wDYaj/9N1nXRy/fNc54N/5GPx3/ANhqP/03WddHL980Yv4PmEdxtFFFecaHNeNPGOn+EP7J/tOG9l/tK9Sxh+zQ+Ztd+hbkYH0yfQGrfjPXoPDHhbVNZuivl2cDSAMwUO/RFyeBliBz61tVS1PTLTUxbC+h81badLqIFiAJEOVYgHnB5wcjIB6gU01oI81s/jJpdn4Si1LXQtzcoLiKd9IKzwPNDJGhSJi/JcSo6gn7pOTkVoXnxf8AD1rBHctDeNZPcG3FzvgRSQVBZQ0oZwCxGEVm+Rvlxgno9V8E+HdW1IX+o6ZHPdi5ivN7SOAZo1KI5UHBwpx0wcLnO0YzF+Fng9LK2s4tKkitbe3+yrFFe3CK0W9pNrhXG/DszDdnBORWl6fYWpi6f8XNOitvEzaxGwfRL+a1maAIiKPtTwwITI4+dguS3CDBJK9KmT4w6HNZNd2mn6pdwQwy3F29sbeVbSOJgrs7LKVbGQf3ZfIPGea6KbwD4ame5dtOIkuDI0rpcSqzGSbz2bIYEES/OpHKHO3GTUr+C9Els7m2uYLq6jubSSxla6vp5neBzlk3u5bk985HbFK8OwanPN8T7O0mu4rnT9Tuxay3BuLi2t40jt4Y7uS33MGmLNgx/wAIJYfMFXlRr6J46s9X12DTYNN1OJLlbh7W8mSMQ3CwOqOVw5ccsMblGRz0q03gnw+yX6nT/lv1kS4HnSfOHmeZv4uMySO3GOuOmBWD4S+HB0HxfLrc2rNdIouVtrdYnjEYnlEjZBkZBjaBiNIweSQTzR7jQalbxB8UYtM1SPy9Lvm0eGa8hubwxpiVraNy6w/vAch1KkuoBwcE4zV3xX8VNA8MajcWGorcfaoZjFt8yCIPiGOVmVpZEUgLKgxncScAGtK8+Hvhi8vrm7utOaSS484yI11N5WZlKysIt+xWYE5IAJPPXmmx/Dvw5HvaK3v47h5TM10mp3S3BYoqH98JPMwVRARuwdoyOKLwDUr+J/HUWlWPhbUrK2e70nWJgZLldoEVubaSbfgsDnam7gH5Vb+LaDe8PeM7TVzdrPYahpcltax3xS+RAXt5A22RdjuMfIwIOGGOQK0dY8PaZrNrY2+pwSTxWUqzw7p5AQ4Rk+Zg2XBV2UhiQwYgg5qv4f8ACWi+Hxcf2ZaODcRpDI1xcS3BMaAhYwZGYhACcKMKMnileNvMZhw/EaGaO08vw14jNze7Ws7cwRK1zGyM/mK5l8sAKpyrMrDK5X5hl9r8TNDudOa+RL5bZJ7a3dniAKtMoYZGc4XOG75Bxmp0+GvhZIlSOxuUZGUxypqFyssQVWVUjkEm9EAdxsUhfmPFLJ8OPC5eFodOaAwLEIkjuJREGjGI3aLd5bsBxuZSSODkcU7wDUwr34os4s00/QNVS4mks5Fhuo4t09vcO6q0e2XAY7D98rj+LFTJ8ULR7xEg07VLhphDDHYx28QnWdprqJlZ2mCcNauD0Axncwb5W+Bvhbb+HrlrjVNQbVZkS2jt8LLGsQgLlDhpXOcuflBVBjAQV0tv4J8P21+l7Dp+25SXz1fzpDh/Mmlzjdj79zMf+B46BQG3BbC1MJPilpcsUUsGk6zNBugjuZUii22kk0xhVJMyAk7wclNwA5zyK1fEfjiy0LU5rSax1G5S1iinvbm3RDFaRyOURn3OGOSrHCBiAMkAVzur/Ca1u/EFtd2OoGx0xJIJZbJUkJdop2mzvEoU5Zj/AKxJCv8ACVrrdb8HaHrmpJf6nZvLcBEjbbcSxpKqNvRZEVgsgDEkBwQMmk+QNSpa+OLObw9q2uS6fqVvpunvLGJJUjJuTG7Rt5Sq5P31KjcFzkdua4nXfirqunnxEBo0sFzYLKbeyuIUMh2W8Em6R1n2YBmLfLncowMMOfSx4d0r+wbjRTZq2mXHm+bAzMwbzXZ35JyMszHg8dsYFYy/DjwsEuVfT55jciRZnnvriV5BIiI2XZyxysaDrxjjFEXBboNTktH+JmqW+q3kfiiyaCKLzYYbeCyQSzTRvbRkBxdOAWkuVATbgbh852knqZPiDZW8OoNf6VrFlNYWv2ue3uIUDhfMMeFIcq3K5BBKkdD2rRvfBPh6+lnkutPEjzecXJmkHMpiZyMNwcwxEEYKlQRjmqE/w18LXEeyawuXyGErG/uN0+5tx85vMzL8wBG8tjtii8H0Hqc5o3xRum1dbfWNJkWxO5WvbYJsjJvpLZGcGTcE+RcnaeSTwK3tU8bsfDOl61oen3F3De6ilokJRfMnjMjJuj+cKN23cpZgMEE45weIvh3pmoaNfWmlY064u7aWzadjJMoillaST92ZApbc7srHO0ngY4ravPCukXnh+y0W4t5P7PshF9nWKZ4WjMYwhV0KsCMdQaG4bi1OYk+LGkRLePNpurRRWNsbm+kdIVW0Illh8p8yffMkLKNu5eQd23JEEnxk8OpoEmrLFcSQQzPBOkdzaMYiiqxO/wA/y3yHXAR2Yk4AyCK6a18D+HbWzubWHTgIbm2W0mDTSMZIxJJIMsWJ3b5ZG353EtknIGK958PvD17DDHexajc+UssavNqt28hSTbvjZzLuZDtX5CSvHSi8OwanJp8VL9tfmhj8PXdxp0dxdIpgEXmyxRQQyhxumCjiQsQ2DhkAG7cK0B8U7FXlMOn6pqaN588f2O3jj8uCKC3ldnMkwzxcKQRgnkbcgFuktPA/h+0vZLuCykWaRGjObmVlw0aRNhS20EpGgJAydoPXmks/A3h2yDC207Zugltj+/kP7uRIo3HLd1giGeo28YJOS8OwalK3+IWn3Os2llbafqkltdXYsY9QEcYgMxhM2zlw/CjrsxngE12decWvwxS38cQa2mpsthb3Iu4bBY3G1xB5IBPmeWRjnd5fmHoXIr0eply/ZGgqG7uYLO1mubuaOC2hRpJZZWCpGgGSzE8AAAkk1NXK/Fb/AJJd4w/7A15/6Iekld2GH/CxfBP/AEOHhz/wZwf/ABVauh+ItE1/z/7C1jTdT8jb5v2O6Sby92cbtpOM4OM+hrerkLT/AJKn4g/7Aum/+j76uqrhlCLlchSuxdY8EaBrGrHUtQtJnu28kuUu5o0kMTboy6K4VircgkEiop/APhuYRhrGVTHF5SGO7mjKr5plBBVwQwclg33hk4IFch8QtTjg8SarFrmsS6bFFZQvpUUmrzaXbzsWbzm86IEvIuBhCG7fL8xasmL4i6zpNiuoz6bNLAbS1jliuHkkuBcS27tDn7qDdIoRisaZMik4xWKjJrRjPWNK8Pafpd0Lq2W5e6EAtvOubuW4cxhiwUtIzE8seTz+FW3020fV4tUaLN9FA9sku48Rsysy4zjkopzjPH1rzTw94+8Q3fxEHh3UrXTEEUrW88aSRRy/LEG89A1wZWRm6L5PCkHecGrWreK/E48Y3em6c+ixWK6vFpERntZZJFL2S3JkYiVQQDkbQBnPUY5XJK4XOvvPCWh3onW7sEmWe7a9lV3cq8zQ+SWIzjBjO3b074zzVCP4eeGo7UwrZ3WTJHKJzqFwZ1aNWVNsxk8xQqu6gBgAGYY5NeeaT8W9Yvo7GV00eGeU2kf9mGOQ3N0sqKZLiI7+IoyWyCrcRtlgcUXvxO8V6fD4dNzbaLLJqmnQ6ipxHaxymUj/AEZHnuk+dRyXAfO9fkHeuSe1wuj1fw54Z0jw3E8ei2n2ZHRIyPMd/lTO0fMT0yaoR+BPDsceoRrYOY79XSdWuZmBVpGlZVBb5BvZmwuOSa6iisuZ9xnNSeCdCeS+LQXflXrM89uL+4EDMzbmYQh9iktySFBySe5rTtdEsbTUbi9tkljuLmZribbPIEkkMaR7mTdtPyxIBxxjIwSSdKijmYBRRRSGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAPh+/+Fc3qX/JU/D3/YF1P/0fYV0kP3/wrm9S/wCSp+Hv+wLqf/o+wr0cL/DM5bh4N/5GPx3/ANhqP/03WdamoX5gumjEYOAOc1l+Df8AkY/Hf/Yaj/8ATdZ07xFPFaz3FxcypFBEm+SR2CqigZJJPQAV4XFeLrYTBxnQdpOSXfo+5thoqU7MuJqoz88RA9Qc1fgmSZN0ZyP5VxJ13St0QGo2jGWVIECyhsyOu9F47leR6jmt7SXK3YUdGBB/nXyOV5/i/rEKOK1Unbaz127HVUoR5W4lbxp4e1DXxpP9meIL3Rfsd6lzN9mGftKL1ibkcH3yPUGqHxb0u41nwjHYWttHcvLqVhujltjcR7BdxFjJGCN0YUEsMj5Qckda7SivvFJq3kcVjxLUvC2p+CdSi1LSbc3MjQXkvk6FpXkwWzGOBF8uHdIAx2ljkncQcKcYNWLxT4+ttLV53uzNe6nLotmLy0VHzLFE8F180EJYIRMCPLAx1XKk17vVS406yub21vbiztpby03/AGeeSJWkh3ABtjEZXIABx1xVe07oLHj6y+OLUaw1jJqNtFYm7uYYIdLhC30n9oTBd37rJ3RBWOzDNuD55ybvgbxbq+p+PbKyu9VvJ4riPUXuLRrKNLaIwzokfkTBAZFAJBId+epB4r16s2w0LSNO1C6vtP0qwtb66Obi4gt0SSY5z87AZbnnmjnTWqCx41ql1450jUryDQoLmzsp9Qvp0lNpLIskpn+XzAlrO3lleQR5ecnD8VdvNb8dJe+JLWO61Ekb5bS7TS5jBbKJkxEqGz3uxRmUOrTj5SxUcV7VRR7RdgseU67Lrmt/CG1uJ012z1KPULZ5fLgEt1JFHeoGk8sQKSNgMgXyVOFAKkZBxtPl8X+GdCiig/tue2uLW6k8mHTkZrGQXsSoUxEzHMcsjkMJCdmVXAxXt9FCqW0sFjw+y1T4i6hpMzyXGr2U9pY6jcR7dORmu5Y3j+zI2+3XO5WbhUjZsdAQa7Pxtruu6U2nT2VrqEkE+l3gkjsrFrgre4hNuCArFR/rhk4X+92rvaKTmm9gseJy6/49gvtSRBq16TaebEItOMUdsVSNipV7UCVyd4GyZsk/cGOJfEnivxdNbak+i2niGFZNRlXT3GltGRCttAVVw1vIwVpWlwWQcggumK9nop867BY4X4TjUnsNbu9Zs57S7vb9LlkliaPJa0t9xAIzgMGH1UjtXdUUVDd3cAooopDCiiigAooooAKKKKACiiigAooooAKKKKACsrxXpP8Ab/hbWNH8/wCz/wBo2c1p52zf5fmIU3bcjOM5xkVq0UJ21A5n7N44/wChg8Nf+CKf/wCTKf4f0XVbXX9T1fXNTsb25u7W3tFWzsXtkjSF5mBIaWQkkznuPuiujorWVaclZsVkFFFFZDCiiigAooooAw9Y8M2Gr3YubufV45AoTFpq93apgf7EUirnnrjNU38D6S7sxu/EWScnHiHUAPyE3FdRRT5n3FY5X/hBdI/5+/Ef/hRah/8AH6P+EF0j/n78R/8AhRah/wDH66qijmfcLHK/8ILpH/P34j/8KLUP/j9OTwPpKOrC78RZByM+IdQI/Izc11FFHM+4WOV/4QXSP+fvxH/4UWof/H6P+EF0j/n78R/+FFqH/wAfrqqKOZ9wscr/AMILpH/P34j/APCi1D/4/R/wgukf8/fiP/wotQ/+P11VFHM+4WOWTwPpKnIu/EXQjnxDqB6jH/Pak/4QXSP+fvxH/wCFFqH/AMfrqqKOZ9wscs/gfSWOTd+IugHHiHUB0GP+e1J/wgukf8/fiP8A8KLUP/j9dVRRzPuFjlf+EF0j/n78R/8AhRah/wDH6P8AhBdI/wCfvxH/AOFFqH/x+uqoo5n3Cxyv/CC6R/z9+I//AAotQ/8Aj9OfwPpLuzG78RZJyceIdQA/ITcV1FFHM+4WOWPgfSSgX7X4iwCT/wAjDqGfz872pP8AhBdI/wCfvxH/AOFFqH/x+uqoo5n3Cxyv/CC6R/z9+I//AAotQ/8Aj9H/AAgukf8AP34j/wDCi1D/AOP11VFHM+4WOV/4QXSP+fvxH/4UWof/AB+nN4H0lgoN34i+UYGPEOoDvnn99z1rqKKOaXcLHK/8ILpH/P34j/8ACi1D/wCP0f8ACC6R/wA/fiP/AMKLUP8A4/XVUUcz7hY5X/hBdI/5+/Ef/hRah/8AH6P+EF0j/n78R/8AhRah/wDH66qijmfcLHMP4J0p0RTd+IQEGBjxBfg/iRNz+Nb9haR2NnFbQtM0cS7VM8zzOR7u5LMfckmrFFDbe4D4fv8A4Vzepf8AJU/D3/YF1P8A9H2FdJD9/wDCub1L/kqfh7/sC6n/AOj7CvQwv8MiW4eDf+Rj8d/9hqP/ANN1nWf8SbdLvQ9etpp1t4prCWNpnBIjBjILEDqBnNaHg3/kY/Hf/Yaj/wDTdZ1X8bzNbWeqTx3Udm8ds7rcSLuWEhCd5HcDrj2r53jBtYOm1vzx/J+pvhfjfofOfg+K1k8UaVDJ440W8D6jb3Qt4bKVJJZIofJRVJ4Hyj8+a+l9M/4/ovx/ka+bPh5NrEXi/RdQ8QwvM2py7INW1XTmLygqWVIm85hEWUEj5Fr6T0z/AI/ovx/ka+Tx3/Iyw6vfWPa3xW6JdvX0OmH8ORB40s/FF3/ZP/CJalZWHl3qPffaYt/m24+8i8HBP4f7wrpaKz9Z0bS9ctFtdb02y1G2VxIsV3AsyBgCAwDAjOCRn3NffXvocRoUVyv/AArrwT/0J/hz/wAFkH/xNH/CuvBP/Qn+HP8AwWQf/E0e6B1VFcufh74LKBD4Q8O7ASQv9mQ4BOMn7vsPyFCfD3wWhJTwj4dU4IyNMhHBGCPu+nFFkB1FFcr/AMK68E/9Cf4c/wDBZB/8TR/wrrwT/wBCf4c/8FkH/wATR7oHVUVyv/CuvBP/AEJ/hz/wWQf/ABNH/CuvBP8A0J/hz/wWQf8AxNHugdVRXLr8PfBahgvhHw6A4wwGmQ8jIOD8vqAfwpv/AArrwT/0J/hz/wAFkH/xNFkB1VFcvJ8PfBcjs8nhHw67sSWZtMhJJ9SdtN/4V14J/wChP8Of+CyD/wCJo0A6qiuV/wCFdeCf+hP8Of8Agsg/+Jo/4V14J/6E/wAOf+CyD/4mj3QOqorl4/h74LjdXj8I+HUdSCrLpkIIPqDtpv8AwrrwT/0J/hz/AMFkH/xNHugdVRXK/wDCuvBP/Qn+HP8AwWQf/E0f8K68E/8AQn+HP/BZB/8AE0e6B1VFcr/wrrwT/wBCf4c/8FkH/wATTk+HvgtCSnhHw6pwRkaZCOCMEfd9OKLIDqKK5X/hXXgn/oT/AA5/4LIP/iac/wAPfBbkF/CPh1jgDJ0yE8AYA+76cUaAdRRXK/8ACuvBP/Qn+HP/AAWQf/E0f8K68E/9Cf4c/wDBZB/8TR7oHVUVyv8AwrrwT/0J/hz/AMFkH/xNH/CuvBP/AEJ/hz/wWQf/ABNHugdVRXLyfD3wXI7PJ4R8Ou7ElmbTISSfUnbWpomgaNoKSpoWk6fpqSkGRbO2SEOR0J2gZ60aAalFFFIYUUUUAZeqTazHcKNLsNOuYNuS9zfPAwbJ4CrC4IxjnP4etT7V4p/6A+if+DaX/wCRq36Kd/IRgfavFP8A0B9E/wDBtL/8jUfavFP/AEB9E/8ABtL/API1b9FF/IDA+1eKf+gPon/g2l/+RqPtXin/AKA+if8Ag2l/+Rq36KL+QGB9q8U/9AfRP/BtL/8AI1H2rxT/ANAfRP8AwbS//I1b9FF/IDA+1eKf+gPon/g2l/8Akaj7V4p/6A+if+DaX/5Grfoov5AYH2rxT/0B9E/8G0v/AMjUfavFP/QH0T/wbS//ACNWb8QGla88OQbd1pLeyGRcZDyLbTPEpGORvVSP9pVHfFeeafqHxEtNFhngGo7tklstgNKiSO3RLNHWRVEancJN4CltpIChc1ajdCPVftXin/oD6J/4Npf/AJGo+1eKf+gPon/g2l/+Rq81tdS8QWfiq31dU8RXumAw29xc3GimO4ntg9zwYkTPDtFyERsYJUA5ONNqPj/UItKnurfWZdYt9l1a2b6UEtmb7A58yWUINkn2hmQoWUAY+XndVez9Auex/avFP/QH0T/wbS//ACNR9q8U/wDQH0T/AMG0v/yNXF+HNV8aTfDzXrq5M82rxjNnvs3FwvyLu+SS3t1cg7ioVCDwMsevLQX/AIw0+TWH0p/EjJPcT3FjJLog36hcBYFjS5UxDyYyARuAi/iOQV20lC/YLnrv2rxT/wBAfRP/AAbS/wDyNR9q8U/9AfRP/BtL/wDI1eW6l4g+IFv/AGlBajVbsJqCh71LF40htyZfliQ2RcsCIgSFuRgk5HUdH4t1nxVafD3RZLWPUpPEFwmJZdLtTtEgjYjekltIyKxAHMa4J5KCjkfkFzr/ALV4p/6A+if+DaX/AORqPtXin/oD6J/4Npf/AJGry2HWPiS+ljUQ2qmecSx/Ym0uMCBRaJIJACgYv5hcAM2CRtwTVt9K1LVPhr4wt1bW5ZL7VQ0clzYCG4uYT5CktC0QGCAwPyDgHIHIo5O9guej/avFP/QH0T/wbS//ACNR9q8U/wDQH0T/AMG0v/yNXlN1f/EXTodJFnNdrDMbjEb6dtigZJ9kULJBaSuIjEAcnZnJIkGAKsJ4p8X23iOKG5n1mTY5nv7L+yQRFEt4iEW+2MvMgibOVLnnOc8B+z9AuenfavFP/QH0T/wbS/8AyNR9q8U/9AfRP/BtL/8AI1eUw+I/iTNqdpuivLe3dSyLNp8gEqmWYNvCWz7XCCPbukhH3SQ4JNWU1Tx3aW8EWp33iA20kFvcTXtto0c1xFK9vIzQrEsWCglVQcqWXIBZc7gvZ+gXPTftXin/AKA+if8Ag2l/+RqPtXin/oD6J/4Npf8A5GryzU9Y8T38HjGz1WZwmh2v2m3YwxoZruYpNaL8uSpiI2YDc7gSW4Ne5VMlyjRgfavFP/QH0T/wbS//ACNR9q8U/wDQH0T/AMG0v/yNW/RU38gMD7V4p/6A+if+DaX/AORqPtXin/oD6J/4Npf/AJGrfoov5AYH2rxT/wBAfRP/AAbS/wDyNR9q8U/9AfRP/BtL/wDI1b9FF/IDA+1eKf8AoD6J/wCDaX/5Go+1eKf+gPon/g2l/wDkat+ii/kBgfavFP8A0B9E/wDBtL/8jVtWrTNbxtdRxxzlQXSNy6qe4DEAke+B9KlopXAfD9/8K5vUv+Sp+Hv+wLqf/o+wrpIfv/hXN6l/yVPw9/2BdT/9H2Fejhf4ZEtw8G/8jH47/wCw1H/6brOqHxGmtrfRdcmv4DcWkdjK80IODIgjJZc+4yKv+Df+Rj8d/wDYaj/9N1nUPjNYHttSW7tpLu2Nuwkt413NKuw5QDuSOMe9fOcYNLB02/54/kzfC/G/Q8F8KXVhJL4VluNd1jU44L+C2t9FvvLhksHeN/LkkwuZQFHynoc5z2r6D0z/AI/ovx/ka8lstY+H3iDXtCSa3ks9dsXVLGK8tpbaZSowEyQAw/2STyK9a0z/AI/ovx/ka+Lqzc8fh3KEovmWjVvtdLWv629b7nWlaEtSDxp4e1DXxpP9meIL3Rfsd6lzN9mGftKL1ibkcH3yPUGtXWdZ0vQ7RbrW9SstOtmcRrLdzrChYgkKCxAzgE49jVfxLr8GgwWrSW11eXN3MLe2tLRA0sz7S2BuIUAKrMSxAABya5q++KWgaavl6ul3p2oh5Y2sLoRrOGjhMpxhyrBlwFZWILMoznp+kpN9DgNP/hYvgn/ocPDn/gzg/wDiqP8AhYvgn/ocPDn/AIM4P/iqsW3jXwzcaN/ao1/So7BWWOSaS8iCxSEZ8t23YV/9nOav22vaRdaiNPttVsJr8xiYW0dwjSmMgEPtBztwynPTketKy7AZR+IXgsIHPi/w7sJIDf2nDgkYyPve4/MUJ8QvBbkhPF3h1jgnA1OE8AZJ+96c1ftvFGgXV29ra65pU1ykwt2hju42dZTuwhUHIY7W46/KfSoZvGfheGURTeJNFjlIchGvogcJnccbu2059MH0p28gKn/CxfBP/Q4eHP8AwZwf/FUf8LF8E/8AQ4eHP/BnB/8AFVdHi/w0ZrWIeIdHMt0qvboL2LdMrZwUG75gcHGPQ1U0fx94X1a1sZrbXdNQ3ztHbRS3UaySsrFSFXdk8jt6ii3kwG/8LF8E/wDQ4eHP/BnB/wDFUf8ACxfBP/Q4eHP/AAZwf/FVafxp4Wjlljk8S6IskTiKRGv4gUckgKRu4OQRj2NXrLXNJv8AUbrT7HVLC5v7XIuLaG4R5YcHHzqDleeORSsuwGSvxC8FsGK+LvDpCDLEanDwMgZPzepA/Gm/8LF8E/8AQ4eHP/BnB/8AFVS0z4oeE9Q1A2kerWsX7yWFZpriJI3kjl8sop3cseGUd1IPcVqa1428OaPbavJdazYNNpUDXF1ax3MbTxqo6FM5BJIABxkkDvT5elmFyKT4heC43ZJPF3h1HUkMranCCD6Ebqb/AMLF8E/9Dh4c/wDBnB/8VWpdeI9Fs9MtNRvtX0+1sbsK1vPPcokcu4ZXaxOGyORg02TxPoMd3c2smuaWl1axmWeFruMPCnXc65yo5HJ4pWXYDN/4WL4J/wChw8Of+DOD/wCKo/4WL4J/6HDw5/4M4P8A4qruoeKdKsNZh024uo1mZJZJX8xNluI0R280k/JlZFIyOnPSq+neM9I1PSdd1PTJlu7LSHeOSeOaLy5SsKTEpIXCbdsgG5mUAg5IAzTsuwDI/iF4LkdUj8XeHXdiAqrqcJJPoBupv/CxfBP/AEOHhz/wZwf/ABVaEXinQJby4tE1zSzeW0bSz24vIzJCq/eZ1DZUL3J4FZmmeP8AQNTv7qCyvbeW2tiwe+W6g+zkLEkjMrb8soEgBIBAIOccElvIB/8AwsXwT/0OHhz/AMGcH/xVH/CxfBP/AEOHhz/wZwf/ABVXT4v8NC2s7g+ItHFveOY7aX7bFtnYHBVDuwxBIGBmqVj4/wDC11HO51zTrdYr2SwzcXUce+VCAQuW56jHc0cvkAf8LF8E/wDQ4eHP/BnB/wDFU5PiF4LckJ4u8OscE4GpwngDJP3vTml8aeONF8Hxp/bE+2WS3uLiOFGXzJFhjMjBQzDJIGB6kgVYHjLwz/Zf9pN4h0dbASeSbhr2IRrJjOwtuwGx2zmi2l7AVP8AhYvgn/ocPDn/AIM4P/iqc/xC8FoQH8XeHVOAcHU4RwRkH73pzVjTvF+h6hf6za2+o2xbSFSS7kMybERk37s5+6B1JwOD6VPqHijw/p0bSahrmlWiKEJae7jjADglCST/ABBWI9cHHSiy7AZ3/CxfBP8A0OHhz/wZwf8AxVH/AAsXwT/0OHhz/wAGcH/xVbR1rS1VmbUrIBWRCTOnDOAUHXqwIIHcHioIfEuhT6RPqsOtaZJpcDFZbxLqMwxkYyGcHaDyOp7ilZdgMz/hYvgn/ocPDn/gzg/+Ko/4WL4J/wChw8Of+DOD/wCKp9p468OXWuf2XHq1kJ5IoZbZzcx7LsSlwohO7Ln92c4HcdaZaeO9Ck+2Ne3kGmxWrRo815cwrEzPu2qrhypPyHjP65w+XyAdJ8QvBcbskni7w6jqSGVtThBB9CN1amia/o2vJK+hatp+pJEQJGs7lJghPQHaTjpVPTvFVjf6Do2rxLJHaars8nznjjZAylhu3Pg8KeFLH0BAJGho2taVrlu8+i6nY6jAjbGktJ0mVWxnBKkgHkcUmvIDQrn/AIgahc6T4D8Sajp8vk3lnplzcQSbQ2yRImZTggg4IBwRiugrmviXbT3nw48VW1pDJPczaTdxxRRKWeRjCwCqBySSQABSjugYv/CJ6r/0PXiT/vxp/wD8i1W8Of2jY+NNa0i+1q+1a2h0+yu4mvI4FeN5JLpXAMMaAgiFOoPf1q1/wn2jf8+viP8A8JzUP/jFUPDd+usePte1K1tdSism0ywt1kvNPntN8iS3jMFEqKWwJEJIGPmFd9eMFB8qRCvc7Kise/8AE+g6ddyWuoa3pdrcx43xT3caOuQCMqTkcEH8ag/4TTwt/wBDLon/AIHxf/FVwcrLN+isD/hNPC3/AEMuif8AgfF/8VR/wmnhb/oZdE/8D4v/AIqjlYG/RWB/wmnhb/oZdE/8D4v/AIqj/hNPC3/Qy6J/4Hxf/FUcrA36KwP+E08Lf9DLon/gfF/8VR/wmnhb/oZdE/8AA+L/AOKo5WBv0Vgf8Jp4W/6GXRP/AAPi/wDiqP8AhNPC3/Qy6J/4Hxf/ABVHKwNqeCK4VVnijlVXVwHUMAynKkZ7ggEHsRUtYH/CaeFv+hl0T/wPi/8AiqP+E08Lf9DLon/gfF/8VRysDforA/4TTwt/0Muif+B8X/xVH/CaeFv+hl0T/wAD4v8A4qjlYG/RWB/wmnhb/oZdE/8AA+L/AOKo/wCE08Lf9DLon/gfF/8AFUcrA36KwP8AhNPC3/Qy6J/4Hxf/ABVH/CaeFv8AoZdE/wDA+L/4qjlYG/RWB/wmnhb/AKGXRP8AwPi/+Ko/4TTwt/0Muif+B8X/AMVRysDfqE20BuluTDGblUMYl2jeFJBKg9cEgHHsKxv+E08Lf9DLon/gfF/8VR/wmnhb/oZdE/8AA+L/AOKo5WBv0Vgf8Jp4W/6GXRP/AAPi/wDiqP8AhNPC3/Qy6J/4Hxf/ABVHKwNGLSdNhWZYtPtEE1x9rkCwqN82QfMbjl8gHcecgVerA/4TTwt/0Muif+B8X/xVH/CaeFv+hl0T/wAD4v8A4qizA36KwP8AhNPC3/Qy6J/4Hxf/ABVH/CaeFv8AoZdE/wDA+L/4qjlYG/RWB/wmnhb/AKGXRP8AwPi/+Ko/4TTwt/0Muif+B8X/AMVRysDforA/4TTwt/0Muif+B8X/AMVR/wAJp4W/6GXRP/A+L/4qjlYG/RWB/wAJp4W/6GXRP/A+L/4qj/hNPC3/AEMuif8AgfF/8VRysDforA/4TTwt/wBDLon/AIHxf/FVuqwZQykFSMgjoaTTQyWH7/4Vzepf8lT8Pf8AYF1P/wBH2FdJD9/8K5vUv+Sp+Hv+wLqf/o+wr0cL/DM5bh4N/wCRj8d/9hqP/wBN1nUHjcZs9UBe7T/Rn+azGZ1+Q8x/7fp74qfwb/yMfjv/ALDUf/pus6g8a2Tana6nYJM0DXVs8AlXqhZCNw9xnNfOcYtLBQb251+TN8L8b9D5t+FF4Lrx3bx6XZ2erxBy0t7rMkX9owqCcsv752yMdAo/WvpzTP8Aj+i/H+RrxTR/DesxX/hS01nSvD+iWujXCeXfW1wDLeusbII0XaCN/Ugkk4r2vTP+P6L8f5GvkMXWhWzLDzhbeOzv9rutNu1rdTqimqckxfFOhzaudOubC9FhqenT/aLad4fOTlWR0dMruVlYggMpzgggiuT1f4b3uqiW6u9eibVriaRp5xYkReW9tJbiOOPzMqFWQsCWY5znPbU8fz6umveELfQr2K0nub2ZHM6PJEyi1mbDxq6lwCAQNw5APauEtfi9qd7qfh20tl0xZ9QW0juLdoiWjedARICZlYoGZfuxuOxcGv0aKlbQ4Dotb+Ff2+9hvbTWGtLmBLZIdkcqKoihkiOfJmjfkPxh1xjB3AkV0fgXwdD4T+3C3mjdLlYFCIjgRiKIJgF3diDgkZY4zjJ615xf/E7XJdNOrJp9vbiwjuomil85c3sFhPNMpAkAeMOqIAwP3XIOcFdPU/iB4h0m+k03Vbvw9aSxyAtqUttKtsAbcSrDs83O9mJUNv5xwpPFNxm1ZsNBNd+Her2GjawdGumubid0k06xs98EFncCbzVuMTzuq4PURhcgt8pzxuWPwxtbJLaOC7XZBLp0g3Qbmb7Jk8tu5Lkk57Ek81R13xRq8/gj4e69FeWtjJqU9lNeIEbZJ5sBfyx84IBbCgEnkr16HE/4WX4ktbXTpdRn8PpcXWn2eow2YtZkkv8A7Q2DBbkynLxgDLYbJYZVRyX77QaFvSvhdqVvrOpWkmoQDRJltmeZrRWln2Xc9wUjPmZi2l0Ukhs5yACOLq/Cq7EV1bjX7f7JeRpb3QOnZkMSXEkyCNzL8jZkYFiGBwCFUiue8VfE68u9KgtLTUNPsr+PE186GRTaPHqtpCFkAbKoY5H3qeSPQHlNR+I+uW8z6pbtbX6W9pdRJLa5WyuVF5axi7CNKBtVXfkyY+VvnCkkO1RhodZefCyK40u4tBqMaNNp+qWXmfZASDezrL5n3uqbSuP4s5yvStXwx4KuNC8VXupxaqF0+481v7Ot0mSJpJHVjI4eZ038HmNI8liTmuc1Dxdqmp/B2/1p7i0s72K6jjS7tJ0MTILiMbz5M0oUFSQyiRj19ar2PxB8S3t3dxaf/Y2pQWNte3YubS2kZdTSAQ7Vtx5pC7mlZN2ZBujOM5qbTa3DQ1bj4XtcQeI4Z9WiZdUt9QtoWFl81ut1OZiSTJ85VmPTbkbehGTBqPwru9S1LVLm+8SPKl3bahaxJ9nf90t0pGSPN8slMjlUQsB82eCOetfi9qz6A9zcyaLDO9xHFBcL5EkbExu7xMi3pVHGwAGSZC27hcgiqGleMvFHiLxBoEltrFjZT6hPYzLYtFIUjV7C6aTcglBdN6Zxx8ypk/LVWn3DQ9T8ReFL7VU0i4h1Ozh1OytZrSSSbT/PglWZUEhEJkG05QEZZsAkHcCa5m6+Ej3VlJp0uuqNMWS8uLdY7BEmSa5jdGLuG2sg8xiEVE6KM4UVnaJ468Saxq2n2tgNKtb3UXhillnjnniTFvPIxSPzVAyYhgAjg8liM1Ho/wAVtW1C+0VJW0Sza8n0+E2EkcjXE6TorSTxNvAEasxQZVuVOW6ApKa0QaGxqPwsvNXvb++1fxBDLeXbPITBp/lxqxjgRcKZGyoNuCQSc7iMjrW1beCLo+FvGOl6hqsEt14keeSS4gsvJSAy26Q8RmRicbN3LZOeT3rO8X+LPEen+J7yy0j+yFs7Z9NhxdQSPIz3k7wg7lkUAIQrYwSeRkdRy1/8XtWsmsoHGlPex3DwXcAgKecq3slvvj3TgqNsRYhVmIyM4HNJKbQaHU6t8LItS057R9U8vfeXt4XW2BJa4QqAQW525Gc/eAxxVS9+FNzqd5qN5quvQPd3jSSMbbTvKjVjHAi/IZGyB5Ckgk7txGRWz4D8Vaxr2vanpuo2ttCdHQwXzxxsoe5Mr7PLyx+TylVyDk/vV54Nct4f8deIXKOq6Z/ZcF9ZWcsUiTyTyfabpodwlaU425BwQ2enyjFC5+4aFzxP8LNX8Q2l9FdeKbe3N+kouRaaY1uhZ9uGAjmVmwEGRK0u7npxh+sfCaXUdSubv+20CzzXRaForhEaG4dXeNvJuYy3zA8k7SDgqSM1hS/EHWtTGkOl7ppujdJLJp9ikyzWjeXP/o1z8xVjlV4yhJU4UgBquP8AFqa8uII9Pv8AQLezaCwNzqlwryW9nLNHcvIsmJFH3oI0ALLhnIJJwKq1RBodn468EyeJtJtrG11FLERWlzZlnt2nyk0DQkj51IIznJJzjHvWZ4h+HFzqN9cT6drg06K4KCSJLdxlFg8rAeOVGBxyMHHYqwri/B/xL8QC58O6XJHaTpOluWe7niWa7EjsHeN5bhHOwcBRFISVIJXIr0nxT4luNI8GW2p2t/pU7SzwwvqRjY2cKPIFaZlDk7VB/vgZ6sBUtTi0g0I/BXgyTwpY3VvJdpqltJY2tsYfswRnaC3WEnJcqQ4QfKcYJOWPblfB/wANtVs9G0++N7Hp+vxTTFVvoFvVjt2jEEULBZFBZYo4+VbGS33gTnj4vEev63byWVprqb7rU442voZLko8T6nLEFiCzqUTAXBU7tmV3YwRc8H+MtZ0jTYFvNUs1kvfsj3Or6tJczW9t5ou2yyPPtQEwog2mNctz/CtVyyV9QOxg+FM1nDa2VjryppkTWUkkctlvld7ZAgw4kAVSFHy7SQe+OK6SfwaT4G0XQLa9jin0lbUwXLW4eNpINuC0W4ZU7egYHng5Ga4W4+KV3NptzZzTabFqk00MUCQCZGkt5LJZWuIw+19vmFwrlQBgDk8nL0vx/wCIfD0GrXd9dW+r2kL2sX2by3NxE82nxPbnJkPySS/ISQMuWYHqFXLN7hodvB8NWEWqNdanbPdag9nLI8OnJCiNBdPcNtRW6MXI5JP8RLkmq1l8LrnTbuG+0/XIBfQymSM3Gn+bFtKyqwKeYCTiXghhjHIIOK9H0/7T9gtv7QMRvPKXzzCCE34G7aCSQM5xkmrFZ+0kOxw8XgNU8G+GtAa+jlXRmjJkktspcBYnjwUDDAO/PU9Me9W/h94VuvCtrdQXOqtewyMnkQIJhDbIq42xiWaVgD6btvAwB362ik5tqwWCiiipGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAD4fv8A4Vzepf8AJU/D3/YF1P8A9H2FdJD9/wDCub1L/kqfh7/sC6n/AOj7CvRwv8MzluHg3/kY/Hf/AGGo/wD03WdHihbh2vEspEiumiIheRdyq+35SR3AOOKPBv8AyMfjv/sNR/8Apus6y/ijM1t4b8Rzpy0WnTuPmI5ETHqCCPwINfO8YRc8HTius4/kzfCu036HmWuaf4ph1jwq/ivXNNubMaxD5UdnYsjmXY+3JL8DG717V7Jpn/H9F+P8jXyx4Rv9BuPFGi/Y71ru9TV7OOGOXUJpgUa33SSBWfGVkJUHp25619T6Z/x/Rfj/ACNfIYijKjjcLCXdfZUd5Lojqi7wkxnizxZp3hh9KivyXuNTu1s7aFJI0Z3IJJ/eOowMevUqACWAL18YeGX06e/XxFozWEEgimuRfReXG56KzbsA+xqPxj4Zj8Tx6bFNcvBFaXEkz7Fy0ge2mgKg5+U/vt2efu4xzkcHD8HZY7CBP7dxf200EkF0v24HbFHLGqPm8LAbZnx5bRgE9COK/REoNas4dTutY8a6BpbadHLqVrNcahLbx21vBPG0komlWNJFXcCyZcEsM8A4z0rKv7zwZ4z/ALJtdT1CzGozR+dbWkerLFdASR5KgwS5YFDztZlI55HNY9r8K5bN7SOz1e2hslu7G9uITZSSs8ltIHAjkkmZkVsYIYuRk4OCQZdG+FiaZpEFl/agmaKXT5DILbYWFpEqbfvHG7aTnnbu707QWzEdj4c1Xw/cQjTPDupaZcJYIIPs1ncpIYFTChSFJK4wBzVZfG3h5LQXV9qtlp1u800MMl9cRwifymKuyZblcg8+2ehBPF/CDw74k0vVRN4isY7O3s9Ig0u3AEQZhG7HrHI+8AfxkR5z/q15zzXijwN4t/sRtI0fTkmE2m3GjSXDmF1MRnLxyYaRTHlWyWAc5BGzhWo5I81rge0WviLRLu/msbTWNNnvYXaOW3iukaSNlzlWUHII2tkHptPpVOXxr4XjZ0PiLRzKsBufLW9iLmLy/M3gbs7dhD56bSD0rEk8B3UMUD6Vq8Ntexajf33my2Xmqy3TyMylQ6/MocANnHy8rjiqOifC2PTdKgs21MStHcWc5lFqFLC3so7Xb944zsL57biOepVodx6m5pvxE8MXulx6lLrGn2NjKsbRy3d7AgYugfbjeSrDOCGwcg4yOa2JfEmhw6hb2EutaYl9cKrw2zXSCSUMcKVXOSCemOtcX4Y+GT6Teafc3mrQ3j2kaxALZeWGC2otgeZGwdq5PrkjiuZsvAXiTSfEWk6XZwJPoVtcaXcS37pEPMNrbpExH7zfHkRjEYRxkk7xkinywezFqevT69pFvq0elXGq2EWpyrvSze4RZnXk5CE7iOD27GotN8TaDqe3+zdb0y83TfZx9nu45My7S2zgn5tqscdcKT2rmPFPw/l13xJJqMWrHTba4iEN0lokyTXKBGXa7CbymGG43REjsR1rOg+GupxXtjqX/CQWf9rWH2ZLV00vZAI4Yp4wJIxLl2K3D8h1AwuABkGbRtuPU7VPFXh57+3sU13SWvbj/U24vIzJL/urnJ6HpXIXd/8AD2bxxcXk97ZtqFqgvLq6/tLFrDJEyxL5qeZ5YlG8AFlyB36UaP8ADAafYCCTVVnm+06dcGb7IFJ+yz+bjG7+Lkf7Oc89KoR/Ca4S2it5NYsLiG0sVsLISadIjRIsyyq7vHOjtINv3lKcnOOuaXIuoj1CxvLbULOG7sLmG6tZl3xzQuHRx6hhwR9Ky4fF3hueC8nh8Q6PJDZgNcyJexlYATgFyGwoPvioPCGlaxolrFYajqaanaQ24C3Mok+0PMZJGbcWZvkCmNVyWbg5Y9a8+8PfC3VJNF0ebVdRtbPVNNiVbOFbFXSE/aFmYTYkxNkoMFSmMk9STUqMdbsZ3Glaj4O8P2cctnrOlwQaxcPcRzy6isn2yUkKSru5LngDAJxgAY6Vs2+v6PctqC22rafM2n5F4I7lGNtgsD5mD8mNrZzj7p9DXn1x8KrqS3vxHr1ss+q29xbak7aaGR0mlMjeQvmDyiMkAsZOxIJArqtL8IQ2HhPVtDMkN1Hfz3kztcQFkIuJXfa6hgWwH2k7gTjt2clHuLU07HxLoWoQLPYa1plzCySSCSG6jdSse3zGyDjC7lye24Z6iqGt+OPD+k217I+p2l1cWkIuJLO1uI3n8s4wwTcDj5gc9MGuRj+GGrxWgWPxXm48m6tFM1rLcRxW86QqyRiW4Z1IMAYFpGGWYbcYAS9+E811pV1pX9t240yYySgHTVadZXjVHPnF8heCQFCtyAXKjBfLC+4anbXHi7QreWQXGq6fFbRKxkunvIVjRg+wocvkMGOOmM8ZzxTrjxf4atrK1vLjxDo8VpdBmt55L2JUmC/eKMWw2O+OlcjB8LVhbTY/7WD2WnSRC2he1yVhjuluEjZt/OAuzdjpg4JHPL+Pvh94iT+1bbwzBHfR61b3kNxK6RbYRPcmYLh5FKbd5+dfMJx9wHBAowbtcNT2PS9Vg1Ga/hiWSOexuDbzRyABlO0Mp4JyrKysD6HnBBAzPEfjPQtAi1EXmo20l5Y2zXUthFPGbnywMkiMsD09cCq2j6brEPirVNTKWsNpfXQWSKQlpPJii2RupU7QWfJOf4cDg8DC8S/DWfWm1mBdXtodO1KWW5McmmpNNHNJB5JIlLfcx2Chu2/bkGUo31YzrX8XeG00z+0n8Q6OunCUwfajexiLzMZ2b92N3tnNUtUvPCWt6xYaffarp1xqNpMt3b2Q1AB94UOrmJXG/CkONwIHDDsaw/Efw6utT1HULjT9d/s+O+uRNLElu4+X7MkG0PHKjg/JuBBxzgqwFUIfhQLXwtLpo1EXM262k3iDymk8ixS1Cbtzbd2wtu527iMHqWlHuLU7RfGnhd7O4u08SaK1rblVmmF/EUiLEhQzbsDJVgM9cH0q1/wkmh/bbOz/ALZ037XeoJLWD7Um+dTyGRc5YHHUV4/oXw48Sa5NPe+IHGi3lstglk0a+XkwRXEbbhbXIbG2fAYSITj7qr8tdbY/DWbT9U0W607VotPSxWJbgWiXSvdKjs5Ri9yysh3EYdXYAnDDjDcYLqGp1uo+KdG0q5uYtY1Kx01YSi+bd3cMasWBIABfIOAfvAZ7Z5rYt5ormCOe3kSWCVQ6SIwZXUjIII4II71yd14KS58cweInvFIinSYWxgzytvLD97d/013Zx2x3yNjwhoo8OeF9L0YT/aBY26Qebs2b9oxnbk4+mTUO1tBmxRRVTVtQtdJ0u81HUJfJs7OF7ieTaW2RopZjgAk4AJwBmpGW6K5b/hONL/58vEv/AITmof8Axir+g+JdO1y6urWy+3R3NqkcksV5YT2jhJC4RgsyKSCY3GRn7pqnCSV2hXQ6/wDD1nfXb3E02qLI+MiDU7mFOBjhEkCjp2Hv1qD/AIRPTv8An41v/wAHV5/8drfopczAwP8AhE9O/wCfjW//AAdXn/x2j/hE9O/5+Nb/APB1ef8Ax2t+ijmYGB/wienf8/Gt/wDg6vP/AI7R/wAInp3/AD8a3/4Orz/47W/RRzMDA/4RPTv+fjW//B1ef/HaP+ET07/n41v/AMHV5/8AHa36KOZgYH/CJ6d/z8a3/wCDq8/+O0f8Inp3/Pxrf/g6vP8A47W/RRzMDiNZs9D0q7htppteknkiefauuXKhEVkUszPOqj5nUDnJ5x0NQpJ4IeC8nTxWzQ2e0XMg8TzlYMnA3nz8Lk8DOKueK/DNzrGth4n2Wt1Ym0ml4YwssqSIdpIyDhwccg7e2cYyfDKS2OlT2GrwxXmmxoIXkst8bOsskm50DgkHzWGAwOcNntWiatqxFuzfwndTamn9salCunnMkkviC5VHjEMMxmU+fzGFuI8twAT9CWTXHg+LXZNJOuX5uILae6unHiK42WixNErCY+flCfOUjI6K3THONe/CK6ls9RjtPEFvbzahbT2k7/2WoTypre1iYJGjqqkG0DA9AHIwSN1T6n8JpNQa7ik1xUszHcLarHZlJYmlvIbvLyrIC4Dw442HDdQfmL93+YDomsfC66KNYbXrsaQV3C9PiK5EGCcZ8zztuM8daztHuvB2qx2nla7fQz3fmG3t5vEVwssqo7oXVfPJZSUYgjtVqDwLJb+FLbTbe/gj1C3v11JbpoZZo3nEm8l0lmd2B5z+9BzyCKxLD4TzWyCCTWraezmuILu7ibTQGlkhmeVAjeZ+7TLAMuGyAcFdxpJx7ga6S+CHs0u08VlrR5vs6zDxROUaXGdgbz8FvbrVvVrHwvo8ttFq+u3dhLcttgS68RXMRlPAwoaYbjyOnrXJTfB65nt7VJ/ERcWwlhittt4tslvKkavEALvzQD5Y480pyRsroPiB4DvvFNha2Fl4gk0zT4rfyJLdYpHVyCpV/llXONuCH3ggngH5qPdutQHiTwSUvWHipitlj7Uf+EnuMQZOB5n7/wCXnjnHNZl3q3hS28P6dq5uteeDUbz7DaoNenVpZPMZMgtcBdvyE53dMdzinn4XNG2mzWmrxR3enmSSBpLIOhka7+0Auu8EgcrgEH+IEdK0x4DdvB+maJJqal7O7e7adLbaHLNKSoTd8o/e+p6UXj3AbZHwXfXNvb2Xih7i4uN3kxQ+J7h2l253bQJ8nGDnHTBp1gvg3UGIsPE0t0QSCIfE1w/QEnpN2Csfop9KxJfhFbyXtg7amWtIbS0tp4Cs6B2t1KpIgjnVAec4kSUAj0JBqWnw11satM76tZxPbW9vb2t2ungRyRiCaB0MQlyGCup3ZAz0XHyh+7/MB0zL4NWaSJvE0oljgFy6HxNcbkhIBEhHncIQwO7pyPWki/4QyaGzmi8USSRXshhtXXxNcFZ5AQCiHz/mYEjgZPNcsPglGIZrc6yJbd4sKJYpyY5TAsLOqC4EOCFPBjLYONxwDW9cfDqca7f6jY6vbRf2hNIbiKfTknAiZom2pubAcGL7xDDkfLlQaT5f5gLMy+Fkm06OHVtUuhfNGI3t9fuZAqyBvLkOJs7HKFVYAgt+JG7/AMInp3/Pxrf/AIOrz/47XB+FvAuoWWnTpJayQG/1+K88uaWNmsrG3m86GIlCQfmXAClsCXBPBNet1MnbZjRgf8Inp3/Pxrf/AIOrz/47R/wienf8/Gt/+Dq8/wDjtb9FTzMDA/4RPTv+fjW//B1ef/HaP+ET07/n41v/AMHV5/8AHa36KOZgYH/CJ6d/z8a3/wCDq8/+O0f8Inp3/Pxrf/g6vP8A47W/RRzMDA/4RPTv+fjW/wDwdXn/AMdo/wCET07/AJ+Nb/8AB1ef/Ha36KOZgYH/AAienf8APxrf/g6vP/jtbqjaoAzgDHJyadRSbbGPh+/+Fc3qX/JU/D3/AGBdT/8AR9hXSQ/f/Cub1L/kqfh7/sC6n/6PsK9HC/wzOW4eDf8AkY/Hf/Yaj/8ATdZ1V8eGIafq5ublrSAWkhkuFXcYl2HLgYOSBzjHarXg3/kY/Hf/AGGo/wD03WdSa24XUZAQ3QdFJ7V89xfCcsFDkTbU09PR+p0YRXm15Hjnw7vvFF01m134VsptP87CavKqWU7xdpTb4JB/EZ9BXsWmf8f0X4/yNUvNX0f/AL4P+FWNPnRLyNn3KBnJKH0PtXwlGNavj6VT2PKuaOyffz0+6y8judNxg0ZXxX8U3/hPR7O80+XS4lefZM988YITaT+7SSaFXbIHHmA46A15tP8AFHXNPu71rBIngvLtp4ZNUZIkH+jWrLbqJriIREmRiQGcjJ+RuTXvH263/wCen6Gj7db/APPT9DX6fGVlqjz/AGU+zPGdZ+K/iCz1bxBDFp2mxLp9tdSpa3E0PnARWxlSU4uRJIjMAMLCBtOQ5xXT+H/G+oX3hrxTfmfSdROlWvnwXljG628j+SZDEQXY7kIAbDDqOFOQO01ZdN1bS7zTtQ/fWd5C9vPHll3xupVhkYIyCRkHNLe/2de6bPYXR32k8TQSJ8w3Iw2kZHPQ9abaa2F7OfZnk4+K2opos00l9oUztJapDfW9u32YSSRyPJbt5k6L5ieWBlpUH7xQQD8tYUHj7xJqWp2eoS61p+mwXK6VM1g8LZCvJMkm0mYAAuuG4/iRc/Llvere4s7a3ighbbFEgRFwTgAYA5qX7db/APPT9DT5kvsh7KfZni3hv4peKNdjijig0S3ubm4tof3nlyGzaRyrJJFHdNIxUdCwh5UgqM8aNx498V2lveTyt4caNptUt7YSo9ssbWkxjV5JHlK4YA8fLg4+bnj1j7db/wDPT9DR9ut/+en6GlzL+UPZT7M5f4b+L4vFGixSXF1bPqJaUFI1SMSLGwVnjVZpgyAso3q7DJ7HiuM1H4k64lzfQ2dz4fF4L/7EmnSW87XFmPt0Vuss+19pV0kLj/V9V2l+a9Vaawa5S5YRG4RGjSUx/OqsQWUHGQCVUkd9o9Km+3W//PT9DSTV72H7OfY8Z1j4s6tpus6xYRPpV69hZ3xbbbGLZcW1u0mWU3DPsZkbAKKNv3ZGwTUHi7xz4r0jWbOOYWlzdWMztL9ijljgaJ7TzC8kRkJk8r5mwGBbaMbT09t+3W//AD0/Q0fbrf8A56foaakv5Reyn2Zw/h/xhq2o+OW8PSRWUiQLJeS3cMbBJbRkT7OyZc4Zmdweo/dNjGRXI+Kfi7qWmeItZsdMXTbmO0jvFRJItrwywxlh5hE28hirf8skBHKs2DXqmn2ekWGp6hqFsGF7flTcSu8khbaCFA3E7VGThVwOTxzWl9ut/wDnp+hpXSewezn2Z5D4l8f+INLuNR0bUr7QrKe3aaNtUa3ljhci2hlSFE83KysZWAO8/wCrJCk8Va8Ua5qun+Bvh5fQ6rHbrctEl49yXJuS1jKwUuJFOWZcDnJdkPba3qn263/56foaPt1v/wA9P0NPm8h+yn2Z4vcfEjxNZaENQRNKWwW8g04PJEWMGbRJjLJJNcxqQS2wBmXkglicK0d98RNa1ObQ7a4u9L0mWXUNJBtYZd896slynmPDJHKUMWAVIG8YJBboD7Z9ut/+en6Gj7db/wDPT9DRzL+UXsp9mc5428T/ANleF01TSLrT2ikuordr6cmW2tlaQI8r7WGVXkH5l56kc15Lp3xS8Q6f5cELafqSXF1dypdzzxxxXh+2SIIYHnuY9gCqCMebgOoxjk+8W01hawiG2EcMQJISOPaoJJJ4A7kk/jUv263/AOen6GlFpK1h+zn2Z5HL8SNelvDbWd14eF5NfCzFi9tO8+n5u0gUz4cBsqxYZMeSBt3DJEbfFPW7PX9as9SttNSHTVulkB8tJVESErP5f2hpmjcgHaIgArg7yATXsH263/56foaPt1v/AM9P0NPmX8ovZT7M8M/4XDrQ02S4eXQRFbXzwS3AEO6aIQxyKYYTeBZDl2B2TOeF+XJIF66+LWvrrGtwwaVZGKzW5KW8zxx3EaRqSk7p55mdGwCVEK4Vs7jgmvZft1v/AM9P0NH263/56foaOZfyh7KfZnnXgPxRPc2/jrVLzWLPV7ewnV47iwVzbbFtI2PlpucgZzkKTk57nFcnp3xh1W8mit31Dw5ZwveJEdUuYf8AR1ie3lkBwlywzui25Mg64KqRivcft1v/AM9P0NU7yPTLy9sLu5G+4sZGlt3yw2MyMhOBwflZhznr60Jrqg9lPseT6d8Vdeub+COS30nzy1ko0hIpReXSzRqzyxEvwqZ38ofl4JBwTn2/xJ8Sa7ocdy93pOlxw6hpzT3CNEfIWScLJDKiXTsoGVyz+XkblKKTke0WkemWl9fXluNlzesj3D5Y7yqhV4PAwoA4xVz7db/89P0NHMukQ9lPszwC1+I/iHSRJdfabOWK5tNPMdvOWcWiO1wHnLTXKbl3IFJZ15kjG4bcN7H4E8RNr+g2U981lHqkkPny29tcxSjyy7okg8t3G1thIwzAcjJINbn263/56foaPt1v/wA9P0NKT5ug/ZT7Ms1yvxW/5Jd4w/7A15/6Ieuh+3W//PT9DWf4ggsNd0HUtJu55Etr+2ltZWi4dUkUqSpIIzgnGQamKadw9nPsdFXIWn/JU/EH/YF03/0ffVU/srUP+h/8R/8AgNp//wAiVZ0DS4dL1W/1K613UdWvbuGG3aS9SFdkcTSsoURRIOszkkgnp6V2Vq0ZwcUQqU09jk/Gmn6fJ4s1abxX4d1LW7WayiTS2trKS6WJhu3om0HyZSxB8w7eMfN8tZGua34ym8Sf2fbadraaWyPa3FtLbGWNUNmxDLKITvPm4G/z85GDHzmvYvt1v/z0/Q0fbrf/AJ6foa5VJrdF+yn2ZxfwasbvT/DNzFf2s9rKbrcEmjKEjyohnB7ZBH4V3tZWqw6PrFk9nq1ta31o5BaC5gEsbEHIyrAjg1g/8IR4B/6FPw3/AOCqH/4ik/ed2Hs59js6K4z/AIQjwD/0Kfhv/wAFUP8A8RR/whHgH/oU/Df/AIKof/iKXKg9nPsdnRXGp4L8Bo6unhXw4rKcgjS4QQfX7lJ/whHgH/oU/Df/AIKof/iKOVB7OfY7OiuNPgvwGwUN4U8OEKMAHS4eBnOB8nqTSf8ACEeAf+hT8N/+CqH/AOIo5UHs59js6K4z/hCPAP8A0Kfhv/wVQ/8AxFH/AAhHgH/oU/Df/gqh/wDiKOVB7OfY7OiuM/4QjwD/ANCn4b/8FUP/AMRSt4L8BOcv4U8OMcAZOlwngDA/go5UHs59jsqK4z/hCPAP/Qp+G/8AwVQ//EUf8IR4B/6FPw3/AOCqH/4ijlQezn2OzorjP+EI8A/9Cn4b/wDBVD/8RR/whHgH/oU/Df8A4Kof/iKOVB7OfY7OiuNfwX4Dd2d/CvhxmY5JOlwkk+v3KP8AhC/ARQIfCvhzaCSB/ZcOAT1P3PYflRyoPZz7HZUVxn/CEeAf+hT8N/8Agqh/+Io/4QjwD/0Kfhv/AMFUP/xFHKg9nPsdnRXGf8IR4B/6FPw3/wCCqH/4ij/hCPAP/Qp+G/8AwVQ//EUcqD2c+x2dFcafBfgNgobwp4cIUYAOlw8DOcD5PUmk/wCEI8A/9Cn4b/8ABVD/APEUcqD2c+x2dFcZ/wAIR4B/6FPw3/4Kof8A4ij/AIQjwD/0Kfhv/wAFUP8A8RRyoPZz7HZ0Vxn/AAhHgH/oU/Df/gqh/wDiKVvBfgJzl/CnhxjgDJ0uE8AYH8FHKg9nPsdlRXG/8IX4CCFB4V8ObSQSP7LhwSOh+57n86T/AIQjwD/0Kfhv/wAFUP8A8RRyoPZz7HZ0Vxn/AAhHgH/oU/Df/gqh/wDiKP8AhCPAP/Qp+G//AAVQ/wDxFHKg9nPsdnRXHxeDPAkUgeLwt4dRx0ZdLiBH/jldKl5aoiojqqqMABSAB6dKTXYPZz7F6H7/AOFc3qX/ACVPw9/2BdT/APR9hW9aXMUsu2N8tjOMGsHUv+Sp+Hv+wLqf/o+wr0cL8BlNNPUPBv8AyMfjv/sNR/8Apus6saz/AMf7/Qfyqv4N/wCRj8d/9hqP/wBN1nVjWf8Aj/f6D+Va1Njowf8AE+RRooorA9MqatqVnpFhNfancx21pEMvJIcAeg9yTwB1NY0HjfQJY712u57c2Vq17NHdWc1vIIFBJkVJEDMox1UGs74oo8droGoNHJLYabq0N3eJGhciIK679o5IVmVjjsM9qwviB4p0LXdB1u30SO11maPQ7+R9RtisiWSmA/KZOcM5AG0HPGSMCqSMZTs2ekPfwLpv29fNktvKEw8qF5HZSMjCKCxOOwGajsNWsr+9v7O1mL3NiyJcIUZTGXQOo5AzlWB46Zx1rwTxjpdnoNj5GkwJax3fg25e52DBuHXy8PJ/ebk/Meeaval5X/CU6kdW2/8ACNjWNP8A7U3/AOr2f2cnl+b28vzNmc8dM0+Un2rvax7dp+rWWoXV/bWc3mTWEwguF2sNjlQ2MkYPDA5GetU5fE+lR+IxoPnyyarsWRoYbaWURq3Qu6qVQH/aIrivgp/Zf2rxp/wj5Q6V/a/+j+Wcpt8mP7n+xnOMcYxjivJfEOhgL8Q/E+hw3EUia5/Z73MDSO8MH/LywAbLbmYZ9ASAQKSjqEqrUU0fVFU9Z1Sz0XSrrUtTm8iytkMksm0ttUd8AEn8BXzHDaTaf8P/ABRf+Cb+/wD7AuLm3t5jb2E0MQiGfNlhDzySkcgNnb1IzgcRR6faL4M1e08NXtzJpHiDVLHSreNbKS3gd9+5pIfNmkc5C4Ytjk4+j5CXXfY+p7K6hvbOC6tmLQTxrLGxUqSrDIODyOD0NTV8y340dvjZbm0Y+ILmXUIoRaOl9aXmlqvGUPyxmNAMnPbHbJr07466zZ6doWm2OsWnm6VqV0Ibmd3nWOFQCRvEJDvk9Fzg49qTiWqujb6HplFfJukTXGifDnTvEWlxNMLTxVJ9itFDhY0aJlChWZmGWxwWJ56k81reAPD97Pr+o+HvEZkn0nw3dTaxqUm8gT3MkKBBkdNpWRgRT5CViL2Vj6D0fxPpWs6le2OmTy3E1lI0U7rbSiJJFIDJ5pXYWGR8oYmpvEmvab4a0iXVNaufs1jEVV5NjOQWYKAFUEnkjoK+ZPDVho/hrQ/hxqGowvawatqUmo3kqRyzAmAv9mjCjdnPmcADJzznFa9qT4i/s8ukqHxR4xe6MbjDfZLYfdPoR/SjlEq7a21PoLQ/EOl67aXdzpd2Jre1ne2mdkaMJIn3gdwHTPXpVn+1dP32Kfb7TffAtaL5y5uAF3Ex8/MMc8Z45rkvhLDYR6b4h/s27iu4pNcvJHMaOoRmcHYQ6jkDAOMj0Jrzu4glik1C5MUgXwAscdvuGdyC5MjY/wC3VIhn/aPalYt1Gkme8wXENx5n2eaOXy3Mb7GDbWHVTjoR6VJXz54n1h9I8PRxNPqdtrN1pkuqqE1VrOMTTySSZRUG+eRSdpTlQAucAlhdgub/AFLTrvUZNa1cXE/iSw04NDfyoiQSLbM4RA2wEmRucd8dM5OUPbdLHuEt1bw3EFvLPEk8+4RRs4DSYGTtHU4HJxU1eEatq2p2DavY22q6kILG61iGEvdyO4RdPSVAzklm2u5KkkkcelT6ld3+j3lvZjWdXGlXVhp11qVxLeSSSQI8zrLIrkkxAgKGK4AGSMYzRyh7byPcKhuru3tFja6uIoFkkWJDK4UM7HCqM9SSQAO5rgfhverd6L4wNjrN5e2UGpzRWd5LK920cYt4SNhJJdQxYjru685yeD0TX72P7BaQa1c37Nf6V515a6rLcwSBrkKyusgDwyOv3otxXA6DuKI3V0R9AUV8+Ta7cCzt5V8Q6oPEj2OqvqtkL2QrbypBKVHl5xFtYfLgDIAPOM1oazLfaZus4vE17awT6Xp99JLqF5cMjStM6sGmUl4EcAAsuAPajlF7byPc6K5L4Xag2o+FRIXuZFjuZollmu/tYkCueY5tqmSPsrEZwOSetdbUtWNYvmVwooooKCiiigAooooA5F/iBo0fjPUvDUwuYrrTrM3txcOgECxhVY/NnOQrg9PxrL0r4q6Xq9lpE2l6TrNzNqs89va2wSFZGMKhnY7pQoUZ7tn2rz/XPhv4n1bxTc38liEt9Svr032LiMObMGEwx53dXEOPbcc4q5ongrW7C+8NNq+g6tdW1hpUu/8AsvUIraRL2eYvJ8wnjO0KccHB9xV2Ry89S+x6TqHjX+z59KtLrw/rK6nqcssdtYhrYyMI0Ds5YTbAuD3bPtTLX4haRcrpaxw3oub6/k002zRqJLaeMEyCUbsAKByVLdRjNc3Np2s2vjvRtXtvDOs3Wm2GlSxQRz38Es6XMsmW3vJOSRtAGQzdQB0xWZo/w815vEdtcaqI0WaPUtQuJ4pAUhvLoLGI1H3jtjA+bGOtFkVzTvod3p3jm11J4JdO0nWbrS57j7NHqUNurwM2SC2A3mbMg/Ps2+9SSeOdITx9F4QH2htUeEzF1QeUh2lthOc7to3Yx0PWuc8K/wDCY6F4Y0XR7bw3Ep0u2Md1JLcxFbrYpCrb7XyGdsEtIFAyeDWFpHgPxVp2p+GNbupLK71A6q17qaQwiOaITxlZMytKVdEG1QqqOOmaVkHPPSyPUNC8Q2utahrNpaRXAOl3ItZpJFAR5NoYhCCScAjOQKqePfGOmeCND/tTV1uJIjIIkit1DSSMQScAkDgAk89BXO/C6HW9Gtry21nw5qMN1qOpXN9cXImtWhQyNkZxMXPyhRwv+NU/F/hPxD4t8U6ldSfY7PTbOyksdPju4ftHntMhEswCSr5bYwgLZ4ycUWVyuaXLotTs7vxVY29/4esxHcTS65uNr5aghVWPzGZ8kYABHTPWodd8WRaZ4htNEt9M1HU9Subd7oRWfkjZGrBSzGSRAOTgVwWg6V4o0/WvB19qvhy9u49H0E2ZW2uLUstyxCtnfKox5aDkE/e+tWNQ0bVL/wCI2oa7qfhvxDJaNp9va2X9n6nFbSIOXlVylyh4dgMZYEjPoSWQueTWx1d342+z6vY6T/wj2sy6tdWz3f2OM226KNX25djMEGTjGGPX14qhd/E7T7fw1BrsekaxcWEkxtn8pYN8Mwk8vy2VpQS27+7uHfNYGoeBdV1rX/EV+TqullNIgstGmXU3E27azusjLIS2HIU7yQeSCeDVm48JX9x4V8BaTaaGmnW1rqEF5qdsk6uIfLDMwyWJcM5ByCx9adkLmnqdhY+LI7jxFa6HcaXqNlqU9q94Y5vJYRRK4TLtHIw5J4xn3xWidf0YasNKOraeNUPH2M3Ked0z9zO7p7Vnabp8h8da1qlzp0kP+jW9pbXbXCOs0Y3u4WMDKYZsHcTuwMYxzx/9g+IoLey0m106RGt9Va7e+zaSWtyrTiTzZBIGmEoXIGwDBOdxwMKyL5pI9Qnmigj3zyJGmQu52CjJIAGT3JIA9zSfaIftX2bzo/tGzzPK3DftzjdjrjPGa8U/4RPxneaZeRa4+q3sqS20zQxXPlLcOl1G7PE5uztxGJMLshXJU8MorsPH/h3V9T1O7v8ARmvI7qDR5Y7N7a78jddbwyK2GG4cdG+T1oshc8rXsd3dXENrA811NHDCn3pJGCqv1JpLu5gs7d7i7miggjGXklcKqj3J4FeQ33hvxrd6hriXUl5PBPJN5a71NvNGZA0SjdckIVUDpCvQgs2cmvpuka94j03UPm1o2s7X8M8s16txHPi6IiWGF5QEKBCCTs47tkUcoe0fY9roooqTYKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA0dC/wCP0/7h/pVTUv8Akqfh7/sC6n/6PsKt6F/x+n/cP9Kqal/yVPw9/wBgXU//AEfYVvT2PKxf8QPBv/Ix+O/+w1H/AOm6zqxrP/H+/wBB/Kq/g3/kY/Hf/Yaj/wDTdZ1Y1n/j/f6D+VFTYrB/xPkUaKKKwPTCiiigAorG8a6rPofhDWtVtFje4srOW4jWUEoWVSQCAQcceorhbzxn4p09dTa6Giyrpq2VxN5cEq+bHcNt8tcyHay4Y7zkHj5RzTSuRKajoz1OivLL/wAd6yPEcWnaZdaHetdXVxZwxQ207CB1jkaIyT7gjEtHhkAUjnBO0mul8GeLJfFGoym2ijTT4LK3eYkHzFupAWaLrgbF25GM5b2o5WJVE3ZHXUV5BYeMvEUtxqtrpQ0yNbSPUbxmvFnnLeTdPGqDMuQCAO+F7LjAHR6H4n13xHrJGkQ6ZDp1rHZyXUd0HMsgnjEjbHU4XarLgFTuORletHKJVUzvKK8b8LeOdXtfBF/JI0V1Np3hxNUjmuS7vLMWnGHbdyv7tfQ8nmrV94n8Qaq+mX0U1taaSniGKweGESLO4Rtrlm34KswPybemDk0+UPbJo9aorzPwR4413xJcWLNYhLTUreWWKQaXdIlkQMx+ZK+I5gw/uFeeBkHNelQiQRIJmV5QoDMi7QT3IGTge2T9aTViozUldDqKKKRYUUUUAFFFFABVbUrGLUbNra4e5SNiCTb3EkD8ejxsrD8DVmigTVyhoukWWi2jW2nRNHG8jSuzyNK8jt1ZnclmJ9SSav0UUAlYxrDw1pllqv8AaUa3c16FZUkur2a48sMQWCCR2CZwPugdMdK2aKKASS2CiiigYUUUUAFFFFABWb4m1T+w/Deq6t5Pn/YLSW68rdt37ELbc4OM4xnBrSrm/iZ/yTfxX/2Cbv8A9EvQiZOybNL7H44/6Avhv/wdz/8AyJUGmX+qnX9Q0jXNPsbS5trW3u1azvHuEdJXmUAlooyCDCex6ivSa89v/wDkqetf9gXTv/R99W0opK6OChXqTqKMnoUtW8XaVpOprYXi6n9qf7iw6XdTLJ8u47WSMq2B1wTjvWpf6ja6e1ot3L5Zup1t4flJ3SEEgcDjhTyeKy/EekXl/qWmXdjJAjWi3H+tLfeeIqvTsDjPI46V5lbfCjXZbO7tp72x06O5mtZT/Z8gUxNHHOkjJthjGW8xDyCSAQWOATnZHXKUk9Fc9srMude0221JbCe6C3bPHGI9jE7pA5QZAwMiN/y+leeWXw91dfFmm6tdPZIkItSUs5kjFt5SBWjiDWzOY2IJKiSMHeQR3Oj4j+Hw1jxw2qS2WkzWE72klwZh+9fyllVkK7CGDB4+rf8ALMAjAFFkPnk1oj0WivH7f4X6tFq2mXEl1BJb2uxYxFOkbWipM7qIi9vI2NrKCFaPpg5GMdT4v8KXer+JINRht9MvI1gjhT7dJIjWTrKXM0WwZLMCARuT7i/NgkUrIanK2x1Fnq9ne6ba39o8k9pclRE8cLsTuOASAMgZ6kgADk4FRReINMl0rTtSjuc2WotEtrJ5bfvDLjZxjIzkdQMd8V59pnwzutObRWtP7NheAW7XzRlgbiSO6SXcTt+YhFYAt0zjgVV0b4aatY3Ghm4TRrl7J9Pdr1pZPOgW3jRHhiGzlGZS4yV5Y5HQh2RHPPserxX1tLf3FlHKGurdEkljwcqr7tp/HY35UahfW2n24nvZRFCZI4txBPzO4RB+LMo/GvPvFfgO51Lxbdava2Oi3UM/2V5oLxmT7T5QlVopMRtlCHjbJzzCgKkYIs3vgm5uPhrbaDPFpt5eQXUd0kU5b7OoW583yQxViFEeYgdv3e2CRRZFc0tdDt9Nv7bU7KO7sZPNt3LBX2lc4JU8EA9QaTU9QtdLsmu76TyrdWVS+0tgswVeACepA/GvLL74WXraaItOlsbW4ltpkvHjOPtbm7imQOTGwZdiSJllbG/G1lJFblt4Iu1+HFx4dkMKyTXCy+W06vEieajsqmOGIKMK2FCDBNFkJSl2PQaK8o1X4bXZeeOystDudO8y7+y6fcs8cNqJli2yoqoQHVkfgAffJDA5rK8QfD3WrODWLm1S2uRc2gimckXFzdviNQR+5EkYyu4qJXHoB1BZdwdSS6Hr+p6paaYm++d4ogjSGTynKKAVBywGAcsMAnJ5xnBxJqd/baZYy3l9J5VtEAXfaWxk46AE9TXk958L7+7guh9k0K2hljuRFpsbu1tbs5tNoUmMcE27sxCjBcYB5NNufhtr91rV5e50W0E6zRlbZtokVnUxhsQhvlCgYZ3HGVC9KLIHOfY9jorgPiN4NvvEl/51rFplwrWT2kZvpHVrGUtkXEO1Wy4+qn5R8w5q5pPg1rLRvE0KyW8Gq6vJcn+0IU/ehZN3lljgHK7s46A5xSsXzO9rHZ1l2/iDTLnV30uG53XyGVWi8thgxiIvzjHAmi787uOhx5lqnw41m80oWVrpvhiwtnYmS3hkd1D+WEEy+ZCybs7sgRq3T95nmt/wX4M1XR9etdQ1G5tZtkU6yGOR2ZmkiskB5UZ5tpCfqvqcOyJ55N7HV2HiTS7/AFWXTrW4ka5jLr80EixuyHDhJCoRyp4IUkjnPQ1PLrWmxa3Bo73kX9pzRtMlsDl9i4yxx0HIxnGe2cGuKsvBOtDxJNcS6zJZ6bBPdT2Is5EdozO+5vkkhIB5bJZpBydoQcDoL3w9cTa1o95FeENaW1xBNdsqC4dnVFWQAJsJG0nkAe2OKVkClJ9DVvtb02x1Sw026vIo7++YrbW+cvJhSxOB0ACnk8dupFWxOhujb7ZPMCCTPltswSR9/G3PHTOe+K5698OXEtz4cmN615Np18bie6u1RZpY/InQKPLRV4aYYGBwD365ni/wZL4h8SwXcws5dOCWyTQTknzBHK7sCuCCCGAwTzyDxRZDvLsdzRXkMfwolSTT0EelC1UqL2MFv36reJKin5fmCwqUAPA4UfLzTL/4U3v2IxaVLp9m7pdRz+WcCeNryOaCJsxsNixIY8FSFzgKykguy7i55fynq+q6ha6Tpl1qGoS+TZ2sTTTSbS21FGScAEngdhUtvOlwJCglAR2jPmRsmSDg43AZHoRwexNeN6l8LNWuNAlskh0m4aW0nt4o725ylg7tu8yDy7ZFGehUIuPUjIqz4w+HHiDV47yKzl0gCWe7uIJpWIkt5JJd6MC0L44AB2bGB5DHpRZdyeeX8p6vY31tfCc2kokEMzwSEA/K6nDD8DSafqFrqCztZy+YIJnt5PlI2yIcMORzg9+leR6v8KdQur64e3TTY7SS7uphDFKkRxKyssmXtpQsigFQVAIABDjkVLqHgq/TXtPsh5so1G7uDqcyxs8bWXmiZVkkKhd5ZSmO4lftzRZBzy7Hq2lalaarZ/atPl8238ySLdtK/NG7I4wQDwysPw9Kt1keFdK/sXRxZbdv+kXE2PN83/WTPJ97av8Af6Y46ZbG469SzWO2oUUUUFBRRRQBo6F/x+n/AHD/AEqpqX/JU/D3/YF1P/0fYVb0L/j9P+4f6VU1L/kqfh7/ALAup/8Ao+wrenseVi/4geDf+Rj8d/8AYaj/APTdZ1Y1n/j/AH+g/lVfwb/yMfjv/sNR/wDpus68u+LXxC1jQPG93p9hHZ+REkZBkjJY5QE5596yxNWNKHNI78ky+tmGIdKja9m9fVHpdFeG2Pxg1iKQfbbGyuI+4QNG355I/SvUfB3i7TvFNq72RaK4jx5tvJjcvuPUe/8AKuWliadV2i9T3MdkeMwMfaVY+73Wp0NFVr7ULOw8n7dd29t58ghi86RU8xz0Vcnlj2A5qDXtXttD0uS+vFldFZUWOFN8kjuwVEVe7FiAPrXQeRdE2q6fa6tpl1p+oRedZ3UTQzR7iu5GGCMggjg9jWfdeF9Hu0vVuLPet6kMc/71xvWEkxjg8YJPTGe+azZPHVhZTww67aXuiPJMYS2oGJI0/dtIGMiyMhBCEcMSDgEDNXbjxbplvqVtaPIClxylyssTRBfJebexD5VdkZ5I54xkZIepF4sqr4E0GC+jv7S0aO+gme5tme5meKCV925lj3hVBLElVwD37Yt+DPDkfhrTLi3Eqz3N3dS3t1MsQiWSaRssQmTtHQAZPAHJqtY+ONGvri6FnN51jbOUm1GN0a0QCJZNxlDYAwwGT3BHbNbFvrWl3NhFfW2pWU1lLIIo7iOdGjdy20KGBwSWIGPXijUFybooWvhDQ7WW6lgsdj3Uc0Mx85zuWZzJIOW4yxJ46dsCon8E+HnvLO5awPmWiQxxgTyBCIf9VvTdtkK9i4JFO1PxnoGnQW00uqWckU8vlB47iMhQG2M7Hdwqtwx7Hirn/CSaHusV/tnTN18M2g+1Jm45x+75+fn0zRqFoGRdfDrwvc2kVrLpriCO1+x7Eu5kDw5LbH2uN4BJI3ZwTkYqxJ4H8PyarFqLWL/aYp0uUAuZRGJUACyeWG2bsADdjJ75q7J4o0CP7b5muaUn2EgXW67jH2cltoEnPy/Nxzjnimx+K/DsqWrRa9pLrdOY7creRkTMDgqnPzHJHA9aNQtDyK2n+C9B066e4srSWKQpJGmLqbbAshy/lKWxFk90CmughjEUSRqWKooUFmLHA9SeSfc80y6uYLO2kuLuaOC3jUs8srBVQDuSeAKzR4o0ApZuNc0vZeErbN9rjxOc4wnPzc8cUasekTXoqi2saYkQkbUbIRlZGDGdQCsZxIc56KeG9D1rGn8e+GIruziOtae0F0krJdrdRGBWj8rKM+7AciZCB3GfbKsNyS3OnopryxxxNK7qsSruLscADrkn0rHXxZ4cayW8XX9INm0nkrOLyPyy/wDdDbsbvbrRYbaRtUVieIvFOkeH2hi1C8hF3M8aRWiyp50m+QRhlQkEgE5JHYGubvPiv4ftdVg00iSW8lWLCR3NqcNITtQkzAE4G4kZUArzllBdmS5xW7O/orCtfFuhTQwGXVdPtp5bUXht5byEyJFt3lztcgqFBJYErgZzjmo/EfjDSPD5T7fcAg795jZT5W2FpfnyRjKocepI+tKw+dbnQ0Vl6V4h0jVbK0urHUbOaK6by4tk6MWfbvKDBOWCgkgc4Bqpa+L9DnvdRs5NRtba6sGkE0NxPGjhEALSbd2dgH8Rx0NFg5kb9FZNr4m0K7ube3tNa0ye4uVLQRRXcbNKASCVAOWAKsOPQ+lUdR8c+GrGHzH1rT5VF3HZOIbmNjHK7bQG+b5cYYnPQKx7UWDmXc6Siua0fxtomsWENzp93DLI8kUb232iETQGR9q+Ypfjntkk9gTxVuHxZ4cntLi6g1/SJLW32maZL2MpFu+7uYNhc9s9aLBzp9Taoqvp99aajaJdafdQXVq+Qs0EgdGwSDhhwcEEfUVYoHe4UUUUDCqWuTWNtomoT6wIzpkVvI90JI/MUxBSXyuDuG3ORg5q7XN/Ez/km/iv/sE3f/ol6ETJ2VzA/szwH/0Icv8A4Rtz/wDI9bvg8eGobu/tfDmjrpNyqRSXMR0iTT3ZGLiNiHjQsMrIAecYNerV57f/APJU9a/7Aunf+j76tZRsrnDRruc1FpGlRXmPjrTo5vEGpyazpMmoRy2kS6ZK+ly6lDAwLeavlRkFJG4w+V7fNxisyK78aaVZLd2mkyfaBa21vJaR224mR4GVXMjbncRyBN2XbCsxPSs+U63Us9Uew0V5noV94zXx59h1OaR9PilaNi9s4jmiEXyyKyW2wOW5IM+OSuwcVZ1M+LJ/Fd0lrqWo2umNqkVnGkVlEypbmzEjzB2jJOJcruJKgkgg8AHKP2ml7HodFeO6Xr3jmaOya8TVo9QJtVFqNLAt5Yii+fLJIU+SQHzCF3L91cKd1F5qPxAs4dBEdzdytc2EVzNJPZnAumPzwyLDayFUUY6+WfmOXOOHyk+2XY9ioooqTYKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDR0L/j9P+4f6VU1L/kqfh7/sC6n/AOj7Crehf8fp/wBw/wBKqal/yVPw9/2BdT/9H2Fb09jysX/EDwb/AMjH47/7DUf/AKbrOvn74+f8lN1D/rlD/wCi1r6B8G/8jH47/wCw1H/6brOvEPiu9tH8b43v/L+xrNaNN5i5XYAm7I7jGeK4czV6SXmj6ngiXJj5yte0JfnE8qrtPg9PJF4+sEjYhZklRx6jy2bH5qPyrqdZj8JWulX81jqmkTTnT7mBYoYWDPK8+9GGVx8q4X/61cj8I/8AkoWlf9tf/RT15Mafs6sFe+qP0KvjFjcBiJcjilGW6a6Puj3nxD4b0jxF9i/tqyS6+xTrcwbmYbJB0PBGR7HIPpS+J9H/ALc0o2qXL2lwksdxb3CKGMUsbh0baeCMjBHcEitWsDxzrNxoWhG8tTbRsZ4omuLpS0NujOFaWQAg7QD6j3IFe8j8mkkk2yjF4W1K513T9V1zWo72WznMsdvDZ+TAo8mSPCqXYhiZCxYs2cAACucf4SpJp1vaPrB2wwJEGFqOStvJEDgsRjMgbHtjvkVR8R9TF1BH9q0GUgwiKKKGbfqoedoy9tlhgBVB6SDOfmK4Y0NU8beJpvD9pPcX+k2C3SW18J4reRRbx/bYonVyZeVIcEn5flDL33CtTFum+h29t4OuDpniSDU72wvbjWpFkkP2Fo4UKxogGwS7j9wHO8HPenReDrlvBF7oV9rM1zcTu0kV3IryfZ3DBo9okkdyEZVIDOT7jjHK6Z4010RySwrp39n2bWnnRypNJNL9ou5ITtkaQ7cBQeQ3pwMYjufinfDSvMs4tPuL6Kx868jj/wCXSb7SkTBwZFChVYsVZlPAyyjmizHzQL/hn4SW2gzIyao9xHHNaSxJJBwnk/M4+91kkJcntwOcU6T4Vr/aH2hNVzHI8huIHW4RHU3UtwoAinjGVMxHzBxwCAOQcwfEzVo00ea7OjLa3ErxyG3kgnmnxIqqY4ku+MgkHa0pBH3a3/iB40vvDurPbWradGI7JbqKG6R2k1GQyMpgg2sMOAoPRvvrxjJo1EvZ22K1j8Nr7S1u/wCydfFvO0UkFrcyRXE0lvHJIHcYa58vJxjKonOD1qO6+FrXTWpl1CzREthZywW8F1BDJCHLj5Uugxclmyzs+Tg4znOxp2ueILvwXrWsoNNlu4muvsNskDqP3MkiAOxc7i2wdAuM964a1+Lmt37XJtrCwt7ZZDcLd3EchjisZJY4oZpAGHPzSO3QYT+HrQrg/ZrdHqGsaPea74evNP1K4t4Z3uPMgkgjLKqxzCSHerH5jhU3jIB+YDArmL/4dXt82ovNrVmr6rbm21DytLVAyeYzgw4fKP8AO2WcyEnB7DFC18ceIdQeWLTp/D7rb297cfbZI5Ft7tYWjVGjbzMIjGTBYs4G04yKyJvixq40yyaBNNaZ5Jo5ruRIEtTIixssSObzyznzD8wlJG0/JkHAkxylB6s2/EHw81JtOuRa6hHepbpdmyshbiJy086TkPIzlWwyYxtUEcHHWjwz4I1S/m1XU/EZitLy8a+RYRbpwtxDbR7yFkcKR9nb5Q7ZD8t1p8XjXxCbgTSRaOlnNc3FnFA+5WieO0e4DPPvKFcoVOFxj5s9q2fhv4x/4SLT2GpXVkdQE3lAW4jWOQ7A5EbJNKJMAnJDZHdRRqCUGzRl0C51DwpqegapcQi2mgNnbzW6EOITCq5cMSN2/fwOMbfeszTfA9xF4ittb1PU7e5vYp1lZYLLyIiFt3hUBd7EH94SWyegAAFY99448QP44v8AQdNtNOR43eGCK6eNZH/c7lmwZ1dl3kDasXTPz5BFZmo/FLWDp1pqNjYWtrp95LJFFNeqqBGjjTejmSeJQTI0iD5sjym4bsrMHKG76HXeJfBU+r6xcXVvqcNtb3b2klzFJZ+a5NvLvXY+9doPQ5DeoxzVXRvh3/ZtxYS/2p5n2VrVsfZ9u7yROP73GfP/AA2988VdE8Y6/earaPeQ6ZFp8+pJprW0as8yM1mJy3nByjAMdvC4I5BpPFHj280/x3b6Dp8lid88NtIksO50Mo+WT/XKxUFl+6jDqC6k0a7BeHxENn8K5LfQpNFOtQvps8CpMTpyNOZBafZtySMx2LtAONpYcgMAcVdm+Ht5fTz3Gqa3FNcTbwxgsTEoBtHtwADIx6Pu5JyRjjPHnnh3xn4i8P6VDNc6nDqD3lhp9xi63MYFm85nmYy3CqQCoQ/Mi5dMbQAp9I8B+J9c8SamVu10y3s4LOGeVIQJnmaRplBSRJWRVxEGwN/3sZ4zTd0TDklZWIvC/hG9s/HU2pXqkWlraRxxEBUS4uiixyTrGGYqPLjjT5jnlu3JZrvw4n1htUil1iCOxu5bm5REsf3sc01u0GWk3/Mqq5O3AJIHzY4rC1j4h6mbu8tDLpXD3SNYxiaO6tRDKFQyOsgPzj5hgLx03DJrSn8Zavc6t/Z01pDEdP1G2tb1182MM8t2qxbCHHBhG8qdwO9QcjIJqO8LWNS6+HiSeLBq8V/tgaW3ne1bzwBJCiqjIEmWPjapw8b9+xxWbY/DG+t5xdTeIluLxBahHktZCn7iYSglDMQN2CCE2LzkAc5z7P4g+IV0rSrjU30OAanaWt4Lr7PIsNikrEMZQZfmAwvO5BlueOa6DT/GGozfDiPxM62M5gupftRgjcI1tHcvG7xgsSCI138k9D68Go17N9PMSD4crCNCC6kB/ZaRJxbY83ZcpPn73GdmO/XPtWZqvgG+0nSdBl0Jlvr/AEeC1t0QQovmeU5JkKtIobO4nYXXnnfmqafEfxCdX0q3m0+wgS9SG4jimeOJ5opZGwFaSdCHWPbnakmWyMLkVnaH4y1TT2lWfVbaCKedY2v9XaSWC2AE7YxvXltoA+YdO/Ao1Jbh2PSPhrpd9o/g60tNWjSK+M1xPJGm3CmWeSQDCkgYDjgEgdia6evEtU+LmuaWbOW80i3+ztbQ6jPtjk3LaviJmXJ6+cRjI+6w4PWvYdFe9l0exk1VYkv3gRrhYlKoshUbgASSADnqTUtPdmtOcX7q6FyiiikahVbU7G31PTbuwvo/NtLqJ4Jo9xXcjAqwyMEZBPSrNFAmrmD/AMIrZ/8AQR8Sf+FDf/8Ax6rWkaDZaVd3N1bNfS3Nwkcck15fT3TlELlVDSuxABkc4GPvGtSinzMlU4J3SMy61/TbS4mguLnZLDNBA48tjh52CRDgfxMQPbviubvviboEWnfarJr28/eQoESxuFLrJMsRdMx/OFJ/hzzherAHQ1fwba6nrQ1F7/UIMzW1xLbQvGIpXt33xlsoW68EBgCPcA1Vm+HumSafaWqXmoQ/ZbdLeGVGjLrsnSdW5QgsHjXqMYzxTViXz9C34f8AFkWrXOpJ5KLDZW8dwZoXeQOGaZSApRWyPJ9Oc8dMkm8deHYhCRfvM00UU0SW9tLM8iSqzIVVFJOVRmIAyBycZGZ/Dvhe08Oy3U2nyXEkk8SRkTuMfI0jjooxzK3rwB+PN+G/hytjpatNeTadq5vpr0T6bIH8kOCiwqZUIZFj2ryg5GRijQLz0OmtPF2h3kSy2t+ssbSwQqyo5BeYAxjp3BH074pNX8XaLpGpLY391IlyTECEt5ZFQyNsjDuqlULNwNxGayLT4c6ZZ3Fq9rf6pFbwS285tvMRkmlh+67koXye4DAewPNUPF3g3WtX8VfabC9gt9JuHs3uk80hmMEu/lDG24kYA2vHjuGxRoJymlsQeKtf8B3kbaje6Ja63dLJDAry6Q8ryRvMI90btEfMRSx5TIJIUcsAV1y38BaR4mOm6t4T0WNGtUujdDSllALSFPn2xnYoIGXYgc1bsfhVoWn211BYSz2qymMxyQ21qssHlzJMu2QQ72G6NOJC+cc+tdBrvhWy1qa+lupblGvLNbGTy2UAIHLgjIPOSfb2ouhcsnq0jjdXHw5s4b8WvhbQ7q6td48s6SsccjI4V1SUxbGKk8hSSMHPQ1f0ew+Gusak1hYeH9De5BlAD6MI1cxttkCO0YVyrcEKTipz8LtBF/qFzGZIzevJIwW3ttyM7bmKy+V5vXPBcjBxjGAJPDPgibTl8+81a8N2kt21usTRtFaiaZnJQNHksV2g79wHzYxRdCSlfVI0/wDhAvB//QqaB/4Lof8A4mlXwJ4RRlZPC2gqwOQRp0IIP/fNdHRSuzbkj2Ob/wCEC8H/APQqaB/4Lof/AImuBd/B1vPE83grRrmK7mmitLe00i3Mkm24WBSXdlUZbJxgDDDJGDn2KubtfB2mRzpLcxm4aC5kuLUlmXyd8omK8NhgJASMjpgdBy0yJQ7I4K5ufBM2j3l1pXw/s5HhtZJXkfSLcx20oEm1Jdpz1jOSmVGRlhkVO8/w+hsraWXwVp0k07zQJHDpVuS8sU0cJVc/3pJVC5PTriuxm8AeGpT8+nNtKsrILmUI+S5yyhsMQZHwSCVzwRgUsvgDw3LcTzSWEjPMGBH2qbau4qxKLvwjbkRtygHKg5zzRdEckvI87sdc+H9tepZ614P0WyvpbmWLyjYWqNDH57QpvBbLklSD5e/oTwuDWt4tg8G6Lfraw+CNHkWGe2S7u20qAwQJK3IPRi20EjCkDjPXFdlZeCdCsZ4JrKC7gmiJPmR39wrSZcuRIQ+ZBuZjh9wyx9TU+qeE9F1XU11C/szJcqUJxNIqOUJKF0VgrkZOCwPBI6UXQezlboed3erfD62SFr/wFa200vklI7rT7KL91IjmOQyO4jVSI3ABYNlcba0NDf4a6z4oudBs/DGhfbITKuTY2pDtGQrjapLrgnqyqGwdpNdTH4C8PxWMtpFBexwShVk2ajcqzoqlVjLCTcYwGICE7Rk8Vo6R4b0zSLuW40yKe38zJaFLmXyMnqRDu8sE9SQoJOfU0XQ1CV9bHnF7ffD211i50o+BNPmv4pEjWK3srCQylpBGMbX+T5iOJNhwfY4jM/gu9bT10jwFppE11bwXEtxpVsEt/MlKFGwcl/lblQyjjJ5Fd1a+AfDdtqKX0NhILmNzIha6mZUPmCXCqXKqN43bQMZJ45OZI/A/h6K7t7mKxeOWCRZV2XMqqXV2dWZQ2HIZ2wWBwCQOOKLoXs5eRwN8PC2neMtQ0y78BaTJZxGOKDyNJti7t5RlkkZi4ARUU8bc+mTxTNO134bayjtp3gqxvrskO1vBYWUsmwoz+YxDlRwjZUsHzxtyRXp83h3SptVOpTWaveE7i7OxB/dmPlc7T8hIxj9azJvAmhvpgsljvRFHzAW1C4YwfIUwhMmVTaSCgIUjgii6D2culjjJNT+GseipqE3hDT47QtIAG0u34KwLMeB6qVH164HNU4Nc+GtzEZLXwPYXKxB2uWt9PsZVtlRkDMzq5Vh+8Q/IWOD6ggdxZfDrw/Ha26Xtq13MlusEjNNKsch8kRM4i37VYqoGQM8DnIBrQPg7RXhkinhurkSQtbs1zfTzOY2ZWK7nctjKg9eO1O6Dkl5HFO/w/hCTXXgW0t9Pecwx38ukW4gfBcb8jJA3R4AYBjuUgYORe8K6J4T1q6uo5PBehW6/Zra+t0k0yFZBBOrbQ4AI3Bo5M4PTH46Ov/DnR9T067s7aNbaK9kT7VvMkw8oS+a0cSs+2Hc4zlRjvgnBHSafpS2mrajfmTfJdiKNVC7RFFGp2oPX5mkOePvdOOVcag76ozf+EC8H/wDQqaB/4Lof/iaU+BPCLBQ3hbQSFGBnToeBnPHy+5ro6KV2a8kexzf/AAgXg/8A6FTQP/BdD/8AE0f8IF4P/wChU0D/AMF0P/xNdJRRdhyR7HN/8IF4P/6FTQP/AAXQ/wDxNH/CBeD/APoVNA/8F0P/AMTXSUUXYckexzv/AAg3hLeH/wCEX0LcMYP9nw5GOn8Nb1tbw2tvHBbRRwwRjakcahVUegA4AqSilcFFLY0dC/4/T/uH+lVNS/5Kn4e/7Aup/wDo+wq3oX/H6f8AcP8ASqmpf8lT8Pf9gXU//R9hW9PY8zF/xA8G/wDIx+O/+w1H/wCm6zrwn4yHb8YnP2hLbDWx8903LF8q/MV7gdce1e7eDf8AkY/Hf/Yaj/8ATdZ14d8Wnkj+NavDbi6lWW0ZIP8AnqQEwv49PxrizL+EvVH0/BX+/VP+vcvzXfQ6n4gi90/wXdxx3NpPbyRgSXl5ZPFLLn+GILCqLn3Yn3rzL4R/8lC0r/tr/wCinrrdbureL/hLxaXWt32o3VvIbnT72IRrZp5iszsSx3FeAu0d/SuS+Ef/ACULSv8Atr/6KevOqy5q8H5r8z7LAUvZZXiV/dk9rXvDtZfLo+mh9H1U1TU7DSbQ3Wq3trZWwIUzXMqxICeg3MQKt1j+LdM1DWNFkstK1NdMmlYB5zCZCY/4lG10K56bgwIGcYOCPXR+cyvbQIfFPh+d7NIdd0qR73P2VUu4yZ8MVOwZ+b5gRxnkEUkHirw9PDdzQa7pUkVooa4dLyMrCCcAuQflH1rlP+Fd3Lfuzqenw2ky2yXUNtphTIgkLIIS0reXxgHO/nJGM1HefC5LjTNNtU1VopLC2EMciRMm5xOswc7JFYDKkYVgechgarQz5p9juTrWljSV1Q6lZDTGAIuzOvknLbR8+dvJIHXrxVe18T6BeeZ9k1zS5/LhNw/lXcbbYh1kODwvv0rHi8FovhBdDe5jyb2K9llCSusjJcJMwIlldvm2YJLnrn2rL1f4ZRalDJG2pNEryX8uY4SpzcypIOQwPylAD/eH92jQbc+iOkvvGXh200b+1G1rTpLNt4ieO6jImdRkpGd2Gb2Bpbfxboz2sM93f2tgs8nlQrdXMSNI2FOAA55+YfL19ulcmfhpdLbzGDWLVL25iube5mktJrgSxzLErHE1w7BwIVAO8rjqtSr8OJ4PMa01e3Dzxy28/wBp05Z1aGQRghVZsBv3fU7lOcFTiiyFep2Oqh8V6I0sEFxqlha3c7skVtNeQ+ZJiRoxtCuc5ZGAxzwQQCCBK3ibQVN8G1vSwbH/AI+wbuP/AEfnH7zn5eeOcc1ytt8OEhgv421ISNdQpEHNsMptvJrnP3u/nBe33Ae+BRg+FSQw3cLX8FzEyOlt9qW7doA0qy9roLnKqcosZyAfqaBefY9Hsby11C0iurC5hurWUbo5oXDo49Qw4NT1h+FdJ1DRtPitL7VTqSoHJklR/M3M7NgO8jEoFIUBizcZLHpW5Us0je2oVHJBDJLFLJFG8sRJjdlBKEjBwe3HFSUUDCiiigYUUUUAFFFFAGJp3hTRtO1eTU7S1dLt2kYFp5HRDI26QojMVQsRk7QM9626KKBJJbFDWtIstas1ttRjd41kWVDHK8To6nIZXQhlI9QRVRvC+kN4c/sH7K66UQQ0CzyLvBYswZg25txJ3ZJ3ZOc5NbVFFxcqYIqoiqihVUYAAwAKKKKBhRRRQMKKKKACsD4hTzWngHxNcWsskNxDplzJHLGxVkYRMQwI5BB5BrfrE8c2NxqfgnxBYWMfm3d1p9xBDHuC7naNlUZOAMkjk0ImWzNv/hXOgf8APXX/APwodQ/+P1z9jpkWiePtZ02yn1B7IaZY3Cx3d9PdbZHlu1YqZXYjIjTIBx8ora/4Tu8/6EnxJ/39sP8A5KrI0+4vdV8aatq9zo99pdtLp9naRrePAzu8clyzECKRwBiZOpHetptW0POw8aiqLmTsZPiDX9XXVdUttIa0gg0yCF5nmsZ72SZ5SdqpFCwYKAOWw3U/LgE1Us/iTpyhZdQfFu9otyJoYiIVPkNMy73IZsqjlQUU/Kc10mteF9J1m6Fzewzi58ryGltrqW3Z4852MY2UsuSTtORyarz+CvDs9obWXS4jbZgPlhmVR5PEeADxgEjjqCc5rO6O1qd9DL0n4laJqXiWLQ0WeG9kYxbZnhBWUJvaNoxIZAQMjO3bkEBjxntqyrfw/p9tq8upW63UVxKxeREu5lhdiMFjDu8sk4HO3Peq15a+KHupWs9Y0WK2LExpLpMsjqvYFhcqCffA+lJ2KXMt9TeornBZ+Ltpzrmg7sjB/sabGPp9q+lJ9j8Yf9B3QP8AwSzf/JVFiuZ9jpKK5v7H4w/6Dugf+CWb/wCSqPsfjD/oO6B/4JZv/kqiwcz7HSUVzf2Pxh/0HdA/8Es3/wAlUps/F20Y1zQd2Tk/2NNjH0+1fWiwcz7HR0Vzf2Pxh/0HdA/8Es3/AMlUfY/GH/Qd0D/wSzf/ACVRYOZ9jpKK5v7H4w/6Dugf+CWb/wCSqrxt4lku3tY/E3hl7lAS0K6TKXXG3OV+1543L/30PUUWFzPsdZRXM3EPiqC3aabxB4eiiiQvJJJpEoVQMkkn7VwAPX0p0dr4sZNw13QGDKCpXR5sfX/j65GKLBzPsdJRXLQR+KrhXa38ReHJQjtGxTR5WAZTgqcXfUHgiiePxVbqjXHiLw5EHdY1L6PKoLMcBRm76k8AUWDmfY6miub+x+MP+g7oH/glm/8Akqj7H4w/6Dugf+CWb/5KosPmfY6SiucFn4u2nOuaDuyMH+xpsY+n2r6VHLH4otjG114h8OxxtIsY3aRKm5icBQTddSeBRYXM+x09Fckj+JHv3sU8T+GGvo4xK9uNJlMioTgMV+15AJ71Z+x+MP8AoO6B/wCCWb/5KosHN5HSUVzf2Pxh/wBB3QP/AASzf/JVH2Pxh/0HdA/8Es3/AMlUWHzPsdJRXOLZ+Ls/NrmgkYPTRphzjj/l6qKKLxVM8qw+IvDkjRP5cgXR5SUbAOD/AKXwcEHHoRRYXM+x1FFc39j8Yf8AQd0D/wAEs3/yVR9j8Yf9B3QP/BLN/wDJVFh8z7HSUVzf2Pxh/wBB3QP/AASzf/JVKLPxdhs65oJOOMaNNwf/AAK+tFg5n2Ojorm/sfjD/oO6B/4JZv8A5KpWs/FxY7Nc0ELngHRpiQP/AAKosHM+x0dFc39j8Yf9B3QP/BLN/wDJVb1ktylpEt9LDNchf3kkMRjRj6hSzED23GkCfka+hf8AH6f9w/0qpqX/ACVPw9/2BdT/APR9hVvQv+P0/wC4f6VU1L/kqfh7/sC6n/6PsK3p7HmYv+IHg3/kY/Hf/Yaj/wDTdZ14T8Y75tM+Mb36IHe1a2nCk4DFVVsfpXu3g3/kY/Hf/Yaj/wDTdZ14j8VHSP44wvLE88az2haJE3s4ATKhe5PTHeuLMv4a9UfT8FW+u1Lq69nLTvqjPvfFmsro+ptr2hTOL+CS2tb+WNo3iR23eXvIxIoxwDyMcHtWR8I/+ShaV/21/wDRT122s6naz6f4lP8AafiXUWvLSZ1tL21IhixIPnGWwAjDbkDiuJ+Ef/JQtK/7a/8Aop68yV/bQu76r8z7ii4PL8S40+T3X3t8PZ7fLR7nvPiHxJpHh37F/bV6lr9tnW2g3Kx3yHoOAcD3OAPWl8T6wND0o3S2z3dw8sdvBbowUyyyOEVdx4AycknoATVy+0+zv/J+3Wlvc+RIJovOjV/LcdGXI4YdiOag1/SLfXNLksbtpkRmV1khfZJE6MGR0bswYAj6V7Wh+ZO+pzl54xvdGvLG38R6Kbb7VcGFZbKZ7xWHkvJlFWISMcptK7BjOckU26+IelQXloRLbyabOokN2JHHlxm3kmDFSnORHgAEnnnB4N+y8HwQ6xbard6pqmoahBL5izXUkeMeU8YTYiKqqBI5+UAknJJrKPwu0NrSG3e41ExwxLEp81QflheIHIXqA5P1A7ZBehHv9Ce18fWs8mq3DWksOjaZL5dzeTh4njHko4JhZBJks+3GM8Z7gVp634pt9O8KS69Hb3MlvGyAxzwyW74aRUJKugYY3Z+7zjjrmo7LwjFbWGswS6nf3c2rMHuLm5WB3yEVBhfL8vG1RwUIqCy8C6dZ+Ep/D9vc3cdtNOLgzR+VG6uHVwUVECIMqOFQDr3OaNB++SJ498OtJHH9snWVvM3I1nOrQiPbvMoKZiC7lJL7RhgehqWLxrocto9xHNeuFdUMS6fcGY7gWUiLy95UgEhguODzVa18B6ZHNezXdxe3099bz215JcOmbhZhGHLBFUA7YkUbQAAOmeayY/hPoken/Y47m4jiMqyN5dpZoJAFZQsirAFkGHbBcMwJyCKNBXqDp/ijpS6nbQW1td3NpNNBGt1HbzMGWWCWZWRRGS5/dhdo5+Yn+EitP/hYGhB1JujJDN5Ytvs1vPNLKXRnx5ax5BwjHjPQ5weKi0b4eaZpF1pktreagyaf5RiikaMqxjhlhUthM/dlbOCBkD3zNo/gPS9K1Gzvbee9aW1cOgd1IJ8uSPnCjtK34gfiaAvadSb/AITvw6ZrKNNQaQ3nkCJ47eV0zMQIgzhSqFieAxB71Jqvi/TNI1Sez1GXa6mFY0gimnmkeQSEKI0jOeImPyluhyF4zx0nw41K01nTodIv0j0CCaxmlWSb95IbZgw3J5ZDMdqgFXQDurEA11fiLwVYa7NfS3NxMhvFgWVfJt5kxF5m3CzROM/vDk4zwMY5yaAnPsaWseItN0i3s5b+S4X7Y2yCKO1lllkbbuwI0UvkAEnjjvUEfi3RZNZXSlupBeM4iAa3lEfmbN/lmQrsD7edmd3tVPVfBGn6j4UsPDzzzrY2aJGheKC4dgq7Rnzo3GfcAH0xUOmeAdP027tHt7/VDZ20qXEdjJMrRecsYjEhO3eTgZxu255xS0HedyaHxtpo8Talol75ltcWtylvHIY5GjlLQJMMuF2IfmYBS2TsyPSl/wCE88PiJ3a4u1ZZY4fKbT7gSs0gYptj8vewYI2CAQcHmpb/AMIWF7NfSST3kb3d6l85ikClZFgWEBTjIG1QfXPOe1ZOgfDLSNEvBdQXd9LP50E7M4hTe0KyqhYJGoJxK2T1OASc5y9Be/c0NJ8a6drHieHSdLWWZHtJ7prlopIl/dyRx4XcoDgmRvmUkApjvxj23xS0trxkvLW9tbVftu+draZiv2eZYySgjyFIbcWPC4KnkHG1oHgy00TV4r63v9QmWC3ltbe2mdDFBHJIkjKuEDHlFwWYnHHpiBfAWnA6nuvL91v4r2FlLR4iS7cSShMJnhgSN2cbj1GMGge+O8RePdH0a11J2NzPcWlvLOsaW0uyby03FUl2bCQMZwTtGScAHD9b8aWejy6KbuC6+y6lBLPvW3leSIIqtgxKhfoxzkDbg59smf4VaLcX93dz3moySXEVxCdxhyiTRtG6h/L3kANlQWIUgYAGQeluvDtvdtp73VzdSzWdtLaiQlAZBIqqzMAoG75QeABknjtRoP33cjtfF2h3epRWNvemSaQhUdYZDCzFPMCebt8vds+bbuzjtWTbfEHTrnSbq4hhuHvILN7026Qysgj2NJHvmCbELoFbBORu796kPwp0GC5ea3eaN3g8ksYLZ5AfKEW9ZWiMitgA/KwXPbk1b1r4daRq+pJd3E1xF5cBt444YoE2J5ZjwJPL80jDE7S5XPbtRoK9Qs2fj/QbiwjnM10szFF+zCynaYsyFxtjCb3XaGO9VKkAnNXtR8T6dZ6fpmoG6t/7PvnO2d2YDYIZJSwwp52xk4baMZ5yApxtc+G2i6zIJbt5zMohVGZIZQojRkHySRshyHOcqeQCMVr3HhWxl0zSbFZJIY9McyQGGOJBuMMkXKBNmMSscBQMgcYyCtBrn6jLrxXaDwbqfiLT4bme3s7SW6VJ4JbUyhIy4A8xAcEfxAEfWm2/jbRZ7F7qOW8bZIsTQrYXDTBmXeMRBN5BXncFxjnNVdK8A6XpvhzW9GhmuDb6vG8dw6pDEVDx+WdiRxrGpx328nk5pNf8A6drc00lxd3sfnSJJIi+U8b7YzGAySIysMHuCQeQRT0C8yebx1oI0qW+tr+KVAF8vckgDs0PnL0QnaUBYsAcYPcEU2Lx94dMrxTX/lSRKxkdoJlhVkj8x1ErIFJCZbGc4GcVSt/hnocC2wSS9/caY2lKTIvMZVlEhG3BkCu6hvRjweMGtfD2xvPD89jbTSmXfPcQ+e2U82S2eD59oB2gPngg55z2o0FeodDoHiHTde+0jTZZ2e2ZVmSe2lgdCwyMrIqnkc9OhrWrkPh/oGsaQ2q3XiG9W6vb6WNsiUSlVRAoywjjBPXgIMe5ya6+pZpBtq7CivEPiF8RdTbWLvTtGn+yWtvIYmlQDfIwOCc9hnpj8643U18TRWqXmqLrKW033Z7kShH+jNwa4Z46MW1FXsfV4XhatVhGdaooc2y3f6H1DRXylY3GrXdxHa2Et/PM/CQws7M3sFHJp1zcazbRwvczahCk674mkZ1Ei5xlc9RkdRWf9oaX5TrfBzUuX26v6f8ABPquivlm8/t+yt4J73+1LeCcZikl8xFkHqpPB/CorW51i7MotJtQnMUbSuIndtiDqxx0A7mn/aGtuUS4QbjzKuren/BPquivk5dS1FmCre3ZYnAAlbJ/WprifWbe8a0uJdQiu1bYYXZ1cN6FTzn2pf2iv5Rvg6SdvbL7v+CfVdFfLpg8ShLxzFrGyzOLltsuID6P/d/HFZ/9qah/z/XX/f5v8aHmFt4ijwe5/DXT+X/BPrKivk3+1NQ/5/rr/v8AN/jR/amof8/11/3+b/Gl/aK/lL/1Mn/z+X3f8E+sqK+Tf7U1D/n+uv8Av83+NH9qah/z/XX/AH+b/Gj+0V/KH+pk/wDn8vu/4J9ZUV8m/wBqah/z/XX/AH+b/Gj+1NQ/5/rr/v8AN/jR/aK/lD/Uyf8Az+X3f8E+sq8lTR9f1B7S3tJr6KCO/uE1Q214bdsteq5PDBuYTkEc7SAMcCvJ/wC1NQ/5/rr/AL/N/jR/amof8/11/wB/m/xprMkvskS4JnL/AJfL7v8AgnqE/h/xhJp1xaXcGsXcr2skFtINWQRIn78FZ1Zj5jMrR4JDHplkwalu9K8bsgs4YdTWCB7l3lj1FE+0RPcQusUZ8zcrCJZUUkKFJ4IBzXlX9qah/wA/11/3+b/Gj+1NQ/5/rr/v83+NP+01/KT/AKjT/wCf34f8E9K03w340ttUsmtzqdjpv2iSURG4W4kiLXTuTN/pKK+6MoCT5x4bgHk73jrQ/EWo+JFk0+K9liEtpLazLeqltbbGJk8yEsNzZ2sDtbgcEYwfF/7U1D/n+uv+/wA3+NH9qah/z/XX/f5v8aP7TX8of6jytb234f8ABPS5dC8ZnTQ0EfiGMx+QRaTaoJmmnEcgmdpFuY2WJiY8BX4Kk+Xg4rovBumeLoPGd9da/PciydpiqK/mW7IzAxKpM5KlBxxCmecs3BrxL+1NQ/5/rr/v83+NH9qah/z/AF1/3+b/ABo/tNfyguB5J39t+H/BPUH0Txtf+KZjLDqlho886+cIdWf7ouQSUPnsyhoifuLGRyNvCkyWnhzxWb/Sl1SHVLtLe7tpI5W1JWihhjuHLeahfMjlfLIbDnA6ggg+V/2pqH/P9df9/m/xo/tTUP8An+uv+/zf40f2mv5Q/wBRpf8AP78P+Cez6t4U1qfxxfXljLfW1ldTLI8keoPGrFLZlTKh87RKVyAOccgiufsdE8bW2j79Wk124jQhpreG+EEnmCFx5qym6kLJv2krmMcAiM8rXnH9qah/z/XX/f5v8aP7U1D/AJ/rr/v83+NH9pr+UHwNLf234f8ABPSLW08eX3h21XTZNQLywtdR38l6ux1ks0Cpgvv3CTd1AAJDAjkiaHw140ktJXe71tZIbeV7SI3pgKTeZEUVsXMpkGBKcu7DDYI4FeY/2pqH/P8AXX/f5v8AGj+1NQ/5/rr/AL/N/jR/aa/lF/qNL/n9+H/BPTPER8U6Hp1zfh9Si1RLtRD9o1QPb6jM8zoscMIJKjy5M7cIMovynbuHbeC7KSx17VoPtE11Hb2djazXErl2muUWQyOWPJJRoc18+/2pqH/P9df9/m/xo/tTUP8An+uv+/zf40f2mv5SlwRNO/tvw/4J9ZUV8m/2pqH/AD/XX/f5v8aP7U1D/n+uv+/zf41P9or+U0/1Mn/z+X3f8E+sqK+Tf7U1D/n+uv8Av83+NH9qah/z/XX/AH+b/Gj+0V/KH+pk/wDn8vu/4J9ZUV8m/wBqah/z/XX/AH+b/Gj+1NQ/5/rr/v8AN/jR/aK/lD/Uyf8Az+X3f8E+sqK+Tf7U1D/n+uv+/wA3+NH9qah/z/XX/f5v8aP7RX8of6mT/wCfy+7/AIJ9h6F/x+n/AHD/AEqpqX/JU/D3/YF1P/0fYV4r+zze3Vx49kSe5nlT7FIdryFhncnrXtWpf8lT8Pf9gXU//R9hXqYSt7anzWsfDcQZc8uxfsHLm0TvsHg3/kY/Hf8A2Go//TdZ14j8UpZIPjnBLBC1xLHPZukKkAyEBCFBPr0r27wb/wAjH47/AOw1H/6brOvCfjJevpnxikvo1V3tWtp1VuhKqrAH8qwzJ2pp+aPU4Li542pFK96cvzR1vjAJa6Fqsg0hrdI7Ca2S8fUY5IT5sxdkXAyz7ww2jpivM/hH/wAlC0r/ALa/+inq14i8ewa3pJsZfDmnRbfMMMiSSExM7bmZQTjJOTVX4R/8lC0r/tr/AOinrzJ1IzrQ5X1X9bI+4w2Dq4XLMQq0bNqXW/R/3pfPb9T6Prkvilb3dx4SP2CW/jljvbOVvsMPmymNbiMuQmxi21ctgA5285GQetplxPFbQSTXEqRQxqWeSRgqqB1JJ6CvZR+aSV1Y8lvdQ8Z2tjDNPf68JJ4LmWNbbSY5iLhZMRQuoiJSMrg7mxnJO9RxVXxbqfivUtA1DR7iw1RrqQ3y3CxaczR+UYmMKpIF2vzgDaxORhj6+q6dr+j6mkT6bq2n3aSyGKM29ykgdwu4qME5IUE49BmrJ1GyW9Fm15bC7JCiAyrvJ2lsbc5ztVj9AT2qr+RlyXXxHk1/c+LZn+2abDqeoPZtcmwnv7D7PKSbYZ3IEUYD5C5UbunzdT0Hh268V33grXXlupBqqq50+Wa2dZQwQEK6yW0IYbh1EfQ9SRmu6a+tFF0WuoALT/j4JkH7n5d3z/3flIPPY5qeN1kjV42V0YAqynIIPcGi5ShrueL6Z4m+IE/9pT3+n6pb2ojlvYFisB5qpI6JDAAUOWjHmO3Bbpw3Q5Oop4v1y1M11p99PfQYitpbi1dQ6i/sZEL4ijONocn92pwjZHymvepbmCKaGGWaNJpiREjMA0hAyQo74AzxUtHN5E+ybVmzyO0uPFt5qOnf8hOxuLiGygvrz+zYvMRhJeecoYxbSgIj2k5ADK3O8ls268YeJbSSOHUdS1C2vIJbOJYY9OjZZ1ku2jZ5zsPlsyKNoGzOcqDnj26qF1oul3epQajdabZTahbjENzJAjSx/wC65GR1PQ0XG6btozyYRa9o19PqqR66t1qOmrOYrezEoglluizqf3TYaNHXj5jhfutjAy72PxjrKWl1Pp11LqkFxCkElxbOqEJfxOjSERx/LtGSdifKCcDBr3ymTzR28Mk08iRQxqXd3YKqqBkkk9ABRzCdLzPKNPm8V32paeEbVdOa7NnFe3jabCJlAivDKCxi24EixAEggblx9/5syTxl4ktbqxj1O+1CG7jutOge1h05GWdJJQsplOwmORhnCgrkcqDnI9sjdZI1eNldGAKspyCD3BqjcaLpdxqkOpXGm2UuowjEd08CtKg9FcjI6noaLjdN20Z5bbXHjXTdV0q2hjktre4WK8lBgkkjeaaVpJ0lZLeQgru2jLxYwDyOmfqGo+L9cs9ZguItfgsTFHcIDYYljdblN0ar9nGfkJOAZc7eGPzCvcajguIbgyCCaOUxuY32MG2MOqnHQ8jijmB03tc8ptJfGEX2p7Zr2zt7RRLHZxabEsdy76hcK4P7vP8AqRGx2kH5gxPJJyrXxFrviDUBozX1/dDVLKdLmAWapDbk3cUTPFKqAuixNL825hnvnhfbJJoo5IkkkRHlJWNWYAuQCSAO5wCfoDWVZ2nh/StTmayg0qz1G7kCSmJI45ZnKlwGxgsxCs2DzgE0XE6b7nlR1HxHrmk6hbxyanf27G7ilgOnLHDCI7oJCIZFQbztUggFuhyFxzci8QeNJtQ1qSNdSt7SGynvIhe2YjVZYZkIhDGBQA8e8Z3ycchgQa9ctbaC0h8q1hjhi3M2yNQoyxLMcDuSST6kmmX9la6jZyWmoW0F1ayjDwzxh0cZzyp4PIouHs33PKbW98WareWOoQNc2keqpBItxDYRM9tbSXEhEe8oeRFsJ3ZALE4qhqXi3xNYNJBqGp39tdWpRYlTT42Fypvpod9wfLIi3RJGVI2BixK7vuj21VCqFUAAcADtVC90XS76/t72902yub22/wBTcTQI8kXOflYjI59KLg6b6MtWtwl1D5sSyqu5lxLE0bZVip+VgDjI4OMEYIyCDUtFRS3MEM0EUs0aSzsViRmAMhALEKO5ABPHYGpNtiWiiigYUUUUAFFFFAHzTbTWlv8AE1JtS2/Yo9W3TbugQTc59sVr67oviJ/EeqzX0ksGlXt+qzXM8xS3uUaX5CPmHmqOD8ucAdsVyPiX/kY9V/6+5f8A0M1WsYI7m6SKa7gs42zmaYOUXjPIRWb24B618/z2vFrqfr7w0pKNaMre6ltfz013+/ppofQlpotpY+IPD8y6Wlpdw65NaiVbaODzIhCxBCoPukj5SxZiBndzXlvxAbZo3gp9qtt03OGGQf3r9aik+Hl6NXTS4tW0qfUGgNyIY/Pz5fllw2TEByAOM5yRx1xzb6Fq6ahHYPpV+t9Iu5Lc27iRh6hcZIretUk48vLb+l/keVluDowqxq+35mlfVW09/XV7e8/LTzPV/HzwT+HdXfUhNp1zquoWs0a3gDxIRFhmiaMv5iBcfMB3C4yKxPhxdtZweLNHtrqzurNtGu7hri3iYGRhGABudVbC5PGAMknmvN7i3mtrh7e4hkinRtrRupVlPoQeQa3dL8Ha1f6rHp8lnLY3EsElxH9sieIOqKWO35cnpUe2lOopKJ0PLaNDCSo1aqs9dlZWS1Su3ol38x3huf8AsPUtN1Gwv9PuLx3CeT5MjPb7uNx3oE3DsQTzWt8QUWT4v6gkihkbUEDKwyCCV4IrnF8Paks11DeWtzZzW9s120c9tKGKAjnAQ4HP3mwvqRVq/wDB+sWuqnT4rZ72ZYI7lzaRvIqI6hgW+XIxnntUJy5OW3U6pRofWPbe0V+Vrps2ne+isv13PSvFW608OazY6ZY2BRfFiwQ2xtowhHllgvQYycDOQcZGQOK8m8SJcR6/qKXtpb2V0s7iW2twBHE2eVUAkADpwTWxrPgfVNLa4jL213cw3wsDbWheSVpDH5gZV25K44z1yDxXPX9jd6dctb6haz2twoBMU8ZRhnpweadeUpfErGeU0KNFfuqilfXazei138u3XcrUVu2PhTWbnU9NsprG4sm1CQR28t3C8cbk9wccj6Zpi+G9R824WSGSOOGOaRZjBKySiI4faVQ9D3OAO5FY+zl2PT+t0L251/V/8n9xi0Vo3OhavbWZu7nS7+G1AUmaS3dUAb7p3EY57etJBpVxcaYL2FWkU3K2qxpFISzsCQAwXZnj7u7d7Y5pcr2sX7em1zKStsZ9FW9S02+0ucQ6nZXNnMV3CO4iaNiPXBAOKmfQ9WS2trh9LvlgumVYJDbuFlLdAhxhie2KXK+w/bU7J8ys9tdzOoq5JpeoRJK8ljdIsU32eQtCwCS/88zxw3t1rVsfB+s3E93DcWklhJbWUt+VvY3iLxxjnbleTzx296ahJ6JETxNGmrykvvOeorSi0HV5br7LFpV+9yIxL5S27l9h6NjGce9T+HvDOq6/fR22n2czAzLBJOYn8qFmOB5jAHbQoSbskE8TRhFzlJWWu5jUVqRaJcSajqNkHXzbFJXkKxySAiPO7G1SQOOrAAdyKZc6Fq9tZm7udLv4bUBSZpLd1QBvuncRjnt60ckuw/rFO6XMtf1M6irum6TqWpiU6bp93eCIZk+zwtJsHqcA4p39j6n/AGeL/wDs69+wnpceQ3ln5tv3sY+9x9eKXK97FOtTT5XJX9e+xQorTl8P6zDdw2suk6gl1MpeKFrZw8igZJVcZIABORTLbRdVuoopLXTL6aOVHkjaOB2Dqhw7AgchSQCe2eafJLsL29K1+ZW9V5/5P7mZ9FaX9g6v/aX9nf2Vf/2ht3fZvs7+bjGc7MZxj2qxr3hu/wBE1GzsblVluruCKeOOEMzfvPuqQQDu7Y9aOSVr2F9Zo8yhzK7V1r07mLRWhfaJqtgIjf6ZfWwlcxxma3dN7A4KjI5Oe1LLoerQ6hFYS6XfJfSjMdu1u4kcey4yeho5ZdhqvSaupL7+2/3GdRW9b+FNVl0/VblrdoZNOkgiltZUdZ2aViqBU29cjvjqMZrKNheC/NibS4+3B/LNv5Z8zd/d24zn2ocJLdChiKU21GSdt/uT/Jp/MrUVqHw9rQu5LU6PqP2qNBI8P2V96qTgErjIBPemJoerSX01lHpd+15Cu6WBbdzJGPVlxkDkdaOSXYPrFJ/aXfdbGdRW1r3hvUNG8Sy6FIi3WoRlFC2oaTeWUMAowCThh2q3pngvV764gt5IHsp5p47dEu7eaMZfO1i2wqBwepyewNP2cr8ttTN42gqaqua5Wrr0fX0OaorWvvDur2WoR2U2m3nnzOyQKIH/AH+DjMeRlh9KpX9jd6dctb6haz2twoBMU8ZRhnpwealxa3RrCtTqW5JJ313K1FXNN0u/1SR00yxurx0Xc628LSFR6kAHAp8ejapLZy3cWm3r2kW7zJlgYom3G7LYwMZGfTNCi30G61OLs5K/r3PQ/wBnL/koEn/XjJ/6Ele5al/yVPw9/wBgXU//AEfYV4b+zl/yUCT/AK8ZP/Qkr3LUv+Sp+Hv+wLqf/o+wr6DLP4PzPyLjf/kZ/wDbq/UPBv8AyMfjv/sNR/8Apus6+fvj5/yU3UP+uUP/AKLWvoHwb/yMfjv/ALDUf/pus6+fvj5/yU3UP+uUP/otanNP4K9f8zTgT/kYy/wP84nnldf8I/8AkoWlf9tf/RT1yFXNI1K70jUIr7TpfJuos7H2hsZBB4II6E14dOShNSfRn6pjaMq+HqUY7yi196sfSXi7Qr7XBpf9na7d6R9ku0uJfs4z9oResbcjg++R6g03x9pdzq3h0wWUEd3LFcQXJtJWCpcrHKrmIk8DcF78ZxnjNeJf8LJ8Wf8AQV/8lov/AIij/hZPiz/oK/8AktF/8RXrf2jT7P8Ar5n58+DMa7+/HXzf/wAiej6hompeJfE+nXtzoVxo1lHc7ppUvEjvJFFvMu52hc4Xc6qArFsZzgcVg3Xh3x3c2enu7XJv7e3TEj3ibkk+xzRuVOThizKNwHUhuxI5b/hZPiz/AKCv/ktF/wDEUf8ACyfFn/QV/wDJaL/4in/aVPs/6+ZD4Kxj+3H73/8AInpXhvRdYtNG8aGGz1KyuL8lrBLy+We4yLZEBMokbB3qcZbjjmjwtpviaz8atNejUJ9NliPmy3tzlIjsXCxKtwysNwPLQq3JO49/Nf8AhZPiz/oK/wDktF/8RR/wsnxZ/wBBX/yWi/8AiKP7Sp9n/XzH/qXjNPfj97/+ROq8TeG/F95qt3PaQaq16kt+0F6upIsIjkjZbdYozJ+7ZQQpO1eckls5GrP4b8Qx+IZLa0m10WZu08m/bV2eGOz8rEiMjSF2l37iGKk8qQwAxXAf8LJ8Wf8AQV/8lov/AIij/hZPiz/oK/8AktF/8RR/aVPs/wCvmL/UnGfzx+9//InR6N4e+I811KuuX2oxWk1uzu1reoZI5o4nhRYwXAxIWSbBIG5RuOaSaPxXp1npOnyXd1aalqV1LpkUct67zyW7xoz3Wwzz7XiKtgq5wG/hyBXO/wDCyfFn/QV/8lov/iKP+Fk+LP8AoK/+S0X/AMRR/aVPs/6+Yv8AUnG/zx+9/wDyJ6j8QdM164uLZdHj1a4tkspY4hY6iLZornK+XLKS6l1AB4y3fKnNO0/QNZ/4RPxTHqkl1c6xfrdRxLJeM8RUqwjEaltkYOfRTzz0AHln/CyfFn/QV/8AJaL/AOIo/wCFk+LP+gr/AOS0X/xFL+0qfZ/18y/9S8Ze/PH73/8AInX2/h7xqurXQnvNVgtjDJHG9m6MgjMG1EUPdBVdWwQwhB3D7+CTVeTRvHI0ez8uDVmurSeUxQtfMBcqUj2tcH7cXX5wwG2SRcZOznFcx/wsnxZ/0Ff/ACWi/wDiKP8AhZPiz/oK/wDktF/8RT/tKn2f9fMn/UnGfzx+9/8AyJ6j8UrLxNqFrZweHILnzPKlZprW8MXlzYUJuAliLL97nLAEDKN0rldQ8N+OCQ1u97BHNNNLKLSVfMWVli2ykLcwhgNr8FmGeqHOa5j/AIWT4s/6Cv8A5LRf/EUf8LJ8Wf8AQV/8lov/AIihZlTXR/18wlwVjJO7nH73/wDInoFt4V1j+39H1bUxql5PBrNxJJ/xMWCR27RyLG4i83YFyVyq5bBIwRxTdW8GX1947muPs+opYTarBePdRag0eI1s5o2C4kDod7KPlAOGGDgccD/wsnxZ/wBBX/yWi/8AiKP+Fk+LP+gr/wCS0X/xFH9pU+z/AK+Y/wDUrGfzx+9//InXppfjwanoGYdQ22ktqs851AMskIk/fB1E6gtsPVo5C3ZgcCul+HWia7o5sv7XuNRm83Softn2y+Nzi8DHft3M2ODj5flOB1PNeV/8LJ8Wf9BX/wAlov8A4ij/AIWT4s/6Cv8A5LRf/EUf2lT7P+vmC4Kxid+eP3v/AORO0j8OeMLXSoRFPq8001ohv0bVS0jyC5QskTM5EbGHzACpUdMkHBpknhzxfc2WqMkut2wFpdDTIG1YmWJ2ceWJGEhDuF34LMwAI5JAI47/AIWT4s/6Cv8A5LRf/EUf8LJ8Wf8AQV/8lov/AIij+0qfZ/18xf6k4z+eP3v/AORPQJPD3ifTdUmuNKm1W6jivplgiudVZ0e1NkSud7nn7ScZILDjHyiqHhTRfF8GvWV7q9lfSWVrcm5jinu1lkTNrMjKC9xJyXKAfOF+bOF5A47/AIWT4s/6Cv8A5LRf/EUf8LJ8Wf8AQV/8lov/AIij+0qfZ/18w/1Kxl788fvf/wAifRsTF41ZkaNmAJRsZX2OCR+Rp1fOH/CyfFn/AEFf/JaL/wCIo/4WT4s/6Cv/AJLRf/EVP9oU+z/r5mv+p2N/nh97/wDkT6Por5w/4WT4s/6Cv/ktF/8AEUf8LJ8Wf9BX/wAlov8A4ij+0KXZ/wBfMP8AU/G/zw+9/wDyJ9H0V84f8LJ8Wf8AQV/8lov/AIij/hZPiz/oK/8AktF/8RR/aFLs/wCvmH+p+N/nh97/APkTOvdQm0nxxdahbLE81tfySosq7lJEhPIqt4n1y58R65darfJBHcXBBZYE2oMADgZJ7dyapObjUb9m2vPd3MhOEXLO7HsB3JPQVqaB4duNS8WWeg3vm6fcTzCJ/NhO6IkZ5Q4P8q8u8p+6tm/xPu+Shh7VqluaMdX15Vq/O2h3EHi3SIviPHqy3xW0TShbiYRPxKLfZjGM/e4zjFTaP4v0KPw/p+n3c0LzNo0tlI9xHNsjkMu4I5jw+1h1KE15/pegyah4gn0uJpnaLzvmiRCx8sMc4Z1GPl/vfTPSp7jwbr1vpwvpbFRAbZb0bZ42fyGxiTYG3beeTjjviuiNarq1Hv8Apc8mrl2XtxpzqtNKNtUnpzKPTzf3ffran4ntH+JNhrT+TeWlpJb7nggeISiMAZCyMzEjHBY5OBnFbui+INL0jxS9+/ima7tpTeypEsE3lwNIp2E7h98kgHCkDH3q4bVPC2saXYG8vrQRwBkV8SozRF13KHQEsmRyNwFJpPhfWNWs/tNhaCWI79gMyK8mwZbYjMGfA67QcVMalVS+HW9+ptUweCqUVer7ijyXvGzVu7Vk9b6W+47e18VaOnhq3tZL3/SV8O3dgymJz++eVWRM4xyAeeg9auax4q0PVLTULKHVvsTSf2fMl0YZcOYUAdOFzuB5GRgkdR1rhLjwXr8Gmm/lsQLYWy3uRPGzeS3STYG3bfU4474q7aeA9QbRNU1HUGFmLO0W7SIlHeRWIADKG3R5HILDnFWqlb4eXp59jlngsti/ae2+10cXq5J2tZ9bfLfubl54utj8V73VbLVFTS5JHaJ57Z5oTuiCHfFlWAOMEgZ4HBrH+IWraRqOs6XPo0hVYLZI5jCZHhjIYkLCsuGCgHphRnt1JqP4J1WS6eHT41uBGIUd3kSEec8YcwrvYb2GcYHPHSqD+GtVj0c6pNbJDZh3j3TTxxsXQ4ZQjMGLD0Az19Kic6rTTju7nVh8PgadSnUp1dYxUUrpXVtLqybbWuvyR6lc+NfDs2oaRd3d7bvdR6pHdyzWUE8KMgXDSTRMCvmYwPkLHg84OKp6n4y0LUtQutT+2fZ5ZdHvdN+yCOQorHIhKcYAcHnpgjnrXL6D4CbU/D1jqbXpEl9d/Zbe2t1hkdiMZJ3ypg9fl69CcA5rN/4QjX3tRdRWO6B45Jo/38QeSNDhiE3bjjHIANaurXavy76nn08vyuM2lWacbx1aXe6V0l93bTqdjqni7SLhNYRL8uk/h+3sYVMb4MykEr04xzyePesbwb4jstJ8N2sD3/2W+i1yK8B+zGbbGImUsVyARkgEbgcHisOHwbrs2mtfx2S/Z1tTetmeNXEA/wCWmwtu28HBxz2zQfBfiDy7R/7POLqSKKNfNTcGk/1Ydd2U3diwANZupWclLl/BnbHCZfGlKh7VWbV/ejula233qxs/EvWdH1WDSF0toTcwib7QLPzltV3MCPLSQAqTyTgAc9+tdLP400NtGtpLq6jutQiexdGtIZraWQRMpIuFOY22gEAhm6jAWuHXwL4gZrhVtLc/Z3WKY/bYMRuxKhWO/AbIIweQceoqK18Ga/dXNxbxWGJ4Jmt2jkmjjZpFGSiBmG9sc4XPGKaqVlJy5d/ImWEy6VKFN19KbbvzK+rvq+23bS3kehjxf4c024uLqLUBfmfxIuq+VHBIpWEq395QNyk9PYYqj4b8S6V4d1i/vJfER1aOS1vDBavBN5CyOysqncAdz4+bCgf7RrltP8Fy3WmvdyzTW23TLjUQJIVIfypAhRcOT36sARjoetZmqeFtY0uwN5fWgjgDIr4lRmiLruUOgJZMjkbgKbrVVaXL59f8/wAzGGXZfPmoqs237ru4620svd6f3de56Kvi3w9Jea863sIbVJ7XUElvY7lhE6nLxMYsOSh5XB29BkUWXjLRr280+4utUj057LXX1CXZayKtzG2PmVV34PBBDN0Y8npXnOk+F9Y1az+02FoJYjv2AzIrybBltiMwZ8DrtBxVgeDNeLWKiyQyX0azQRi4iLtGylg5XdlVwD8xAAxgnNCr1nqo/g+9ypZXl8W4SrWf+KOlo8r3XZa39TU0LW9OtfE3iu7nuNlvfWd9FbvsY72kzsGAMjPvjHeug1TxdpFwmsIl+XSfw/b2MKmN8GZSCV6cY55PHvXm+q6Te6VdpbX0OyV0WRNrK6yK3RlZSQwPqCa2n8A+JEHzaeu7zordlFzEWSSQgIjDdlScjg4xnnFRGpVScVH8GdGIweBlKNapVtdK2qs7Nbd9l950nwu8QaFo1jatqN7HbXcWprcSefFLMDD5e3MaqCqvkkEkA46HgCnXPi/Sob/wZMsv2qHTLu6muY1jYbQ9wXUjcBn5cMPp2NcqngnXpLue2S0haWAqsmLuHajsxUIW343kgjZnd7VDD4R1yafT4Y7BvNv2lS3UyIpZoiRIDk/KVwc7sU1UqqKio/g+6/UieDy+pWlXlWu3v70bfDL525W3v0vseg+H/F+h6HdadBcao2oodTub2S7SGQC3jlhaMLhlDEksGYKMccZpNN8T6DpHhqw06LWFmuLbSNTtjJFBKo86Z0aMLlAecHnjGOcV5jpOjX2rTTRWEKv5KGSV3lSOONR/EzsQoHuTWl/whmvAXxkskhWyZEnaa4ijVC4yvLMAQR0IyDkY6inGvVtpH8/L/IitlWAU/wB5Ws9G1eK/mSurf32tLX06naN4p0W506OwOoCCSfw1DprXTRSFYZkcsUbClipGBlQRWT4m17TLrx14Zvre/N1aWMNlHPctG6ndGRvJBGT68ZrF8P8AhG41zw7qGpWlxGstrPFAIZGSNX355MjsAvToeuasW3gTU7jTpWVHGqpqa6Z9gZQpLmNnzvLAfw/Q5zmhzqzS93+l/XqOGHy/D1JP2rTV002tOZLXa+1tfh/E7O28c6JBe3FzPcvcr/wlTajGnlMT9nMbKJBkYGMrxweOlR/8JjpEbvp326yFvNZX1vHd2ttcgWzzspDM0rNI2dvIVRgscbq8/tPCet3kVtJbWLSJcTSQRkSJy6DL554AHOTge9Z+r6VeaRdLb6hD5cjIsqFXV1dD0ZWUkMD6gkUPEVUrtaegQyfATnywqNy7JrpdXtbpr+T7HqHgnxnpXhWHVBdavJrMr/YUjaSKUDYhcSCItyAitlS23noBXI+G7nRdN+IDzXeoSz6WjzeVeASDflWCM4ADkHI3AdcnqKxtF8O6prUUkmnWyvFG6xl5JUiUu33UBcgMx7KMn2qSbwxq0GlNqNxbJBaLI8RM08cbb0OGUIzBiwPYDPX0qfaVJKPu6LVbm0cFg6VSqva2lUSjLWKe1lZJKzsm1p1em1vR9V8Y6KdHubeDU4HnOgHTx9mtpIkMvm5KqCowu3oTjjrzUGteKtE1XT9QsItU+yS3Fpp+LxoZcF4Qd8Zwu7IJyDjBI6jrXktFDxc3ukOHD+HhZqUrp36b3T7W3SPSNV8SaTP8bIdejvC+krcwSG4Mbg7VjQMduN3UHtVvwf4s0mxe5bUL4q0mvxXwJjdsxDeWbgH+8OOvPSvLKKlYmSlzebf3ms8loTpKi27KMY9No7dN+567YeLtK0qOCC31uG5ll1S5vjcTWUssUUckZQRyK21juzltmce/fH8YDQ/Eks13pl6Lf+zdMVnSNZXt2cPtEUXmbSi4YdQBnoO586ooliXJcrSsKlk1OjUVanOSl8tdbu6svTy3Wp23hXVdP/4RO40i61L+yrn+0ob4XJjdhIiqQU+RScg/MM8Z7itD4ieLdN1/Q3j052ikk1ee7NuVI+RkVVcnGMn5jjOeTXnNFT7eXJyGryqi8QsS27p36Wu1Z9L9F106WPUv2cv+SgSf9eMn/oSV7lqX/JU/D3/YF1P/ANH2FeG/s5f8lAk/68ZP/Qkr3LUv+Sp+Hv8AsC6n/wCj7Cvbyz+D8z8x43/5Gf8A26v1Dwb/AMjH47/7DUf/AKbrOvn74+f8lN1D/rlD/wCi1r6B8G/8jH47/wCw1H/6brOvn74+f8lN1D/rlD/6LWpzT+CvX/M04E/5GMv8D/OJ55Wt4U0f+3/Een6V5/2f7XKI/N2b9nvjIz+dZNdX8KP+SjaB/wBfS/yNeHSSlNJ9z9Tx1SVLDVKkHZqLa9UjeuPhxptxNqVj4f8AFMWpa1Y799g9k8DMUJDBWZiCRjtx71w2naJqupwyTabpl9eRRnDvb27yKp68kA4r2XSvDOo+FfiVq3jDxCkVjokFxdzpK86EzCTeEVVBJyd2cHBrb+GMb2/hrwzdRXNxdWk1xIZQl7HbQWjMxwjKMNKxJACtnn0Fd6wsZySa5d/u0s9T5SWf1cLRc4zVVWjZuy95qTlG8Uotqy00ettXZP5/sdF1W/i82x0y+uYzJ5O+GB3G/GduQPvY5x1pg0nUTqR04afdnUAcG18lvNzjONmM9PavYdd1G/0TwN4zl02eexnbxVMm+FyjBSFPBHIzgfhXSzzmTxtqKWk8UHiHUPDcX2OVyFLSndkA9icKfw9qhYSL0vr/AMP/AJHTPiGtFOfs1y621fTl1em3va27Hz3eaNqdjEst7pt7bxtIYleWBkBcdVBI6jHSi90XVLB4EvtNvbZp/wDVLNA6GT/dyOeo6V7/AG8k2n6Z4BHjS7inuotSlWaSSYS7H2SBN75IJVimTngjrxVfx7e3EWmW9rqmlQ2puNWhe1abWXvJXw4PmRoVO1CuRjcuM9PVvBxUXK/9WIp8SVp1Y0lTTTb1TVnaTV1ezdrXdk9H0PI/DngjVNT8RWGmaja3ulR3cjRC4ntHAVlQtjB25PHTNc9e2pttSuLRCZWilaIELy5BxwPevZNf1nVZfj9Daq93e29pco0NkkigD9yC20MwUHBbkkZrydbiTT/FAubyI+bbXnmSx5BO5Xywz0PQ1hVpwhou7V/uPTy/GYjEP2lS2tOMlFd25fPay7djs4vhxp9vcW2m674ss9O164A22It2lCFh8qvICApOR1/DNcddeHtQi1+60e0hbULyB2UiyBm3gd128kfy7167eeE4/EHja88SQabaeJPDmooHEn9pfZvsrYXJfB3ZUKw24784xWn4UXQbLVvGem+D7eK8nzbm1toNSe3eZFQbxHPktw24nBx0HSul4WMmlayv53f+fy+48ann1WjBzcnUlyptWgoxbaTTaacbX2n2vzWPIvCngjVPEF5qtssM9tJp1u80qvA5bePuxY/vtzgH0PXFZ3hrQpNY8U2eizO9nLPP5Ds8eWiPOcqSORjpxXu9tql3e+PtX063WGz1RvD7xeVa6i026cEeWGcqv71QTzzgHr1ryT4eRXUPxX0uLUCxvUvys5d958wEhstk5Oc855rOdCEXBLW7s/vO3DZtia9OvOdouMFKK0bWj17NXWnQxPEXhy/0S8vFmtbprKC5ktkvGgZI5SjFcg9OcdMmqcmj6nHpq6hJp14lg2MXLQMIjnp8+MfrXslxqd1qmi/FODV7me6tLO9jEMTtkRKJ3GEH8PCDp6V1/inVEi0vUr62060m8OSadsju5tZdIJFK4EaW4VlD9hwM+ueKr6pCV5KVl/wWvu0Od8RYmk4UpUlKV0m7pJ+7CWl7avm2XbRdvCtX8F3dpY+HptPM+pXGr2puRbwW5LRgYyOCS3XrgVg3+k6lp0MMuoafd2sUwzG88LIHH+ySOfwr33wf/wAhz4af9gef/wBBFc74qGr2Hwt1qHxlfpd3l5fxyaaWuFmLKGBZ0wThCu7A7ZxgZpTwseVyX/A2T/G5WGz6t7aNCdnd27Sd5zjokre6opvyPMdE0WLUdG1m+kubiJ7CNHSOOzeZZNxPDOvEfTq3X8KhuPDmt20M8txo+pRRQY815LV1Eeem4kcdR1rsvhx/yTz4h/8AXrb/APoUlesz6xqC/FbWbIXc32K30Fpo4N37sPlTu29M8nmlSw0akItu1/8AN/5GmNzuvhcTVpwipKN3q7aKNN2Vl1c3vf7tD5xl0HWIbu3tZdK1CO6uBmGFrdw8o9VXGT+FObw9rSm3D6RqKm4cxw5tnHmsM5VeOTweB6V7Z4SvrrVNJ+G15qNxLdXZ1G6UzTMXcjD9Seew/Kql34l1lvh/46vP7SuhdQav5UMokIaFC6jah/hGOOPU0fVYW5rvv+CYv7dxXtPZKnG6ai9Xu5ygrabaX/A8X/srUP7S/s77Bd/2hnb9l8lvNzjONmM5xz0ptxpl/bXwsriyuor0kAW8kTLISeg2kZr6PS7th46vN8STazeeH7c26G4Nu87ZfeqyjlWPy8jnj2qp/a9vH8RfDFvrdpZadqMVnNHHu1FrySJ3A2JK7KPm++B8zfe9xmngor7XW34mMeJq8npRvaHNuv5b6Ldq+l7fPoeRweArtfCt1q+ptdafNb3kdqbOazYOQ+35+SD/ABdMc4rL1nw1c2/ie60fR477U5IQrDFjJFKwKhiTERuXGcc/XvXsN3aeI7H4cXcHi27NxfDWbdlDTiVkQyJjJBOAeSB2B6CtN7OaXxz4/nsrm7e5UWo+wWdxHbSTL5SfMZW+ZFGf4SPfPAqnhIuyStt69f8AIyp8QV4yqTnJSS5rWa5d6aWtr/aeraXd9V4x4X8C6vrt7qlqbe5tJdPtmnlSW3feWA+WMLj7zdgfQ9cViWuhavdm4Fppd/ObYlZxFbu3lEdQ2B8pHvX0dfXFzN4+uYNOmaOS/wDCpNuI7nKyzh22FXzhmAY4brgk1S8DzXSeENLgsLH7bqVneTrqm7WGtTBMJCWklK581T77uMcHnD+pQb5b9yf9ZsTGDquCd+Wyula6d222tLqy13st9H4tpng+fUvBU+u2kss1wl8LFLKKAu0hKq2QQc/xdMdqwotLv5prqKGxupJbVWa4RYWLQhThi4x8oHfPSvXtV1YD4f8AiLVdNW3hZPE6zx/Z5DJHvCxnKttXIJGc4HWpviJcWOleFNT1zTJFE/jAwlFHWOIIGlH4scH/AHqylh4Wunsrv8f1sd9DOcT7TklC7nK0fJ+62nbsnJ3/ALrPMvGHhn/hHINEk+2faTqVjHe48vZ5e4fd6nP14+lc5XafEc3z2vhR720lto10aCKEu6N5gG47xtY4BDL1wfauLrlrJRm0lY9zLqk6uHjKpLmeuqt3fbQs6dfXOm38F7YytDdQOJI5F6qRXQ6J4snHj6x8SeIJZruSOZZJmRV3MAMAAcDpjjisHR9Pm1bVbTT7ZokmuZViRpW2qCTjk10dl4KmT4jW3hXU7iISGdY5ZbZ9w2ldx2kjrj1HXtVU1U05drr0uZ4yWE9+Na3NySv/ADcnXzt+pa0fW/D+jeJ5NXt7nVbnzRcK0T2Uce3zI3AwRM2cFh2HGfpW9rnibRtMjs7i1mkvNRm8MRaaY4ijQxsyYYuwbIZf7mPTkVzukSaBrPifS9MXw+ltHLqUUQkjupcvCXClZAxOWI7oUx6VtHwDYyeIrd9Pu45rCXW5tLeCeBwsTKCwAKyBnXHGdyniuiHtHG0LPX+tzxsSsJGqpYrni1HrbVK+nu3S69rlPxT420/WfCrafJFdXt7+6EE95BEJbUL94echBkz05VeOuTVjwH440fw9pmnxTw30NzA1x9o+ywxsLoSLhC7Fgfk7L0PB60268E2NxpGmXUb/AGGGKwuby/nRWlZ9k5RQqM+MngYyB6msjx5oNhYaj4cttCXct9pdtMXJYebK7MC5BJ25wOBwKG60H7R26f1/XoVThl2Ip/Uo3s3J+SaTT8ttUt/tPXU1JPHGmv52ILz5/DC6KMov+uGPm+99zjr19quSeOfD13caveXsGqC41azt7W4hSNDHH5ewNtO8FgQvGQMH65Cp8PrD+zdc06zuft2vW19aWYldGhSF5GIbHzEMvbJAPynj1yrX4dnVLqCLQdUF2hv20+d5oPKMTqpfcAGbcm1WweDx0p/v1pa/9NGUf7Kld8zjbrqtLRl20TsrXs21p5vtvGmnXsYXXEvkMGsNq0TWqK3mbiCY2yw29BhhnA7VneMPFsXiLRbWHyJIbsX91eTDA8sCVgVCnOTjB6gVuRfCm5mvIFjurpbea1luI0msvKunMbBWQQu4GfmUglxkH8Kof8IDbwnWXvtXmgh067gtc/YG3yeb0OxmUjHp0PUE8ZmUa7Vmt/T1N6NbKY1FUpzd46pWlpd8u1ure3f0F8KeMtP0jTvDlvcw3bPpupyXspjVSGRkAAXLDJ474HvV608e6ZDeaLK0F6VsrG7tpAEXJaUsVI+bp8wz0/GmaR4W0OPxPD4U1ffJqa6uYnubcsC9uI+FKk7Vy2ORlhz6DOFpPhm11vxpfaTa3r2tpF57rNJDuIWME4K7vbHU0J1YpJW3t81b/IUqeX1pTnNSS5XJvWzjLm1Vu/M7dTuzqukHRLrWLjUbYXtz4YOm+RFPGwEuAoXbu8zdwMjZtHPzGqF38TLG41KC/CXsTTXNnNeW0VpbKuIWVm/e48yTlBtBK45GSOKytE+Gkut6bBe6bd3ckd6ZRZFrA7W8sc+cyuRFlgVH3s4qHU/h3JYeHLPVWvZZBcLA4KWpaEiU4wJFY8rxneqDsCTircq9rpWX9f5nLCjlXtHCpU5pXslZ6a6Lbo479GvUgTxZZDTPEFu0dyZNR1SO+jO1cBFdmIbnryOmR711ll8StAg8QXOprbalbvJqJunaGGMvcxFAojdi4K7Tk4GQenGc1g3nw0L3uoWWi6r9tvdPvILS5SW28lR5p2qytubIB4IwO+M94rL4fQaje2semawZrZtROmXEr2uxopNpYMq7zuQ7TzkHjpSi8RF2S/LuzarHKK8XKU3a2vxbOMd9NLpK19+mpOvjjTF0k2vk3rSf2Reafu2IAZJpt6t977uOvv2NM8U+NtP1nwq2nyRXV7e/uhBPeQRCW1C/eHnIQZM9OVXjrk023+HUd4dPlstYD2UxuRPNJbFGh8jlyF3HeCOnI6jOKz/Gej6Tp3h7wtdaSZHF7DM807qVaQrJgZTcQpA4wDjjqetTJ1lF821v8v8AP+ma0aeWyrwVK7lzN7PR+83e6VtYvRav/Cza8B+ONH8PaZp8U8N9DcwNcfaPssMbC6Ei4QuxYH5Oy9DwetQ2fjuyt/EmmXv2e4a1h0VNJnDRozAhNrMqklWGecNjI61N4m8DaTa3lxJaX1zbaXp+nW9zdyvAJJGeXAQKu8AlieRlQMd65278KJZ+L9O0i61FFs78QyQ3qxZBjlA2MUyMdeRnj3olKtBKPb+v0FSp5ZiXOsr3mm3dPbd9N/evbV2atpYTxJ4iXUdZ0ue2lllgsI444zPbwwD5W3HEcK4Vcn7uWPua9O1bXtB0WTU9TTUEu2v9Xsr7ybaaKU4jbe4UK+cDnlwhyQMcZrhYvhzcBraO7v1tp5JbvzEaLIigt+HlznnJBAXHPrTI/Acdzpkup2WqNJpx0yfUIXe22SO0LqjxMu8hTlhyC1ODrRu7av8Ay/4JGJjl1dU4KpaMdNE7P3r2va28Xt5lvRPHFjbprUF2lxHFeakNRhmS0guHHzHKlJflU4PDDJB7GtPT/F6x+DPEd7fzxPqFzcStpu6eNp1MwKSlkTG3CjOdqgk8da4TxToP9g/2R/pP2j+0NOhv/wDV7fL8zPydTnGOvH0rDrL29SDszuWVYPEx9pT2bTv6dO+trPyv3Ok8K63Z2Ol65pWprcLaapDGhmt1DyRMjhlO0soYdiMit3xN43sdV8Pajplvb3UYb7HFas4U5igQrmQ5+8c54yPevPqKzVaSjyr+v6udtTLaFSr7aV73T36q2v8A5Kl8vU63w3rOjw+E9U0XWDqEf2u5hnWW1iSTaEzkEMy9c/17YPUt8TrJ9Vlv2srnc2txagIxtx5CQmLBOfv4wcYx715TRVRxE4pJdP6/Uyr5Phq85TqJvmv172v9/KvuPV9L+IOh6RZ2tnaQahNCJrszSTQRAhJxwVQsysV44bg498Dntc1PSvEFvdy3N3eE6dYxxWAaG3tw8nmfMvlRrwuGJABOMHLcgVxNFEsRKS5XsKlk9CjP2sL83frvd/fdrTozr/DniDTIfDiaRrK3qRwaimpRS2iK5dgoVkYMy4BAGG5I54qXxx4xi8T6VbRiCSG5W+ubqRcDYFkK7QDnJIAOeBXF0VPtpcvJ0Nv7Noe2Ve3vJtrybVn94UUUVkd4UUUUAFFFFABRRRQB6l+zl/yUCT/rxk/9CSvctS/5Kn4e/wCwLqf/AKPsK8N/Zy/5KBJ/14yf+hJXuWpf8lT8Pf8AYF1P/wBH2FfQ5Z/B+Z+Pcb/8jP8A7dX6h4N/5GPx3/2Go/8A03WdfP3x8/5KbqH/AFyh/wDRa19A+Df+Rj8d/wDYaj/9N1nXO/Ev4VW3i/Uf7TtL02WoFAj7k3xyY6Z5BBxxnnoOKvH0Z1qXLDe5y8KZlh8uxzq4l2i4tX36p9PQ+XaK9ck+A/iQORFqGjsvYtJID+Ww0z/hQ/if/n/0X/v9L/8AG68T6nX/AJWfqC4kyt/8v4nk1Fes/wDCh/E//P8A6L/3+l/+N0f8KH8T/wDP/ov/AH+l/wDjdH1Ov/Kw/wBZMr/5/wATyat3wh4o1DwrqMl3pogfzYzDLDcJvjlQ9mGR6etd5/wofxP/AM/+i/8Af6X/AON0f8KH8T/8/wDov/f6X/43VRwuIi7xi7mdbPsorwdOpWi4vdHFeLPF994kt7O2ntrCxsrTcYbWxh8qJS3U4yef/r1zdes/8KH8T/8AP/ov/f6X/wCN0f8ACh/E/wDz/wCi/wDf6X/43RLC4ibvKLJoZ7k+HgqdKtFJHk1Fes/8KH8T/wDP/ov/AH+l/wDjdH/Ch/E//P8A6L/3+l/+N1P1Ov8Ays2/1kyv/n/E8mor1n/hQ/if/n/0X/v9L/8AG6P+FD+J/wDn/wBF/wC/0v8A8bo+p1/5WH+smV/8/wCJ5NRXrP8AwofxP/z/AOi/9/pf/jdH/Ch/E/8Az/6L/wB/pf8A43R9Tr/ysP8AWTK/+f8AE8mor1n/AIUP4n/5/wDRf+/0v/xuj/hQ/if/AJ/9F/7/AEv/AMbo+p1/5WH+smV/8/4nAeEPEd34V1yLVdPjgkuI1ZQs6krhhg8Ag/rWMxyST1PNesf8KH8T/wDP/ov/AH+l/wDjdH/Ch/E//P8A6L/3+l/+N1TwuIa5eV2M1n2URm6qrR5mkm/JXt+bPJqK9Z/4UP4n/wCf/Rf+/wBL/wDG6P8AhQ/if/n/ANF/7/S//G6n6nX/AJWaf6yZX/z/AInk1Fes/wDCh/E//P8A6L/3+l/+N0f8KH8T/wDP/ov/AH+l/wDjdH1Ov/Kw/wBZMr/5/wATyaivWf8AhQ/if/n/ANF/7/S//G6P+FD+J/8An/0X/v8AS/8Axuj6nX/lYf6yZX/z/ieTUV6z/wAKH8T/APP/AKL/AN/pf/jdH/Ch/E//AD/6L/3+l/8AjdH1Ov8AysP9ZMr/AOf8TyaivWf+FD+J/wDn/wBF/wC/0v8A8bo/4UP4n/5/9F/7/S//ABuj6nX/AJWH+smV/wDP+J5XaTfZrqGfy4pfLdX8uVdyPg5ww7g9xW14t8U3viie1e8htLaC1i8m3trSLy4ol77VycZ+td1/wofxP/z/AOi/9/pf/jdH/Ch/E/8Az/6L/wB/pf8A43VLC4hJxUXZmMs9yeVSNWVaPNHZ9rnk1Fes/wDCh/E//P8A6L/3+l/+N0f8KH8T/wDP/ov/AH+l/wDjdT9Tr/ys2/1kyv8A5/xPJqs6de3Gm39ve2UrQ3MDiSN16qwORXqH/Ch/E/8Az/6L/wB/pf8A43R/wofxP/z/AOi/9/pf/jdNYOutVFilxFlUk4yrRaZxo8YSxXtveWmj6PbXMV2l40scDlpJFbcASzkqpPUJtBqez8fapaSRvHBZEpqr6uNyP/rmXaV+99zHbr711f8AwofxP/z/AOi/9/pf/jdH/Ch/E/8Az/6L/wB/pf8A43Wio4pbJnHLM8ikrSqRfq2clD471OOKCFreykto7aa0eF1fbNHI5dg+GByGPBUgjFZ/iPxLd67e2F1LDbWr2NtHawLaqyqqISV6k88/oK73/hQ/if8A5/8ARf8Av9L/APG6P+FD+J/+f/Rf+/0v/wAbpOhimrNMqnmuR05+0hUinr367/ec3c/EbVpUujDa6fa3N1cQ3U1zBG4keWI5V+WKjPcAY68DJqE+P9ViurafT4LLT/Ju2vnS2Rts0zDaWcMzdQSMDAwTgV1X/Ch/E/8Az/6L/wB/pf8A43R/wofxP/z/AOi/9/pf/jdP2WL7MzWYZAlZTj+Pa35aLt0OLXxXsu1li0LQ44VjKCBLdgAS27eJN3mhgehDjA4HHFWNT8e6tqUV7Hcx2pS6lglICt+78kYRVy3T1zkn1rrP+FD+J/8An/0X/v8AS/8Axuj/AIUP4n/5/wDRf+/0v/xul7DFbWZX9qZE2pOpFteb73/NLXyOEn8U383jH/hJdlumofaBc7VU+XuGOMEk449aTT/E1zp/iC61eztbSOa4SVGiw5jUSKQ2Mtu7k8k13n/Ch/E//P8A6L/3+l/+N0f8KH8T/wDP/ov/AH+l/wDjdL6vib35X3NP7YyTl5faxtbl67djh7LxXc22iw6ZNY6dexWxlNq93CZGtzIPm2jO088/MGweauWvje7g042EVlYWsM3lrcy20TI8yoQeV3eWCcDJCgnHJrrP+FD+J/8An/0X/v8AS/8Axuj/AIUP4n/5/wDRf+/0v/xumqGKW0WRPNMjnvUjvfrve/56+uu5ieJ/iJcXWs6hceH4I9PhubuO7abyyJ5THygk+ZlwDzhQM9881Sj+IGpQXtpcWdnp1qsF21+0MSPsnnIxvfLk9CeAQBnpXUf8KH8T/wDP/ov/AH+l/wDjdH/Ch/E//P8A6L/3+l/+N1TpYpu9mZQx2QQgoe0i0lbW+ulte+m3boclp3jvVdPhsooIrMx2s08u10YiUTDDo/zcrj0wfes/xF4jn1uz020e0s7S209HjgjtlcAKzbjkszE89+vrmu9/4UP4n/5/9F/7/S//ABuj/hQ/if8A5/8ARf8Av9L/APG6l0MS1ytOxtDNcjhUVWNSKkvXrf8Azf3s5N/Hd/KWFzZafPFLZx2NzE6ybbhExsLYcYZccFdtZWqazLruuJe6rK0CfJGPs0efIjUAKI1LDoBwCw+teg/8KH8T/wDP/ov/AH+l/wDjdH/Ch/E//P8A6L/3+l/+N0PD4mWjiwp5tklJ81OrFPb+vuXySWyMLxP8Qrq/8ZxazpoYRW9v9ljjuVGJUIIfeoOPmLMSAfTnjNUIfHeoQSIkNnYR6clnJYjT1WTyfKkOX/j35JAJbdnius/4UP4n/wCf/Rf+/wBL/wDG6P8AhQ/if/n/ANF/7/S//G6p0sU23ZmUMfkEIRpqpGyVlv5/jq9d9X3ON1rxjc6wpW703SuLGPT4isDEwxoxKlCWO1ucE+nauYr1n/hQ/if/AJ/9F/7/AEv/AMbo/wCFD+J/+f8A0X/v9L/8brOWGxE3eUWdVHPMnoR5aVaKXzPJqK9Z/wCFD+J/+f8A0X/v9L/8bo/4UP4n/wCf/Rf+/wBL/wDG6n6nX/lZt/rJlf8Az/ieTUV6z/wofxP/AM/+i/8Af6X/AON0f8KH8T/8/wDov/f6X/43R9Tr/wArD/WTK/8An/E8mor1n/hQ/if/AJ/9F/7/AEv/AMbo/wCFD+J/+f8A0X/v9L/8bo+p1/5WH+smV/8AP+J5NRXrP/Ch/E//AD/6L/3+l/8AjdH/AAofxP8A8/8Aov8A3+l/+N0fU6/8rD/WTK/+f8TyaivWf+FD+J/+f/Rf+/0v/wAbo/4UP4n/AOf/AEX/AL/S/wDxuj6nX/lYf6yZX/z/AInk1Fes/wDCh/E//P8A6L/3+l/+N0f8KH8T/wDP/ov/AH+l/wDjdH1Ov/Kw/wBZMr/5/wATyaivWf8AhQ/if/n/ANF/7/S//G6P+FD+J/8An/0X/v8AS/8Axuj6nX/lYf6yZX/z/ieTUV6z/wAKH8T/APP/AKL/AN/pf/jdSQ/AfxEZAJtR0hE7lJJGP5FB/Oj6nX/lYnxJla19uip+zl/yUCT/AK8ZP/Qkr3LUv+Sp+Hv+wLqf/o+wrI+Gfwzs/BU0t69297qUsflmTZsRFJBIVcnngck9u3Na+pf8lT8Pf9gXU/8A0fYV7uBoyo0uWe5+WcUZjQzHHuth3eNkr7XsWtU8FeFdXv5b7VfDWiX17LjzLi5sIpZHwABlmUk4AA+gFVf+FceB/wDoTfDf/grg/wDiaKK6z50P+FceB/8AoTfDf/grg/8AiaP+FceB/wDoTfDf/grg/wDiaKKAD/hXHgf/AKE3w3/4K4P/AImj/hXHgf8A6E3w3/4K4P8A4miigA/4Vx4H/wChN8N/+CuD/wCJo/4Vx4H/AOhN8N/+CuD/AOJoooAP+FceB/8AoTfDf/grg/8AiaP+FceB/wDoTfDf/grg/wDiaKKAD/hXHgf/AKE3w3/4K4P/AImj/hXHgf8A6E3w3/4K4P8A4miigA/4Vx4H/wChN8N/+CuD/wCJo/4Vx4H/AOhN8N/+CuD/AOJoooAP+FceB/8AoTfDf/grg/8AiaP+FceB/wDoTfDf/grg/wDiaKKAD/hXHgf/AKE3w3/4K4P/AImj/hXHgf8A6E3w3/4K4P8A4miigA/4Vx4H/wChN8N/+CuD/wCJo/4Vx4H/AOhN8N/+CuD/AOJoooAP+FceB/8AoTfDf/grg/8AiaP+FceB/wDoTfDf/grg/wDiaKKAD/hXHgf/AKE3w3/4K4P/AImj/hXHgf8A6E3w3/4K4P8A4miigA/4Vx4H/wChN8N/+CuD/wCJo/4Vx4H/AOhN8N/+CuD/AOJoooAP+FceB/8AoTfDf/grg/8AiaP+FceB/wDoTfDf/grg/wDiaKKAD/hXHgf/AKE3w3/4K4P/AImj/hXHgf8A6E3w3/4K4P8A4miigA/4Vx4H/wChN8N/+CuD/wCJo/4Vx4H/AOhN8N/+CuD/AOJoooAP+FceB/8AoTfDf/grg/8AiaP+FceB/wDoTfDf/grg/wDiaKKAD/hXHgf/AKE3w3/4K4P/AImj/hXHgf8A6E3w3/4K4P8A4miigA/4Vx4H/wChN8N/+CuD/wCJo/4Vx4H/AOhN8N/+CuD/AOJoooAP+FceB/8AoTfDf/grg/8AiaP+FceB/wDoTfDf/grg/wDiaKKAD/hXHgf/AKE3w3/4K4P/AImj/hXHgf8A6E3w3/4K4P8A4miigA/4Vx4H/wChN8N/+CuD/wCJo/4Vx4H/AOhN8N/+CuD/AOJoooAP+FceB/8AoTfDf/grg/8AiaP+FceB/wDoTfDf/grg/wDiaKKAD/hXHgf/AKE3w3/4K4P/AImj/hXHgf8A6E3w3/4K4P8A4miigA/4Vx4H/wChN8N/+CuD/wCJo/4Vx4H/AOhN8N/+CuD/AOJoooAP+FceB/8AoTfDf/grg/8AiaP+FceB/wDoTfDf/grg/wDiaKKAD/hXHgf/AKE3w3/4K4P/AImj/hXHgf8A6E3w3/4K4P8A4miigA/4Vx4H/wChN8N/+CuD/wCJo/4Vx4H/AOhN8N/+CuD/AOJoooAP+FceB/8AoTfDf/grg/8AiaP+FceB/wDoTfDf/grg/wDiaKKAD/hXHgf/AKE3w3/4K4P/AImj/hXHgf8A6E3w3/4K4P8A4miigA/4Vx4H/wChN8N/+CuD/wCJo/4Vx4H/AOhN8N/+CuD/AOJoooAP+FceB/8AoTfDf/grg/8AiaP+FceB/wDoTfDf/grg/wDiaKKAD/hXHgf/AKE3w3/4K4P/AImj/hXHgf8A6E3w3/4K4P8A4miigA/4Vx4H/wChN8N/+CuD/wCJo/4Vx4H/AOhN8N/+CuD/AOJoooAP+FceB/8AoTfDf/grg/8AiaP+FceB/wDoTfDf/grg/wDiaKKAD/hXHgf/AKE3w3/4K4P/AImj/hXHgf8A6E3w3/4K4P8A4miigA/4Vx4H/wChN8N/+CuD/wCJo/4Vx4H/AOhN8N/+CuD/AOJoooAP+FceB/8AoTfDf/grg/8Aia0NE8J+HNBunutD0DSNNuXQxtLZ2UcLshIJUlVBxkA49hRRQB//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_14_39146=[""].join("\n");
var outline_f38_14_39146=null;
var title_f38_14_39147="GC chlamydia nucleic acid tests";
var content_f38_14_39147=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70321&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70321&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Screening for gonorrhea and chlamydia: Nucleic acid amplification (NAAT) and nucleic acid hybridization tests",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Manufacturer",
"       </td>",
"       <td class=\"subtitle1\">",
"        Test name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Test method",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        NAAT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Roche Diagnostics Corp.",
"       </td>",
"       <td>",
"        Amplicor",
"       </td>",
"       <td>",
"        Polymerase chain reaction (PCR)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Abbott Laboratories",
"       </td>",
"       <td>",
"        Abbott m2000 Realtime",
"       </td>",
"       <td>",
"        PCR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Becton, Dickinson &amp; Co.",
"       </td>",
"       <td>",
"        BDProbeTec ET",
"       </td>",
"       <td>",
"        Strand displacement assay (SDA)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gen-Probe, Inc.",
"       </td>",
"       <td>",
"        Aptima, Aptima Combo 2",
"       </td>",
"       <td>",
"        Transcription mediated amplification (TMA)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Nucleic acid hybridization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gen-Probe, Inc.",
"       </td>",
"       <td>",
"        PACE 2",
"       </td>",
"       <td>",
"        DNA hybridization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Qiagen (Digene Corporation)",
"       </td>",
"       <td>",
"        Hybrid Capture 2 CT/GC",
"       </td>",
"       <td>",
"        RNA hybridization",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CT:",
"     <em>",
"      Chlamydia trachomatis",
"     </em>",
"     ; GC:",
"     <em>",
"      Neisseria gonorrhoeae",
"     </em>",
"     .",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_14_39147=[""].join("\n");
var outline_f38_14_39147=null;
var title_f38_14_39148="HAS-BLED risk score";
var content_f38_14_39148=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F75259&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F75259&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical characteristics comprising the HAS-BLED Bleeding Risk Score",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Letter",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical characteristic*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Points",
"       </td>",
"       <td class=\"subtitle1\">",
"        HAS-BLED score",
"        <br/>",
"        (total points)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Bleeds per 100 patient-years",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        H",
"       </td>",
"       <td>",
"        Hypertension (ie uncontrolled blood pressure)",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1.13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        A",
"       </td>",
"       <td>",
"        Abnormal renal and liver function (1 point each)",
"       </td>",
"       <td>",
"        1 or 2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1.02",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        S",
"       </td>",
"       <td>",
"        Stroke",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1.88",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        B",
"       </td>",
"       <td>",
"        Bleeding tendency or predisposition",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3.74",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        L",
"       </td>",
"       <td>",
"        Labile INRs (for patients taking warfarin)",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        8.70",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        E",
"       </td>",
"       <td>",
"        Elderly (age greater than 65 years)",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        5 to 9",
"       </td>",
"       <td>",
"        Insufficient data",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        D",
"       </td>",
"       <td>",
"        Drugs (concomittant aspirin or NSAIDS) or alcohol abuse&nbsp;(1 point each)",
"       </td>",
"       <td>",
"        1 or 2",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        Maximum 9 points",
"       </td>",
"       <td colspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * \"Hypertension\" is defined as systolic blood pressure &gt;160 mmHg. \"Abnormal kidney function\" is defined as the presence of chronic dialysis or renal transplantation or serum creatinine &ge;200 &micro;mol/L. \"Abnormal liver function\" is defined as chronic hepatic disease (eg, cirrhosis) or biochemical evidence of significant hepatic derangement (eg, bilirubin &gt;2x upper limit of normal, in association with aspartate transaminase/alanine transaminase/alkaline phosphatase &gt;3x upper limit normal). \"Bleeding\" refers to previous bleeding history or predisposition to bleeding (eg, bleeding diathesis, anemia). \"Labile INRs\" refers to unstable/high international normalized ratios or poor time in therapeutic range (eg, &lt;60 percent). \"Drugs/alcohol use\" refers to concomitant use of drugs, such as antiplatelet agents and nonsteroidal anti-inflammatory drugs.",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      Based on initial validation cohort reported by Pisters, et al, with insufficient events at HAS-BLED scores &ge;5 to give rates; actual rates of stroke in contemporary cohorts may vary from these estimates.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Lip GY. Implications of the CHA2DS2-VASc and HAS-BLED Scores for thromboprophylaxis in atrial fibrillation. Am J Med 2011; 124:111. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_14_39148=[""].join("\n");
var outline_f38_14_39148=null;
var title_f38_14_39149="Survival after transplant COPD";
var content_f38_14_39149=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55546&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55546&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 497px\">",
"   <div class=\"ttl\">",
"    Actuarial survival by procedure type for adult patients with COPD",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 477px; height: 277px; background-image: url(data:image/gif;base64,R0lGODlh3QEVAdUAAP///4CAgAAAAAAzmf/AwP8AAMDAwEBAQP+AgICZzEBms8DN5qCz2RBAnyBNpuDm8/Dz+f+goNDZ7BAQENDQ0FBzuXBwcDAwMPDw8P9AQGCAv//w8HCNxlBQUKCgoCAgILCwsP9QUDBZrP9gYJCm05CQkP8gIP8wMLDA3+Dg4GBgYP8QEP/Q0P/g4P9wcP+wsP+QkE8jaZ9TeZ8TOaBzmZ9jiZ8jSXBTWe4jKaCDqe+DiSAjSY92o0BNZp9DaQAAACH5BAAAAAAALAAAAADdARUBAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t3EGFEQgASUpQ72/uMTFnxQBAgdDFgIXExPAzc/RxtbXlQcCykIYAhMAJQIW3uDiFkIGAevsBtjv8IMG3ADzy/b29fTq7AEHPQviCRyYJ5++e8ryGTQSYEcFghAjwjFIwRkAEAI6VLxwMSOSADcGQJBIsmQZCuIuGMAA4IMAEB0EeGj5MubMI+tiMDDJsycX/23bBLijcOEbOgBEjSZZJ+Ohz6dQ3azTITKq1atl1r3QibWrVy7rNsxw+rWs2SjrAOCoerat248BAIzg+rZu3bQEaJC1y7dsWgAQ2PYdjPUvgAo7CSuOapjB3sWQSxoOPDKyZYmGDye+zFlgZsedQ8PLTFm0aWOZASjg8eK0a1upGQywseG17VipAciucbt3q9y6B2z2TbwUcAA5hBdfPuo4AR8DaLBgTr3TcSGyZ5wgUL37pevYB8jg7r28JPDhh5tfvwh9evbwFbl/H78+ofn0hbyIYL+/HvzYNVBBZS+YYAJ//iU4B4BCQMBBAyQMEYGBrSloYRsMDrGAAwo8IP+hCzBMd+GIZ2Q4BAQJNJDAEASEsMIKIZBH4oxfmEiEBCKIIAERLMAgI41AamFjESkmUFmQSIIVFxYPKOBAQElGicWQR5DQAAdHSqklFFQeAUEFDajHIoJblilEl0ig4IADYhJwggkI1GamlmgmwcCaUBLR4gojtDBnlHUqcacCeQ7Rwggw/vgniYEuMWihQmyAgAnbLTpjo0ykSOgREShqaYKYMoFiA5t+imSoTYxaqqmXLpnGqBV4mMR+rIZmwK23AkMBrivB1caoGshqRIEH1npZUNvEBdQ27uDkKhvAClvEhMUauxiuE8gEgDYl3MqSs3E8oMEAwSJBbQRyWjv/mAcCfCCENhcccFM9/fjz7BvikistERFkUECM6vbl0k0WBGBBtiCkU+8B98KRb7lHbNBpwHax624RyTR8psYOa6BilhRD5EGzICRcBQbZzvuBBQcL5Sse4n4cckQMC2HBMlUkw9EQMbU7L0Mcz/EAmEY2QQC6M8cyD7IeqYEqGAsoILMSLf6LdNKsUHDABB8ccIBGazwdRtRTJyFxCFanizUqI78hthhkr8jE2f96urYoGJTAzs8lBq1H1Gw6IbHdd4OyLD1pvF0G4GIW/oozuO7itN99bBi447FcQDkZiqNx5+VQHO0n5plY8MHeYW/+x+dFO1H1CQiISDolh+Oc/7jqgJDNwb5LvDCCgSNUODsku0ae+iMSjKvBjlCwgMAJdQ/vCAY3U9CBybdH8sCDqz7RwsTSM9KzASp0cLwkKK7ZePiYCFDCAerYjkbndLAOMvuWvAT/1+dbojvvTzia2vDHBxVAY2D9u0TyyMW8KFQtBFcjoB4wEJMJHGVynNgeqSAluAigDYIDlOAcUuAODPQKg51IH+iiQDeAiZAOFzAfBj6gggR2wn5UGNwL6eAyAPjDhp743w4RMYESCKED5kPhKBa4vCEWQgXOKArfzEA/Qmiwe1UQoBPNgAEoWpANVSyECtcXwA9GcItfoIDkMIQ7T+CwCi08Ixq14DW3tf/xE0K0QgsJN8cpgGBnbIQFExsIR/D1EQu1AyIrrsjBQ7LhZl47wAXnd0dSjNGRcDChJhUJizdqQYuYXAK7hHKBSfaNGHnEwgPlGMohfOACH4gfJ2cxSC3EMYSYFAr8bjZLWjByC3tspRBoqLkvKtEalwSmIUOJkW1U45jYYIAIHNA6YXIBGcPoZTEWUAF9hQGUThQGMLRpjJhh8ZNmxGX4muHMNVKSJBAggfruh4VbSjAjBgDBBJKYPZMwQGoJAGA9PRg99qnkTPI7ZU8WoDxCcmEDI8gAH+92s3V4LQBTHEMYVfEATaHgCwRAAOEI4COsHW4bCeVcJeEBgc+RgJ7/YCDACKB3ghGUVF3F45U7s7JSgaBAartLA0lnWoCaTtSaGxWk8hpZBpIeVZhJjcWoREDGNYhOejk9oTiX0lOSeNINr4sd6Q7njmlAY5xAqws3GwAxOPgOeMILEvmaRQVueasc4RjHy+oSswowdQ3Og54LaVQRZez0CfCS10EWS69+1KwvyZTD957qH3VktAkFaxkIFLKPhXU1KtIsWx5IKjtTZWwjHeEnxj5rFYYyUA8yNUEBMoCAF6izN0xDqRVW1jJ3uAQm2gKXZa74UT1s4AUI8JcJRiBSUWyAANAtbRNYkAEyAYC61j2CCzKAhkh615RR6NkHbpIUYwr3MvGc/2cfetTcUBCgAPAtgAmkS7UCIEBP9l2CvzYRVYj8VEUC9cNVL/Fe7hLgRbVhQURdUJsWNNfB0C2ACyLamvfeFwD9ygAMirBfCAMAwg5+wXYvDFHatlcK1oskeHnqGib+dQ9hpe8jCiyEERQABi1YAex0DAAL99i+74UT9FjgYxdIGG0bHsJ+fWzh9852BQXgD/QmnN8pFCUoKWXxazpKqqru4a3LjasjaAwABNgXBgVojZGJnN8m5/cFQM7vCuBkZu4quQA/vq+b7wtnkRZgBHmmgkwEAAAVsDZnh35LS9f00kIEtqCNILONI2Bm7lSayXHWc6YBIF8EeNq6S27zpv/3HOgpCCWWvISmbcjW1kFMdsZFDWlRr1s3E6yA1itIbpxH4KYCsPm+aBMppYmwXxYUINf+8rOm4yRfAhj5wlI4HRSb1s/i5MuvM76pIJx87BHIaUJFFZGRlxtnKK+APz6GqLmhDYD9AmDcNlZ2oCMA5WRTQY0U7MC3qr2c9FE10kStqbaJ0amqifkJJwykd0Ib1EjDIOC8xoWNO10FbagAe6qmTvK6HAmnXsUDV/6AETNenZaK4EoBnrFIZSwQrSHunfXZuAK8vAhnZ0C2JsiACyhbhhboHADPJU8LCHDbSBFgdECn9NWgy3QiDF3cGUA6FkDuzJHzOz4mRzkmiJz/ARPzPAwZWEFtnLzhSlMt2EOAnr9OIIT4wncIG1B7pHK+BYtj/Or2cW0FimuJkHr66yCNshCcLHazD53pBBBRfC8M5xAAAG2tgW/ThWDk2UqoAIBXQsLBmOjepJeaKcdESAseBiOzaLb/MruZ3W7nMlfZzPeFPadn60ILW34IEp5SCjzQj8tqtPPE0TvfOxHSrstWvl0/8RW6fnoE2NhfR5W962Of3xA4/9gt2IAJdn57ITD/CrpEVpZVGqTPB5QU0KV05pPw/TxvAMqYx3DX5++CIUgfzfU3cpK9j3luw7f17VcFK5FVh6VlSCJ88YAozed68ed3noYACCJTf8Yd/y3QbLI1dLBjY2IXdGh2ArLDJ1pQAndHcjOiQo12DREQf6UmWxPldniGYTjHHy0APeGGX633XtlVce1iAWiFd0mCAt2kAS/2CQP2BJQSBze3BRRgAVdWQySIJB3FaDDlCXtyAjvnOn/2Bja2fkqAAR6gDeP3e58ChOQyhJzgbCeQKJvATvhETlEShQ5wgqXwPQ/IhYVwABfgAfv2hGbyU69lCn5nh4SgC3YUMBpEVVO4HHUkFcA3I//EVg5FHX9UiElziAyQiKBwNI+QSHxoLI/YRKfgJnBSdIIASV6zYuTnOJYYemfoIn2CGo2oJS3VTSLAAZEICoeihodgipLkhv8zgwIa4ABshQKYmAmSQimCGAec6IOzIwEkIAIDoAAkwIqYsEyG8AEjaIASNIsN4AAcYIaDES++ODsLwAHCiBjFeBaQVBSqpVBz9AAkoAADIAIkcItn+IAvQHR4sCwfUICp6EgQAIzdqAHDd48IsF00eAI6l4yO0F+sIgEcAI2IQY2W8FzIxZBaAALwgwFFgYr/aE0A8ACOMY+22AoeVwYqwBFs6Hti4JAUA4zCSJDpeIYQN3BdUDNFkQJINI6Y5IzQKI0UeYYPR1MR9xPk0C4+FIYtGYsvxI3eCI5EaJNYkBICUEM72YkgWQTleI6XSBIc+Q0pkALuw5NZOQTwKI//9GiP2LBJJLSH7liWUhCQHuMABEkcLilCECmRDBCUPuGF6zBOWeWWQ3CXOySStFiSZpEMzgQMZLVXcMkFMDmMMykRBgAMMaEs7uMtjvmYXeCT0TiNXgFFM5FY88IP7PBYnBkGTvmNVoFaAJBZCKMwjsWUqZkEWykgXckTHjABF+CWGbOZtTkGZzmP9UgS4mBBGNUSLJMtdLVawakGcjmQBQkPiSRevkeYz5mXA1ABCcAACwCVEYGdzykEIpkAFaAA0DgApKIAHJAACfCdfEkM4jmeSPAA3+meHKAAUjMA86gA3Nmd3/kO80mfUfCdDOCe55me69me77kA8dkctEmg/2xgnwuAn/rZAPwpAv6ZAMW5CgMqoWNgoObZAALSoabwoSB6Bs4IJiWqlvwVoSnaBytKohVgotYBozH6BzPaopyAojn6Bjtaoy7akDj6o4QQpDYKCT5qpHSApENaCEvKpHbgpIwQpVKKB1R6CFZ6pXoQpOBpB1vKpXzgjF9aB2Eqpp5RpGiamGq6pk+AAu75URIwc0+Qn0swpzRHCWcaoxDwk9AYUO/5BPK4BAswAHLjCXuaogkwABwgBBKAAh0VEAcKhBXAPAnAnt2pGgNAnhqgAKAoBIW6IgeKHStSocCoAMX1Uxrgnu3Rpm7qKPypAAmwI6GqqQ4AjQ4AABywnf+LqgCaGpINIAIp0gBEUKuD+quLSir8+QAoMI8J4ACbKh+u+qpKkCL8KRzGGq3QCAADkKvc6quDSgLkcqkDkCfZKgSDuqgBsatRMwAecqyJkKggWhkQGY3n+qvRKAT5mq7j6p7Ccq/8GhDqeqzwigjyKqGX6p3j8p6G+qu/Co0oIBvguqkSMI8oUI4NVKvdVAEPsqnqCgDquqsJoCbRGq/TSq1H0K7dWqoNS7AUC63yOLFCgALpKQL/2rASAK0VsK0fq64QII9rUrIGe7IoewULcLGL2qhfIJILwADB2qpF2weyoZ4aMJlRIAEYup1P+gcHG7W10LVeOwtgm6JN0qj/9sk8EjCEFTqyQyAB7rkZLcW2DTKpQ5CfD9oHYwuiUjMSizoAO1KwRlCo1yo318qogAGN0NiofTqPhgsYHPIIeUughZoYfSuzAJC23wmfISmp+aobl8ufACCujQqt8Gi4pBseZYq3RBu2RLCrQ9CrAxCP0SqPhXuojtEAw/cA3QqyhiuPFdq75ToEjVulq8u66OqrQqCuwritSxCRYUIE3fRRuhuNGOqgsVq9Q6CfRNpKvAIFyBAABbhVQiC+F+ELPdiWWaC9yVuughut+amf+qkeoAsY8rgZbnsn0Xq/0EoE6ku8rYQsE+CPQkABwIARH/BbRWBW1aDA0uAMZwUA/xjwRz10BR7zusFLu6Tqnu4psNzZTbn6AD/pr7rBTY3rnd2ktELAVtsbStuQV+04BF/oMkWhRhYxBHh1Djc8DjmMDkszwVYgG1DysdOrBCQbjbRauMHLn9QkvCtbrMrRCJEbHy28EEKQAgEADTwoBC0MAFucDtyAD1+cEGFsO9rQnFZwq3HgJJBbvIuSLFJEBIWlh0SwxV28WGCMEPAzxkNQxlpQqBrwBuOSuqr7v8qgWETQRVwTAPuWLRiAV0OAWhihERYRyZBMbXx8F2z8J3VsBHnjEioADFC0DlXpQy7zWzZBE8A1E6asLSZUFCUgwF0RxfCxyUhgAB1QQj2jb/+kPBRFYUzldRS/7MVYhsnG2xd+KcdcVcx8URTwogSyrMyYEMkAEBPZuDHQ/Ba/+ZuyeZoMUy/e/M3gHM7iPM7kXM7mfM7onM7qvM7s3M7u/M7wHM/yPM/0/M1mHAfZLACuYpoW1c31DM4X9c8A7c8CvTAEXdD9jNDeHNAKndANzc0P7dARzdAKjZpzcA6vOZbAGQZJ1dHT6tFUdLIbBdIfKQdiGUsu0YPOGdJvKYba6NIlvZQsPdMwTQce4BLj5cwivdMtzdE8/dIyDdQ+LdRc+9NEXSMfbdQ1vdRDTdNBfR9KzdRNHdNTLdVgMNJRfdWZLCRZXdVW7QUkTdVa7dT/X60khnArZ4DWZqDWZcDWY+DWb33PYADXYkDXcy3Xd93WeH3NfN3Xfv3XgB3Ygj3YhF3YSLEOsEwIvRAAe10IJtTYhPC9kB0Iko0IhNgNvIfMf2DACLwIPfwSjTBtod0uFn0IFuMSW40FyIA4zFzDfzDDrqkIJJRXSikIzURoi8AuL4wI2rBZLxcIQIEz0kzNgEDHuN0I7OKEiYAyiik+yvANk/0H7DIBW5PYe2AQ+ZzaUmDc0/MBz5QIHcARtGwI3CIOF5MIBsCb28CSfIDd+kzK2h0FjOzIi0AB3m3dxc00ixAT7jDehJAtSOHffmAQGN0MVtcHoZwMyo3e2WJo//G9BbjCLLmdEeJQ24DgEiVg3oWAEpCDASdtACkNCBS0DbrcHvrdCAJOCC1zAIK54VcGNoTQmDftM4Zd4zZ+4zie4zq+4zze4z7+40Ae5EI+5ERe5HaRKwNcmUZOEsmwDCgzAS2+5PAwQy+RDEaEAf5wPTbjNSqwC+pAAW3zPpKk0lKuCgZcw88QADPcEgbDNaScLQEARQVzUGXuCkCxCxXBMKFcDzcD4MlgMjHRAYxd569gEPbQDpEswbvcDSm5DdVM6KWwENAwMiXAe/oMAi6x6IXWLQYO6aywENazDdj4lQdMaMnQLFesFJ6+6qze6q7+6rAe67I+67Re67Z+6wW47jhBAAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Data from patients undergoing lung transplantation between January 1994 and June 2003, based on the Registry of the International Society for Heart and Lung Transplantation Twenty-second Official Report - 2005. Although the difference in five-year survival between groups was significant, factors other than the choice of procedure may have influenced this result.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Trulock E&nbsp;et al. Journal of Heart and Lung Transplantation 2005; 24:956.",
"     <br>",
"      <br>",
"       For additional and updated information, please see the International Society for Heart and Lung Transplantation slide set \"Overall Lung and Adult Lung Transplantation Statistics,\" slide titled \"Number of lung transplants reported by year and procedure type\" at: file://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_14_39149=[""].join("\n");
var outline_f38_14_39149=null;
var title_f38_14_39150="Severe varicose veins PI";
var content_f38_14_39150=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F71564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F71564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Severe varicose veins",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 216px; height: 294px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is a picture of varicose veins, which are swollen and twisted veins in the legs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Patrick C Alguire, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_14_39150=[""].join("\n");
var outline_f38_14_39150=null;
var title_f38_14_39151="TTE sinus venosus defect";
var content_f38_14_39151=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/53750/sinvette_conv.mp4?title=TTE+sinus+venosus+defect\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sinus venosus defect viewed via transthoracic echocardiogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 433px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SVC: superior vena cava.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Brian Soriano.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_14_39151=[""].join("\n");
var outline_f38_14_39151=null;
